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Abstract 
Background  
The prevalence of diabetes, chiefly type 2 (T2DM), is particularly high in the United 
Arab Emirates (UAE). Effective management of the disorder and its co-morbidities is 
needed; however quality of T2DM care is variable and suboptimal worldwide. In the 
UAE, few studies have been undertaken to systematically review the prevalence of 
T2DM and its risk factors and any changes in these trends overtime. Also, studies on 
the quality of T2DM care and factors influencing it are lacking. 
Aim 
To examine the quality of care provided to people with T2DM in Abu Dhabi, 
particularly Al-Ain, and identify factors influencing it. 
Methods 
This was a multi-method study involving systematic reviews, and quantitative and 
qualitative approaches. Quantitative data were collected from a random sample of 
medical records of people with T2DM to assess the quality of T2DM care and 
improvement overtime and investigate any differences in the care provided to 
different age groups and genders. The qualitative method includes semi-structured 
interviews with healthcare professionals to investigate factors affecting the quality of 
T2DM care.  
Results 
Findings from the quantitative study demonstrated that the care provided to people 
with T2DM is sub-optimal for glycaemic and blood pressure control. Better 
glycaemic control was more common among people aged 40 and above. However, 
encouraging progress with regard to intermediate outcomes of diabetes control 
including glycaemic and lipid between 2008 and 2010 was found among both 
genders. Four main themes emerged from the thematic analysis including 
motivation of healthcare professionals, training of healthcare professionals, team 
work and Emirate cultural impact on diabetes care. 
III 
 
Conclusion 
This study has provided a picture of T2DM prevalence and risk factors for its 
adverse outcomes in the UAE. Findings from this study can help policy makers, 
managers and healthcare professionals to plan and execute better quality culturally-
appropriate interventions to improve diabetes care, and reduce its burden. 
Strengthening the collaboration and joint planning between different health 
authorities in the UAE through the development of a national planning framework 
is highly recommended to reduce the burden of T2DM epidemic and improve the 
quality of its care. Also, reinforcing the role of the primary care in providing T2DM 
care, and strengthening the collaboration and co-ordination between the primary 
and secondary care settings in the UAE is required to optimize the care provided to 
people with T2DM. 
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Chapter 1 : Introduction 
 
This chapter addresses the following topics: an overview of diabetes mellitus (DM); 
specifically type 2 diabetes mellitus (T2DM), the worldwide prevalence of T2DM, the 
health and economic impact of T2DM, diabetes care, the quality of T2DM care, and 
interventions to improve it. This overview is essential to present a solid platform in 
which to start the study. 
1.1 DM  
DM is a chronic metabolic disorder caused by defects in insulin secretion, insulin 
action, or both (1). This disorder is defined by the International Diabetes Federation 
(IDF), and the global advocate of diabetes care, as a state of raised blood glucose 
level (hyperglycaemia) associated with premature mortality (2-3). Similarly, DM was 
defined as “ a clinical syndrome characterized by hyperglycaemia in the fasting state 
due to absolute or relative deficiency of insulin or defect in its receptors or other 
abnormalities” (3-5). 
The deficiency in insulin or inefficiency of its action influence greatly almost all 
metabolic pathways including carbohydrate, protein, lipids, minerals and water 
metabolism. As a result, metabolic instabilities appear, and long-standing 
derangements result in structural and functional changes in the cells of the body and 
often cause permanent or irreversible damage (3-5). This leads to the development of 
various complications related to diabetes including biochemical, functional, 
symptomatic and morphological alterations (3, 6-9). 
1.1.1 Classifications of DM 
Many attempts have been made to classify diabetes; however the World health 
Organization (WHO) established the most accepted classification worldwide and it 
was originally proposed by Irvine (4). Other classifications for instance, by the 
National Diabetes Data group have been used (5). 
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DM is classified mainly as either primary idiopathic or secondary to other pathology 
as seen in figure one. There are four known subtypes of DM (10). The first subtype is 
called type 1 diabetes, which is caused by a failure of pancreatic beta cells to produce 
insulin, and it accounts for 5-10% of all diagnosed cases of DM (10). Secondly, T2DM 
which accounts for roughly 90% of diagnosed cases of diabetes, and is associated 
with insulin resistance and other environmental factors such as obesity/overweight 
and physical inactivity (10-11). Gestational diabetes is the third form of diabetes, and 
it develops in approximately 2-5% of all pregnancies, but in most cases resolves post-
partum (10-11). There are other specific types of diabetes that result from various 
causes such as genetic syndromes and malnutrition, but these account only for 1-2% 
of all diagnosed cases (10-11). 
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Figure 1:  Classification of DM 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Modified from reference No. 11) 
Diabetes mellitus 
Primary idiopathic 
Secondary 
Insulin-
dependent 
Non-insulin 
dependent 
MODY
1
 
 
IGT 
2
 Diabetes 
IDDM 
(Type 1) 
Insulin 
dependent 
maturity onset 
NIDDM 
(Type 2) 
IGT Endocrine 
disorders 
(Inherited) 
Insulin 
resistance 
Pancreatic 
degeneration 
Liver disease Tropical 
diabetes 
Hormonal 
imbalance 
Gestation Pancreatic 
disease 
Malnutrition 
Related 
Drug induced 
(1) MODY: Maturity onset diabetes of the young                       (2) IGT: Impaired glucose tolerance 
 
 
4 
 
1.1.2 Aetiology of DM 
In both major types of DM type 1 and 2, the precise aetiology is not yet certain; 
however it has been widely accepted that this disorder is associated with many 
factors including genetic and environmental factors (12). In T2DM, there is a strong 
association between the disorder and both genetic and environmental factors such as 
nutrition, obesity and physical activity (12). Potential factors associated with 
increased risk of T2DM including ethnicity and geographical differences, gender 
difference, nutritional factors, severe and prolonged stress, thrifty genotype 
hypothesis, drugs, physical inactivity, genetic factor, and other factors including age 
and parity are discussed below. 
1.1.2.1 Ethnicity and geographical differences (urban vs. rural) 
There is a large body of evidence linking ethnicity to an increased risk of diabetes. 
For instance, higher prevalence rates of T2DM were reported in South African 
Indians compared to South African blacks (8.9% vs. 4.2%; respectively) (13). Another 
example is the difference in the prevalence of T2DM among Aborigines and Malays 
living in the same community (4.4% vs. 11.3%; respectively) (13). 
Previous research supports the role of geographical differences in increasing the risk 
of developing T2DM. For instance, Japanese people living in Brazil had higher 
prevalence rates of T2DM compared to those living in Japan (14). Equally, Japanese 
American living in Hawaii and Los-Angeles had higher prevalence rates of T2DM 
compared to native Japanese (14). Since Japanese Americans are genetically 
indistinguishable from native Japanese, geographical differences were associated 
with developing T2DM (14). 
In the Middle East, Elmugamer et al found higher prevalence of diabetes in urban 
areas compared to rural areas in the UAE (p=0.000) (15). Similarly, Al-Nuaim found 
that Saudis living in urban areas had higher rates of diabetes compared to those 
living in rural areas (age adjusted prevalence: males 12%, females 14% vs. males 7%, 
females 7.7%; respectively) (16). In contrast, Elbagir et al did not find any association 
between geographical location and development of T2DM in Sudan (17). This 
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finding might be due to the fact that urban areas in Sudan do not differ dramatically 
from rural areas. 
The differences in the prevalence of T2DM between urban and rural areas can be a 
consequence of the following: (1) people living in urban areas might be more 
affluent and prone to unhealthy diets compared to those living in rural areas; and (2) 
people living in rural areas might be more involved in physical activities due to the 
nature of their lives which reduces the risk of developing T2DM and other 
associated risk factors such as overweight and obesity (12). 
1.1.2.2 Gender difference 
Some prior have investigated the relation between gender and prevalence of T2DM, 
but this association is still not certain. Previous research showed that T2DM  is more 
common among women (18); however Lerman et al documented that T2DM is more 
prevalent among males than females in Mexican population of all age groups (16.7% 
vs. 9.5%; respectively) (19). 
1.1.2.3 Nutritional factors, body weight and fat distribution 
Several studies have shown that high Body Mass Index (BMI), is directly associated 
with a higher risk of T2DM in many ethnic groups (20). Similarly, many studies (e.g., 
21-23) indicated that obesity is a risk factor for T2DM. The use of energy rich food, 
rich in saturated fats, refined sugars and deficient in complex carbohydrates (fibres) 
may contribute to the development of obesity and T2DM (20). Studies (e.g., 24) 
found a strong positive correlation between the development of T2DM and excessive 
intake of processed carbohydrate particularly sucrose. Similarly, Hinsworth found 
that low carbohydrate and high fat diet increase the risk of developing T2DM (25, 
26). In contrast, no association was determined in a study carried out elsewhere (27). 
1.1.2.4 Severe and prolonged stress 
Some studies (e.g., 28) have reported that due to the activation of hormones caused 
by severe and prolonged stress, notably the glucocorticoids, which causes glucose 
intolerance; the risk of developing T2DM might increase with stress (28). 
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1.1.2.5 “Thrifty” genotype hypothesis 
In 1962, Neel proposed that a protective effect is caused by the deposition of fat 
during a feasting period and used up during a famine (29). More clearly, in the days 
when human population was subjected to uncertain food supply and famine 
through factors such as drought and hurricanes, followed by overproduction as a 
result of improved environmental factors resulting in a state of “feast”, there was 
definite compensations in people, as seen in figure two (29). 
This proposal suggests that the high energy diets readily available along with a 
sedentary life style may lead to both hyperinsulinaemia and insulin resistance; 
therefore beta cell destruction may occur and subsequently T2DM (29). 
1.1.2.6 Drugs 
There are some studies indicating the role of some pharmacological medicines in 
developing T2DM. For instance, some studies demonstrated that corticosteroids and 
oral contraceptive steroids may contribute in causing glucose intolerance and T2DM 
in susceptible individuals (30). However, the role of other drugs such as B-adreno-
receptor blocking agents is not yet well-defined (30). 
1.1.2.7 Physical inactivity 
The role of physical activity in reducing the risk of developing T2DM has been 
commonly reported in previous research (31-33). For instance, a study carried out on 
an African America population in the US, indicated that the degree of inactivity and 
obesity increase the risk of developing diabetes (33). 
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Figure 2:  The “Thrifty” genotype hypothesis  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Modified from reference No. 29) 
 
1.1.2.8 Genetic factors 
The exact mode of inheritance of T2DM is still not well defined despite the large 
number of studies focusing on this area. However, the association between T2DM 
with genetic factors is well documented; many studies have (e.g., 34-36) 
demonstrated statically significant results supporting the familial aggregation in 
T2DM. 
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1.1.2.9 Other factors 
Other factors mentioned in the literature that are associated with increasing the risk 
of developing T2DM include age (e.g., 37, 38), and high parity (e.g., 39). 
1.1.3 Prevalence of DM worldwide 
Globally, the number of people with diabetes is increasing at an alarming rate, and 
diabetes is considered as a key threat to human health, and the epidemic of the 21st 
century. Approximately, 200 million people live with diabetes, and a dramatic 
increase in this number is expected by 2030 as highlighted in table one (40). Further, 
the IDF estimates 380 million people with diabetes by 2025 (1-2).  
Developing countries face major epidemics of diabetes particularly type 2 mainly 
among adult population over the age of 25. The dramatic rise is in countries with 
relatively young populations, and still developing economic infrastructure, as they 
undergo the predicted increases in prevalence of diabetes associated with changes in 
lifestyle and economic development, and population growth, leads to risks not only 
for individuals, but for health systems, social systems, and state economies (40). 
Even when based on changes in population size and demography alone (40), the 
highest predicted future increases listed by the IDF are expected in the „African 
region‟ (estimated: 98.1 % increase 2010 – 2030), followed by the „Middle East-North 
Africa‟ region (estimated: 93.9 % increase 2010 – 2030) as shown in table one (1). The 
Middle East-North Africa region already has some of the highest rates of diabetes in 
the world. 
As shown in table two, five of the six countries of the Co-operation Council for the 
Arab States of the Gulf (GCC) are included in those currently ranked “top 10” for 
diabetes prevalence among the 216 countries for which data are available (1). These 
GCC countries based on the highest prevalence of diabetes are United Arab Emirates 
(UAE), Saudi Arabia, Bahrain, Kuwait and Oman (1). 
In the UAE for instance, the prevalence rate of diabetes, chiefly T2DM is worrisome 
(1, 41, 42). As seen in table two a gradual increase is expected between 2010 and 2030 
in the prevalence of diabetes in this country (18.7% vs. 21.4%, respectively) (1). 
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However, there is a variation between rural-urban settings, age group and different 
nationalities living in the UAE (41). 
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Table 1: IDF regional estimates for diabetes (20-79 years): 2010 - 2030   
 
 2010 2030 2010/ 2030 
Population 
(20-79 
years) 
No. of people 
with diabetes 
Comparative 
diabetes 
prevalence 
Population 
(20-79 years) 
No. of people 
with diabetes 
Comparative 
diabetes 
prevalence 
Increase in the No. 
of people with 
diabetes 
Region  Millions Millions % Millions Millions % % 
NAC 320 37.4 10.2 390 53.2 12.1 42.4 
MENA 344 26.6 9.3 533 51.7 10.8 93.9 
SEA 838 58.7 7.6 1,200 101.0 9.1 72.1 
EUR 646 55.2 6.9 659 66.2 8.1 20.0 
SACA 287 18.0 6.6 382 29.6 7.8 65.1 
WP 1,531 76.7 4.7 1,772 112.8 5.7 47.0 
AFR 379 12.1 3.8 653 23.9 4.7 98.1 
Total 4,345 284.6 6.4 5,589 438.4 7.7 54.0 
 
(Modified from reference No. 1) 
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Table 2: Top ten prevalence of diabetes (20-79 years): 2010 - 2030 
 
2010 2030 
Country Prevalence (%) Country Prevalence (%) 
Nauru 30.9 Nauru 33.4 
United Arab Emirates 18.7 United Arab Emirates 21.4 
Saudi Arabia 16.8 Mauritius 19.8 
Mauritius 16.2 Saudi Arabia 18.9 
Bahrain 15.4 Reunion 18.1 
Reunion 15.3 Bahrain 17.3 
Kuwait 14.6 Kuwait 16.9 
Oman 13.4 Tonga 15.7 
Tonga 13.4 Oman 14.9 
Malaysia 11.6 Malaysia 13.8 
 
(Modified from reference No. 1) 
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1.1.4 Health and economic impact of DM 
Through its various complications and a widespread high prevalence (42), DM is a 
major contributor to morbidity and mortality worldwide. T2DM is not only 
associated with an increase in overall age-adjusted mortality of twice as that of non-
diabetics, but it is also associated with roughly 5-10 years reduction in life 
expectancy of middle aged people with diabetes (43). There are many complications 
associated with diabetes such as dyslipidaemia, hypertension, blindness and non-
traumatic amputation. 
Dyslipidaemia is a significant risk factor for developing macrovascular 
complications in diabetic patients. The Centre of Disease Control and Prevention 
(CDC) recently reported that 70-97% of individuals with diabetes suffer from 
dyslipidaemia (43, 44). This contributes to an excess, risk of coronary heart disease, 
which is two to four times higher in people with diabetes compared with non-
diabetic population (45). 
High blood pressure is another of the co-morbidities of diabetes. It has been 
documented that the prevalence of hypertension in the diabetic population is 1.5 to 3 
times greater that of non-diabetics (43). Hypertension can increase the risk for renal 
insufficiency, diabetic retinopathy and possibly neuropathy in diabetic individuals 
(43). Hence, diabetes is the most common reason for renal replacement (45). 
Furthermore, diabetes is the leading cause of new cases of blindness among adults 
aged 20-74 years (43). In the US, diabetic retinopathy causes 12,000 to 24,000 new 
cases of blindness yearly (43). It is the most common reason for blindness in the 
under 65 (45). 
Diabetes is the most common cause of non-traumatic amputation worldwide (45). It 
has been estimated that more than 60% of non-traumatic lower limb amputations 
occur due to diabetic foot ulcers in the US (43). 
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Coma and death could be consequences of sudden development of short-term life 
threatening complications of diabetes if not treated promptly, such as ketoacidosis 
and severe hypoglycaemia (45). 
Besides that, the project increase in the number of people with diabetes will cause a 
major burden for health systems (12). In China for instance, the WHO predicts a total 
of US$ 557.7 billion net loss in national income as a consequence of diabetes, stroke 
and cardiovascular diseases in the 10-year period from 2005 to 2015 (46). It is a major 
public health issue, carrying huge societal and economic, as well as personal, cost 
and risk (46). This risk has been acknowledged by the United Nations through 
Resolution 61/225, which issued a call for Member States to implement strategies to 
address the diabetes problem (46). 
1.1.5 DM care 
The main goals of managing people with diabetes are screening for complications 
and achieving tight glycaemic control along with the management of other co-
morbidities such as hypertension and hypercholesterolaemia to prevent or delay 
diabetes related complications which are addressed in section 1.1.4. Studies such as 
the Diabetes Control and Complications Trial (DCCT) and The UK Prospective 
Diabetes Study (UKPDS) underlined the importance of active medical intervention 
or management in reducing diabetes related complications (47). Evidence has 
confirmed the association between strict glucose and blood pressure control and 
reduction in microvascular complications (48-56). For people with T2DM who are at 
high risk of cardiovascular diseases, careful management of risk factors including 
smoking, hyperlipidaemia, and hypertension is important (48-56).  
1.1.5.1 Prospects for health improvements in DM 
As addressed in sections 1.1.4 and 1.1.5, controlling or normalizing blood glucose 
and screening for or controlling the related co-morbidities such as hyperlipidaemia 
and hypertension are essential for people with diabetes. Evidence indicates the need 
of both primary and secondary prevention programmes to improve health outcomes 
in diabetes, and prevent or delay diabetes related complications (52-60). 
14 
 
Previous research shows (e.g., 53) that secondary prevention measures including the 
control of blood glucose, blood pressure and lipids reduce diabetes related 
complications. Also, encouraging people with diabetes to discontinue smoking is 
important, and can help in achieving the desired treatment outcomes (54). 
Regular screening for retinopathy, nephropathy, peripheral neuropathy and 
peripheral arterial disease is essential as it can help in detecting or managing these 
conditions (52). 
Based on the scope of this thesis and the aim of the cohort study addressed in 
chapter five, the following section will focus on secondary prevention in diabetes 
including blood glucose, lipids and blood pressure control. 
Blood glucose control 
Results from the UKPDS showed that the reduction in the mean Glycated 
haemoglobin (HbA1c) (7.0% v 7.9%)  (optimal range ≤ 6.5) by 11% among people 
with diabetes who were treated intensively, lead to a significant reduction by 25% 
(95% Confidence Intervals (CI) 7% to 40%) in microvascular endpoint (58). 
Additionally, UKPDS demonstrated a reduction in the risk for myocardial infarction 
associated with the reduction in the mean HbA1c; however this reduction in the 
myocardial infarction risk was not statistically significant [AOR 0.84 95% CI 0.71-
1.00] (58). 
Blood pressure control 
In terms of blood pressure, results from the UKPDS showed significant 
improvement in the control of blood pressure for those patient who received 
intensive treatment control (mean BP 144/82 mm Hg compared with 154/87 mm 
Hg) (47, 49). Added to the improvement in blood pressure, people with diabetes 
who received intensive blood pressure control had a significant reduction in the 
followings:  diabetes related endpoints 24% (95% CI 8% to 38%), deaths related to 
diabetes 32% (95% CI 6% to 51%), strokes 44% (95% CI 11% to 65%), reduction in all 
microvascular endpoints 37% (95% CI 11% to 56%) (47, 49). Moreover, in the same 
trial people with diabetes allocated to the intensive blood pressure group were 
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significantly less likely to develop retinopathy than those were treated normally (47, 
49, 57, 58). 
Lipid control 
Many studies indicated the importance of blood lipids control and the use of drugs 
such as statins to regulate blood lipids as a secondary prevention measure in 
diabetes. For instance, the use of drugs to control blood lipids was found to be 
beneficial for all subjects with diabetes, even for those who did not have existing 
coronary artery disease as indicated by MRC/BHF Heart Protection Study (59).  
The Collaborate Atorvastatin Diabetes Study (CARDS) found that the use of 
Atorvastatin in people with diabetes reduces the risk of acute coronary heart disease 
events by 36%, coronary revascularisations by 31%, stroke by 48% and mortality by 
27% (59). 
1.1.5.2 Interventions to improve DM care 
Improving the quality of diabetes care remains important worldwide (60, 61). There 
is increasing evidence that diabetes care is suboptimal on the international level in 
terms of standards attained, degrees of variability and levels of accountability of 
health professionals (62, 63). 
The most recent report of the US Agency for Healthcare Research and Quality 
(AHRQ) of the strategies used for improving the quality of care provided to people 
with T2DM such as audit and feedback, case management, team changes, electronic 
patient registry, clinician education, and clinician reminders demonstrated that most 
strategies lead to a small to moderate improvement in glycaemic control (51). The 
report emphasised the use of two or more of the listed strategies to improve diabetic 
care as this was successful than employing a single intervention (51). 
Most of the intervention studies were published in western countries (e.g., 53-55); 
however, little work has established from other countries, particularly those located 
in the Middle East. 
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1.1.6 Quality of DM care 
Defining quality of care 
Due to the growing demand for health care, rising costs, constrained resources and 
variation of clinical practice; improving and measuring quality of health care are 
becoming important issues. These are now in national agendas of health systems in 
many countries, including the USA and UK (62, 63). 
Formulating a concise and meaningful definition for quality of care was a challenge 
for experts for decades. A frequently quoted global definition of quality in health is 
that used by the Institute of Medicine; which is “the degree to which health services 
for individuals and populations increase the likelihood of desired health outcomes 
and are consistent with current professional knowledge” (64). Furthermore, Maxwell 
and Donabedian have developed the most recognised disaggregated definitions of 
quality (64-66). Maxwell defined quality in health care based on mainly six 
dimensions including:  accessibility, effectiveness, equity, efficiency, acceptability, 
and relevance (64-66). Donabedian‟s definition; however covers many of the same 
dimensions including effectiveness, efficiency, efficacy, acceptability, equity and 
legitimacy as highlighted in table three (66). 
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Table 3: Quality dimensions  
 
Quality dimension Donabedian 
1998 
Maxwell 
1992 
Effectiveness × × 
Efficiency × × 
Access × × 
Safety ×  
Equity × × 
Appropriateness × × 
Timeliness   
Acceptability  × 
Responsiveness  Respect 
Choice 
Information 
Satisfaction   
Health improvement ×  
Continuity   
(Modified from References No. 64-66) 
Measuring quality of care 
Experts worked for more than 25 years to create measures that are both reliable and 
valid so that they can be used to assess the quality of health care. Quality measures 
include process of care and outcomes (67). Outcome measures have been included to 
not only measure the rate of morbidity and mortality, but to assess various kinds of 
functional status as well (68-70). Assessing health care system performance by using 
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quality measures is becoming an essential tool internationally and a legal 
requirement in many countries (71-73). 
In the UK due to the movement from assessing both cost and activity to assessing 
the quality of health care services; performance measurement and quality 
improvement are emphasized for the National Health Services (NHS). Also, as a 
result of the need to assess quality, a national performance frame work has been 
developed (74). 
Several factors other than health care have been shown to have substantial effects on 
health as measured by mortality rates such as, lifestyle, environment, poverty and 
social structure of society. For instance, 31% of the decline in coronary heart disease 
in women in the US between 1988 and 1992 was a result of changes in lifestyle (diet 
and smoking) (72). 
Quality indicators are divided based on the three main components of health care 
including structure, process and outcome (70). Outcome measures examine the 
mortality, morbidity, quality of life and patient perception including measures of 
patient satisfaction (70). Variations in outcome between health care providers might 
be due to difference in type of patients, measurements, chance and difference in 
quality of care. Regarding type of patients, factors including age, gender, severity of 
the disease and related co-morbidities are the patient characteristics that create 
differences in type of patients. For example, a 40% reduction in the mortality rate of 
stroke patients in Edinburgh, Scotland disappeared when results were adjusted for 
case mix (74, 75). Despite all the limitations in the use of outcomes, they remain the 
ultimate validators of the effectiveness and quality of medical care. Examining the 
process of care itself is another method to assess the quality of care, in addition to 
assessing outcomes (71, 76). 
Process measures have four main fundamental advantages over outcomes which 
include reduction of case mix bias, lack of stigma, prompt wider action and they are 
useful for delayed events (69-70). However, process measures used in performance 
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management should be valid; therefore they should be either self-evident measures 
of quality or be evidence based.  
Quality standards and indicators 
The science of quality measurement is still developing in many developing 
countries, while these measurements are used more widely in developed countries. 
However, there are some attempts to standardize international quality measures, e.g. 
by the Organization for Economic Co-operation and Development (OCED) (68-70). 
Quality indicator sets have been developed by national bodies, for instance National 
Performance Assessment Framework in the UK, National Committee for Quality 
Assurance in the USA and several international bodies such as the OECD (68-70).  
Quality standards differ from quality indicators and it is essential to distinguish 
between them. Quality indicators have been defined as “measurable elements of 
practice performance for which there is evidence or consensus that they can be used 
to assess the quality of care provided" (71). On the other hand, quality standards 
stand for "the level of compliance with a criterion or indicator" (71-73). Basically, 
indicators are related to the care provided to the patients, while outcomes of care for 
these indicators are referred to the standards. For instance, it is a standard from the 
National Service Framework for Coronary Heart Disease in England that all patients 
with diagnosed coronary heart disease receive low dose (75mg) aspirin where 
clinically appropriate (48). Yet, in general meeting such absolute standard is a 
challenge.  
Use of quality of care indicators in diabetes care 
Despite the large number of indicators used to assess the care provided to people 
with diabetes, international agreement on the indicators to assess diabetes care is not 
specified. The Diabetes Quality Improvement Project (DQIP) was used in the US in 
the late 1990s for evaluation and improving the quality of diabetes care (72). Later, 
the comprehensive set of national measures provided by DQIP was updated as the 
National Diabetes Quality Improvement Alliance (73). The measures are based from 
data extracted either from hand-written medical records or electronic records to 
assess: (1) recording of care (HbA1c, eye examination, lipid profile, assessment of 
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diabetic nephropathy, blood pressure and foot examination); and (2) the percentage 
of targets achievement of HbA1c, lipid and blood pressure. Added to these 
assessments, a patient survey measuring smoking cessation counselling, nutritional 
education, satisfaction, self-management, and interpersonal skills of the health care 
team was used (73). 
In the UK, the assessment of diabetes care used indicators taken directly from the 
general medical services contract for UK general practitioners (74).The assessment 
includes recording of several indicators of care such as BMI, smoking habit, HbA1c, 
cholesterol, blood pressure and retinal screening. Also, it includes achievement of 
HbA1c, lipid and blood pressure targets, and prescribed treatment such as 
therapeutic intervention for poor glycaemic and blood pressure control. Besides, 
since the introduction of the Quality and Outcomes Framework (QOF) in 2004 in the 
UK, the quality of care indicators have been used chiefly in UK primary care settings 
(74). 
Others (e.g., 70, 71) have also assessed the quality of diabetes care using a 
combination of process, intermediate outcomes of care, and clinical interventions 
such as the use of appropriate pharmacological treatment to control blood glucose or 
blood pressure level. 
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Chapter 2 : UAE 
 
This chapter is classified into three main parts. The first part provides an overview of 
the UAE‟s location, government and people; and its, economic and social 
development. Also a general overview on health profile in the country is 
highlighted. Providing this information is needed for the reader to have a good 
understanding about the UAE and its health, which is the country of focus in this 
thesis. 
Secondly, due to the differences in the bodies regulating the health services in the 
UAE, an overview about Abu Dhabi the capital of the UAE is provided along with a 
brief description on the health profile. Providing this information is important as 
both the quantitative and qualitative components of this thesis as addressed in 
chapters five and six respectively took place in Tawam hospital that is located in the 
capital Abu Dhabi. Understanding the health system followed, and reviewing the 
diabetes profile in Abu Dhabi city can help drawing the picture about the burden of 
diabetes epidemic in the capital. 
The final section focuses on reviewing the interventions initiated in the UAE to 
tackle diabetes and improve its care. Reviewing these interventions is useful as it can 
help in providing some recommendations both in the hospital and policy levels. 
Also, being aware of the interventions initiated to improve the quality of diabetes 
care would be productive for the systematic review carried on the quality of diabetes 
care in the GCC as addressed in chapter four, section three.   
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Section one 
This first section of chapter two presents an overview of the UAE. A brief 
description of the health system, health and diabetes profiles is provided. Reasons 
for providing this information are listed in the opening of chapter two. 
2.1 Background 
2.1.1 Location and geography 
The UAE is located in the southeast of the Arabian Peninsula in southwest Asia on 
the Persian Gulf. It‟s bounded by two countries from the west, Qatar and Kingdom 
of Saudi Arabia, Sultanate of Oman from the south, and the Gulf of Oman from the 
east as shown in figure four. The Arabian Gulf encircled the UAE from the north and 
North West as seen in figure three. The total area of the country is 83, 600 square 
kilometres (77, 78). 
Figure 3: Geographical location of the UAE 
 
 
 
 
 
 
 
 
 
 
Source: http://wwp.greenwichmeantime.com/ map-United-Arab-Emirates/index.htm 
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2.1.2 Government and people 
UAE was established in December 1971. It‟s a Middle Eastern federation of seven 
countries named emirates including: Abu Dhabi (the capital), Ajman, Dubai, 
Fujairah, Ras al-Khaimah, Sharjah, and Umm al-Quwain (77, 78). 
In 2010 according to the estimates from the national bureau of statistics, the total 
population of UAE was 8, 264, 070 of which 6, 161, 820 were males, and 2, 102, 250 
were females (78). Only 947, 997 (11.5%) of the population were UAE nationals (78). 
Total life expectancy at birth for all  people residing in UAE including both nationals 
and non-nationals was estimated in 2008 as 77.4, females had higher life expectancy 
at birth compared to males(80.2 vs. 63.5; respectively) as highlighted in table four 
(77, 78). 
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Table 4: UAE‟s profile 2008 (Demographic, socioeconomic and health indicators) 
Demographic indicators Value Health expenditure indicators Value 
Area in square kilometres 83,600 GDP/ capita US $ exchange rate 64,009 
Total population in thousands 8,073,626 Total expenditure on health (per capita)  
(average US$ exchange rate) 
1,551 
% of urban population out of total population 81 Government expenditure on health (per capita)  
(average US$ exchange rate) 
1,044 
% population growth rate 6.1 Total expenditure on health % GDP  
 
2.4 
  Public % of total health expenditure                                             74.4 
Health status indicators Value Coverage with primary care services indicators                                          
Value (1-year old immunized) 
Total life expectancy at birth (years) 
 Male 
 Female 
77.4 BCG                                                                                                                98% 
63.5 DPT3 92% 
80.2 Measles vaccine 92% 
Prenatal mortality rate/ 1000 total births 10.4 HBV3 92% 
Neonatal mortality rate 4.9   
Infant mortality rate/ 1000 live births 7.6   
< 5 mortality rate/ 1000 live births 9.8   
Maternal mortality ration / 1000 live births 1.5   
 
(Modified from references No. 77, 78) 
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2.1.3 Economic and social development 
Before the discovery of oil, UAE was considered as one of the poorest countries in 
the region. People living in the UAE relied on its few natural resources such as 
fishing and revenues from pearl business (79). However, after the oil discovery, it 
became the main revenue and nourished the UAE‟s economy (79). In Abu Dhabi, oil 
was discovered in 1958 and it started exporting in 1962. In recent years, the country 
has developed rapidly and vastly in many areas such as industry, economy and 
tourism. Hence, the gross national income increased between 1972 and 2002 
dramatically (4.7 billion AED vs. 229 billion AED; respectively) (79). Also, gross 
domestic product increased from 6.5 billion AED in 1972 to reach 260 billion AED in 
2002, with an annual growth rate of 13% (79). 
The UAE gives high importance to education, and the government allocates all 
required funds to ensure high quality of education to all UAE citizens (78). As 
highlighted in table four, the rate of literacy among both genders male and female 
aged 15 years and over is high (92% vs. 93%; respectively) (79). 
Added to education, the UAE gives great importance to environmental protection, 
and many initiatives have been established such as MASDAR city in Abu Dhabi as 
which aspires to be one of the most sustainable cities in the world (80). 
The Ministry of Health (MOH) in the UAE has developed remarkably in the field of 
information technology and e-government. The country has occupied grade level 
one among the Arab countries for its distinguished programme of the e-government, 
and globally it occupied grade level 21 (79). 
2.1.4 Health profile 
2.1.4.1 Overview  
Six different authorities provide health services in the UAE, five of them are 
governmental and the last one is the private sector. Each authority has its own staff 
and system (77, 79). The public healthcare services are administered by three main 
authorities in the UAE including MOH, the Health Authority Abu Dhabi (HAAD), 
and the Dubai Health Authority (DHA) (79). The MOH managed the Northern 
Emirates healthcare system including Ras Al Khaimah, Ajman, Umm al Quwain, 
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Sharjah and Fujairah;  however  in 2009 the Emirates Health Authority that has 
similar regularity function and initiatives as HAAD and DHA has been established 
pursuant to Federal Law No. 13 of 2009 (81). 
2.1.4.2 Health policies and strategies 
The biggest change in the UAE‟s policy is the withdrawal of the MOH from the 
direct health care delivery (77, 79). Similarly to Dubai which has its own government 
health system that has existed for more than 30 years, Abu Dhabi recently has 
established its own health authority. Reforming the relation between those different 
health care providers and the MOH in the UAE is required as this relationship is 
ambiguous (77, 79). 
2.1.4.3 Brief history of the health care delivery system 
Before the discovery of oil in the UAE, the health situation was considered to be 
poor (79). Rich people used to get treatment abroad, while those who were not able 
to afford the expense of travelling abroad used traditional remedies instead. 
In 1938, a medical officer was appointed by Britain for the Trucial Coast, and an 
Indian physician was sent to Dubai in 1940 to serve in a dispensary (79). After that, 
in 1949, Al Maktum Hospital was built in Dubai by the British government, and 
British physician from the Indian Medical Service was appointed in the hospital to 
establish a modern medical service (79). In the 1950s and 1960s, American Mission 
hospitals were commenced in three cities including Sharjah, Al Ain and Ras Al 
Khimah (79). 
Furthermore, Abu Dhabi received technical and material assistance from Egypt in 
1960s; however in 1965 one physician was employed by the Abu Dhabi government 
and three others started practicing in the private sector (79). 
In 1971, after the union of the seven Emirates, a rapid growth in the health system 
occurred, though lack of coordination between these Emirates appeared (79). 
Until 2001, free healthcare services were provided to all people residing in the UAE 
either national or expatriates. However, due to several factors such as the significant 
rise in the healthcare cost, the government considered the cost sharing in the form of 
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user charge for the expatriate who constitutes over 70% of the population as well as 
considering a new compulsory health insurance schemes to encourage investment in 
the private healthcare sector (79). 
Furthermore, based on the regional health systems observatory report the health 
care system in the UAE is improving. “In the early 1990s, the UAE had a modern 
health care system with facilities and professionals capable of providing excellent 
care, and performing advance procedures such as organ transplants and complex 
heart surgery. Although, the facilities are concentrated in the cities of Abu Dhabi and 
Dubai, people living in other Emirates have access to at least basic facilities” (79, 81). 
As shown in table five, the health care infrastructure in the UAE has progressed  in 
line with other health care developments, for example in 1971 there were only seven 
hospitals in the UAE with 700 beds; however in 2000 this number increased to 51 
hospitals (78, 79,81). 
According to the annual statistical report in 2002, there were total of 26 hospitals all 
over the UAE [15 (57.7%) hospitals in urban vs. 11 (42.3%) hospitals in rural areas] 
(79). Added to these hospitals, 106 healthcare centres are distributed between urban 
and rural areas of the country (35% vs. 67%; respectively). Almost all levels of health 
services are decentralized in the UAE (77, 79). 
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Table 5: Healthcare infrastructure in UAE: 1970 to 2000 
Years 1970 1980 1990 2000 
Population  
 
580,000 1,040,000 1,844,000 3,108,000 
Hospitals  
 
7 20 29 30 
Total number of beds 
 
700 3000 4300 4473 
 (Pop./ bed) 
 
1/1500 1/3500 1/4200 1/6900 
Healthcare centres 21 65 90 115 
 
Total number of 
physicians  
 
200 1000 1500 2350 
Pop./ physician  
 
1/2900 1/932 1/1230 1/353 
Total number of 
nurses 
 
1000 3300 4600 6300 
Pop./ nurse 1/580 1/315 1/400 1/490 
(Modified from reference No. 81)
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2.1.4.4 Health information system 
The health information system in the UAE is developing. “Building and 
maintenance of the national health information system is a strategic objective to 
support and enhance the country cooperation strategy and all its strategic elements,  
including disease surveillance, trend analysis and burden of disease studies , health 
systems development, health and biomedical research, decentralization, 
privatization and public-private partnership, and health promotion and healthy 
lifestyles” (77, 79). 
2.1.4.5 Human resources 
In 2002, the total number of medical physicians was 2304, nursing staff 5779 and 
technicians 12,100 (84). There is a significant increase in the number of healthcare 
professionals in the MOH; though a shortage in availability of trained Emirate 
physicians and nurses exist in the country (77, 79). 
 2.1.4.6 Morbidity and mortality trends 
Maternal and child health 
As highlighted in table four,  a number of key indicators such as infant mortality rate 
(7.6) and neonatal mortality rate (4.9) reflect the remarkable changes in the provision 
and impact of health services (78, 79).  
Due to the sustaining maximum immunization coverage as addressed in table four, 
the incidence of immunizable childhood diseases have been declined dramatically 
(78, 79). 
HIV/ and other sexually transmitted diseases 
The WHO reported that UAE and other neighbouring countries have among the 
lowest number of HIV/AIDS cases globally. Besides, in 2003, 560 cases of syphilis 
were reported, 117 cases of gonorrhoea and 43 cases of other sexually transmitted 
diseases (78, 79). 
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Communicable diseases 
The rate of many communicable diseases have been declined remarkably in the 
recent period; still controlling some communicable diseases such as tuberculosis and 
viral hepatitis pose a problem in the UAE (78, 79). 
Non-communicable diseases (NCDs) 
Based in the WHO-report of the country cooperation strategy 2000, cardiovascular 
diseases (28.7%), cancers (8.6%) and diabetes (2-3%) had been the leading causes of 
mortality (77). 
In 2008, total death from NCDs in males and females respectively were 3,200 vs. 
1,400 as shown in table six (78, 79,). The highest death rate per 100,000 was attributed 
to cardiovascular diseases and diabetes in both genders, females and males 
respectively (203.9 vs. 308.9) (78, 79). 
Table 6:  Mortality from NCDs, 2008  
                Males          Females 
Total NCD death (000s) 
 
3.2 1.4 
NCD deaths < 60 (%) 59.7 47.1 
Age standardized death rate/ 100,000 
 
  
All NCDs 448 340 
Cancers 63.4 64.4 
Chronic respiratory diseases 11.6 23.1 
Cardiovascular diseases and diabetes 308.9 203.9 
(Modified from reference No. 83) 
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2.1.4.7 Life style and environmental factors 
Tobacco consumption poses a problem in the UAE. In 2006, the estimated tobacco 
smoking rates in adults aged 15 years and over among males and females 
respectively were 25% vs. 2.6% (81). However, the country has an anti-tobacco 
programme that has four main elements including legislation, smoking cessation 
units, a community- based component, and school-based components (81).  
As a consequence of the life style in the UAE such as physical inactivity and high 
consumption of fat foods, the prevalence of obesity and overweight are alarming. 
For instance, based on the WHO data estimates on 2008, the prevalence of obesity 
among males and females respectively were 30.2% vs. 43% (79). 
2.1.4.8 Health education 
Health education is important for all people residing in the UAE; however public 
communication is difficult in the UAE due to the diversity of nationalities and 
languages. Notably, there is no reference centre for health education in the 
community (81). However, awareness programs are now delivered through special 
radio and television production units (81). The efforts to promote health education in 
the UAE are increasing, but sill more emphasise should be placed on important role 
of health education by the government of the UAE. 
2.2 Key issues and main challenges 
Based on the WHO report 2002, there are some critical challenges the MOH should 
build up to achieve the desirable goals of good health including: (1) strengthening 
the organization of health services; (2) health financing; (3) resources for health; and 
(4) health education (77, 81). 
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Section two 
This second section of chapter two presents an overview of the capital of UAE, Abu-
Dhabi. A brief description of the health profile is provided. Reasons for providing 
this information are listed in the opening of chapter two. 
2.3 Abu Dhabi 
2.3.1 Population  
Abu Dhabi is the capital of UAE, and it has been growing rapidly in recent years. 
The population of Abu Dhabi is estimated to be 1.9 million, 21% of whom are 
nationals (78). In 2009, one in five residents are nationals of whom 2/3 are under 30 
and half under 19 years old (78). 
2.3.2 Health profile 
2.3.2.1 Overview  
In 2001, the General Authority of Health Services (GAHS) was established by the 
Abu Dhabi governments; however the GAHS was split into two chief organizations 
in 2007 namely: (1) HAAD; and (2) Abu Dhabi Health Services Company (SEHA) 
(82).  
The HAAD is the governmental regulative body of the Healthcare Sector in Abu 
Dhabi. It monitors the health status of the population to ensure excellence in 
healthcare for people living in Abu-Dhabi. HAAD has several responsibilities 
including: (1) defining the strategy for the health system, monitoring and analysing 
the health status of the population and performance of the system; (2) shaping the 
regulatory framework for the health system; (3) inspecting against regulations; (4) 
enforcing standards; and (5) driving programs to increase awareness and adopting 
of healthy living standards among people living in UAE (82, 83). 
However, SEHA is considered as the operator of public health assets in Abu Dhabi. 
Based on the Abu Dhabi Amiri Decree No. 10 0f 2007, SEHA‟s mandate is to own 
and manage either directly or indirectly, public health facilities. Also, SEHA is 
expected to implement the policies and projects approved by HAAD (82). Currently 
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SEHA is collaborating with a number of healthcare groups such as Johns Hopkins 
Hospital for the management and operations of Tawam Hospital in Al Ain (82). 
In 2007, mandatory health insurance was introduced to all residents of Abu Dhabi 
including both nationals and expatiates (82, 83). 
2.3.2.2 Morbidity and mortality trends 
In 2009, HAAD statistics showed that the diseases of the circulatory system are 
number one cause of death in Abu Dhabi, accounting for 24% of all deaths (84, 85). 
While In 2010, as shown in table seven, the mortality rate in Abu Dhabi was 1.26 
deaths per 1000 people in the population (84, 85). The top three leading causes of 
death in Abu Dhabi city in 2010 were namely: cardiovascular diseases, cancers, and 
preventable injuries such as those caused by road traffic accidents (84, 85). Among 
nationals, diseases of the circulatory system and cancer increased remarkably as seen 
in figure four from 2008 to 2010 (84, 85). 
 
Table 7: Crude mortality rate in Abu Dhabi, 2010  
 Death (%) Rate /1000 of population 
National  population 967 (34) 2.66 
Expatriate population 1888 (66) 0.98 
Total population 2879 (100) 1.26 
(Modified from reference No. 84) 
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Figure 4: Top three causes of death in Abu Dhabi: 2008 - 2010 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Modified from reference No. 85) 
 
NCDs 
The prevalence rate of DM among 76,070 adult residents in Abu Dhabi in 2005 was 
approximately 19%, hypertension 34%, hypercholesterolemia 18% and obesity 23% 
(86). Among emirate females and males, diabetes was more prevalent among age 
group 60-69 (59% vs. 56%, respectively) (85). Similarly to UAE nationals, the 
prevalence of diabetes was more common among the same age group of expatriates 
(female 61%, male 53%) (85). 
Based on the WHO Statistical Information System and World Health Statistics 2007, 
DM was one of the five leading causes of death in Abu Dhabi (85). As shown in table 
eight and it amounted for 11.9% of the total deaths (85). 
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Table 8: The main leading causes of death in Abu Dhabi, 2007 
Causes (rate / 100,000 population) 
Accidents and poisoning 37.5% 
Cardiovascular diseases 29.8% 
Cancer 21.7% 
Congenital anomalies 10.7% 
Diabetes mellitus 11.9% 
(Modified from reference No. 85) 
However, HAAD reported a 15% raise in the mortality rate caused by DM from 2004 
and 2007 (85). 126 deaths were attributed to diabetes in 2004 and the number 
increased to reach 201 deaths in 2007 as highlighted in table nine (85). 
Table 9: The rate of death in Abu-Dhabi:  2004-2007 
Causes 2004 2005 2006 2007 
 
Accidents and poisoning 
 
563 
 
565 
 
503 
 
633 
Cardiovascular diseases 413 424 378 506 
Cancer 298 294 315 370 
Congenital anomalies 146 156 131 177 
Diabetes mellitus 126 133 130 201 
Other causes 443 874 993 867 
Total 2489 2446 2450 2754 
(Modified from reference No. 85) 
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Section three 
This final section of chapter two presents an overview of the main interventions that 
have been initiated in the UAE to tackle diabetes and improve its care. Reasons for 
providing this information are listed in the opening of chapter two. This section 
starts with an overview of the UAE government‟s aims on health. Then it 
concentrates on the initiatives that have been undertaken by the MOH, HAAD and 
DHA respectively to tackle diabetes or improve its care. 
2.4 interventions to tackle DM and improve its care  
2.4.1 UAE‟s government  
The UAE‟s government aims to ensure access to primary care for all people living in 
the UAE including both citizens and non-citizens, and to improve the quality of 
health services (78). Also, its long term target is to build a world-class health care 
system that ensures universal access to health care services, provide world-class 
health services, and reduce epidemic and health risks (78). 
2.4.2 MOH 
The MOH has implemented many initiatives to reduce the burden of diabetes in the 
UAE and improve its care for people who are living with diabetes. One of these 
initiatives is the establishment of the national strategy for diabetes control for 2009 to 
2018. This program has several important objectives that aim to address the maxim 
of the MOH „act on diabetes now‟ (86). These objectives include the following (86): 
 Focusing on primary and secondary prevention of T2DM 
 Improving the quality of care provided to people with diabetes at the three 
levels of health care 
  Monitoring and evaluating diabetes care 
 Promoting and encouraging research focusing on diabetes 
 Strengthening  the participation of the community in diabetes  
 Empowering people with diabetes on the management of diabetes 
Many steps have been undertaken by the MOH to support screening for diabetes 
and promote awareness on the disease, its risk factors and complications. Awareness 
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campaigns for preventing and living with diabetes, for instance, have been held in 
Sharjah, with a focus on encouraging physical activity among people (87). 
The world diabetes bus is another activity that began in 2010, and started from the 
capital Abu Dhabi moving to the other emirates (88). It aims to screen for diabetes 
and its risk factors such as overweight/ obesity, hyperlipidaemia and hypertension 
(88).  
Additionally, the MOH has obtained international expert experience in diabetes by 
establishing the Rashid Centre for Diabetes Mellitus and Research in Ajman, which 
is the first centre of excellence with Swedish expertise for diabetes and obesity care 
in the region (89). This centre aims to provide a healthy and enjoyable life for people 
with diabetes living in the UAE (89). 
2.4.3 HAAD 
In 2006, the Abu Dhabi government aimed not only to improve access to health 
services, but also to improve the health outcomes for all people residing in Abu- 
Dhabi; therefore policy and system planners designed specific strategies to achieve 
the desired aims of the government (90). 
Overall, there was lack in the skills needed for effective programs to tackle non-
communicable disorders including diabetes in Abu Dhabi such as data collection, 
planning and monitoring; hence experts advice both at local and international levels 
was sought to establish evidence-based programs for screening for NCD‟s, 
particularly diabetes and cardiovascular diseases (90). A program called „Weqaya‟ 
that means in Arabic prevention was initiated at Abu Dhabi (90). This program 
involves screening, planning and acting (90). As a consequence of the program, 
approximately 94% of Abu Dhabi citizens were screened for diabetes and 
cardiovascular disorders risk from 2008 to 2010 (90). Based on the results from the 
screening program, and acting process of Weqaya, health and non-health sectors and 
programme governance were involved to address the high prevalence of diabetes 
and its risk factors such as overweight/ obesity and physical inactivity (90). 
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Furthermore, specialized diabetes centres have been launched in Abu Dhabi such as 
the Imperial College Diabetes Centre (ICDC) which is considered as state of the art 
in diabetes treatment, research, training and public health (91). 
2.4.4 DHA 
Many initiatives have been carried out in DHA to either prevent diabetes or improve 
the quality of its care. In terms of improving the care provided to people with 
diabetes, a quality improvement program was adopted from the chronic disease 
management model in the primary care centres (92, 93). Improvement in the care 
was indicated by the metabolic measurements for diabetes such as glycaemic control 
(93). 
The Harvard affiliated Joslin Diabetes Centre was launched in Dubai in 2009, aiming 
to provide treatment, prevention, education, lifestyle management, and podiatry 
services (94).  
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Chapter 3 : The thesis 
3.1 Rationale for the thesis 
Diabetes is a complex disorder that needs effective management strategies to achieve 
the desired therapeutic outcomes as addressed in chapter one. To summarize, the 
main goals of managing people with diabetes are screening for complications and 
achieving tight glycaemic control along with the management of other co-
morbidities such as hypertension and hypercholesterolaemia to prevent/delay 
diabetes related complications. Effective management of diabetes can help in 
preventing both micro and macro-vascular complications (47). Studies such as the 
DCCT and the UKPDS underlined the importance of active medical intervention or 
management in reducing diabetes related complications (49, 50). 
However, due to the increasing evidence that diabetes care is sub-optimal on 
international level in terms of the standards attained, the degree of variability and 
the level of accountability of health professionals; improving and measuring quality 
of health care are becoming important issues world-wide (60, 61). These are now in 
national agendas of health systems in several countries such as USA and UK (62, 63).  
The UAE has the second highest prevalence rate of diabetes globally (20.1% among 
the adult population) based on the data from the IDF as addressed in chapter two; 
therefore this disorder represents a real challenge to the health planners, policy 
makers and health care system thinkers, and increases the economic cost to the 
society (1). The increased cost includes its effects on morbidity, employment, 
productivity, premature mortality and the increased use of health services. For this 
reasons, actions are needed to prevent a dramatic increase in the prevalence rate of 
diabetes in the UAE, and to improve the quality of diabetes care (1). Strategies and 
interventions should be initiated in the UAE targeting diabetes and its related risk 
factors. Also, effective management of diabetes is essential to alleviate the symptoms 
and minimize the risk of long, debilitating and expensive complications. 
Efforts to reduce the burden of diabetes epidemic in the UAE, and improve the 
quality of its management should be informed and supported by evidence-based 
knowledge. Despite the alarming prevalence rate of diabetes in the UAE, there is a 
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shortage in research studies focusing on the prevalence of diabetes and its risk 
factors in the country; however as reported in chapter two, the MOH and the HAAD 
established some evidence-based screening programs for diabetes and 
cardiovascular disorders recently, and the country is encouraging research studies 
on the field of diabetes. 
Furthermore, many previous research studies were carried out to assess the quality 
of diabetes care and identify factors influencing it in Europe and America. Some of 
this research included systematic reviews and meta-analysis to examine the quality 
of care provided to people with diabetes and identify factors associated with it. 
Results from these studies demonstrated that the care provided to people with 
diabetes is sub-optimal, and diabetes care is influenced by many factors related to 
healthcare professionals, patients and the organization of services. However, few 
studies have been reported from the GCC in general and UAE in particular on the 
quality of diabetes care and factors affecting it, even though the prevalence of this 
disease is reaching an alarming rate in the region. Also, there was lack of studies in 
the systematic focusing on diabetes, its risk factors and management. Determining 
and examining the current standards of diabetes care, and investigating and 
understanding factors influencing it could potentially aid the implementation of 
appropriate quality improvement interventions in the UAE and other GCC states, 
and significantly improve diabetes care.  
3.2 Research questions, aim and objectives  
Research questions 
1. What are the estimated prevalence rates of T2DM in the UAE from the 
available data, and what are the trends in prevalence across time? 
2. What are the common reported risk factors for adverse outcomes in people 
with T2DM in the UAE from available data, and what are the trends in 
prevalence across time? 
3. What is the quality of T2DM care in Abu Dhabi compared to international 
standards? 
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4. Is T2DM care in Abu Dhabi improving over time? 
5. Do inequalities in T2DM care associated with age and gender exist in Abu 
Dhabi? 
6. What are the factors both (facilitators and barriers) affecting T2DM care in 
Abu Dhabi from the perceptions and experience of healthcare professionals? 
Aim 
To examine the quality of care provided to people with T2DM in Abu Dhabi, 
particularly Al-Ain, and identify factors influencing it. 
Objectives 
The thesis was designed to fulfil the following major objectives: 
1. To systematically review and demonstrate the followings:  
 prevalence of T2DM in the UAE, and trends in prevalence across time 
 risk factors for adverse outcomes in people with diabetes including 
overweight/obesity, hyperlipidaemia, „pre-diabetic‟ hyperglycaemia, 
and hypertension and their prevalence rates in the UAE 
 quality of T2DM care in the UAE 
2. To examine the quality of T2DM care using quality indicators, both process 
and intermediate outcomes of care, in accordance with the American Diabetes 
Association (ADA) targets 2012 in Abu Dhabi. 
3. To identify any improvement in the quality indicators between 2008 and 2010 
in Abu Dhabi. 
4. To investigate the relationship between age or gender and the quality of 
T2DM care between 2008 and 2010 in Abu Dhabi. 
5. To identify and provide further understanding on the factors affecting the 
quality of T2DM  care from the perceptions, attitudes and experiences of 
healthcare professionals in Abu Dhabi. 
3.3 Thesis outcomes 
Several outcomes are expected from this thesis. Based on the first objective of this 
thesis listed in section 3.2, production of systematic reviews on: (1) the prevalence of 
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T2DM; (2) risk factors for adverse outcomes in people with diabetes including 
overweight/obesity, hyperlipidaemia, „pre-diabetic‟ hyperglycaemia and 
hypertension; and (3) the quality of T2DM in the UAE are expected. 
 
Data obtained from these systematic reviews can make the available evidence more 
accessible to healthcare professionals, researchers and decision and policy planners 
and makers in the UAE. They can obtain from the results of these systematic reviews 
an overview of the commonly reported risk factors of adverse outcomes of diabetes, 
and changes in the prevalence of T2DM and its adverse outcomes over time from all 
the available data in the UAE. Also, the systematic review on the quality of diabetes 
care in the UAE can provide a better understanding of the current quality of diabetes 
care, and identify any improvement in the care overtime.  The accomplishment of 
these systematic reviews can help establishing appropriate preventive measures, 
improving the quality of diabetes care and planning and executing better quality 
interventions studies.  
 
Production of useful baseline data on the quality of T2DM care in Al-Ain, and 
investigation of any improvement in this quality overtime are expected outcomes 
from the achievement of the second and third objectives of this thesis as outlined in 
section 3.2. Also, identifying differences in diabetes care provided to different age 
groups and genders in Al-Ain is a proposed outcome from the accomplishment of 
the fourth objective, which could assist healthcare professionals and policy planners 
and makers in addressing the problem and planning for quality improvement 
enterprises.  
Factors influencing the care provided to people with T2DM in the UAE from the 
perceptions and attitudes of healthcare professionals have received little attention. 
Identifying factors affecting the quality of T2DM care in Al-Ain including both 
facilitators and barriers based on the perceptions, attitudes and experience of 
healthcare professionals are expected from the achievement of the final objective of 
this thesis. This can help optimizing diabetes care, also researchers can benefit from 
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the data to investigate the factors affecting the quality of diabetes care in Al-Ain or 
UAE from the perceptions of patients. 
 
Finally, one of the objectives of the UAE‟s MOH and HAAD is encouraging the 
research studies focusing on diabetes and its care; including understanding 
motivators and barriers to providing high quality of diabetes care. This study was 
undertaken within this objective, making the results immediately accessible and 
available to real-life practice (see chapter seven, section 7.3). 
The corresponding methodologies used, and a reference to presentation of the 
results for each objective, are listed in table ten. 
Table 10:  Outline of the five main objectives and the methodologies used. 
Objective Methodology Presentation of results 
1 Systematic reviews 
 
Chapter four 
2, 3, 4 Quantitative: cohort study 
(descriptive & longitudinal analysis) 
 
Chapter five 
5 Qualitative: semi-structured 
interviews (thematic analysis) 
 
Chapter six 
3.4 Outline of the thesis 
The introductory chapters, chapter one and two aim to respectively present the 
background of: (1) health and health systems in the UAE; and (2) diabetes care in 
UAE, particularly Abu Dhabi, along with key concepts such as quality of diabetes 
care. The objectives and rationale for the thesis have been presented in this chapter. 
Chapter four represents the systematic reviews carried out to fulfil the requirement 
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of the first objective. Chapter five addresses the methodology, results, discussion 
and conclusion from the cohort study carried out to examine the quality of T2DM 
care in Al-Ain, which fulfils the requirements of objectives two, three and four as 
listed in section 3. 2. Methodology, findings, discussion and conclusion from the 
qualitative study that was carried out to accomplish the requirements of the final 
objective outlined in section 3.2 are addressed in chapter six. A summary of the key 
findings from chapters four, five and six, and a discussion of the contributions made, 
comparison with other work, strengths and limitations, implications for clinical 
practice and directions for further research are reported chapter seven. 
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Chapter 4 : Systematic reviews 
 
To achieve the first objective of this thesis which is to systematically review and 
demonstrate in the UAE the following: (1) prevalence of T2DM; (2) risk factors for 
adverse outcomes in people with diabetes including „pre-diabetic‟ hyperglycaemia, 
overweight/ obesity, hyperlipidaemia and hypertensions and their prevalence rates; 
and (3) quality of T2DM care; systematic reviews were  carried out. 
 
A review of all the studies carried out in the GCC on the prevalence, risk factors for 
adverse outcomes from diabetes, and quality of T2DM management was carried out 
for the states of the GCC instead of UAE alone. This was because: (1) shortage of 
studies on diabetes risk factors and management  in  UAE; (2) similarities in 
government, political environment, economy, health system, culture and lifestyle 
between the six Gulf states including Saudi Arabia, Kuwait, Oman, Qatar, Bahrain 
and UAE ; and (3) possibility of transferring successful diabetes management 
strategies (where available) that could  represent good models for each other, even if 
thus far perhaps less rigorously validated than alternative international standards. 
This chapter is classified into three main sections. The first section includes the 
systematic review carried out on the prevalence of T2DM in the GCC countries. 
Secondly, the systematic review on the risk factors for adverse outcomes particularly 
„pre-diabetic‟ hyperglycaemia, overweight, obesity, hypertension and dyslipidaemia 
is presented. The final section in this chapter presents the systematic review on the 
quality of T2DM management in the GCC countries. Each section includes a 
comprehensive explanation of the followed methodology, results from the 
systematic review and discussion and conclusion. 
 
Each systematic review was performed separately; therefore repetitions may occur 
in the introduction and discussion between the three systematic review sections. 
Prior to presenting the systematic review sections, an overview on the systematic 
review, its importance in health and the followed frame work and methodological 
46 
 
steps for these systematic reviews performed in this study are addressed in the 
coming section. 
4.1 Overview of systematic review 
A systematic review is “a review of a clearly formulated question that uses 
systematic and explicit methods to identify, select and critically appraise relevant 
research, and to collect and analyze data from the studies that are included in the 
review” (95). 
 
Systematic reviews aim to identify, evaluate and summarise the findings of all 
relevant individual studies, thereby making the available evidence more accessible 
to decision makers (95, 96). When appropriate, combining the results of several 
studies using “meta-analysis” gives a more reliable and precise estimate of an 
intervention‟s effectiveness than one study alone (98). Systematic reviews have 
increasingly become essential tools in healthcare; data from them can be a starting 
point for developing clinical practice guidelines for policy makers. Also, healthcare 
professionals can utilize from the systematic reviews to keep up to date within their 
field (96). 
In brief as highlighted in figure five, the framework for the systematic reviews that I 
carried out included three stages: planning, conduction and finally reporting and 
dissemination of the review findings. 
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Figure 5: Frame work of the systematic reviews  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Modified from reference No: 96) 
 
Details of  the process of the systematic reviews carried out for the three topics 
presented in this chapter including prevalence, risk factors for advocated outcomes 
and their prevalence rates and quality of T2DM management in the GCC are given  
in figure six. This include: (1) formatting well defined review questions to maintain 
the transparency for the review process (2) revising the review questions using 
Stage one: planning the review 
 Identifying the need for a review 
 Preparing the review  proposal  
 Developing a review protocol 
 
Stage two: conducting a review 
 Selecting the  studies 
 Assessing the quality of the selected 
studies  
 Extracting and monitoring data from 
studies 
 Synthesising data extracted 
 
Stage three: reporting and dissemination 
 Writing the report and 
recommendation 
 Getting evidence into practice by 
publishing the systematic reviews 
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PICOS elements (Population, Intervention, Comparators, Outcomes, Study design); 
(3) defining the inclusion/exclusion criteria for the study; (4) formulating search 
terms; (5) devising a search strategy; (6) reviewing the search strategy; (7) appraising 
the retrieved studies critically; and finally (8) planning for dissemination (96). 
To ensure transparent and complete reporting of the systematic reviews that, I used 
the PRISMA checklist for each review (See appendices 1, 2, 3). 
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Figure 6: Methodoloigcal steps in systematic review 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Modified from reference No: 95, 96) 
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Section one: Prevalence of T2DM in the states of the GCC 
 
This section presents the systematic review carried out on the prevalence of T2DM in 
the GCC countries. It involves the following: introduction, methods (review 
questions, inclusion/ exclusion criteria, search, study selection process, data 
extraction, quality assessment, and data synthesis), results, discussion including 
limitations and implications of the review, and finally conclusion. 
4.2 Introduction 
The World Economic Forum describes chronic diseases as one of the „top 6‟ Global 
Risks (1). They carry enormous levels of morbidity and have become major causes of 
mortality. DM is a chronic metabolic disorder caused by defects in insulin secretion, 
insulin action, or both. If ineffectively controlled, the resulting chronic 
hyperglycaemia is associated with numerous disabling complications (46). 
4.2.1 The T2DM problem  
DM is a chronic disease characterised by insufficient insulin production and/or 
insulin resistance (1). Through its various complications and a widespread high 
prevalence (1), DM is a major contributor to morbidity and mortality worldwide as 
outlined in chapter one. Insulin resistance with a relative or real insulin deficiency is 
the hallmark of T2DM. Over the last 3-4 decades, prevalence of T2DM has risen 
dramatically across the world (40). It currently accounts for over 90 % of all diabetes 
cases (46). Various factors including population growth, ageing, continued 
urbanisation and lifestyle modifications encouraging sedentary lifestyles and 
obesity, will lead to further increases in prevalence.  Diabetes is a major public health 
issue, carrying huge societal and economic, as well as personal, costs and risks.  This 
has been acknowledged by the United Nations through Resolution 61/225 (2006), 
which issued a call for Member States to implement strategies to address the burden 
of diabetes in their societies (43). 
4.2.2 T2DM in the Gulf region  
The GCC exhibit some of the highest rates of T2DM in the world. Five of the IDF‟s 
„top 10‟ countries for diabetes prevalence in 2010 and in 2030 are projected to be in 
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this region as addressed in chapter two (1). Rates in Qatar are also relatively high 
(15.4 % comparative prevalence) (1). The anticipated prevalence for diabetes 2010-
2030 in the Gulf countries total population are: United Arab Emirates (UAE) 18.7-
21.4%, Kingdom of Saudi Arabia (KSA) 16.8-18.9%, Bahrain 15.4-17.3%, Kuwait 14.6-
16.9% and Oman 13.4-14.9% (1). The recent and rapid socio-economic development 
of the GCC countries has been associated with this rising prevalence. The IDF 
suggests that even in the absence of further economic development (that is, based on 
changes in population demography alone), the number of people with diabetes in its 
Middle East-North Africa region will increase 94% from 2010 to 2030. Only the Sub-
Saharan African region is expected to see a greater increase in the number of cases of 
diabetes (98%) during this period (1, 97). 
Management strategies for T2DM are anticipated to be more effective when built 
around particular population and country parameters. Strategies should aim to 
prevent the onset of T2DM in the UAE through population-based primary 
prevention initiatives, and lifestyle interventions for people at high risk of T2DM 
such as obesity and overweight. My aim here is to review the prevalence of T2DM in 
the GCC countries, to help establish that the problems in these states are broadly 
similar; and that their health systems are potentially suitable for implementation of 
similar management strategies. This is of particular current interest given the recent 
move within the GCC to co-ordinate control of diabetes care e.g. (43, 46). 
In addition to reviewing the general T2DM burden in these countries, I aimed to 
review, where possible, rates by age, sex, residential environment (urban/rural) and 
ethnicity. These were all anticipated –based on previous studies and preliminary 
scoping searches - as putative covariates of prevalence, and thus areas wherein sub-
populations may benefit from specifically targeted management strategies. 
4.3 Methods 
4.3.1 Ethics statement 
Ethical approval was not needed as this study was a systematic review of the 
literature on the prevalence of T2DM in the GCC countries. 
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4.3.2 Review questions 
A literature search was used to identify material relevant to the following review 
question: 
- What is the prevalence of T2DM in the GCC countries?  
4.3.3 Inclusion / exclusion criteria 
Inclusion criteria 
Types of studies 
Studies that used designs from the used list of acceptable methods including: 
observational study (cross sectional, descriptive, ecological, cohort, case-control).  
Types of participants 
Subjects residing in the GCC countries at all ages, sexes and ethnicities were 
included, resident and expatriate populations, urban and rural, of all socioeconomic 
and educational backgrounds in the GCC. I didn‟t differentiate between studies that 
used all residents (nationals and non-nationals) and those restricted to nationals in 
this review.  
Exclusion criteria 
 Studies that used qualitative methods such as focus group and based on 
opinions 
 Studies where population is mainly pregnant women with T2DM, or people 
with other types of diabetes such as type one. 
4.3.4 Search  
I developed a systematic review protocol (see appendix 4) using the Centre for 
Reviews and Dissemination (CRD) guidelines (96). Medline and Embase were 
searched separately on 15/07/2009 and the search was repeated on 03/07/2010 (via 
Dialog and Ovid, respectively; 1950 to July week 1 2010, and 1947 to July 2010) using 
terms identified from PICOS deconstruction of the above review questions such as 
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diabetes mellitus, non-insulin-dependent, hyperglycaemia, prevalence, 
epidemiology and Gulf States, and database- and manually-derived alternatives 
(appendix 5). The search strategy (see appendix 6) was trialled, reviewed by 
independent professional colleagues (E.H., K.P.), and updated before use. Further 
relevant studies were identified by searching the reference lists of the database-
derived papers, contacting expert investigators, screening conference proceedings, 
citation searching and hand searching the International Journal of Diabetes and 
Metabolism and the Saudi Medical Journal, for the periods 1993- 2009 and 2000- 
2010, respectively . 
4.3.5 Selection  
The initial search produced 792 studies. After excluding duplicated studies (17 
studies), the titles and abstracts were evaluated by one reviewer (L.A) to determine 
eligibility for full text screening. No limitations on publication type, publication 
status, study design or language of publication were imposed. However, I did not 
include secondary reports of prevalence, such as review articles without novel data 
synthesis. The inclusion criteria required that the study population be of a GCC 
country, but otherwise all ages, sexes and ethnicities were included, resident and 
migrant populations, urban and rural, of all socioeconomic and educational 
backgrounds. Studies of general-, working-, university- and healthcare attending- 
populations were included. I did not specify diagnostic criteria, but required that 
they would detect at least predominantly type 2 (rather than other forms of) diabetes 
and they were incorporated into our data synthesis.  
Twenty-eight studies were identified. The full texts of these studies were each 
examined by two reviewers (L.A and A.Mc). One study (98) was excluded as the 
data were already included in other studies (99, 100), and no further (relevant) 
synthesis had been performed. The full text of a further study (101) could not be 
accessed, thus the abstract alone was used for review. Additionally, I could not fully 
access the data published in three studies (102-105), and the extracted data were 
therefore similarly limited. The selection process is summarised in Figure seven. 
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Figure 7: Flow chart of study selection process 
 
 
 
 
 
 
 
 
 
 
 
 
4.3.6 Data extraction/quality assessment 
The data captured for each study included data relating to, (1) methods (study 
design, recruitment, measurement tools, and analysis), (2) participant characteristics, 
(3) setting, and (4) outcomes (those observed, their definitions, and results of 
analysis). Study quality was assessed using a checklist adapted from the CRD 
 (n= 788) records identified through 
database searching 
Medline (n=361) Embase (n=427) 
 
 
 (n=4) additional records identified through other sources 
 (n=2) from contact with expert (n=2) from searching 
reference list 
 
Duplicate studies  
(n =17) 
Records screened  
(n = 775) 
Records excluded  
(n = 747) 
Full-text articles assessed 
for eligibility  
(n =28) 
 (n=1) of full text articles 
excluded: 
The data is available from other 
studies included in the review; 
and no further (relevant) 
synthesis had been performed 
Studies included in 
synthesis 
(n =27 ) 
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guidelines (9) (see appendix 7). Data extraction was performed, in duplication, by 
two reviewers (L.A and A.Mc). 
 
4.3.7 Data synthesis 
I was looking to estimate the prevalence of T2DM in the GCC countries between 
1980 and 2009. To estimate the prevalence of T2DM, the related data was entered to 
STATA version 11 for statistical analysis. To assess the difference in prevalence of 
T2DM between different GCC countries and years, and to investigate the reasons for 
heterogeneity between the studies included in the review a subgroup analysis was 
carried out. Subgroup analysis was performed for each country separately, and for 
years, which were classified as: (1) 1980-1989; (2) 1990-1999; and (3) 2000-2009. 
Publication year was used instead of the definite start year, as the last was not 
indicated in many studies. 
Further, the data synthesis was designed around several proposals produced, for the 
most part, a priori, but also included an appraisal of potential association between 
diabetes and urban/rural residency, after preliminary scoping searches 
demonstrated that data pertaining to this were commonly reported.  
These proposals were therefore: 
1. prevalence of T2DM is increasing 
2. rates of T2DM  in the GCC states are similar  
3. prevalence increases with advancing age  
4. there is a sex difference in prevalence 
5. there are differences in prevalence between urban and rural populations  
6. there are differences in prevalence between national and expatriate 
populations 
In addition, prevalence in children was separately considered. 
In consideration of the above proposals, synthesis included summarising the results 
of the data extraction process, considering the strength of evidence relating to each 
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of the questions, and examination of results inconsistent with the formed 
suggestions. 
 
4.4 Results 
Twenty-seven journal-published studies were identified for inclusion. A summary is 
provided in table eleven, and further details are available in appendices eight and 
nine. The studies were carried out (where reported) and published between 1982 
and 2009. Six studies were published and undertaken in the 1980s, thirteen in the 
1990s, eight in the 2000s.  Eleven studies were of Saudi populations, three Kuwaiti, 
two Bahraini, six Emirati, four Omani and one Qatari. Sample sizes ranged from 336 
to 600132.  All were cross-sectional studies. In 17 cases, the general population was 
the target population; in four cases, the sample was patients registered with primary 
health care centres. Three studies estimated prevalence in working populations with 
or without dependants, one in a university population, one a population of 
schoolchildren, and one a „clinic-attending population‟ (clinic type unclear) . In one 
working population, and the university population, the sample was entirely male. 
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Ref/dates of 
study* 
Country Sample 
size 
Prevalence rate Age & prevalence Age & sex 
Bacchus et al/ NR 
(1982) 
KSA 1385 No diabetic cases in people <24 years 
0.3%: age group 25-34 years 
2.6%: age group 35-44 years 
9.6%: age group 45-54 years 
11%: age group 55-64 
  
Anokute et al/ 
1985-1987 
KSA 3158 Overall prevalence 'positive' FBG 
(unconfirmed DM): 6.0 % 
The age specific prevalence increased 
with age to a maximum of 33.8% for 
the age group ≥ 50 years. 
 
Fatani et al/ NR 
(1987) 
KSA 5222 overall prevalence DM 4.3%  prevalence DM lower in men (2.9 
%) vs. women (5.9 %; p< 0.001) 
 
Balasy & 
Radwan/ 19892 
UAE 1517 Age adjusted prevalence rate for DM: 5.69% 
Prevalence of DM among males vs. females: 
1.81% vs. 2.58% respectively 
The age specific prevalence of DM 
was steadily increasing until age 59 in 
both genders 
Prevalence of DM among males vs. 
females: 1.81% vs. 2.58% 
respectively 
Abu-Zeid and Al-
Kassab/ 1989 
KSA 1419 Overall prevalence DM 4.6%  Prevalence of DM in men (5.5 %) 
than women (3.6 %; p < 0.05); 
overall prevalence IGT: 3.7 %; 
higher in women (4.9 %) vs. men 
(2.5 %; p < 0.01) 
Abdella et 
al/1989-1990 
Kuwait 783162 Overall prevalence DM: 7.6 % Prevalence generally increased with 
age in both sexes in both areas (rural 
and urban)  
(no test for significance) 
Prevalence was generally greater in 
females (no test for significance) 
 El-Hazmi et al/ KSA 23493 The prevalence of T2DM: 4.9% The prevalence of DM peaked in the  
Table 11: Summary of included studies 
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1991  The prevalence of IGT: 0.7% age group≥ 30 years (P<0.001) 
El-Hazmi et 
al/1991 
KSA 2060 The overall prevalence of T2DM: 6.89%; 
IGT: 0.77% 
  
Al-Lawati & 
Mohammed / 
1991 
Oman  4682 Prevalence of DM: 10.5 % by WHO criteria, 
8.2 % by ADA criteria 
Prevalence of IGT 10.5 % by WHO criteria, 
5.7 % by ADA criteria 
  
Al-Nuaim/ 1991-
1993 
KSA 13177 Overall prevalence DM: 12 % in urban males, 
7 % rural males, 14 % urban females, 8 % 
rural females 
Overall prevalence IGT: 10 % in urban males, 
8 % in rural males, 11 % in urban females, 8 
% in rural females 
 
  
Mahfouz et 
al/1993 
KSA 600132 Prevalence DM 9.7 % in males, 9.8 % in 
females Prevalence IGT 8.1 % in males, 12.9 
% in females 
 Prevalence DM 9.7 % in males, 9.8 
% in females 
Al-Shammari et 
al/ 1993-1994 
KSA 2990 Overall prevalence DM 12.2 %   
Glasgow et al/ 
1995 
UAE < 33 % of 
> 29809 
The rate of DM from the two databases for 
UAE citizens >30 years: 5.7% and 11.2% 
In one of the databases the rate of 
DM increased from 1.4% in the age 
group 30-34 years to between 8.9% 
and 11% in the age group > 40-44 
years.  
 
 
Al-Mahroos & 
McKelcue/ 1995-
1996 
Bahrain 2002 Overall prevalence DM: 29.8 %  prevalence DM in males 40 - 49: 
22.9 %; 50 - 59: 29.6 %; in females 
50 - 59: 35.4 %; 60 - 69: 37.6 % 
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Townsend/ NR 
(1997) 
UAE 336 Overall prevalence unclear 
6.2% , > 30 years found to be diabetic 
19% of subjects >20 years had IGT 
 in previously undiagnosed: 4.8 
  
El-Hazmi et al/ 
NR (1998) 
KSA 25337 The prevalence of T2DM and IGT: 5.63% and 
0.5% respectively in males, in females: 4.53% 
and 0.72% respectively  
 
The prevalence of T2DM was 0.12% 
and 0.79% in people< 14 and people 
aged 14-29 years respectively. In the 
age ≥ 60, the rate increased to 28.8% 
and 24.9% in males and females 
respectively. 
Prevalence of T2DM in males vs. 
Females respectively: 5.63% vs. 
4.53% 
Al-Nozha et al/ 
1995-2000 
KSA 16197 Overall prevalence DM 23.7 %  prevalence higher in males: 26.2 % 
(95 % CI 25.2 - 27.2) vs. females 
21.5 % (95 % CI 20.6 - 22.4; p < 
0.0001) (significance unclear); 
overall prevalence IFG 14.1 % (no 
gender difference) 
Malik et al/ 1999-
2000 
UAE 5844 overall prevalence DM: 21.4 % (95 
% CI 20.4 - 22.4 %) 
Prevalence in UAE citizens 25 %, expats 13 - 
19 %  
 
 prevalence in men 20.4 % (18.8 - 
22.0 %); prevalence in women 22.3 
% (20.9 - 23.7 %_ 
Asfour et al/ 2000 Oman 5096 Crude prevalence of DM: 10% in both gender. 
 
In both gender, the prevalence of IGT 
increased with age, it peaked in the 
age group (60-69) 
(11) Asfour et al/ 2000 
Al-Asi/ 2000 Kuwait 3282 Overall prevalence of DM: 17%   
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Al-Mahroos and 
Al-Roomi/ NR 
(2001) 
Bahrain  2013 overall prevalence DM 30 %   
Moussa et al/ 
2000-2002 
Kuwait 128918 Overall prevalence DM: 34.9 per 100000 (95 
% CI 24.7 - 45.1) 
Significantly higher prevalence 
T2DM with advancing age (p = 
0.026). 
Prevalence of DM in males 47.3 per 
100000 (CI 28.7-65.8); females 26.3 
per 100000 (CI 14.8-37.8). 
significantly higher prevalence 
T2DM in males (p = 0.05) 
Al-Lawati et al/ 
NR (2002) 
Oman 5838 Prevalence of DM among male and female: 
11.8% vs. 11.3% respectively (P=0.275)  
Prevalence of DM rose with age and 
exceeded 20% in both genders at the 
age of 50 years 
 
IGT was more prevalence among 
males than females 7.1% vs. 5.1% 
(P<0.001) 
Baynouna et al/ 
2004-2005 
UAE 817 Overall prevalence DM 23.3%; 
prevalence by age and gender: males: 5.1 % 
20 - 29 years, 11.1 % 30 - 39 years, 29.5 % 40 
- 49 years, 35.5 % 50 - 59 years, 55.9 % > 60 
years; females: 1.7 % 20 - 29 years, 5.3 % 30 
- 39 years, 26.2 % 40 - 49 years, 27.1 % 50 - 
59 years, 43.3 % > 60 years 
  
Saadi et al/ 2005-
2006 
UAE 2396 Overall prevalence DM: 10.2 % (9.4 % in 
males, 11.1 % in females); prevalence in 30 - 
64 years population: 20.6 % (17.7 % in males, 
22.1 % in women) 
  
Al-Moosa et al/ 
NR (2006) 
Oman 5840 overall prevalence DM: 11.6 % (11.8 % in 
males, 11.3 % in females 
  
Bener et al/ 2009 Qatar 1117 Overall prevalence DM: 16.7 % (15.2 % 
males, 18.1 % females) 
Age significantly associated with DM 
(p = 0.0001, multiple logistic 
regression analysis); peak age DM 40 
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NR: not reported 
(*): the publication year was used instead when the study date was not reported 
 
- 49 years (58 %) 
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4.4.1 Prevalence of T2DM and association with time and countries 
21 studies were included in the sub-analysis based on methodological consideration 
(99, 100, 104-123). The sub-analysis suggested that estimated prevalence had 
increased across the three time periods listed in the data analysis section respectively 
(3.58% [95% CIs, 1.94-5.23; 2 studies] 101, 102; vs. 4.01% [95% CIs, 3.58-4.43; 10 
studies] 106-116; vs. 5.06% [95% CIs, 4.02-6.09%; 10 studies] 116-123, 104, 105). The 
differences in the estimated prevalence rate of T2DM in the GCC countries between 
the three periods was not statistically significant p=0.9. 
Subgroup analysis by country indicated that the estimated prevalence rates of T2DM 
between GCC countries are comparable. The lowest estimated prevalence rate was 
found in KSA 4.01% [95% CIs, 3.60-4.43; 10 studies] 104-108, 110,111, 113, 114, and 
116; followed by Oman 4.5% [95%CIs, 3.16-5.85; 4 studies] 103, 104, 116, and 126. 
Bahrain, in contrast, had the highest estimated prevalence rate of T2DM among GCC 
countries at 5.17% [95%CIs, 2.48-8.93; 2 studies] 115 and 117.  However, the 
estimated prevalence rates between Qatar, UAE and Kuwait were close (5.12 [95% 
CIs, 0.39-9.85; 1 study] 125; vs. 5.10% [95% CIs, 2.90-7.30; 3 studies] 100, 120 and 121; 
vs. 5.14% [95% CIs, 1.45-8.82; 1 study] 109; respectively). Although as mentioned 
earlier based on the IDF data the prevalence of T2DM in the GCC is one of the 
highest in the world, different results found from this analysis. High prevalence 
rates of T2DM in the GCC was found, but not as described‟ the highest in the world‟. 
4.4.2 Prevalence of DM and age 
Four studies (all studies in which testing was well described) demonstrated a 
significant association between advancing age and prevalence of diabetes (109, 120, 
122, 123). There was otherwise, where reported, an apparently similar association of 
unclear significance, or in some cases, such an association until 40 - 49 (121), 59 (104) 
or 60 (115) years, after which point the prevalence appeared to decrease, or fluctuate. 
Fatani et al (107), report an association (multiple logistic regression analysis; 
P<0.0001) between age and blood glucose levels. 
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4.4.3 Prevalence of DM and sex 
Significant sex differences were reported in six studies (including that of 
schoolchildren). All except one relatively old report (106) were in favour of a male 
predominance (107, 112, 113, 117, 121). In nine further studies, however, higher 
prevalence, of undetermined significance (or close to significance: (117)), was 
observed in females. This was the case for males in two studies. A further three 
studies showed no significant gender difference. 
4.4.4 Prevalence of DM and residential environs 
Urban versus rural prevalence was commented on in five studies (107, 108, 112, 117, 
124). All except the oldest study (107) reported higher prevalence in urban areas. 
4.4.5 Prevalence of DM in children 
Prevalence in children was consistently reported to be low: 0.035% (121), 0.027 % 
(116), 0.033% and 0.099% (in urban and rural populations, respectively; (108)). 
4.4.6 Prevalence of DM in national/expatriate populations 
The prevalence of diabetes in UAE-resident expatriate populations, versus that in 
UAE citizens, was considered in only one study (123). The UAE citizens appeared to 
have relatively high rates of disease, although no statistical methods were employed 
to test this suggestion. 
4.5 Discussion 
I reviewed the prevalence of T2DM in the GCC region, and any differences by 
country, age, sex, urban-rural residence and ethnicity, but couldn‟t review the 
prevalence among nationals vs. non-nationals as this was limited only by one study. 
I identified 27 papers for review, and descriptive results from the review indicated 
that prevalence of T2DM in the GCC countries ranged between 4.3%-34.9% for 
studies published between 1980 and 2009. The estimated prevalence of T2DM in 
Qatar, UAE and Kuwait were close as the included studies were carried out in the 
same period between 2000 and 2008; however  lower prevalence were observed in 
KSA and Oman as six of the  studies included  were carried out between 1990 and 
1999, two studies in 1980s and two studies in 2000. The higher rates seen in Bahrain; 
however could be a result of the documented high prevalence rates in the two 
studies (115, 119) included in the sub-analysis by country (29.8% and 30%). 
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The observed high prevalence of diabetes in the GCC states is likely to be associated 
with the high prevalence of risk factors for T2DM in this region. The IDF suggests 
age, obesity, family history, physical inactivity, race and ethnicity, and gestational 
diabetes to be risk factors for T2DM (1, 124). I recently observed that overweight, 
obesity and hyperglycaemia are present at high levels in the GCC states (125). I also 
noted the aging of the GCC populations, which is a likely contributory factor to the 
increasing prevalence.  
The study was also suggestive that prevalence increases with age (at least to 50-60 
years), and that urban residence is associated with higher prevalence. The 
importance of age as a risk factor is consistent with previous data, from many 
contexts (124, 125). The prevalence of T2DM increases with age and among people 
living in urban areas. 
4.5.1 Quality consideration 
There were some inconsistencies in the tabulated results: both generally, and within 
the country of investigation. The studies of El-Hazmi et al (111) and Mahfouz et al 
(113) produced relatively low results, inconsistent with the general trend. The El-
Hazmi et al sample is 39.1 % children < 14 years, which may account for the low 
rates (111). The authors report a „significant‟ increase in prevalence with age, but we 
could not access the full data and the statistical methods used were not well-
described. I have suggested a higher prevalence with advancing age of unclear 
significance, but with rates of 0.12 % and 0.79 % in those < 14 and 14 – 29 years, 
respectively, and rates of 28.82 % (males) and 24.92 % (females) in those > 60 years, 
this is potentially rather conservative. Indeed, the prevalences in these populations 
are much higher when children are removed from the calculation, although 
insufficiently to interrupt the general trends observed. This cannot however, explain 
the low rates reported by Mahfouz et al (113), and so I consider that these may be 
due to inclusion of only previously diagnosed people with diabetes (and omission of 
the often substantial „undiagnosed‟ population), but 
concede that the result could still be relatively low, and of importance given the 
sample size (113). 
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I cannot extend the observed association between T2DM and age to children. Low 
prevalences of T2DM in children have been reported since the late 1990s (date of first 
identified study). However, the data are few; insufficient to evaluate the possibility 
that prevalence in children is increasing, as has been observed in other countries 
(124, 125).  
The relationship between T2DM and sex was unclear. I noted, where tested, 
predominance in males. Wild et al (40) have reported this to be the case („globally‟) 
for individuals < 60 years. Even where these differences may exist, however, they 
generally appear to be slight. By contrast, I did observe higher prevalence associated 
with urban (cf. rural) residence, which again has been observed by others e.g. (130; 
131). 
 
Only a few of the included studies excluded patients with type 1 diabetes (including 
the study in schoolchildren) and/or pregnant women. It is therefore likely that in the 
majority of samples tested, the prevalence suggested includes small numbers of type 
1, gestational, and potentially other forms of diabetes. 
 
The majority of studies relied at least in part on the various WHO criteria for 
diagnosis. There is mild variation in definition by edition of WHO criteria, with 
discrepancies producing differences in estimations of the extent demonstrated by Al-
Lawati and Mohammed (112), and only the later editions (1998 onwards) are 
consistent with those of the ADA. Some studies, however, used definitions of 
diabetes and methodological approaches that led to results relatively difficult to use 
comparatively. Some relied on previous records alone to make diagnoses (where the 
diagnostic criteria used were often unclear), and so potentially missed an 
„undiagnosed‟ section of the diabetes population, which has been reported to be 
potentially substantial (104, 105, 122, 120). By contrast, relying purely on blood 
sampling to estimate of prevalence may have missed a significant number of cases of 
treated, well-controlled disease (109).There were also concerns that loss of difficult 
cases to secondary care (117), or identification only of cases sufficiently severe to 
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merit secondary care (110), may have resulted in estimated prevalences providing 
relatively poor estimates for the general population. 
4.5.2 Limitations of review 
The heterogeneity of the reviewed studies, and variable availability of sub-group 
data, was a major limitation in our review process. All of the reviewed studies were 
published in English. Clarity of reporting was a relatively frequent quality issue, but 
I did not exclude any study on this basis. Indeed, with such paucity of data and 
inability to draw more than broad conclusions anyway, I included even studies 
without full data availability, and one where only the abstract could be accessed. 
One of the main limitations is that sub-group analysis of the prevalence of T2DM 
based on the age groups was not possible to be carried out because of the different 
age bands used in the studies and the lack of patient-specific data. 
Although four studies (112, 117, 121,122) had high rate of loss of follow-up (>20%), 
they were included in the review. In three of these studies (11, 117, 122), the target 
number of subjects that were supposed to take part in these studies was 
unreachable. For instance, in two studies (121,122) 382 and 861 subjects respectively 
were not resident at the address given. Other reasons for high loss to follow-up were 
participants‟ death, travelling abroad, refusal to participate in the studies, and 
exclusion based on health grounds. Bener et al. (123) was included although details 
on the high rate of loss of follow up was not mentioned because it is the single study 
carried out in Qatar, and excluding it from the review would not help us draw an 
estimated prevalence rate of T2DM in this country. All of these factors impact on the 
strength and confidence of the proposals. 
4.5.3 Implications  
The relatively high levels of T2DM in the GCC region, and increasing prevalence, 
suggest that novel, or more widespread, management strategies will be important to 
averting an increasingly unmanageable problem. This may be particularly so given 
the observed associations with urban residence and age, within a context of 
continued urbanisation and unfavourable trends in population demography. The 
nature of the problem is probably similar across the different GCC states (with the 
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possible exception of Oman, for which data are limited). Potentially, then, cross-
implementation of management strategies would provide relatively high levels of 
success, and a co-ordination of effort would likely be relatively cost-effective. Cost is 
particularly important given the size of the problem, the observed impact on the 
working population, and the nature of migrant populations within the GCC region. 
The migrant populations contribute greatly to the currently high rates of population 
growth in these countries. General prevalence could thus be hugely influenced by 
differential disease rates between national and expatriate populations. This is 
particularly important to estimates of future rates of disease as these are usually 
based – at least in part – on predicted changes in population demographics. As the 
GCC countries have strict nationalisation policies, and the vast majority of expatriate 
workers are not national citizens, these countries are at relatively high risk of 
fluctuation in population size and structure, and predictions regarding demography 
are thus relatively difficult to make. Economic change could have a particularly 
strong impact on population structure, and building such possibilities into strategies 
for disease management, when this is itself of significant economic status, is 
important. 
Given these issues, I find the observed infrequent consideration of ethnicity as a 
variable particularly striking, and anticipate that continued study of this issue would 
be useful. Study of physical inactivity – another risk factor for T2DM may also be 
useful. Finally, I expect that study of prevalence in children would be helpful, 
particularly given the recent rise in childhood prevalence reported elsewhere, as the 
available data are minimal. Longitudinal studies in both children and adults are 
desirable, as longitudinal data are lacking and such studies would be the optimal 
way to observe changes in prevalence with time.  
4.6 Conclusions 
This is the first systematic review has been undertaken in the countries of the GCC 
to estimate the prevalence rate of T2DM. There were several methodological 
challenges; in particular, the different populations studied and methods used to 
assess glycaemic status. This review presents the high prevalence of T2DM in the 
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region and the increasing burden of this disorder over time in the GCC countries, 
which is in line with statistics from the IDF on the “top 10” countries for diabetes 
prevalence in 2010 and in 2030 . Primary prevention strategies may be useful in 
reducing its incidence in the GCC region. Finally, I recommend further 
epidemiological studies to estimate the prevalence of T2DM in the area and to 
observe any changes in prevalence rate over time, using longitudinal data collection 
in higher-quality studies that would give accurate statistics on diabetes prevalence, 
including prevalence in key population sub-groups. 
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Section two: Prevalences of overweight, obesity, hyperglycaemia, 
hypertension and dyslipidaemia in the GCC 
 
This section presents the systematic review carried out on the prevalence of 
overweight, obesity, hyperglycaemia, hypertension and dyslipidaemia in the GCC 
countries. It involves the following: introduction, methods (review questions, 
inclusion/ exclusion criteria, search, study selection process, data extraction, quality 
assessment, and data synthesis), results, discussion including limitations and 
implications of the review, and finally conclusion. 
4.7 Introduction 
The increasing prevalence of DM, particularly T2DM, is well documented (1).T2DM 
is currently estimated to account for over 90 % of the global diabetes burden (40). 
Together with similar trends in other non-communicable diseases, it leads to risks 
not only for individuals, but for health systems, social systems, and state economies. 
This risk is in part to do with an anticipated relatively dramatic rise in countries with 
relatively young populations, and still developing economic infrastructure, as they 
undergo the predicted increases in prevalence of diabetes associated with changes in 
lifestyle and economic development, and population growth. Even when based on 
changes in population size and demography alone (40), the highest predicted future 
increases are expected in the IDF „African‟ region (estimated: 98.1 % increase 2010 – 
2030), followed by the „Middle East-North Africa‟ region (estimated: 93.9 % increase 
2010 – 2030; 1).The Middle East-North Africa region already has some of the highest 
rates of diabetes in the world. The GCC include those currently ranked 2, 3, 5, 7 and 
8 for diabetes prevalence among the 216 countries for which data are available (40, 
126). 
This high prevalence in the GCC states is associated with higher prevalences of risk 
factors for T2DM. The IDF suggests the following as risk factors for T2DM: age, 
obesity, family history, physical inactivity, race and ethnicity, and gestational 
diabetes. Of the modifiable risk factors, physical inactivity appears to have been 
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surprisingly little studied in this region, although it is likely to be correlated with 
overweight and obesity, which have been relatively well studied (126-128). 
I aimed to review the prevalence of overweight and obesity in the GCC region. I also 
aimed to review the prevalence of potentially „pre-diabetic‟ hyperglycaemia 
(measured either as impaired fasting glycaemia, impaired glucose tolerance or raised 
random glucose). Added to that, I examined hypertension and dyslipidaemia, which 
are risk factors for adverse outcomes in people with diabetes (129-132). Diabetes is 
complicated by various micro- and macro- vascular conditions and people with 
metabolic syndrome - a collective of obesity, insulin resistance, dyslipidaemia, 
hypertension and hyperglycaemia (133-135) - have a relatively higher prevalence of 
cardiovascular disease than those without (129). Due to the heterogeneity of studies 
identified on preliminary searching, there was no anticipated meta-analysis. 
4.8 Methods 
4.8.1 Ethics statement 
Ethical approval was not needed as this study was a systematic review of the 
literature on the prevalence of overweight and obesity, hyperglycaemia, 
hypertension and dyslipidaemia in the GCC countries, with no primary data 
collection. 
4.8.2 Review question 
A literature search was used to identify material relevant to the following review 
question: 
- What are the prevalences of overweight and obesity, hyperglycaemia, 
hypertension and dyslipidaemia in the GCC region? 
4.8.3 Search strategy 
I developed a systematic review protocol (Refer to appendix 10) using CRD 
guidelines (96). Medline and Embase were searched separately on 15/07/2009 and 
the search was repeated on 03/07/2010 (via Dialog and Ovid, respectively; 1950 to 
July week 1 2010, and 1947 to July 2010) using terms identified from PICOS 
deconstruction of the above review questions such as hyperglycaemia, high blood 
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glucose, blood pressure, hypertension, hyperlipidaemia, cholesterol, overweight, 
obesity and GCC, and database- and manually- derived alternatives (appendix 11). 
The search strategy was trialled, reviewed by independent professional colleagues 
(W.I., K.P.) (Refer to appendix 12) and updated before use. Further relevant studies 
were identified by searching the reference lists of the database-derived papers, 
contacting expert investigators, screening conference proceedings, citation searching 
and hand searching the International Journal of Diabetes and Metabolism and the 
Saudi Medical Journal, for the periods 1993- 2009 and 2000- 2010, respectively . 
4.8.4 Selection of studies 
The search yielded 1331 studies. The titles and abstracts were evaluated by one 
reviewer to determine eligibility for full screening. All studies wherein overweight, 
obesity, BMI, hyperglycaemia, hypertension and dyslipidaemia were investigated 
were eligible for inclusion. No limitations on publication type, publication status, 
study design or language of publication were imposed.  However, I did not include 
secondary reports such as review articles without novel data synthesis. The inclusion 
criteria required that the study population be of a GGC country, but otherwise all 
ages, sexes and ethnicities were included, resident and expatriate populations, urban 
and rural, of all socioeconomic and educational backgrounds. Studies of general-, 
working-, young-, student-, healthcare attending-, and other- populations were 
included. I did not specify diagnostic criteria for the studied conditions, but 
incorporated them into our data synthesis.   
1331 studies were identified. The full texts of these studies were each considered by 
two reviewers (L.A. and A.M.). All studies of diabetic populations were excluded 
(136-138), and studies wherein people with diabetes had been excluded from the 
study population were excluded (139, 140). Further exclusions were made on the 
basis that the studies were: 
- reviews without relevant novel synthesis (141, 142) 
- of a population outside the GCC region (143) 
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- reported trends in prevalence, without providing prevalence rates per se 
(144, 145) 
- duplications of data contained in other studies (146) 
The selection process is summarised in Figure eight. 
 
Figure 8: Flow chart of study selection process 
                                                                              
 
 
 
 
 
 
 
 
 
 
 
 
 (n= 1331) records identified 
through database searching 
Medline (n=428)      Embase (n=903) 
 
 
 (n=6) additional records identified through other 
sources 
 (n=2) from contact with expert     (n=4) from searching 
reference list 
 
  (n= 26) duplicate studies 
removed 
 
 (n= 1311) titles/ abstracts 
screened 
  (n=1254) records 
excluded  
 
  (n=57) of full-text articles 
assessed for eligibility  
 
 (n=12) of full text articles excluded: 
- (n=7) un-relevant population 
- (n=2) no relevant novel synthesis 
- (n=1) data duplicated from another 
study 
- (n=2): data analysis (reported 
prevalence in trends without 
providing prevalence in rates per se) 
 (n=45) of studies 
identified  
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4.8.5 Data extraction/quality assessment 
The data extracted from each study included data relating to, (1) methods (study 
design, recruitment, measurement tools, analysis), (2) participant characteristics, (3) 
setting, and (4) outcomes (those observed, their definitions, results of analysis). 
Study quality was assessed using a checklist adapted from the CRD guidelines as 
outlined in appendices 13 and 14 (96). As the identified studies were relatively few 
and heterogeneous, no study was excluded on the basis of quality alone; rather the 
assessment was used to inform synthesis. Data extraction was performed, in 
duplication, by two reviewers (L.A. and A.Mc), and disagreement regarding any 
study eligibility was resolved through consensus and seeking the opinion of the 
third reviewer (A. Mc). 
4.8.6 Data synthesis 
Data synthesis included summarising the results of the data extraction process, 
considering the strength of evidence relating to various questions formulated a priori 
(see „Results‟), and examination of results inconsistent with our formed proposals. In 
the cases of hypertension and dyslipidaemia, synthesis was limited by the number of 
studies identified, and in these cases description and discussion suffices. 
4.9 Results 
45 studies (43 papers ) 41, 99, 100, 102-123, 147-165 relating to risk factors and their 
prevalence were identified for review. All papers identified were journal articles 
published between 1987 and 2010. Five studies were carried out (where reported) 
and/or published in the late 1980s, 23 in the 1990s, and 15 in the last 10 years.  
Studies of various 20 Saudi, 7 Kuwaiti, 3 Bahraini , 8  Emirati , 4 Omani and 1 Qatari  
populations were included. All were cross-sectional studies; 23 of the general 
population, seven of primary care populations, four of school children, three of 
students, one of a young population, five of working populations. Females were 
exclusively studied in five cases, males in six.  Sample size ranged from 215 to 25337. 
 
In addition to examining the prevalence of the particular risk factors in the GCC 
states, I was interested in the following: 
1. trends in prevalence across time 
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2. differences by country 
3. trends in prevalence associated with age 
4. sex differences 
5. location (urban/rural) differences 
6. prevalence in children 
Only in the cases of overweight and obesity, and hyperglycaemia were study 
numbers sufficient that reasonable conjecture regarding subgroups could be made. 
They are considered separately, for each risk factor, below. 
4.9.1 Obesity/overweight 
33 studies addressed the prevalence of overweight/obesity (summarised in table 
twelve) 
4.9.1.1 Overweight and effect of date and country 
The reported prevalence rates of overweight (BMI 25 to < 30) in adults ranged from 
26.3 % to 48 % in males, 25.2 % to 35 % in females. Although higher values are 
displayed in table 10 , they have been scaled down for/omitted from comparison as 
either the definition of overweight used included the typical definition of obesity, or 
the prevalence was given only by age group, allowing the possibility that similarly 
high figures were masked in the age non-specific data of other studies. A lower 
value has also been omitted where the study population was particularly young 
(156).  Within these ranges, the data were fairly even distributed between the limits, 
and reported sex-non-specific prevalences were also consistent with these figures. 
The data showed no obvious trends or anomalies by date or country, although the 
data from Oman (two studies, reporting combined overweight/obesity rates) 
suggest prevalence there may be relatively low. 
4.9.1.2 Obesity and effect of date and country 
The reported general prevalence rates of obesity (defined as BMI > 30) in adults 
ranged from 13.05 % to 37 % in males, 16 % to 49.15 % in females (again a lower 
value has been omitted where the study population was particularly young; 154). As 
for the overweight data, the reported sex-non-specific data are consistent with these 
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figures, and potentially excepting the Omani data, show no obvious trends or 
anomalies by date or country. 
4.9.1.3 Obesity and overweight and age 
Age as a potential predictor of prevalence of overweight/obesity was considered in 
eight studies (of adult populations), and the results were tested for significance in 
two cases. These latter studies demonstrated correlation between 
overweight/obesity and age (112), and a significantly higher mean BMI in a 45 – 54 
years age group versus a 55 – 64 years age group (19). Similarly, all remaining 
studies indicated that prevalence increased with age to a threshold level (variably 
between 30 – 40 and 50 – 60 years (potentially younger in females) after which it 
began to fall, or fluctuate (149, 150, 155). 
4.9.1.4 Obesity and overweight and sex 
Most studies reported prevalence rates by sex, but only four tested for differences.  
Of these four, in all cases but one, BMI/prevalence of obesity and overweight was 
higher in females (154,104, 118), and where overweight was higher in males (111), 
the combined prevalence of overweight/obesity remained higher in females.  In the 
remaining studies, prevalence of obesity, and the combined prevalence of 
overweight/obesity was again always higher in females, although in some cases the 
„difference‟ was slight. 
4.9.1.5 Obesity and overweight and residential environs 
Six studies considered prevalence in urban versus rural populations. In three, mean 
BMI was found to be significantly higher in rural populations (114; 154). In a further 
two studies, prevalence of both overweight and obesity were significantly lower in 
rural regions (152; 16). This trend (with one subgroup exception (female obesity) was 
also observed where significance of differences was unclear (152). 
4.9.1.6 Obesity and overweight in national/expatriate populations 
Only one study considered prevalences in national versus expatriate populations. 
This reported that the combined prevalence of obesity and overweight was higher in 
Kuwaitis versus non-Kuwaitis (158). 
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4.9.1.7 Obesity and overweight in children 
In keeping with the association with age, prevalences in children/young people (< 
20 years) are lower than those in adult populations. However, there is a greater 
indication that prevalences in the younger populations are increasing. Single figure 
prevalences were reported until around 2000, and have not been observed since.  
The most recent reports (suggesting prevalences of combined overweight and 
obesity > 30 %) provide rates comparable to those in adults. Although less 
considered, there is again evidence for higher prevalences with increasing age in 
these relatively young populations (162, 148, although see 158), in urban areas (41) 
and in females (165, although see 41). 
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Ref/dates 
of study 
Population 
sampled 
Country Sample 
size 
Population characteristics Definitions Results 
% 
male 
Age (years; 
range unless 
specified) 
Residency 
status; area(s) 
of residence 
Overweight 
(if not 25 
to < 30) 
Obesity 
(if not 
> 30) 
Prevalence overweight (%) Prevalence obesity (%) 
Males Females Males Females 
Al-Isa/  
1980 – 
1981 
PC 
 
Kuwait 1171 0 18 to > 60 Kuwaiti 
nationals 
> 25   59.2  32.2 
Al-Isa / 
1980 – 
1981 
PC Kuwait 2067 43.3 18 to > 60 Kuwaiti 
nationals 
> 25  21.7 to 
69.4  (age- 
dependant) 
as Al-Isa, 
1997a (above) 
8.5 to 24.1  (age- 
dependant) 
as Al-Isa, 
1997a (above) 
Al-
Othaimeen 
et al / 1985 
– 1988 
GP KSA 17892 48.5 18 to < 61 Saudi nationals   30.7 28.4 14.2 23.6 
Al-Mannai 
et al/ 1991 
– 1992 
GP Bahrain 290 47.2 20  - 65 Urban/rural 
mix  
  26.3  29.4  16.0  31 
Al-Nuaim 
et al/ 1990 
– 1993 
GP KSA 13177 52 15 to > 60 Saudi nationals   33.1 29.4 17.8 26.6 
Al-Saif et 
al/ 1990 – 
1993 
PC KSA 3261 49.5 30 - 70 Saudi 
nationals; 
urban/rural mix 
  41.91 31.55 29.94 49.15 
Al-
Shammari 
PC KSA 1385 0 16 - 70 Urban/rural 
mix  
   26.8  47.0 
Table 12: Summary of overweight/ obesity 
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et al / 1992 
Musaiger et 
al/ NR 
 SP UAE 215 0 18 – 30 Emirati 
nationals 
   19   9.8  
Al-
Shammari 
et al/ 1994 
PC  KSA 1580 100 > 16 Urban/rural 
mix  
  34.8  28.6  
El-Hazmi 
et al/ 1993-
1994 
Military 
hospital 
KSA 1485 46.1 18 – 91 Saudi nationals  
 
 
 
40.1 31.5 21 40.5 
Al-Rukban 
et al/ 1993 
-1994 
WP* KSA 2990 NRoo < 25 to > 60 94.7 % Saudi 
nationals 
  30.3 24.5 
 
Jackson et 
al/1993 – 
1994 
PC
#
 Kuwait 1705 0  18 to > 60 Kuwaiti 
nationals 
> 25   72.9  40.6 
Jackson  et 
al/ 1993 – 
1994 
PC
##
 Kuwait 3435 50.3 18 to > 60 Kuwaiti 
nationals 
> 25  44.3  - 
75.1  (age- 
dependant) 
as Al-Isa, 
1997a (above) 
17.1- 35.6 (age- 
dependant) 
as Al-Isa, 
1997a (above) 
Al-Haddad  
et al/ NR 
SC UAE 4075 43.9 6 – 17 UAE nationals 
 
Overweight:  85th - 
95th percentile 
Obesity: > 95th 
percentile or BMI > 
30  
8.5 9.3 7.9 7.9 
Al-Turki / 
NR 
GP KSA 14660 42.0 14 – 70 Saudi nationals   27.23 25.20 13.05 20.26 
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Al-Hourani 
et al/ 1998 
– 1999 
SC UAE 898 0 11 - 18  Overweight: 85th – 
95th percentile 
Obesity: > 95th 
percentile 
 14  9 
Moussa et 
al / 1998 – 
2000 
WPo Kuwait 9755 48.0 Mean age + SD: 
Females: 33.3 + 
11.6; Males: 
29.2 + 8.2 
Kuwaiti 
nationals 
  38.3 32.8 27.5 29.9 
Malik et al/ 
1998 – 
1999 
SC UAE 4381 49.6 5 – 17 48.0 % UAE 
citizens; 81.7 
% urban  
IOFT criteria 
  
19.2 19.8 13.1 12.4 
Al-Asi et 
al/ 1998 – 
2000 
WPo Kuwait 740 100 45 – 80 Kuwaiti 
nationals 
    37  
Abdella et 
al/ 1999 – 
2000 
WP** Kuwait 3282 85 54 % < 40 62 % Kuwaiti 
nationals 
  48 27 
Sheikh-
Ismail  et 
al/ 1999 - 
2000 
GP
##
 UAE 724 0 20 to > 60 UAE nationals  30 – 40  27  16 
Al-Lawati 
et al/ 2000 
GP Oman 5838 49.8 20 to > 80 Omani 
nationals; 
urban/rural mix 
  28.9 18.5 
 
El-Hazmi / 
NR 
 GP KSA 11208 41.3 20 – 70 Saudi nationals  32.82 29.09 15.21 23.97 
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Summary of cross-sectional studies investigating the prevalence of overweight/obesity in the GCC region 
 
PC = primary health care-registered population; GP = general population; WP = working population; SC = schoolchildren; SP = student population; YP = young population 
 
* employees of Saudi National Guard and dependents; #attendees at primary health care centres with minor complaints, plus accompanying persons; oadult attendees of the 
Kuwait Medical Council and Public Authority for Social Security (government employed/retired population); **employees of Kuwait Oil Company; ##all subjects recruited 
via family member at UAE University; oo „mostly settled tribal men‟;  ***age-adjusted data 
Saadi et al/ 
1999 – 
2000 
GP UAE 5844 42.8 20 to > 65 UAE residents; 
'80 % urban'  
  48 35 24 40 
Al-Lawati  
et al/ 2000 
GP Oman 5847 48.8 20 to > 60  900 urban; 
4947 rural 
    19.1 
El-
Mouzan et 
al /2001 - 
2002 
YP 
 
KSA 894 100 
 
12 – 20    
 
 
 
13.8  20.5  
Baynouna 
et al/ 2004 - 
2005 
PC UAE 817 49.3 20 to > 60 UAE nationals     28.3 46.5 
Bener et al/ 
2007 – 
2008 
GP Qatar 1117 51.1 20 – 59 Urban/semi-
urban 
  31.9 
 
45.2 
 
El-Hazmi 
et al/2005 
SC KSA 19317 50.8 
 
5 – 18 Saudi nationals WHO 2007 criteria 
 
24.8 28.4 10.1 8.4 
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4.9.2 Hyperglycaemia 
17 studies reported on the prevalence of hyperglycaemia, as impaired glucose 
tolerance (IGT; 12 studies) impaired fasting glucose (IFG; 3 studies 119, 41, 102) or a 
high random capillary glucose (> 10 mmol/L). Generally, IGT was defined as 
venous plasma glucose > 7.8 and < 11.1 mmol/L 2h post glucose loading.  Where the 
WHO 1980 criteria were used, however, the IGT would be defined as venous plasma 
glucose 8.0 and 11.0 mmol/L 2h post glucose loading, and the study of Al-Moosa et 
al (122) involved capillary whole blood rather than venous plasma samples (see table 
13). Impaired fasting glucose (IFG) was consistently defined as a fasting venous 
plasma glucose > 6.1 and < 7.0 mmol/L. The studies of random capillary blood 
glucose and IFG are so few that interpretation is difficult. Additionally, the random 
glucose measurement figures are likely to include instances of transient/„stress‟ 
hyperglycaemia. Nevertheless, both are potentially consistent with the IGT results. 
4.9.2.1 Prevalence of IGT and age 
Broadly speaking, the relatively comprehensive study of IGT is suggestive of a 
recent and on-going increase in prevalence, with the latest published figures 
suggesting rates of perhaps 10 – 20 % in the adult population. Although there are 
some inconsistent figures (see Table 13), I consider that these could be accounted for 
by a combination of changes in prevalence across time and the ages of the studied 
populations. The studies of El-Hazmi et al (111) in particular reports an 
inconsistently low figure, but their sample was 39.1 % children and the authors 
report a significantly higher prevalence with increasing age, although I could not 
access the full data and the statistics were not described. Similarly, the other 
relatively young populations are those wherein reported prevalences are relatively 
low.  Furthermore, of all studies reviewed (including those of random blood glucose 
and IFG), five considered the effect of age on prevalence (148, 149, 109, 110, 103). All 
found the prevalence was higher with advancing age, and in all cases where tested 
(three cases), the relationship was found to be significant (148, 149, 109). 
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4.9.2.2 Prevalence of hyperglycaemia by country 
There was no obvious discrepancy in prevalence by country, but the number of 
studies available prohibited a reasonable comparison. 
4.9.2.3 Prevalence of hyperglycaemia by sex 
Thirteen studies reported differential prevalence rates by sex, although not all 
considered the strength of sex differences. The majority of studies (ten) suggested a 
higher prevalence in females (107, 100, 109, 110, 114, 103, 41, 120, and 123). Two 
demonstrated a significantly higher prevalence (41, 107). Conversely, two studies 
(152, 106) showed a higher prevalence in males (one significantly so; 99), and one 
demonstrated no sex difference (115) 
4.9.2.4 Urban/rural residence and prevalence of hyperglycaemia 
Only one study reported prevalence according to urban versus rural residence (107). 
Prevalence was higher in urban areas. 
4.9.2.5 Prevalence of hyperglycaemia by residential status 
No studies reported on effects of ethnicity, or on the prevalence of hyperglycaemia 
in national versus expatriate populations. 
4.9.2.6 Hypertension and dyslipidaemia 
Only few of the identified studies investigated the prevalence of hypertension (124, 
113, 41, 119, 121, 120) and dyslipidaemia (121, 117, 113, 149). Moreover, variable or 
ill-defined definitions of the diagnosis were used in each case. 
4.9.3 Hypertension 
I identified eight studies that included an assessment of hypertension (114, 153, 117, 
41, 119, 121, 120, 123).The definitions of hypertension employed ranged from > 
140/> 90 mmHg to >160/95 mmHg, and variably included those on 
antihypertensive medication. Additionally, one study (114) depended upon a 
previous (un-described) diagnosis.  Reported rates of hypertension ranged from 6.6 
to 33.6 %. Potentially prevalence has been increasing since 1993/1994 (when the first 
identified studies were undertaken). 
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4.9.4 Dyslipidaemia 
Dyslipidaemia was considered in six studies (114, 148, 149, 117, 120, and 123). 
Dyslipidaemia was defined as: cholesterol > 5.2 mmol/L, cholesterol > 5 mmol/L, 
high density lipoprotein (HDL) < 1.0 mmol/L, low density lipoprotein (LDL) > 4.1 
mmol/L, triglycerides (TG) > 2.3 mmol/L, or a previous (undescribed) diagnosis. 
Reported rates of dyslipidaemia ranged from 2.7 – 51.9 %. This relatively large range 
is potentially partially due to increasing rates across recent years, to consideration of 
different aspects of the lipid profile in different studies and to differing definitions of 
abnormality. Additionally, in the study reporting the very lowest prevalence 
(114)diagnosis was established by „previous diagnosis‟ alone, and thus allowed no 
assessment of the extent of undiagnosed cases. 
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Ref/dates of 
study 
Country  Population 
sampled 
Sample 
size 
Participant characteristics Diagnostic criteria Results (prevalence; %) 
% 
male 
Age range 
(years) 
Residency 
status; area(s) of 
residence 
IGT Hyper-
glycaemia 
IFG IGT Hyper-
glycaemia 
IFG 
Abu-Zeid and 
Al-Kassab / 
1989 
KSA GP 3131 49.4 10 to > 60 98 % Saudi 
nationals; 
„semiurban-
rural'  
2-hour 
fasting 
post-meal 
CBG 7.8 - 
11 mM 
  3.7 
 
  
El-Hazmi et al 
/ 1991 
KSA GP 2060 48.5 14 to > 60 Saudi nationals WHO 
1980/ 1985 
  Males: 0.6 
Females: 1.2  
  
El-Hazmi et al 
/ 1991 
KSA GP 23493 46.1 2 - 70 Saudi nationals WHO 
1980/ 1985 
  Males: 0.49 
Females: 0.9 
  
Al-Nuaim et 
al/ 1990 – 
1993 
KSA GP 
 
31322 52 15 to > 60 Saudi nationals WHO 1985   Urban males: 10  
Rural males: 8  
Urban females: 
11 
Rural females: 8  
  
Asfour et al/ 
1991 
Oman GP 6918 41.9 20 to > 80 Urban/ rural 
mix 
WHO 1985   Males: 8.1 
Females: 12.9 
  
Al-Mahroos et 
al/ 1995 – 
1996 
Bahrain GP 7997 58.6 males 40 – 59  
females: 50 – 69 
Bahraini 
nationals 
WHO 1985   17.9    
Table 13: Summary of hyperglycaemia prevalence data 
 
85 
 
 
Summary of cross-sectional studies investigating the prevalence of (non-diabetic) hyperglycaemia in the GCC region  
El-Hazmi et 
al/NR 
KSA GP 76112 46.2 < 14 to > 60 Saudi nationals WHO 
1980/ 1985 
  0.62    
Al-Nozha et 
al/ 1995-2000 
KSA GP 38312 47.6 30 – 70 Saudi nationals   ADA 
1997 
  14.1 
Moussa et al/ 
1998 – 2000 
Kuwait  WP
# 9755 48 18 – 80 
 
Kuwaiti 
nationals 
 random 
CBG  > 
10.0 mM 
  Males: 
8.25 
Females: 
362  
 
Al-Asi et al/ 
1998 - 2000 
Kuwait  WP
#
 703 100 45 - 80 Kuwaiti 
nationals 
 
 random 
CBG > 
10.0 mM 
  26  
Saadi et al/ 
1999-2000 
UAE GP 6611 42.7 24 to > 65 UAE residentso; 
'80 % urban' 
WHO 1999  WHO 
1999 
  Males: 4.5  
Females: 8.0  
Al-Lawati  / 
2000 
Oman GP 5838 49.8 20 to > 80 Omani 
nationals; 
urban/ rural mix 
  FPG > 
6.1 and 
< 7 
mM 
  Males:7.1 
Females: 5.1  
Saadi et al/ 
2005-2006 
UAE GP 7118 49.1 18 to > 70 UAE nationals; 
urban 
WHO 1999   20.2   
Bener et al/ 
2008 - 2009 
Qatar PC 3332 51.1 20 - 59 Urban/ „semi-
urban‟ 
WHO 2006   12.5    
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WP = working population; GP = general population; PC = primary health care-registered population; NR = not reported; KSA = Kingdom of Saudi Arabia; UAE = Unites 
Arab Emirates; WHO = World Health Organisation; ADA = American Diabetes Association; CBG: capillary blood glucose; IFG = impaired fasting glucose; IGT = impaired 
glucose tolerance 
* government/municipal salaried workers; # adult attendees of the Kuwait Medical Council and Public Authority for Social Security (government employed/retired population); o selection 
of subjects intentionally biased towards UAE citizens .
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4.10 Discussion 
I found the prevalence of overweight to be 25 – 50 %, obesity 10 – 50 %, relatively 
high in females and higher with advancing age to threshold levels between 30 – 40 
and 50 – 60 years.  Prevalence was also found to be high in children, and appeared to 
be increasing in this group. I estimated, from relatively recent reports, the prevalence 
of hyperglycaemia in adults (using IGT as the outcome measure) to be 
approximately 10 – 20 %.  Prevalence of hyperglycaemia appears to have been 
increasing across recent years, and higher prevalence again showed an association 
with advancing age and female sex. There has been relatively little research of the 
prevalences of hypertension and dyslipidaemia in the GCC region and a lack of 
consistency in definitions used for study. Accordingly, estimates of prevalence vary: 
between 6.6 and 33.6 % for hypertension, between 2.7 and 51.9 % for dyslipidaemia, 
and it is unclear what additional factors may have impacted on these ranges. 
 
Potentially, the prevalences of hypertension and dyslipidaemia are increasing, which 
would be in keeping with a more widespread trend (e.g. 166-168). The increasing 
prevalence of hyperglycaemia is similarly in keeping with trends reported 
elsewhere. By contrast, we observed no obvious temporal trend in prevalence of 
overweight and obesity in adult populations, which is not in keeping with reports 
from elsewhere, and despite a relatively well established association with diabetes 
(both epidemiologically (1; 166-169) and pathophysiologically). Importantly, though, 
particular authors have noted a rising prevalence within the relatively well 
controlled environments of their own studies (170, 171), and several of the reviewed 
studies did demonstrate correlation between BMI, and overweight and obesity, and 
diabetes or blood glucose concentration (103; 105; 148). Moreover, the observed 
prevalence of overweight and obesity by age, increasing with advancing age until a 
plateau or decline in middle and older age, is suggestive that overweight and obesity 
may be an important risk factor for diabetes.  
 
I noted differences in the patterns of spread of diabetes and obesity and overweight 
in the GCC region. For example, the observed bias of obesity and overweight to the 
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female population is not obviously replicated in the population distribution of 
diabetes (unpublished data), demonstrating that additional aetiological factors may 
hold important roles in the current expansion of the diabetes problem. 
4.10.1 Limitations of study 
I reported above that individual studies included in our review demonstrated recent 
temporal trends in prevalence of overweight and obesity, even though this was not 
clear from our overview of studies. This is probably illustrative of the general 
heterogeneity of the reviewed studies.  The studies reviewed were relatively few and 
distributed across many years. They were of varied population characteristics, in 
different regions of six countries, and the utilised definitions of particular risk factors 
were inconsistent. I was thus able to make only relatively crude observation, and 
could not provide measures of confidence in our outcomes. The quality of reporting 
of results in the examined studies was also variable. For example, many studies did 
not report confidence intervals or had missing data for key variables. This reinforces 
the need for authors of risk factors studies to use standard methods for reporting the 
results such as STROBE guidelines. 
 
Although quality was variable, it was never alone a reason for exclusion.  Quality 
was, rather, incorporated into building the estimations of ranges for normal versus 
abnormal among the results returned. This was difficult due to the wide variability 
in these results, and the potential for bias has implications for the strength of the 
proposals.  In addition, I may have increased bias by duplication of included data., 
as it is anticipated  that the female sample of one Al-Isa study (146)  is that included 
in the mixed sample of another (147), and the male sample of Jackson et al, 2002 
(148) that included in the sample of Jackson et al, 2001 (149). Finally, all of the 
reviewed studies were published in English, although I had no language restriction. 
Hence, I may have limited capture of publications in other languages due to the 
databases I searched. 
4.10.2 Implications  
I consider the need for further study to identify the major contributory factors to the 
current diabetes problem in the GCC region, and of factors such as hypertension and 
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dyslipidaemia that compound the risks of diabetes, an important outcome of our 
review.  The limited number and heterogeneity of existing studies pose difficulties 
for targeting, designing and developing potential management strategies. The 
relatively high levels of hyperglycaemia, and obesity and overweight (and 
potentially of hypertension and dyslipidaemia) observed – and their possible rising 
prevalence – are indicative that current management is insufficient. The reviewed 
data are suggestive that age and urban residence may be risk factors for, at least, 
overweight/obesity and hyperglycaemia. Enhanced management is thus crucial to 
prevent escalation of the problems as urbanisation and changing population 
demographics continue. 
 
It would be useful to determine that the situation is similar across the various GCC 
states. This is likely but cannot be confirmed from the data reviewed here. If so, 
expansion of existing management strategies, and co-ordination of novel strategies, 
across the region, would probably be relatively successful and relatively cost-
effective. The likely contribution made by overweight/obesity to the diabetes 
problem in the GCC region is suitable for management, at least in part, by primary 
preventative measures, which we anticipate would also be relatively cost effective. 
4.11 Conclusions 
Prevalence of overweight and obesity in the GCC region is high and the ages of 
those affected suggest it may be a relatively important factor in the growing diabetes 
burden in this region. Further the study aimed at elucidating its relative contribution 
to the diabetes problem is desirable, but regardless the reviewed data are suggestive 
that implementation and enhancement of primary preventative strategies in 
particular would be useful in the management of T2DM in the GCC region. The 
current prevalence of hypertension and dyslipidaemia are unclear, but potentially 
relatively high compared to many other parts of the world. More comprehensive 
study of their prevalence is desirable, and standardisation of definitions of these 
conditions will be important if further study is to be maximally useful. Primary 
preventative strategies may also be useful in managing these conditions. 
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Section three: Quality of T2DM management in the states of the GCC 
 
This section presents the systematic review carried out on the quality of T2DM 
management in the GCC countries. It involves the following: introduction, methods 
(review questions, inclusion/ exclusion criteria, search, study selection process, data 
extraction, quality assessment, and data synthesis), results, discussion including 
limitations and implications of the review, and finally conclusion. 
4.12 Introduction 
DM is a chronic disease characterised by insufficient insulin production and/or 
insulin resistance. Through its various complications and a widespread high 
prevalence (1). Diabetes is a major public health issue, carrying huge societal and 
economic, as well as personal, costs and risks. This has been acknowledged by the 
United Nations through Resolution 61/225 (2006), which issued a call for Member 
States to implement strategies to address the burden of diabetes in their societies. 
4.12.1 T2DM in the Gulf region 
The states of the GCC exhibit some of the highest rates of T2DM in the world. Five of 
the IDF‟S „top 10‟ countries for diabetes prevalence in 2010 and in 2030 are projected 
to be in this region (1). The anticipated prevalences for diabetes 2010-2030 in the Gulf 
countries are: UAE 18.7-21.4%, Kingdom of Saudi Arabia (KSA) 16.8-18.9%, Bahrain 
15.4-17.3%, Kuwait 14.6-16.9% and Oman 13.4-14.9% (1). 
4.12.2 Responding to the T2DM problem 
Many countries have responded to the concerns about T2DM by producing and 
implementing national diabetes programmes (at the suggestion of the World Health 
Assembly, aided and monitored by the IDF). The IDF suggests Oman, Kuwait and 
Bahrain have all implemented national diabetes programmes (with no data available 
for the UAE and KSA, and no national diabetes programme in Qatar) (1). The UAE, 
however, published national guidelines in 2009 (172).  I have not been able to 
determine that the KSA has a national programme, but note that it produces by far 
the greatest research output on diabetes among the GCC countries. For all countries, 
the extent and timings of programme implementation are unclear, and in many cases 
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the content of the programmes also. Although the IDF suggests various dimensions 
that a national diabetes programme would ideally include, there are no particular 
suggested standards in any of these themes (1).  Although this reflects the need for 
locally tailored programmes, it perhaps also reflects that there are no standardised 
desired clinical outcomes, even in relatively well-studied populations. Both the 
extent and efficacy of current diabetes management in the GCC region is thus 
unknown. 
4.12.3 Review aims 
The aim of this review was to examine the current quality of management of T2DM 
in the member states of the GCC. Unchecked, the chronic hyperglycaemia of 
diabetes is associated with various adverse macro- and micro- vascular outcomes.  
Glycaemic-, blood pressure- and lipid- control were used as indicator outcomes as 
they are relatively well established correlates of adverse vascular sequelae; 
preliminary searches suggested these were relatively frequently considered 
outcomes; and they are widely incorporated into national guidelines e.g. (69, 70, 173, 
174). I aimed to, wherever possible, specify results according to age and gender, as 
evidence indicates that age/gender specified sub-populations with specific disease 
prevalences and characteristics or severity may exist, and thus that these populations 
may benefit from differential management strategies. Due to the heterogeneity of 
studies identified on preliminary searching, there was no anticipated meta-analysis. 
4.13 Methods 
4.13.1 Ethics assessment 
Ethical approval was not needed as this study was a systematic review, with no 
primary data collection. 
4.13.2 Review questions 
A systematic literature search was carried out to identify information relevant to the 
following review questions: 
1. How good is current control of T2DM in the GCC region, based on 
glycaemic-, blood pressure- and lipid- control indicators? 
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2. Have implemented strategies (including public health/preventative 
strategies) improved management of T2DM in GCC countries? 
4.13.3 Search 
I developed a systematic review protocol (See appendix 15) using the CRD 
guidelines (96). The Medline and Embase databases (via Dialog and Ovid, 
respectively; 1950 to July 2010 (Medline), and 1947 to July 2010 (Embase) were 
searched separately on 15/07/2009 and the search was updated on 08/07/2010. The 
search was carried out using terms identified from PICOS deconstruction of the 
above review questions, and database- and manually- derived alternatives (see 
appendix 14). Keywords used in the search strategies reflected the quality of 
management of T2DM and blood pressure, lipids and glucose in the GCC such as 
DM, non-insulin-dependent, hyperglycaemia, hypertension, hyperlipidaemia and 
Gulf States. The search strategy (see appendix 15) was trialled, reviewed by 
independent professional colleagues (E.H, K.P), and updated (on 02/02/2010) before 
use. Further relevant studies were identified by searching the reference lists of the 
database-derived papers, contacting expert investigators, screening conference 
proceedings including those of The International Conference on Recent Advances in 
DM and Its Complications 2006 and Gulf Research Meeting 2010, citation searching 
and hand searching the available online contents of the International Journal of 
Diabetes and Metabolism and the Saudi Medical Journal, between the  periods 1993- 
2009 and 2000- 2010, respectively. 
4.13.4 Selection  
The search yielded 788 studies. The titles and abstracts were evaluated by one 
reviewer to determine eligibility for full screening.  Studies that utilised designs 
from a pre-determined list of acceptable methods - including randomized controlled 
trial and observational study (cross sectional, quasi-experimental and interventional) 
- were included. All studies wherein glycaemic-, blood pressure- and/or lipid- 
control were investigated (clinical and/or process outcomes) were eligible for 
inclusion. In addition, any study describing primary preventative measures was 
eligible. No limitations on publication type, publication status, study design or 
language of publication were imposed. However, I did not include secondary 
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reports such as review articles without novel synthesis. The inclusion criteria 
demanded that the study population be people with diabetes (at least predominantly 
type 2; unless a study relating to primary prevention), and of a GCC country. All 
ages, sexes and ethnicities were included, resident and expatriate populations, urban 
and rural, of all socioeconomic and educational backgrounds.  General population 
studies and studies at all healthcare levels were included. 33 studies were identified 
as suitable for full review, and were each considered by two reviewers.  Six studies 
were excluded, by consensus, either because data were not (fully) available, or 
because the reporting left us unable to assess, sufficiently, study quality (see figure 
nine). 
4.13.5 Data extraction/quality assessment 
The data captured for each study included data relating to, (1) methods (study 
design, recruitment, measurement tools, and analysis), (2) participant characteristics, 
(3) setting, and (4) outcomes (those observed, their definitions, results of analysis, 
length of follow-up).  Study quality was assessed using a checklist adapted from the 
CRD guidelines (see Appendix 16) (96). Data extraction was performed, in duplicate, 
by two reviewers. Any disagreements were resolved by discussion with a third 
reviewer.  
4.13.6 Data synthesis 
Data synthesis included summarising the results of the data extraction process, 
considering the strength of evidence relating to each of the questions, and 
examination of results inconsistent with our formed proposals. Synthesis was 
limited by the numbers of studies, particularly in consideration of the identified 
quasi-experimental studies (see „Results‟), and thus for this set of data, description 
and discussion suffices. 
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Figure 9: Flow chart of study selection process. 
 
 (n= 788) records identified through 
database searching 
Medline (n=361)      Embase (n=427) 
 
 
 (n=4) additional records identified through other sources 
 (n=2) from contact with experts     (n=2) from searching 
reference lists 
 
  (n= 770) records after 
duplicates removed 
 
 (n= 770) titles/ abstracts 
screened 
  (n=737) records excluded  
 
  (n=33) full-text articles 
assessed for eligibility  
 
 (n=6) full text articles excluded: 
- (n=1) full access to the study 
un- available 
- (n=2) methodological 
assessment 
- (n=2) full access to data un-
available 
- (n=1) data analysis 
 (n=27) studies included in 
the review  
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4.14 Results 
I identified 27 journal-published studies for review: 21 cross-sectional (108, 116, 120, 
121, 165, 175-191) and 6 quasi-experimental studies (192-197). 
4.14.1 Cross-sectional studies 
The cross-sectional studies included one undertaken in 1988/1989, 2 in the 1990s, the 
remainder from 2000 onwards. The studies were carried out in KSA (14), UAE (3), 
Bahrain (3) and Oman (1). In all but one study, wherein subjects with diabetes were 
identified through a general population screening (121), studies were carried out in 
primary care or hospital environments. All involved retrospective review of patient 
records, and a very small minority included a prospective component. Identification 
of individuals with diabetes was in all cases by previous diagnosis. In some cases, 
diagnosis of T2DM was specified; otherwise the populations were mixed diabetic 
populations of predominantly T2DM.  Sample size ranged from 30 – 1236. 
 
I identified fifteen studies of each of glycaemic- and blood pressure- control, and 
eleven of lipid control. In all cases, the lack of standardised targets for these outcome 
measures was reflected in a heterogeneous collection of definitions of control. Data 
that would allow comparison of subgroup outcomes were generally not available. 
4.14.1.1 Glycaemic control 
The identified studies of glycaemic control are summarised in tables 14, 15, 16 and 
17.  One study investigated process measures alone (although several additional 
studies included these). 12/15 studies that reported clinical outcomes considered 
HbA1c levels, 6/15 fasting blood glucose (one fasting blood glucose as a sole 
measure), and 3/15 „post-prandial‟ blood glucose levels (one post-prandial glucose 
and fasting blood glucose alone). 
 
With regard to clinical outcomes, target levels of HbA1c were almost always < 7 %, 
whereas the definition of „poor control‟ was more variable, but generally more than 
at least 8 %. „Good control‟ by fasting blood glucose and post-prandial blood glucose 
were < 7 mmol/l and < 9 mmol/l, respectively.  Fasting blood glucose > 8 mmol/L 
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and post-prandial glucose > 10/11 mmol/L were considered „poor control‟.  Process 
measures variably required documentation of fasting blood glucose/HbA1c testing 
within the study period, or within the previous 6 or 12 months. 
 
The data of glycaemic control was summarized based on the source of care 
provided: primary, secondary, university and private hospitals.   
Results from the primary care are summarized in table 14. The range of achieving 
HbA1c target < 7% was between 6.6% and  33.3% in the seven studies included ; 
however in one of these studies carried out by Al-Shammari et al 60.6% of the 
sample achieved the defined target of HbA1c <8% (155). Frequency of 
documentation of process of care ranged between 73% and 98% in the primary care 
settings.  
Two studies assessed the care provided in secondary settings. HbA1c targets < 7% 
was achieved in 21.8% in one of these studies, and in the second study 77.2% of the 
sample had HbA1c >8.8% as summarised in table 15.  
Five studies assessed the care provided in university hospitals as outlined in table 
16. In three studies HbA1c was recorded (e.g. <7% was achieved by 45% of the 
sample of Afandi et al (180) and 6-8% was achieved by 34% of the sample of Qari 
(181)). However, in the third study carried out by Al-Ghamdi 77% of the participants 
had HbA1c >8%. Frequency of documentation of process of care ranged between 
49% and 97% in the university hospitals (178). 
One study assessed the care provided in private hospitals as outlined in table 17. 
HbA1c < 6 was achieved by 14 %, and HbA1c 6 – 8% was achieved by 40 % of the 
sample. The frequency of documentation of process of care was not reported.  
Plotting the values across time, there was no obvious indication of recently 
improving/declining control. Process measures were less commonly investigated, 
and of variable outcome (0.4 – 98 % achieved). 
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Ref/dates of 
study 
Setting Country Sample size Population characteristics Outcomes and results Study limitation 
% 
male 
Age Glycaemic control indicators  Process outcomes (frequency 
of documentation) 
 
Mean (SD) Range HbA1c levels 
(%) 
 
FBG levels 
(mM) 
 
Post-prandial 
glucose levels 
(mM) 
HbA1c 
levels 
FBG 
levels 
Post-
prandial 
glucose 
levels 
Al-
Shammari et 
al / 1993 - 
1994 
PC KSA 365 NR  
 
„All ages‟ < 8.1: 60.6 %; 
8.1 – 11: 32.2 
%; > 11: 7.1 
% 
     -potential of selection of less severe 
cases 
- potential for non-standardised 
treatment 
-potential for non-standardised 
measurement of reported outcomes 
Khorsheed 
et al / 1998 - 
2000 
PC KSA 138 69.6  
 
Mean:  
Males: 49.7 
Females: 
53.4 
    73 % 98 % 
 
 -very specific population ( employees 
of National Guard) 
-selection bias (single visits/not seen 
after Jan 2008 excluded ;potentially 
individuals with less severe disease 
Al-Turki / 
2000 - 2001 
PC KSA 1236 57.4   < 15 to > 
60 
 
 
> 10: 49.2 
%; 7 - 10 : 
28.9 %; < 7: 
14 %  
 0.4% 92.1 %  -potential for lack of standardised 
measurements 
-sampling methods for the health care 
centres and subjects not clear 
-study limitations not discussed 
Al-Hussein  
/ 2003-2004 
PC KSA 651 45.5 53.2 + 11.7  Mean ± SD: 
9.0 ± 2.0; < 7: 
20.6 % 
Mean ± SD: 
9.9 ± 3.9  
Mean ± SD: 15.0 
+ 5.3  
55.4 %  
 
64 %  
 
61 % -potential for non-standardised 
treatment, measurement of reported 
outcomes 
- study limitations not discussed 
Saadi et 
al/2005 - 
2006 
PC UAE 245 44.9   18 to > 70 <7: 33.3 %   (within 1 
year): 91 
% 
  -data from  subjects in Al-Ain might 
not be typical for all individuals in 
other Emirates 
-potential of under- or overestimation 
of the reported rate of DM diagnosis 
(10.2%) based on disease reporting rate 
-% of subjects  out of those sampled 
households (2455) was underwent 
Table 14: Summary of glycaemic control in primary care settings 
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testing was small 
Al-Kaabi  et 
al / 2006 
PC UAE 409** 39 51.44 + 11.2  < 7: 31.1 %; 7 
– 8: 19.6 %;  
8 – 9: 16.7 %;  
> 9: 32.6 % 
     -limited details on sampling process 
Al-Elq / 
2006 
PC KSA 353 NR 
 
51.6 + 10.8  Mean + SD: 
8.2 + 1.89; < 
7: 27 % 
  (within 6 
months): 
81 % 
  - characteristics of population not  
-non-standardised lab assays 
- lack of actual assessment of DM 
complications --lack of evaluation of 
barriers for not achieving glycaemic or 
cardiovascular  risk factor targets 
- lack of calculation of direct and 
indirect economic burden of DM 
 
PC = primary care; NR = not reported 
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Ref/dates of 
study 
Setting Country Sample 
size 
Population characteristics Outcomes and results Study limitation 
% male Age Glycaemic control indicators  Process outcomes (frequency 
of documentation) 
 
Mean 
(SD) 
Range HbA1c levels 
(%) 
 
FBG levels 
(mM) 
 
Post-prandial 
glucose levels 
(mM) 
HbA1c 
levels 
FBG 
levels 
Post-
prandial 
glucose 
levels 
Famuyiwa 
et al / 1988 - 
1989 
SC KSA 1000  54.2  
 
 1 – 98 > 8.8: 77.2 % 
 
     -selection process and data collection 
not well described 
Kharal et al 
/ 2005- 
2006 
SC KSA 1188 38.5 All ≥ 30 years Mean ± SD: 9 
± 2; < 7: 21.8 
% 
Mean: 10 ± 
4.2; < 7: 25.0 
% 
 81 %   95 %  -specific population  (Saudi national 
guards and their dependents) 
 
 
SC: secondary care 
 
 
 
 
 
 
 
 
 
 
Table 15: Summary of glycaemic control in the Secondary care settings 
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Ref/dates of 
study 
Setting Country Sample 
size 
Population characteristics Outcomes and results Study limitation 
% male Age Glycaemic control indicators  Process outcomes (frequency 
of documentation) 
 
Mean 
(SD) 
Range HbA1c 
levels (%) 
 
FBG levels 
(mM) 
 
Post-prandial glucose 
levels (mM) 
HbA1c 
levels 
FBG 
level
s 
Post-
prandial 
glucose 
levels 
Akbar/ 1999 
- 2001 
UH 
 
 
 
KSA 443 49  54.8 ± 
16.2 
  Mean + SD: 
9.7 ± 3.2 
(38 % < 7 : 
11 % 7.1 – 
8: 51 %; > 
8: 51 %)  
Mean + SD: 13.75 ± 5.5 
(22 % < 9: 7 % 9.1 – 10; 
71 % > 10) 
   -sample selection method not clear 
-limitations of the study not discussed 
Al-Ghamdi / 
2002 - 2003 
UH  KSA 130 41.6   15 - 80 > 8: 77 % > 8 : 69 % > 11: 69% 49 %   -data analysis not well reported 
-selection bias (some T1DM included) 
 
-sample inclusion criteria was not clear 
- study limitations not discussed 
 
Qari / 2005 UH 
 
KSA 200 :30  
 
UH: 47 
+ 14 
 
  mean ± SD: 
7.8 ± 1.8; < 
6: 24 %; 6 – 
8: 34 %  
 
     -selection method of hospitals was not 
clear 
-study limitations not discussed 
 
 
Al-Shaikh / 
Not reported 
UH KSA 392 6.5 
 
46.3  
 
  mean: 9.89; 
< 7: 11.5 % 
 
Mean: 10.5 
 
   -sample selection process not reported 
-extent of co-morbidities e.g. smoking 
status in different populations not noted 
-unclear statistical tests used  
Afandi  et al 
/ 2005 
UH UAE 30 40  All > 18  < 7: 45 %   97 %   -small sample size (30) 
-sampling method not clear 
- potential for non-standardised 
measurement 
 
UH: university hospital 
Table 16 : Summary of glycaemic control in university hospitals 
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PH  = private hospital 
Ref/dates of 
study 
Setting Country Sample 
size 
Population characteristics Outcomes and results Study limitation 
% 
male 
Age Glycaemic control indicators  Process outcomes (frequency of 
documentation) 
 
Mean 
(SD) 
Range HbA1c 
levels (%) 
 
FBG levels 
(mM) 
 
Post-prandial glucose 
levels (mM) 
HbA1c 
Levels 
FBG 
levels 
Post-prandial 
glucose levels 
Qari / 2005 PH 
 
KSA 200  46  49.4 + 
13.7 
 mean ± SD: 
7.8 ± 1.78; 
< 6: 14 %; 6 
– 8: 40 % 
     -selection method of hospitals was not 
clear 
-study limitations not discussed 
 
 
Table 17: Summary of glycaemic control in a private hospital 
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4.14.1.2 Blood pressure control 
The identified studies of blood pressure control (176, 177, 179, 181-183, 123, 141, 185-
190) are summarised in table 18. One study considered only process measures. Three 
studies provided only rates of hypertension (of variable definition) as an outcome. 
The remainder provide (at least) rates of „well-controlled‟ blood pressure, of more 
consistent definition.  Rates of poor blood pressure control were reported as either: 
1. A basic record of „current‟ rates of hypertension, or 
2. Documentation of all (cumulative) rates of treated and untreated 
hypertension 
There may therefore be discrepancies where hypertension assessment is not 
standardised and where cases of well-controlled hypertension exist. This hinders 
comparisons already complicated by differential lengths of diabetes diagnoses. It 
seems clear, however, that blood pressure targets, however described by the study 
authors, are far from met.  The < 130/< 80 mmHg or < 130/< 85 mmHg targets were 
met in between 6.8 % and 32 % of patients with a history of hypertension, and 
between 14.2 and 42.1 % of the remaining samples, with one exception. Target blood 
pressure was met in 83 % of the sample of Afandi et al (180). 
 
Rates of hypertension – of both cumulative and non-cumulative measures, and of 
various criteria were frequently between 30 – 60 %. Although only recorded in three 
studies, documentation of blood pressure checks suggested they were rigorously 
carried out, with almost 100 % documentation of blood pressure measurement 
achieved.
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Table 18: Summary of BP control 
Ref/dates 
of study 
Setting Country Sample 
size 
Population characteristics BP control indicators results (units 
of all BP measurements = mmHg) 
Process 
outcomes 
(Frequency of 
BP 
documentation) 
Study limitations 
% male Age  Additional 
information 
BP<130/80 BP<130/85 BP>130/80 
Mean 
(SD) 
Range 
Famuyiwa 
et al / 
1988 - 
1989 
TC  KSA 1000  54.2   1 - 98 77.7 % Saudi 
nationals 
    -sample selection method 
not clear  
-data analysis not well 
described  
(variable n-numbers for 
each outcome) 
- unconventional definition  
of overweight/obesity 
-limitations of the study not 
discussed 
Khorsheed 
et al / 
1998 - 
2000 
PC KSA 138 69.6    Mean 
(males): 
49.7  
Mean 
(females): 
53.4 
 Saudi nationals 
 
   100 % - results may not be 
generalisable (population = 
employees of National 
Guard) 
-potential for selection bias 
(single visits/those not seen 
after Jan 2008 excluded) 
-potentially individuals with 
less severe disease selected 
-limitations of the study not 
discussed 
Sequeira 
et al / 
2001 
PC Bahrain 266 30.8  58.4 + 
10.8*** 
 Hypertensive 
population 
 9.8 %;     - potential for selection of 
less severe cases 
-limited data on population 
characteristics (e.g. 
ethnicity and co-
morbidities) 
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Al-Khaja 
et al/ 
2001 
PC  Bahrain 357 GP 
clinics: 
27.2  
Diabetic 
clinics: 
34.5 
GP 
clinics: 
58.1 + 
10.5  
Diabetic 
clinics: 
54.8 + 
10.8 
 Hypertensive 
population 
 Diabetic 
clinic6.8 % 
GP Clinic:  
:10 % 
  -limited data on population 
characteristics (e.g. co-
morbidities, ethnicity, BMI) 
-potential for selection bias 
(diabetic clinics for more 
severe cases; patients at GP 
clinics older) 
-study limitations not 
discussed 
Al-Ghamdi 
/ 2002 - 
2003 
UH KSA 130 41.6   15 – 
80 
69% non-Saudi   BP > 
140/90: 
41.5 % 
 -data analysis not well 
reported 
-selection bias (some T1DM 
included) 
Al-Khaja 
et al/ Not 
reported 
PC 
 
Bahrain 220 36.4  54.9 + 
10.7 
 Hypertensive 
population 
 7.5 % 
 
  - control of DM not 
included as hypertensive 
population only 
-study limitations not 
discussed 
Al-Shehri/ 
2003 – 
2004 
PC KSA 403 55.8   29 - > 
60 
98.6 % Saudi; 
military 
personnel and 
dependants 
14.2 %    - results may not be 
generalisable (population = 
attendees of King Fahd 
Military Hospital) 
-study limitations not 
discussed 
Qari / 
2005 
UH KSA 200* UH: 30 
PH: 46  
 UH: 47 + 
14  
PH: 49.4 
+ 13.7 
 UH: 51 % Saudi 
PH:62 % Saudi 
     -limited data re study 
population 
Afandi et 
al/ 2005 
TC UAE 30 40  All > 18     at most recent 
appointment: 
100 % 
-small sample size 
-sampling process not clear 
Kharal et 
al/ 2005- 
2006 
TC KSA 1188 38.5  All ≥ 30 Saudi National 
Guard 
employees and 
dependants 
39.1 % 
 
  99 % 
documented BP 
result during 
period of 
interest 
- results may not be 
generalisable (sample from 
King Fahd Military Hospital ) 
-lack of  data re retinopathy 
screening, foot examination 
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and neuropathy 
Saadi et al 
/2005 - 
2006 
GP UAE 245 44.9  18 to 
> 70 
UAE nationals, 
urban 
residents 
42.1% 
 
   -sampling process not well 
described 
Al-Kaabi 
et al/ 
2006 
PC  UAE 409** 39  51.44 + 
11.2 
 50.4 % 
illiterate 
  53.7 %  -sample selection method 
not clear 
-study limitations not 
discussed 
Al-Elq  
/ 2006 
PC KSA 353 NR  51.6 + 
10.8 
 84 %  
'Arab/Oriental/ 
Persian'; 22 % 
literate; 63 % 
in full time 
employment 
16 % 
 
   -non-standardised  lab. 
assays 
- lack of assessment of DM 
complications 
-lack of evaluation of 
barriers preventing 
achievement of various 
targets 
-  lack of calculation for 
suggested direct and 
indirect economic burdens 
of DM 
 
Eledrisi et 
al / Not 
reported 
'outpatient 
clinics' 
KSA 1107 45.3  All > 18 48.5 % history 
of HTN 
32%    - potential lack of 
standardised 
measurement/reporting 
-sample selection method 
unclear 
El-shafie 
et al / 
2006 - 
2007 
UH Oman 210 28.6 
 
53.7+ 9.1  Hypertensive 
population 
 
34.4/76.1%  41.6/7.7%  - sampling method not clear 
- results may not be 
generalisable (sample from 
Sultan Qaboos University 
Hospital) 
-limitations of the study not 
clear 
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Summary of cross-sectional studies investigating BP control in diabetic patients in the GCC region. 
PC = primary care; SC = secondary care; TC = tertiary care; UH = university hospital; PH  = private hospital; GP = diabetic patients identified in 
cross-sectional study of general population; NR = not reported 
* n = 100 for each hospital; **204 SC patients; 205 PC patients; ***data for final sample not reported;  
†
HTN = previous diagnosis/treatment or BP > 160/95 if patient > 40 years/ > 140/90 if patient < 40 years; 
††
definition of HTN not reported; 
†††
HTN = BP > 140/90 mmHg or antihypertensive medication; 
o
 HTN = systolic BP > 140 mmHg and/or diastolic BP > 90 mmHg or 
antihypertensive medication; 
oo 
HTN = BP > 140/90  
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4.14.1.3 Dyslipidaemia 
The identified studies of lipid control are summarised in table 19. Again process 
outcomes were of varied definition and infrequently studied, but where 
investigated, documentation of measurement within the previous year was achieved 
in 97 % (178), 93 % (121), 87 % (180) and 14 % (182). The latter outlying result is from 
the most recent study, where large proportions of people with diabetes had not been 
screened for diabetes complications and/or cardiovascular risk factors in the 
previous twelve months. Unfortunately, the exact cause of the low documentation 
was not determined as the study did not test the compliance of people with T2DM to 
regular screening. 
 
The definitions of dyslipidaemia used were variable and utilised various aspects of 
the lipid profile. LDL was the most commonly used clinical outcome, with a 
consistently applied target of < 2.6 mmol/L. This was met in approximately 30 - 50 
% of patients, including in the cases of populations being entirely with or entirely 
without a history of dyslipidaemia (183). HDL, total cholesterol (TC) and TG levels 
were also used as measures of lipid control. Thresholds for dyslipidaemia were not 
consistent, yet where each indicator was used in isolation, rates of dyslipidaemia 
were: 27.9 % (173), 30 % (173), 72 % (175), 63 % (175), 44.6 % (176), 44.6 % (176).  
 
108 
 
Ref/dates 
of study 
Setting Country Sample 
size 
Population 
characteristics 
Lipid control indicators 
(Levels of TC, LDL, HDL, TG measurement) 
Process 
outcomes 
(Frequency of 
lipid 
measurement 
documentation) 
Study limitations 
TC LDL HDL TG 
Famuyiwa 
et al / 
1988 - 
1989 
TC KSA 1000  54.2 % male; age range: 
1 - 98 years; 77.7 % Saudi 
6.2 
mM: 
27.9 % 
 
  > 2.3 mM: 30.0 %  -selection process and 
data collection not well 
described 
-unconventional 
definition 
overweight/obesity 
-study limitations not 
discussed 
Khorsheed 
et al / 
1998 - 
2000 
PC KSA 138 69.6 % male; mean age 
males: 49.7 years; mean 
age females: 53.4 years; 
Saudi nationals 
    69 % - results may not be 
generalisable (sample = 
employees of National 
Guard) 
-selection bias (single 
visits/those not seen 
after Jan 2008 excluded 
) 
-potentially individuals 
with less severe disease 
selected 
Akbar et 
al/ 2000 - 
2001 
UH KSA 202 50 % male; mean age ± 
SD: 59.9 ± 12.9 years; 
dyslipidaemic population                 
  < 2.6 mM: 31 
% 
> 1.1 
mM: 28 
% 
< 1.7 mM: 37 %  -interview questions 
unclear, and results not 
discussed 
-study limitations not 
discussed 
Al-Ghamdi 
et al / 
2002 - 
2003 
UH KSA 130 41.6 % male; ages: 15 - 
80 years; 69% non-Saudi 
> 5.2 
mM : 
55.4% 
  > 2.3 mM: 55.4 %  -data analysis not well 
reported 
-selection bias (some 
T1DM included) 
Table 19:  Summary of lipid control 
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Qari / 
2005 
UH/PH KSA 200* UH:30 % male; mean age 
+ SD: 47 + 14 years; 51 % 
Saudi 
PH: 46 % male; mean 
age: 49.4 + 13.7 years; 62 
% Saudi 
     -limited data re. study 
population 
 
 
Afandi  et 
al / 2005 
TC UAE 30 40 % male; ages: > 18 
years 
    97% (within 1 
year) 
-small sample size 
-sampling process not 
clear 
Kharal et 
al / 2005- 
2006 
TC KSA 1188 38.5% male, age: ≥ 30 
years; Saudi National 
Guard employees + 
dependants 
 < 2.6 mM: 
55.5 % 
  Documented 
LDL 
measurement 
within period of 
interest: 87 % 
-specific population  
(Saudi National Guard 
and dependents) 
  
Saadi et 
al/2005 – 
2006 
GP UAE 245 44.9 % male; ages: 18 to 
> 70 years; UAE 
nationals, urban 
residents 
 < 2.6 mM: 
30.8% 
  Documented 
cholesterol 
measurement 
within year: 93 
% 
-sampling process not 
well described 
  
Al-Kaabi  
et al / 
2006 
PC  UAE 409** 39 % male; mean age + 
SD: 51.44 + 11.2 years; 
50.4 % illiterate 
 > 2.5 mM: 
78.6 % 
< 1mM: 
76.4 % 
> 1.7 mM: 59.9 %  -limited details re. 
sampling process 
Al-Elq et al 
/ 2006 
PC KSA 353 Sex ratio not reported; 
mean age ± SD: 51.6 ± 
10.8 years; 84 %  'Arab, 
Oriental, or Persian'; 22 
% literate; 63 % in full 
time employment 
  > 2.6 mM: 65 
% 
  within year: 14 
% 
- characteristics of 
population not well 
described 
-non-standardised lab. 
assays 
- lack of assessment of 
DM complications 
- lack of evaluation of 
barriers preventing 
achievement of various 
targets 
-   lack of calculation for 
suggested direct and 
indirect economic 
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Summary of cross-sectional studies investigating lipid control in diabetic patients in the GCC region. 
PC = primary care; SC = secondary care; TC = tertiary care; UH = university hospital; PH  = private hospital; GP = diabetic patients identified in 
cross-sectional study of general population 
* n = 100 for each hospital; **204 SC patients; 205 PC patients 
burdens of DM 
Eledrisi/ 
Not 
reported 
'outpatient 
clinics' 
KSA 1107 45.3 % male; ages: > 18 
years; Saudi nationals; 70 
% history of (treated) 
dyslipidaemia 
 -< 2.6 mM: 
50.5 %  
(patients with 
history of 
dyslipidaemia) 
-> 3.38 mM: 
17.6 % 
(patients 
without 
history of 
dyslipidaemia) 
   - potential lack of 
standardised 
measurement/reporting 
-selection process 
unclear 
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4.14.2  Quasi-experimental studies  
The six quasi experimental studies identified (192-197) are summarised in table 20.  
The studies were carried out between 1998 and 2007. There were two Saudi studies, 
three from the UAE, one from Kuwait. The study interventions included 
implementation of newly-designed diabetes clinics/services, or use of a flow sheet to 
guide management. There was no public health or primary preventative aspect to 
any of the interventions. 
 
All studies were based in primary care, and based on populations previously 
diagnosed with diabetes. The samples are likely to contain a predominance of T2DM 
patients, except that of Udezue et al (194), which is likely to include a large 
proportion of type 1 diabetes patients (based on age at diagnosis). Where reported, 
the mean durations of diabetes diagnoses were several years. 
 
The outcomes monitored were generally concerned with adherence to implemented 
guidelines, but three studies also monitored some clinical outcomes, including 
glycaemic control, throughout their duration. Generally, interventions successfully 
increased compliance with clinical guidelines and improved clinical outcomes, 
where monitored, over the duration of the study. The studies were followed up for 
periods of 1 year (197), 18 months (192-196), 2 years (193), and 4 years (194-195) post-
intervention.  Unfortunately, there are major limitations with all these studies.  Only 
one study (194) included a control population, and in this case the physicians 
involved in writing the guidelines for the developed intervention were largely from 
the intervention group.  
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Table 20: Summary of intervention studies 
Ref/dates 
of study 
Country Sample 
size 
Population 
characteristics 
Intervention Outcomes observed  Main outcomes Study limitations 
Reed  et al 
2001 
UAE 219 Control group: 52.3 % 
male; mean age + SD: 
53.6 + 10.9 years; 84.6 % 
UAE nationals; mean + 
SD years education: 3.09 
+ 4.49 years 
Intervention group: 64.5 
% male; mean age + SD: 
49.4 + 11.7 years; 83.0 % 
UAE nationals; mean + 
SD years education: 3.12 
+ 4.87 years  
Guideline implementation, 
chronic care clinics 
established, patient and 
provider education, 
improved clinical recording  
Adherence to 
guidelines 
Clinical outcomes: 
HbA1c, BP, lipid levels 
Patient knowledge re. 
DM and patient 
satisfaction 
Some baseline differences in 
clinical outcomes between 
groups; adherence to guidelines 
improved with intervention; 
higher satisfaction levels in 
intervention group  
 
-Potential for different 
clinics to attract 
different population 
types (e.g. in terms of 
socioeconomic status, 
ethnicity) 
-Potential for different 
definitions, 
instruments and 
processes between 
clinics 
Andrews/ 
1998 - 2000 
UAE 721* 43.6 % of patients who 
attended > once male; 
mean + SD age of 
patients who attended > 
once: males 56.8 + 13.2 
years,  females 53.7 + 
12.5 years 
‘Mini clinic’ (provider 
education, computer-
assisted record keeping, 
guideline implementation)  
Adherence to 
guidelines; HbA1c levels 
Significant ↓ in HbA1c over 12 – 
18 months, same as entry at 2 
years; compliance with 
guidelines  
 
-no controls 
-analysis not fully 
discussed 
Udezue et 
al/ 1998-
2002 
KSA 105 48.6 % male; ages: 14 - 
20 years; employees of 
Saudi Aramco Medical 
Services Organization 
and dependants 
‘Young diabetes clinic’ 
(lifestyle, medication and 
other education)  
 
Assessment of 
management via 
monitoring:  
Compliance with 
attendance, use of 
glucose meters; HbA1c 
levels; eye, vascular and 
neurological 
examination results 
 appointment attendance and 
use of glucose meters; no 
significant improvement in 
HbA1c levels; no patients 
developed retinopathy or 
neuropathy 
- no control group 
- analysis not well 
described; co-
morbidities and types 
of DM not stated 
- specific population: 
young people 
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Summary of outcomes of trialled interventions aiming to improve control of DM in UAE, KSA and Kuwait.  All studies were carried out in 
primary care settings. 
* n fell over follow up period to n = 45 in males at 21 - 27 months; **n at study outset/for 1
st
 audit; n for 2
nd
 audit = 1234 
 
Al-Adsani et 
al/ 2001-
2003 
Kuwait 250 Demographics of sample 
not reported 
Clinical guidelines 
developed; training 
courses; implementation of 
auditing 
Adherence to 
guidelines 
 use of appointment/filing 
systems; various clinical 
measures, examinations and 
smoking assessments achieved 
more frequently 
-no controls 
- characteristics of 
population studied not 
clear 
- selection of records 
not clear 
Khattab et 
al/ 2002 – 
2005 
UAE 2548** 51.8 % male; mean age + 
SD: 55.3 + 11.6 years; 66 
% UAE nationals; 90 % 
T2DM diagnosis 
Clinical guidelines and 
information systems 
developed, diabetes nurse 
practitioners introduced; 
DM ‘teams’ formed; 
implementation of auditing  
Clinical outcomes: 
HbA1c, BP, lipid levels 
Documentation of BMI, 
smoking status, 
fundoscopy referral  
Significant ↓ in HbA1c, systolic 
BP and LDL over study period;  
documentation of HbA1c, BP, 
LDL, BMI measurements, 
smoking status and fundoscopy 
referral between 1
st
 and 2
nd
 
audits 
 
Moharram 
et al/ 2006-
2007 
 
KSA 371 46 % male; mean age + 
SD: 55 + 5.8 years; 
military personnel and 
dependants 
Flow sheet to guide 
management  
 
Adherence to 
guidelines 
 documentation of various 
clinical measures and 
examinations;  patient 
education and dietician referral 
- no controls 
- very specific 
population (military 
personnel) 
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4.15 Discussion 
I found management of T2DM in the GCC region – based on glycaemic-, blood 
pressure- and lipid- control indicators – to be suboptimal. Almost universally, fewer 
than 50% of patients meet targets for these clinical outcomes. There were no clear 
differences between primary and secondary or tertiary care (although possibly blood 
pressure was better controlled in hospital settings). This might be attributed to poor 
performance in the primary care settings.  
 
The reviewed intervention studies were largely uncontrolled, and thus difficult to 
interpret. All strategies reviewed here did appear to improve outcomes, but 
involved multiple interventions and are likely to have been carried out against a 
background of evolving healthcare. No intervention studied included a primary 
preventative dimension. 
 
Although I rate the quality of T2DM management in the GCC region as „poor‟, the 
outcomes are similar to those reported from elsewhere. Due to the disparity in 
genetic and environmental contexts, type of health system, differences in 
intervention methods and management guidelines and target thresholds, we do not 
intend to suggest that any particular intervention method is similarly efficacious 
across regions. Nevertheless, I noted that for both clinical- and process- outcomes, 
similar results are reported for other countries in the region such Lebanon (198) and 
Egypt (199-201). In comparison with a selection of reports from various levels of 
healthcare in the UK (175, 202, 203), USA (204, 205) and Australia (206), clinical 
outcomes in the GCC countries were generally lower, but this was not always so.  
Lipid control (175,) and blood pressure control (203, 204) were most frequently 
potentially comparable between these non-GCC countries and the studies reviewed 
here, but Grant et al (205) also report a 34 % attainment of HbA1c levels < 7 %, which 
would be consistent with a number of the results from the GCC region.  Notably, of 
the non-GCC region studies mentioned, this study includes perhaps the highest 
proportions of patients under relatively high level care. Although it may therefore 
underestimate outcomes more generally achieved, it may in fact be a better 
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comparator for the mixed populations included in our review. I note also that in 
many cases the outcomes of the reviewed studies would satisfy the upper thresholds 
of the UK Quality and Outcomes Framework targets (175). 
 
With regard to process measures, these were generally well met in all settings, but 
probably more so in the non-GCC developed regions, particularly for glycaemic 
control.  Finally, and importantly, I note that with regard to intermediate outcomes 
of diabetes control, there has been evident progress in at least the UK and USA (175, 
203, 204), which I have not observed here to be the case in the GCC region. 
4.15.1 Limitations of study 
A major limitation on the strength of the conclusions lies in the heterogeneity of the 
reviewed studies. They were of varied populations, reported on variable outcome 
measures, were from various levels of healthcare provision and different countries 
(although were predominantly from some and notably did not include all GCC 
countries). The outcomes of review are therefore necessarily of only a broad nature, 
and as expected, they were not appropriate for use in synthesis of outcomes with 
estimates of confidence. 
 
All of the reviewed studies were published in English. Overall, the clarity of 
reporting in the reviewed papers was considered relatively low; considered so as it 
often hampered assessment of study quality. In a few cases, we excluded studies due 
to an inability to sufficiently assess study quality (see Fig. 9).  Otherwise, I did not 
exclude studies based on quality, but noted some major limitations, particularly in 
the intervention studies. With regard to the cross-sectional studies, the relatively low 
numbers of papers returned by each search led to difficultly identifying 
inconsistencies versus widening accepted value ranges and extent of possible effects, 
and in turn difficulty considering the strength of our final proposals. Nevertheless, I 
feel the data are sufficient that we might comment on their potential implications for 
T2DM care in the GCC region. 
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4.15.2 Implications 
I believe – based on the mentioned studies from non-GCC countries and the 
intervention studies reviewed here – that the standards of diabetes care in the GCC 
region can be improved. Both of these sets of studies suggest that improved 
adherence to process measures would improve clinical outcomes. In defining these 
desired process outcomes, and the mechanisms to comply, it may be useful to 
consider some of the interventions implemented in the reviewed intervention 
studies. These could potentially be as effective as those implemented elsewhere, and 
there is a degree of overlap.  For example, the use of patient education programmes, 
diabetes specialist nurses and self-glucose monitoring appear to be potentially useful 
and are relatively well developed components of systems elsewhere.  Continued 
auditing of these and other interventions will be important.  Standardising both the 
process and clinical measures for clinical use and for auditing would be useful to 
facilitate comparisons, although this has yet to be achieved elsewhere, and fixing 
standards may be difficult. A review of potentially useful and realistic standards for 
this region has not been achieved and would be helpful. 
 
I also consider that there is a large role for primary prevention programmes in any 
new management strategy. It is unclear whether or not any such intervention has 
been trialled in this region, and a concerted/wide-reaching programme is probably 
essential for feasibility and success of diabetes management. Finally, I have not 
considered strategies likely to produce changes in diabetes management without 
being aimed specifically towards this (e.g. those implemented as part of the WHO 
„Innovative Care for Chronic Conditions Framework‟ adaptations in health systems 
associated with the shift towards management of chronic rather than acute diseases 
(46)), but it is anticipated that such changes will also be an important part of 
managing the diabetes burden in the GCC region. 
4.16 Conclusion 
Up to my knowledge, this study is the first to systematically review the quality of 
diabetes care in the GCC region. I found management of T2DM, as indicated by 
three major intermediate outcome measures (glycaemic control, blood pressure and 
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lipid profile), to be sub-optimal in the GCC countries.  In addition, I found that in 
many of the reviewed studies, there were quality issues that impacted on their 
usefulness. I thus feel attention to the management of diabetes in this region needs to 
be improved, and that enhanced management must include better quality of 
research and production of valuable data. 
With regard to specific management strategies, I have here reviewed several studies 
of interventions, which suggest a number of secondary prevention strategies that 
may help in raising the quality of management in this region. However, other forms 
of intervention – particularly primary prevention strategies, which have not been 
clearly implemented or audited – are also likely to be useful. I anticipate that co-
ordinated implementation of locally-successful/targeted strategies may be 
particularly effective. Continued, high quality review of all forms of interventions in 
the GCC states would also be desirable.  
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Chapter 5 : Quantitative approach 
 
This chapter presents the quantitative component of this thesis. It is classified into 
four main sections including: (1) literature review, (2) method, (3) results, and (4) 
discussion and conclusion. The first section of this chapter represents a background 
about disparities on diabetes care and the literature review undertaken to identify 
disparities in diabetes care and their association particularly with age and gender. 
Secondly, the methods I used to carry out the study in Al-Ain, UAE is addressed. 
Then, I reported the main findings from the study carried out in the third section. 
Finally, explanations for these findings and comparisons with results from other 
studies are outlined in section four. 
5.1 Introduction 
As addressed in chapter one, two and four, the UAE has the second highest 
prevalence rate of diabetes worldwide (90% of cases of diabetes are of type 2) (1), 
and it is one of the IDF‟s „top 10‟ countries for diabetes prevalence in 2010 and in 
2030: 18.7-21.4%, (1).  
Many organizations such as ADA, Scottish Intercollegiate Guidelines Network 
(SIGN) and National Institute of Clinical Excellence (NICE) have developed 
evidence-based guidelines for the control of blood glucose, blood pressure and 
cholesterol levels in people with diabetes to reduce diabetes related vascular 
complications (2-4). The UAE has developed guidelines for the management of 
T2DM, and they are the bases for structured protocols in diabetes care settings. 
 Improving and measuring quality of health care are becoming important issues 
world-wide. However, there is a growing body of evidence indicating that diabetes 
care is sub-optimal on international level in terms of the standards attained, the 
degree of variability and the level of accountability of health professionals (208-210). 
Despite the large number of available guidelines, several studies in developed 
countries have reported unsatisfactory care provided to people with diabetes based 
on evidence-based quality of care standards such as in the UK (203), USA (204, 205) 
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and Australia (206). Similar findings were found in developing countries such as 
Lebanon (198) and Egypt (199-201). 
In the Gulf, as  found in the systematic review presented in chapter four, section 
three on the quality of diabetes care in the GCC countries that the extent of T2DM 
control to be sub-optimal and relatively poor . Assessment of the efficacy of 
interventions was difficult due to lack of data, but suggestive that more widespread 
and controlled trial of secondary prevention strategies may have beneficial 
outcomes. 
Furthermore, disparities in diabetes care and their association with age, gender, 
deprivation and ethnicity have been investigated by many studies (e.g., 207--211) in 
western countries. For instance, some studies have identified that older patients 
were less likely to receive effective treatment compared to younger age groups (e.g., 
208-211). While, the elderly had better cholesterol and glycaemic profiles in another 
study compared to young patients (75, 211). Females were less likely to achieve the 
target goals for cholesterol and blood pressure and to have quality indicators 
recorded (208).  Similarly, women were found to receive poorer quality of care, in a 
large, population-based study from Delhi, India, (208). 
Many studies investigated the association between deprivation and DM care. For 
instance, one study reported that the people living in the deprived areas were less 
likely to achieve the required goals for glycaemic control, and less rate of recording 
for process of diabetes care were found among them compared to those living in 
affluent areas (210). 
 In the UAE, only few studies have assessed diabetes care ( 180, 41), and based on the 
literature review I carried out, no studies have investigated its association with the 
age or gender. Improvement in diabetes care relies to a large extent on examining 
and evaluating the quality of care provided to people with diabetes. Therefore, this 
study was carried out to examine the quality of T2DM care in a diabetes centre 
located in a tertiary hospital in Abu Dhabi, UAE in 2008, 2009 and 2010. The quality 
of T2DM care was examined by using quality indicators, both process and 
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intermediate outcomes of care, in accordance with ADA targets 2012 . Specifically I 
aimed to:  (1) assess process and intermediate outcomes of care with particular 
attention to glycaemic, lipid and blood pressure control, (2) identify any 
improvement in the quality indicators between 2008 and 2010, and (3) investigate the 
relationship between age or gender and the quality of T2DM care. 
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Section one: Literature review                                                
 
Firstly, this section provides a background on disparities in diabetes care. Then the 
literature review performed on disparities in diabetes care along with the search 
method, main outcomes from the literature review and findings are outlined. 
Findings from the literature review are classified into: studies from the developed 
and Arab countries. Finally, a brief summary of the overall content of this section is 
provided.  
5.2 Disparities in diabetes care 
Disparities in health have been studied for decades as indicated by Black report 1980 
(212), The Acheson Report 1998 (213) and recently the WHO commission on the 
social determinant of health 2008 (214). 
The international focus on health inequality is shown by many organizations and 
countries such as the International Society for Equity in health in 2000 that aims to 
promote equity in health and health services (214), and the European Region of the 
WHO (214).  
 
Many western countries are aiming to tackle disparities in healthcare. For instance, 
in Sweden 2001, a proposal was presented to the parliament for a new health policy 
that tackles social inequalities in health (215). In Finland, since 1986 a focus has been 
made on this issue. In the UK and US, there are many policies adopted to reduce 
disparities in health care among people (215). 
Nevertheless, despite this international efforts and consideration of the problem, 
there is a growing body of evidence indicating that inequalities in health exist and 
are increasing (216). For instance, based on the third report of the health committee 
on health inequalities 2008-2009 in the UK, they found an increase in the health 
disparities between the social classes (4% amongst men, and 11% amongst women) 
as compared to the health of the poor, the health of the reach is improving in a faster 
rate (216). 
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5.2.1 What is an inequality in health? 
Kunst and Mackenbach used the following working definition of health inequalities: 
“Differences in the prevalence or incidence of health problems between individual 
people of higher and lower socio-economic status” (217). 
 
Health inequality can be defined as difference in health standing or in the delivery of 
health determinants between various population groups. Inequality in health has 
evolved around three main areas including: (1) difference or variation in health (or 
income) between different groups; (2) inequalities in health or outcome; and (3) 
inequalities or the un-fairness of difference (217). 
“The quality of care should not differ because of such characteristics as gender, race, 
age, ethnicity, income, education, disability, sexual orientation or location of 
residence” (217). Health inequalities exist between different groups of the population 
from different gender, age, and different ethnicity (216). Also, disparities in care are 
found among people suffering from disabilities and intellectual problems (221). 
There are many causes of inequalities in health, however they are complex.  Factors 
studied and found associated with inequalities in health include: poverty, housing, 
education, access to healthcare, lifestyle factors such as smoking and physical 
activity. „Institutional ageism‟ was suggested to be one of the causes, but found to be 
less significant than other listed factors (216). 
5.3 Aims of reviewing the literature  
Prior to examining the quality of diabetes care in the diabetes healthcare centre in 
the UAE, a systematic review on the quality of T2DM care in the GCC countries 
involving the UAE was carried out and addressed in chapter four, section three. This 
systematic review enabled me to review the quality of the diabetes care in the UAE 
and other Gulf countries, and to identify the gap in the literature regarding the 
quality of diabetes care in the UAE, which is essential for achieving the overall aim 
of this study which is to examine the quality of T2DM care in the Al-Ain, UAE. Also, 
carrying out this systematic review enabled me to review and critically appraise the 
quality of studies obtained in the Gulf region. Being aware of the quality of those 
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studies and their limitations helped me in designing this study and improving its 
quality. 
The systematic review obtained on the quality of T2DM care in the GCC countries 
including the UAE, however, did not focus on the disparities in the diabetes care in 
the region. Therefore, in advance to investigating the association between age or 
gender with the quality of T2DM care in this study; reviewing the literature on 
disparities in diabetes care and their association particularly with age and gender 
was performed. The main aims of carrying the literature review are: (1) to 
comprehensively appreciate the evidence on the association between age and gender 
with diabetes care, and (2) to identify the gap in the literature regarding the 
disparities in T2DM care and their association with age or gender in the Gulf in 
general, and UAE specifically. 
5.4 Search method 
A review was carried out in Feb-2009/March-2010. Potential studies were identified 
by: (1) searching the electronic databases mainly EMBASE, MEDLINE, CINAHL and 
the Cochrane Library using various key words such as (quality of care, barriers to 
diabetes care, facilitators to diabetes care, healthcare professionals, diabetes mellitus, 
type 2 diabetes); (2) searching reference lists in the retrieved studies and other 
relevant articles; (3) contacting investigators and experts in the fields for 
information; and (4) hand searching the international journal of diabetes and 
metabolism, which is an Emirate  journal to identify any related studies carried out 
in the UAE and Arabic region. 
The search was not limited to any language to enable the capture of any study 
published in other language than English including the Arabic. All papers from 
developing countries have been referred to along with significant either positive or 
negative findings from other publications. 
5.5 Outcomes of the literature review 
Most studies investigating disparities in diabetes care focused mainly on studying 
the following main factors: gender, race, age, ethnicity, income, education, disability, 
sexual orientation and location of residence. 
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5.6 Findings from the literature review 
5.6.1 Studies from developed countries 
There are many studies carried out in the developed world on health inequalities. In 
this subdivision, a summary on the common disparities in diabetes care reported in 
the literature included ethnicity, deprivation, age and gender are addressed. 
However, based on the objective of this initial study to investigate difference in 
diabetes care between different age groups and gender; disparities in diabetes care 
associated with gender and age are emphasised. 
Ethnicity 
There is evidence showing that people with T2DM belonging to racial and ethnic 
minorities In the US (176, 204, 205) and UK (203, 204) are receiving poorer quality of 
diabetes care, based on different outcomes measure. For instance, differences in 
healthcare access and utilization, and health outcomes have been identified in 
subjects with T2DM in the national sample of the Caucasians, African-Americans, 
and Mexican –Americans that were studied in the third national health and nutrition 
examination survey (218). Similarly, racial disparities in process and intermediate 
outcome of diabetes care have been reported in another study (219). Results from a 
systematic review of studies conducted in the US and UK showed that in the US, 
black Hispanics have higher risk of retinopathy and worse intermediate outcome of 
care (220). While in the UK, Asian found to be at a greater risk of end stage renal 
disease (221, 222). 
However, using data from the Insulin Resistance Atherosclerosis study (1993-1998), 
the rate of treatment for diabetes and associated co-morbidities are similar across 
African, American and Hispanics (223). 
 
Deprivation 
The association between deprivation and the quality of diabetes care has been 
demonstrated by many studies. Variation in the process, outcomes of diabetes care, 
and the existence of diabetes related complications such as retinopathy were more 
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prevalent among more deprived people with diabetes as indicated by many studies 
(e.g., 224-226).  
Furthermore, in the US un-insured patients tend to receive lower quality of diabetes 
care compared to those insured as indicated by many studies (e.g., 219). 
Age  
Many studies claimed that difference in diabetes care exist between young and old 
individuals. Younger age has been linked to poor glycaemic control (e.g., 76, 226, 
227).  
Gender 
Many studies in the literature have indicated that differences in diabetes care exist 
between men and women. The association between gender of people with diabetes 
and the glycaemic control has been studied, but results are uncertain; however more 
evidence pointed out that females have poorer access to care than males (e.g., 76, 
207). For example, in the UK, one of the studies demonstrated that patient‟s sex –
females vs. males- affects significantly the value of random HbA1c (p=0.01) (207). 
Another study carried out among Pakistani with diabetes receiving their treatment 
from either primary or secondary care in Manchester, UK indicated that women had 
poorer glycaemic control compared to men (19% vs. 31%, p=0.05) (228). 
5.6.2 Studies from Arab countries 
Disparities in diabetes care are given little consideration in the Arab world. Few 
studies in the literature found addressing this issue. 
In Oman, a study found that low perception towards a patient-centred approach to 
be more common among women (229). They attributed the low perception among 
this group to two key reasons: (1) the social disempowerment of women; and (2) the 
power imbalances in the healthcare professional-patients relationship (229). 
Summary  
The evidence on the existence of disparities in diabetes care in the developed world 
is associated with number of factors such as deprivation, ethnicity, age and gender is 
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increasing. Many western countries, such as the UK, US, Finland and Switzerland 
are focusing on tackling disparities in health including diabetes care. Despite the 
high prevalence of chronic diseases including diabetes the Arab world, especially the 
Gulf, studies addressing this issue are lacking. Disparities could be attributed to: 
person driven, professional driven, system- driven and disease- driven. However, 
based on the objectives of this study, differences in T2DM care provided to different 
age groups and genders was the area of focus in this thesis. 
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Section two: Methodology 
 
The general aim of the quantitative component of this thesis is to examine the quality 
of T2DM care in a diabetes centre located in a tertiary hospital in Abu Dhabi, UAE in 
2008, 2009 and 2010. The quality of T2DM care was examined using quality 
indicators, both process and intermediate outcomes of care in accordance with ADA 
targets 2012 (1). Specifically I aimed to: (1) assess process and intermediate outcomes 
of care with particular attention to glycaemic, lipid and blood pressure control, (2) 
identify any improvement in the quality indicators including both process and 
outcomes of care between 2008 and 2010, and (3) investigate the relationship 
between age or gender and the quality of T2DM care using both process and 
outcome indicators. Therefore the study aimed to answer the following research 
questions: 
1- What is the quality of T2DM care in the diabetes centre in terms of process 
and intermediate outcomes of care measures compared to the international 
level? 
2- Is T2DM care in the diabetes centre improving overtime in terms of process 
and intermediate outcomes of care measures? 
3- Do differences in T2DM care subsist in the diabetes centre between different 
age groups and genders? 
Details of the population definitions, data selection, data collection and methods of 
analysis are discussed in the coming sections. 
5.7 Materials and design 
5.7.1 Access issues 
Ethical approval 
Ethical approval was granted for the study by Al-Ain medical district (refer to 
appendix 17) 
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5.7.2 Population and setting 
Patients 
The study is limited to people with T2DM who are being followed-up by the 
diabetes health centre at Tawam hospital, Al-Ain.  
People with T2DM from Abu Dhabi whose diabetes are not controlled in the 
primary care settings are referred to this centre. Also, many people with T2DM from 
other emirates are referred and complete their treatment in the centre. Believing on 
the high quality of the diabetes care in the centre, some patients get appointments 
from the centre directly to see the physicians (230). 
 Setting 
Al-Ain 
Al Ain is the third largest city in the UAE; therefore a health centre located in Al-Ain 
was chosen to present the population of Abu Dhabi, also other reasons for selecting 
this centre are presented in the following subdivision named „ diabetes centre‟. 
According to the most recent census, it has a population of about 400,000 (230). It is 
located in the Eastern Region of the emirate of Abu Dhabi, about 140 kilometres 
from Abu Dhabi and 120 from Dubai (230). 
Tawam Hospital- Diabetes centre 
Tawam hospital is located in Al-Ain. It is an educational hospital and training centre 
for faculty of medicine and health sciences of UAE University. This hospital 
provides care to the residents of Abu Dhabi city including Al-Ain and other Emirate 
cities as well (230). Tawam hospital mission is to provide a continuum of quality 
health care which meets the needs and expectations of the UAE population and the 
surrounding GCC countries (230). 
The centre provides an all round service for people with diabetes focusing on 
educating patients and their families (230). The clinic provides different services 
such as insulin pump instruction education and podiatry services.   
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Tawam hospital was selected for this study for several reasons. One of the reasons is 
that before selecting the diabetes centre at Tawam hospital, a pilot study was carried 
out in several hospitals and centres belonging to the HAAD. In summary results 
from the pilot study showed that: 
 (1) The medical records were in-complete and lacked of many essential data needed 
for quality assessment. 
(2) There were some medical records that are un-organized and not possible to 
locate.  
(3) There was lack in the use of glycaemic measurement (HbA1c) in some hospitals, 
which is agreed to be used as in indicator of glycaemic control instead of other 
indicators such as fasting blood glucose in this study; therefore drawing an overall 
picture of the glycaemic control wouldn‟t be possible. 
5.7.3 Pilot study 
Before starting data collection at the diabetes centre at Tawam hospital, a pilot study 
of the medical record review was carried out to: 
 test the viability of the medical records review phase of the project 
 verify accessibility to the medial records and health care facilities at Tawam 
hospital 
 design and modify a data collection tool 
 approximate the time needed to collect data to assist in calculating a sensible 
sample size for the study 
The pilot study revealed that: 
 the medical record review was feasible 
 the facilities and information were accessible 
 a realistic sample size was agreed with a statistician as explained in 
subdivision 5.7.8 
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Summary 
Choosing the diabetes centre at Tawam hospital has many advantages including: 
(1) It is the first hospital in Al-Ain that started computerizing patients‟ medical 
records, and the records are available on an electronic database from 2008, 
making assessment of any improvement in diabetes care from 2008 on-wards 
feasible. 
(2) It has a special centre for people with diabetes that provides the essential care, 
and it follows international guidelines for the management of diabetes adapted 
from (ADA guidelines). 
(3) It provides tertiary care to the residents of Abu Dhabi city including Al-Ain and 
other Emirate cities as well. 
5.7.4 Study design 
A retrospective cohort study, longitudinal data was collected for the period: 2008-
2009-2010. This design was selected to measure the changes in the quality of T2DM 
care including process and intermediate outcomes indicators overtime. Also, the 
longitudinal analysis allows accounting for confounders and bias. 
5.7.5 Data collection 
A data collection tool was designed in Microsoft Word (see appendix 18). The data 
collection tool aimed to collect data on both intermediate outcomes and process of 
diabetes care in the following years: 2008, 2009 and 2010.  Medical records of people 
with T2DM were available electronically from 2008; therefore this year was chosen to 
be the baseline for this study. For each intermediate outcome indicators including 
HbA1c, systolic and diastolic blood pressure (S/DBP) and low density lipoprotein 
LDL, I designed the data collection tool to collect data on three measurements of the 
listed indicators annually for the consecutive years from 2008 to 2010. 
The following data from patient‟s medical records were collected: 
(1) Demographic details of patients including sex, age, and duration of diabetes. 
Data on life style including physical activity and smoking was collected also. 
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(2) Glycaemic control:  
 HbA1c measurement  
 frequency of annual HbA1c measurement  
 the use of anti-diabetic drugs 
 the use of insulin 
(3) Blood pressure control:  
 S/DBP measurement 
 frequency of annual S/DBP measurement 
 the use of BP control therapy 
(4) Blood lipid control:  
 blood lipids measurement including total LDL 
 frequency of annual lipid profile measurements 
 the use of lipid modifying therapy 
(5) The use of anti-platelet therapy including Aspirin and/ or Clopidogrel.  
(6) The presence of diabetes related complications including:  
 coronary heart disease 
 hypertension 
 heart failure 
 atrial fibrillation 
 renal failure 
 peripheral vascular disease 
5.7.6 Patient selection 
A list of patients with diabetes who visited the centre during the period from 
January 2008 to December 2008 was obtained. T2DM patients were identified from 
the list of patients attending the diabetes centre (T1DM, gestational DM and other 
metabolic disorders). From the list, T2DM medical records were abstracted, and the 
patients‟ medical records which were referred to podiatry, dietician and 
ophthalmology were scanned to ensure if they have T2DM. Once the total number of 
patients with T2DM was known, each record was nominated a digit from one 
upward and a computerised random number program was used to determine which 
132 
 
records to select. If a selected record was not available in the computerized database 
it was noted, and a request for the paper-based medical record was submitted for 
review. If it remained unavailable, the next randomly selected medical record was 
reviewed. If more than one medical record was available for the same patient, both 
records were reviewed. 
5.7.7 Inclusion/exclusion criteria 
Table 21 below lists the inclusion and exclusion criteria for the subjects included in 
the study. 
Table 21: Inclusion/exclusion criteria 
Inclusion criteria Exclusion criteria 
People with Type 2 diabetes  
 
People with type 1 diabetes 
UAE nationals and expatriates 
 
Pregnant women 
Patients who have been diagnosed for 
more than one year 
 
Newly diagnosed patients (< one year) 
Age≥ 18 years 
 
 
Both genders: Males and females 
 
 
People with type 2 diabetes who have 
been followed up at the centre from 
2008 
 
 
 
5.7.8 Sampling 
Sample size calculation  
The sample size was chosen based on estimating a proportion „p‟ with specified 
precision. To calculate a 95% confidence interval for p that is expected to be about 
50% (0.50) with a margin of error not > 0.05, the followed formula was used: 
n=(1.96)2 x pq/ d2, q=1-p 
N=sample size, p=proportion, d= margin of error. 
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 This method requires entering a value of p which I want to estimate assuming that 
p=0.50 to obtain a range that is big enough to ensure precision. 
Based on the formula above the needed sample for the study is roughly 384 subjects 
 n=3.84 x (0.50) (1-0.50)/ 0.0025= 384. 
5.7.9 Quality indicators 
5.7.9.1 Study variables 
The quality indicators used for this report were in accordance with the ADA 
guidelines for the management of T2DM that are followed by the centre. 
Process of T2DM care indicators 
For this study the main process indicators were the proportion of people with T2DM 
who had HbA1c, LDL, and SBP/DBP measured during 12-months follow-up in the 
diabetes centre for the consecutive years from 2008 to 2010. Also, frequency of 
performing these measurements within 1-year follow-up was assessed for the same 
period.  
Non-weighted process of care score (NWPOC) was calculated following a model 
proposed and undertaken by Gulliford et al in Trinidad and Tobago (231). I used the 
four measurements listed above: HbA1c, LDL, SDP, DBP for each patient with each 
measurement documented given an equal weighting; hence a patient could have a 
potential maximum score of four. Then the diabetes centre was given an average 
score based on the number of patients selected from the centre. 
 Intermediate outcomes of T2DM care indicators 
 Outcomes of T2DM care were assessed using intermediate outcomes of care. The 
assessment was based on whether the desired target level for the following 
measurements were met in accordance with ADA guidelines (HbA1c <7%, LDL < 
2.6mmol/L, SBP < 130 mmHg and DBP < 80 mmHg). Proportions of people with 
T2DM reaching the required targets for these measurements at each year for the 
consecutive years from 2008 and 2010 were calculated.  
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Also, following the same model proposed and undertaken by Gulliford et al in 
Trinidad and Tobago (231), four-variable outcome of care score (4vOOC) was 
calculated based on the number of targets that were achieved yearly by each patient 
for the four targets described above. A score was given for each patient from zero 
(no targets achieved) to four (all targets achieved), and the average score was 
calculated for the diabetes centre. To make it clear, the assessment was based on an 
average of all the results collected. The following outcome variables were used: 
 average mean HbA1c 
 average mean systolic blood pressure 
 average mean diastolic blood pressure 
 average mean LDL 
5.8 Data analysis 
The analysis of the data involves two phases: (1) descriptive analysis, and (2) 
longitudinal analysis. A description of the main characteristics of the study sample 
was presented in the first section of the analysis.  
5.8.1 Descriptive analysis 
To fulfil the requirements of the first objective: to assess process and intermediate 
outcomes of care with particular attention to glycaemic, lipid and blood pressure 
control; the descriptive analysis presents the results on the assessment of both 
process and intermediate outcomes of diabetes care in the following years: 2008, 
2009 and 2010 in accordance with the ADA targets.  
Process of care was assessed by quantifying the proportion of subjects those had 
each measurement including: HbA1c, SBP, DBP and LDL documented in each year 
from 2008 to 2010. Also, the frequency of these measurements was assessed and 
quantified annually for each subject.  
In terms of intermediate outcome of diabetes care, the first section of the analysis 
presents descriptive statistics such as mean for each measurement listed above for 
the period from 2008 to 2010. Also, the proportions of people with T2DM achieving 
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the standard targets for each measurement annually were calculated and listed for 
the same period.  
Descriptive summary of patients characteristics in each sex at the baseline index visit 
were presented as mean and Standard Deviation (SD) for continuous and normally-
distributed variables, and count and proportion for categorical variables. A T-test 
was conducted for comparison of means of continuous variables between sexes and 
chi-square tests were used for testing differences in proportions for categorical 
variables.  
The means (SD) and 95% (CI) of intermediate outcomes of care (HbA1c, LDL, SBP, 
and DBP) for all patients were determined for each year from 2008 to 2010. Using the 
figure at year 2008 as an index, a paired T-test was conducted to compare means at 
2009 and 2010 with means at 2008 separately with an aim to detect significant 
changes across years. 
To benchmark the quality of T2DM care in this study with the ADA guidelines for 
T2DM management, patients were grouped by sex and three age groups, namely (1) 
18-39, (2) 40-59 and (3) 60 and over. Proportions of those that reached the ADA 
target for each intermediate outcome in each year were calculated. Chi-square tests 
were then performed to compare whether these proportions were statistically 
different across years in each age group and each sex.  
5.8.2 Longitudinal analysis 
To achieve the second objective of the study which is to identify improvements in 
the quality of diabetes care using indicators including process and intermediate 
outcomes in the consecutive years from 2008 to 2010; a comparison of the available 
longitudinal data on the quality indicators was performed using data from 2008 as a 
baseline.  
To assess the changes in the process of diabetes care, proportions of subjects having 
the measurements documented in 2008 was determined and compared with those 
documented in 2009 and 2010 respectively. Also, the same process was followed for 
the frequency of the process of diabetes care.  
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In terms of intermediate outcomes of care, differences in the mean of the following 
measurements: HbA1c, LDL, SBP and DBP were worked out between 2008 and 2009, 
and 2008 and 2010 to assess improvements in the diabetes care. An overall 
comparison of the number of people with T2DM achieved the desirable standards of 
care between 2008 and 2009, and 2008 and 2010 was carried out.  
Moreover, to detect any differences in the diabetes care between different age groups 
and genders using process and intermediate outcomes of care indicators, a 
comparison between the subjects from different age groups and genders reaching 
the standard targets for the process and intermediate outcomes of diabetes care was 
carried out. By doing so, the requirements of the following objective:  to investigate 
the relationship between age or gender and the quality indicators including process 
and intermediate outcomes of T2DM care were achieved. 
Further, a multilevel linear regression model was run to detect any rate of change in 
the intermediate outcomes across years and the associations between each outcome 
and accountable covariates during this period.  
Since in this study repeated intermediate outcomes measurements were performed 
for the same individual at every year during period 2008-2010, a multilevel linear 
regression model was built to detect any rate of change of intermediate outcomes 
across years and the associations between each outcome and accountable covariates 
during this period. Occasions (in this study is year) were set as level 1 while 
individuals were set as level 2 in this model.  I used a random-coefficient model, 
which allows the effect of covariates to vary by intercept and the slope. A time 
variable was also included in the model. A set of covariates was included in each 
model and likelihood ratio tests were performed for comparisons of nested models 
while HbA1c estimates were used to compare non-nested models. Residuals of each 
model were examined by plotting a histogram to see whether the residuals were 
normally distributed. A few observations were detected as outliers in each model 
and hence were excluded from the ultimate analyses.  STATA 11 (College Station, 
Texas, USA) was used for all the analysis. 
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In the model, I adjusted for the potential confounding variables such as age, gender, 
duration of diabetes, life-style behaviours including physical activity and smoking 
and the use of pharmacological medications. 
For glycaemic control, I used HbA1c as independent variable and adjusted for the 
following potential confounders: duration of T2DM, age, sex, use of oral 
hypoglycaemic drugs alone and combined with insulin, physical activity, and the 
existence of co-morbidities including coronary heart disease, hypertension and 
hyperlipidaemia. 
For lipid control, I used LDL as independent variable and adjusted for the following 
potential confounders: duration of T2DM, age, sex, use of anti-hyperlipidaemia 
drugs, physical activity, and the existence of co-morbidities including coronary heart 
disease, hypertension. 
For blood pressure control, I used two independent variables including SBP and 
DBP and adjusted for the following potential confounders: duration of T2DM, age, 
sex, use of anti-hypertension drugs, physical activity, and the existence of co-
morbidities including coronary heart disease and hyperlipidaemia. 
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Section 3:  Results 
 
This third section of chapter five presents the findings from the cohort study carried 
out at the diabetes centre in Al-Ain. The results fulfil the following objectives of the 
study: 
(1) To assess process and intermediate outcomes of care with particular attention to 
glycaemic, lipid and blood pressure control. 
 (2) To identify any improvement in the quality indicators including process and 
intermediate outcomes in the consecutive years from 2008 to 2010. 
(3) To investigate the relationship between age or gender and the quality indicators 
including process and intermediate outcomes of T2DM care. 
The results are classified into two main subdivisions: (1) descriptive analysis; and (2) 
longitudinal analysis of data. 
5.9 Descriptive analysis 
The first division includes a description of the main characteristics of the study 
sample, and results on the assessment of both process and intermediate outcomes of 
diabetes care in the following years: 2008, 2009 and 2010, which fulfil the 
requirements of the first objective. 
 In summary to the explanation in section two, process of care was assessed by 
quantifying the proportion of subjects those had each measurement including: 
HbA1c, SBP, DBP and LDL documented for each year from 2008 to 2010. The 
frequency of these measurements was assessed annually as well. 
In terms of intermediate outcome of diabetes care, the first phase of the analysis 
presents descriptive statistics such as mean for each measurements listed above for 
the period 2008 to 2010. Also, the proportions of people with T2DM achieving the 
standard targets for each measurement annually were listed for the same period. 
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5.9.1 General characteristic of the study sample 
Data from 384 people with T2DM was extracted from medical records. Descriptive 
statistics are displayed in table 22. 
Of these 382 patients, roughly 55% were female (n=209) and the average age was 51 
years old. There was no significant difference of age between male and female. 
5.9.1.1 Complication rates 
As shown in table 22, hypertension was the most prevalent co-morbidity among the 
study subjects (66%). It was more prevalent among women than men respectively 
(70.3% vs. 60.7%, p=0.05). The second most prevalent co-morbidity was 
hyperlipidaemia (44.2%), although not statistically significant this disorder was more 
common among men than women (49.2% vs. 45.7%; p=.21). Coronary heart disease 
was less common in this group compared to other co-morbidities (11.3%), and 
hypertension was more prevalent among men than women (17.3% vs. 6.2%, p <0.01 
respectively). 
5.9.1.2 Medications prescribed 
The medications been prescribed for diabetes, hypertension and hyperlipidaemia are 
shown in table 22. The majority of patients have been prescribed oral hypoglycaemic 
agents (96.3%), and (45.6%) have been prescribed combined treatment of oral 
hypoglycaemic agents and insulin. As highlighted by table 19, no significant 
differences were found between women and men. 
More than half the number of subjects (81.7%) were prescribed medications for 
hypertension, and almost all (91.1%) were on anti- hyperlipidaemia. Similarly to 
anti-diabetic agents, no significant differences found between sexes. 
Regarding the use of anti-thrombotic agents, aspirin was commonly used (84.6%). 
Less frequently, clopidogrel was used for some patients (13.4%) as seen in table 22. 
 
5.9.1.3 Life-style factors 
As shown in table 19, significant difference in smoking was found among women 
and men respectively in this sample (0.48% vs. 42.2%, p<0.01). However, no 
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difference was detected among genders on physical activity (20.2% in men vs. 20.1% 
in women, p=0.97). 
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Table 22: Demographic characteristics of participants 
 All patients 
(n=384) 
Male (n=175) Female (n=209) P value 
Age 51 (16.3) 50.8 (15.8) 51.1 (16.5) 0.8 
Age Group     
18-29 48 (12.6%) 17 (9.8%) 31 (14.8%)  
30-39 49 (12.8%) 27 (15.6%) 22 (10.5%)  
40-49 85 (22.2%) 43 (24.9%) 42 (20.1%)  
50-59 90 (23.4%) 36 (20.5%) 54 (25.8%)  
60-69 49 (12.7%) 28 (16%) 21 (10.1%)  
70+ 63 (16.5%) 24 (13.9%) 39 (18.7%) 0.08 
Medications 
 
    
Oral anti-DM 
drugs 
370(96.3%) 167 (95.4%) 203 (97.1.2%) 0.37 
Oral anti-DM 
drugs + insulin 
174 (45.6%) 80 (46.2%) 94 (45.0%) 0.81 
Anti-lipid drug 
 
350 (91.1%) 160 (91.4%) 190 (90.9%) 0.89 
Anti-BP drug 
 
313 (81.7%) 147 (84.4%) 166 (79.4%) 0.21 
Aspirin 
 
325 (84.8%) 148 (84.5%) 177 (84.7%) 0.94 
Clopidogrel 
 
51 (13.4%) 26 (15.0%) 25 (12.0%) 0.38 
Lifestyle factors     
Smoking 74 (19.4%) 73 (42.2%) 1 (0.48%) <0.01 
Physical activity 78 (20.2%) 36 (20.2%) 42 (20.1%) 0.97 
Complications  
 
   
Coronary heart 
disease 
43 (11.3%) 30 (17.3%) 13 (6.2%) <0.01 
Hypertension 252 (66.0%) 105 (60.7%) 147 (70.3%) 0.05 
Hyperlipidaemia 188 (49.2%) 79 (45.7%) 109 (52.2%) 0.21 
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5.10 Standards of care  
5.10.1 Process of diabetes care measures 
The proportion of people with T2DM who had each individual process of care 
measured including: HbA1c, BP and LDL within 1-year of follow-up for 2008, 2009 
and 2010 and there frequency rates are listed in table 23.  
Also, as seen in table 24 NWPOC score as explained in methodology was calculated, 
using the four process measurements including: HbA1c, LDL, SDP, and DBP.  
Table 23: Process measures performed each year (%) in the study cohort: 2008-2010 
Frequency of HbA1c 
Measurement 
2008                                   2009                                                         2010
Women 
(n=209) 
Men 
(n=175) 
 
Women 
(n=209) 
Men 
(n=175) 
Women 
(n=209) 
Men 
(n=175) 
0 - 1 - 2 - 2 
<3 - 1 - - - - 
≥3 209 
 
173 
 
209 
 
173 
 
209 
 
173 
 
Frequency of lipid 
Measurement 
0 - 1 - 2 - 2 
<3 - - - - - - 
≥3 209 
 
174 
 
209 
 
173 
 
209 
 
173 
 
Frequency of BP 
Measurement 
0 - 1 - 1 - 2 
<3 - - - 1 - - 
≥3 209 
 
174 
 
209 
 
173 
 
209 
 
173 
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Table 24: NWPOC score for 2008, 2009 and 2010 
NWPOC 2008 2009 2010 
Mean ± SD 3.95 ± .21 3.9 ± .24 3.9 ± .22 
 
144 
 
 
5.10.2 Intermediate outcome of diabetes care measures 
The mean results of HbA1c, SBP, DBP and LDL for the consecutive years from 2008 
to 2010 are shown in table 25. Differences in results related to gender are 
demonstrated. However, no significant differences were detected among women 
and men, although a borderline significant was found in the DBP in 2009 between 
women and men. The mean of DBP found to be slightly higher among men 
compared to women respectively (78.1 mmHg vs. 77.3 mmHg, p=0.057). 
Figure eleven shows the achieved standards of care based on the ADA targets as 
explained in the methodology. In 2008, 20% of the study subjects achieved the 
standards of glucose levels which increased to 27% then 41% in 2009 and 2010 
respectively.  As highlighted in table 25, the number of people achieving the SBP 
increased from 2008 to 2010 (162 vs. 172 respectively); however there was a drop in 
the number of people reaching this standard between 2008 and 2009 (162 vs. 175 
respectively). Similarly to SBP, the number of people archiving the target of DBP 
increased between 2008 and 2010, but not 2009 (252 vs. 220 vs. 280, respectively). The 
achieved standard for LDL increased gradually from 2008 to 2010 as shown in table 
25 (56% vs. 72%, respectively). 
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Table 25: Intermediate outcomes of care results: 2008-2010 
 
2008 2009 2010 
 Mean Women 
(n=209) 
Men 
(n=173) 
 
P-value Mean Women 
(n=209) 
Men 
(n=173) 
P-value Mean Women 
(n=209) 
Men 
(n=173) 
P-value 
HbA1c 8.50 8.51 8.50 0.98 8.16 8.1 8.19 0.71 7.50 7.50 7.50 0.9760 
LDL 2.60 2.63 2.57 0.54 2.48 2.5 2.48 0.90 2.27 2.28 2.26 0.8226 
SBP 133.1 132.2 
 
134.1 
 
0.16 133.9 132.9 
 
135.1 
 
0.09 133.01 130.34 
 
131.8 
 
0.1142 
DBP 77.3 77.4 77. 0.62 77.9 77.3 78.71 0.057 76.6 76.19 77. 0.1025 
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Figure 10: Proportions of subjects reaching the intermediate outcomes:  2008-2010 
 
 
5. 11 longitudinal analysis 
The second phase however, includes longitudinal analysis for the available data for 
the consecutive years from 2008 to 2010. To accomplish the second objective listed 
above, a comparison of the data on the quality of diabetes care including both 
process and intermediate outcomes indicators was carried out using data from 2008 
as a baseline. Additionally, quality of diabetes care scores for both process and 
intermediate outcome were determined for the consecutive years from 2008 to 2010 
to identify any improvement in the quality of diabetes care in this period. To bear 
out the final objective listed earlier, each indicator including glycaemic, blood 
pressure and lipid were analysed separately and reported under subdivision 5.11.2 
Proportions of women and men from different age groups reaching the standard 
targets for each indicator was quantified, and differences between different genders 
and age groups was assessed. Finally, to assess the influence of potential factors 
“confounders” on the main indicators including HbA1c, SBP, DBP and LDL, a 
multilevel model was performed adjusting for this potential factors, and results are 
discussed for each indicator separately under subdivision 5.11.2. 
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5.11.2 Intermediate outcome of diabetes care measures 
 4vOOc score was calculated for the diabetes centre as seen in table 26. The mean of 
the score increased gradually from 2008 to 2010 respectively [2.27 (95% CI: 2.18-2.37) 
vs. 2.62 (95% CI: 2.52-2.71)]. 
Table 26: Quality of care score: 2008 -2010 
 
Using data from 2008 as a baseline, table 27 displays an overall comparison of 
diabetes outcomes of care between 2008 to 2009 and 2008 to 2010. Paired 
comparisons of diabetes outcomes of care are demonstrated in tables 24 and 25, 
using the subject‟s data for the following years (2008 vs. 2009 in table 28 and 2008 vs. 
2010 in table 29).  
On average, there was a significant improvement in the glycaemic control in the 
following years 2008, 2009 and 2010 based on the mean average of HbA1c as 
outlined in table 27. Comparing the reduction in the HbA1c level with the baseline 
data from 2008 with 2010 respectively, a substantial improvement was found: 8.5% 
(95% CI 8.33-8.67) vs.  7.5% (95% CI 7.36-7.63); P <0.001.  
In terms of blood pressure, using figures at 2008 as a baseline, there were no 
significant differences for the mean DBP level during the three years as outlined in 
table 27. However, a range of 95% CI for mean DBP level at year 2009 and 2010 was 
not overlapped, hence it can be concluded that a significant reduction was found for 
these two years. For SBP, although a significant reduction was seen from 2008 to 
2010, it was minor. 
The mean of LDL improved significantly as seen in table 23 between 2008, 2009 and 
2010. The average level of LDL was 2.60 mmol/L (95% CI: 2.51-2.70) at 2008, which 
was then increased by 0.17 mmol/L to 2.27 mmol/L (95% CI: 2.21-2.33) at 2010. 
 
Quality of care 
score 
2008 2009 2010 
4vOOC  
(n=382) 
2.27 0.96 2.18-2.37 2.26 0.97 2.16-2.35 2.62 0.91 2.52-2.71 
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Table 27: Mean values of clinical indicators: 2008-2010 
 
Clinical indicator 2008  
Mean (SD) 
95% CI 2009 
Mean (SD) 
95% CI 2010 
Mean (SD) 
95% CI P value  
(09 vs. 08) 
P value  
(10 vs. 08) 
Hba1c (%) 8.50 (1.70) (8.33-8.67) 8.16 (1.52) (8.0 -8.3) 7.50(1.34) (7.36-7.63) <0.001 <0.001 
LDL(mmol/l) 2.60 (0.91) (2.51-2.70) 2.48 (0.58) (2.4-2.5) 2.27 (0.62) (2.21-2.33) <0.0001 <0.001 
SBP (mmHg) 133.1 (13.0) (131.7-134.4) 133.9 (12.7) (132.6-135.2) 131.01 (9.1) (130.1-131.9) 0.13 <0.001 
DBP (mmHg) 77.3 (7.84) (76.4-78.0) 77.9 (7.00) (77.3-78.7) 76.61(5.6) (76.0-77.2) 0.07 0.11 
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Table 28: Paired comparison of outcomes in the study cohort: 2008-2009 
 
 2008 
Mean 
 
(95% Confidence 
intervals) 
2009 
Mean 
 
(95% Confidence 
intervals) 
Mean difference 
(95% Confidence intervals) 
p-value 1 
HbA1c (%) 8.50 (8.33-8.67) 8.16 (8.0 -8.3) .34 
(.26-.42) 
<0.001 
SBP (mmHg) 133.1 (131.7-134.4) 133.9 (132.6-135.2) -0.83  
(-1.9-0.23) 
0.13 
DBP (mmHg) 77.3 (76.4-78.0) 77.9 (77.3-78.7) -0.71 
(-1.5-.06) 
0.07 
LDL (mmol/l) 2.60 (2.51-2.70) 2.48 (2.4-2.5) .12 
(2.4-2.5) 
<0.001 
1 Paired t-test for variables with normal distributions. 
HbA1c: Glycated haemoglobin, SBP: Systolic blood pressure, DBP: Diastolic blood pressure, LDL: low density lipoprotein. 
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Table 29: Paired comparison of outcomes in the study cohort: 2008 -2010 
 
1 Paired t-test for variables with normal distributions. 
HbA1c: Glycated haemoglobin, SBP: Systolic blood pressure, DBP: Diastolic blood pressure, LDL: low density lipoprotein. 
 
 
 2008 
Mean 
 
(95% Confidence 
intervals) 
2010 
Mean 
 
(95% Confidence intervals) Mean difference 
(95% Confidence 
intervals) 
p-value 1 
HbA1c (%) 8.50 (8.33-8.67) 7.50 (7.36-7.63) 1 
(.92-1.1) 
<0.001 
SBP (mmHg) 133.1 (131.7-134.4) 131.1 (130.1-131.9) 2.04 
(1.1-3) 
<0.001 
DBP (mmHg) 77.3 (76.4-78.0) 76.61 (76.0-77.2) 0.63 
(-0.13-1.4) 
.11 
LDL (mmol/l) 2.60 (2.51-2.70) 2.27 (2.21-2.33) 0.33 
(0.25-0.42) 
<0.001 
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Glycaemic control 
Based on the number of subjects archiving the ADA standards of diabetes outcomes 
of care, the proportions of patients who reached the HbA1c target were not 
significantly different between women and men respectively at each year (22% vs. 
18%, p=0.3 at 2008, 28% vs. 25%, p= 0.5 at 2009, and 41% vs. 42%, p= 0.9 at 2010) as 
seen in table 30. However, both genders had significant improvement of reaching the 
target across the years as outlined in table 26 and appendix 19. 
Equally, proportions of people with T2DM who reached the target increased across 
years at each age group for both genders as highlighted in table 27. However, 
significant differences of these proportions across the three years were only found at 
older age group (> 40 years old) for both sexes. At younger age, among men and 
women there were no significant differences of these proportions, although 
borderline significance (p=0.059) was found among males aged 18-39 years. Notably, 
in 2010 the lowest proportion of participants 26% (increased from 11% at 2008) 
achieving the HbA1c target was among females aged 18-39 years. 
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Table 30: Proportions of men and women achieving the standard blood glucose targets: 2008-2010 
 
Intermediate 
outcomes 
2008 2009 2010 
 
 
Targets for 
HbA1c 
achieved: 
 
Women 
N (%) 
 
Men 
N (%) 
 
Total 
N (%) 
 
P-value 
 
Women 
N (%) 
 
Men 
N (%) 
 
Total 
N (%) 
 
P-value 
 
Women 
N (%) 
 
Men 
N (%) 
 
Total 
N (%) 
 
P-value 
 
Yes 
46 
(22%) 
31 
(18%) 
77 
(20%) 
 
P=0.3 
59 
(28%) 
44 
(25%) 
103 
(27%) 
 
P=.5 
86 
(41%) 
72 
(42%) 
158 
(41%) 
 
P=.9 
 
No 
163 
(78%) 
142 
(82%) 
305 
(79%) 
150 
(72%) 
129 
(75%) 
279 
73%) 
123 
(59%) 
101 
(58%) 
224 
(59%) 
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Table 31: Proportion of subjects archiving standard targets for blood glucose by age groups and sex: 2008-2010. 
 
Clinical indicator 
(ADA target) 
Male    (n=173) 
 
 
Female (n=209) 
 18-39 40-59 60+  
Total 
18-39 40-59 60+  
Total (n=44) (n=78) (n=51) (n=53) (n=96) (n=60) 
Hba1c (<7%)      
2008 25% 12% 22% 18% 11% 26% 25% 22% 
2009 25% 22% 31% 25% 19% 33% 28% 28% 
2010 45% 32% 53% 42% 26% 46% 47% 41% 
P value 0.059 <0.01 <0.01 <0.001 0.14 0.02 0.03 <0.001 
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Results from the multilevel modelling are shown in table 28. Results indicated the 
rate of HbA1c changes among women and men adjusted for potential confounding 
factors including age group, oral T2DM drugs intake, intake of combined oral T2DM 
drugs with Insulin, physical activity, co-morbidities including: coronary heart 
disease, hyperlipidaemia, hypertension, and duration of diabetes. Factors that have 
significant impact on HbA1c values are outlined in table 32. 
In men, an annual average reduction of HbA1c level was 0.5% (95% CI:-0.56 ~ -0.43, 
P<0.001) as shown in table 28, which confirmed the results of table 21. Generally, 
HbA1c level of people who aged 60+ was significantly lower than for those aged 18-
39 years  by roughly 0.7% (95% CI:-1.19 ~ -0.14, P=0.01) during this period, but not  
for those aged 40-59. 
Similarly to men, an annual average reduction of HbA1c level was 0.5% (95% CI:-
0.57~-0.44, P < 0.001) in women as highlighted in table 28. In the same line, 
comparing with the 18-39 age group, women who were in successive age including 
those between 40-59 and above 60 years respectively had significantly lower HbA1c 
level on average 0.49% (95% CI: -0.98 ~  -0.004, P=0.05), and 0.77% (95% CI: -1.31~ -
0.23,  p< 0.01).  
In men, prescribing oral anti-hypoglycaemic drugs was associated with roughly 
4.2% (95% CI: -0.85 ~ -0.01, P=0.05) reduction in the HbA1c levels as recognized in 
table 28. However, this association was not significant among women. 
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Table 32: Results from multilevel modelling on blood glucose for men and women during 2008-2010. 
 
→Multilevel model was adjusted for age group, oral T2DM drugs intake (Y/N), oral T2DM drugs with Insulin (Y/N), physical activity (Y/N), 
coronary heart disease (Y/N), hyperlipidemia (Y/N), hypertension (Y/N), duration of diabetes (in years). All binary independent variables were 
using negative responses as references (Y=1, N=0). For age group, group 18-39 was used as a reference.  
→ for multilevel analysis using Hba1c as a dependent variable, one observation was treated as an outlier (id=215) and excluded from the model. 
 
HbA1c 
Men Women 
Β P-value 95%CI Β P-value 95%CI 
 Year -0.50 <0.001 -0.56 -0.43 -0.51 <0.001 -0.57 -0.44 
Age         
40-59 -0.16 0.53 -0.64 0.33 -0.49 0.05 -0.98 -0.004 
60+ -0.67 0.01 -1.19 -0.14 -0.77 <0.01 -1.31 -0.23 
Oral hypoglycaemic drugs -4.2 .05 -.85 -.01 -.005 0.99 -0.57 0.56 
Oral hypoglycaemic drugs & Insulin .46 .12 -.21 1.12 0.33 0.41 -.48 1.15 
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Lipid control 
Based on the number of subjects achieving the ADA standards of diabetes outcomes 
of care, the proportions of patients who reached the LDL target were not 
significantly different between women and men respectively at each year (56% vs. 
55%, p=0.8 at 2008, 57% vs. 60%, p= 0.7 at 2009, and 70% vs. 74%, p= 0.4 at 2010) as 
seen in table 33. However, both genders had significant improvement of reaching the 
target across the years as outlined in table 30 and appendix 20. 
In 173 men, proportions that reached the target for LDL increased consistently for 
the consecutive three years as shown in table 34. Though only significant differences 
were detected at age group 40-59, of which patients who reached the target increased 
from 53% at 2008 to 76% at 2010 (p <0.01). Similar results were found among women, 
a significant elevation in the number of women achieving the target between 2008 
and 2010 respectively was calculated 53% to 71% (p=0.04). Non-significant 
differences were found for either young or old age group at each sex, though for 
females aged 18-39 years old, borderline significant difference was found (p=0.056). 
In 2010, although it was not statistically significant compared to women, men had 
the highest proportion of subjects achieving the targets of LDL (73.99% vs. 69.86%, 
p= 0.4 respectively). 
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Table 33: Proportions of men and women achieving the standard blood lipid targets: 2008-2010 
 
Intermediate 
outcome of care 
2008 P- 
values 
2009 P-
values 
2010 P-
values 
 
Targets achieved 
for LDL: 
 
Women 
 
Men 
 
Total 
  
Women 
 
Men 
 
Total 
  
Women 
 
Men 
 
Total 
 
Yes 118 
(56%) 
95 
(55%) 
213 
(56%) 
 
P=0.8 
119 
(57%) 
103 
(60%) 
222 
(58%) 
 
P=0.7 
146 
(70%) 
128 
(74%) 
274 
(72%) 
 
P=0.4 
No 91 
(44%) 
78 
(45%) 
169 
(44%) 
90 
(43%) 
70 
(40%) 
160 
(42%) 
63 
(30%) 
45 
(26%) 
108 
(28%) 
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Table 34: Proportion of subjects archiving standard targets for blood lipid by age groups and sex: 2008-2010. 
Clinical indicator 
(ADA target) 
Men    (n=173) 
 
Women (n=209) 
LDL  (<2.6mmol/l) 18-39 
(n=44) 
40-59 
(n=78) 
60+ 
(n=51) 
 
Total 
18-39 
(n=53) 
40-59 
(n=96) 
60+ 
(n=60) 
Total 
2008 52% 53% 61% 55% 55% 53% 63% 56% 
2009 61% 55% 65% 60% 47% 58% 63% 57% 
2010 66% 76% 78% 74% 70% 71% 68% 70% 
P value 0.42 <0.01 0.13 <0.01 0.056 0.04 0.80 <0.01 
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Results from the multilevel modelling are shown in table 31. Results indicated the 
rate of LDL changes among women and men adjusted for potential confounding 
factors including age group, anti-hyperlipidaemia drugs, physical activity, co-
morbidities including: coronary heart disease and hypertension, and duration of 
diabetes.  
In both sexes, an average reduction of LDL level at a yearly rate was 0.15 mmol/l 
(95% CI: -0.2~-0.1, P<0.001) as outlined by table 35. None significant differences 
between age groups were reported. 
 
Table 35: Results from multilevel modelling on blood lipid for men and women: 
2008-2010. 
 
→for multilevel analysis using LDL as a dependent variable, one observation was treated as 
an outlier (id=249) and excluded from the model. 
 
 
 Men Women 
LDL  Β P value 95%CI Β P value 95%CI 
Year -0.15 <0.001 -0.20 -0.10 -0.15 <0.001 -0.20 -0.10 
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Blood pressure control 
In terms of blood pressure, in 2009 and 2010 respectively, overall women were more 
successful achieving the ADA targets for SBP compared to men (47% and 52%, P 
<0.01 vs. 34% and 41, p=0.04) as outlined in table 36. Nevertheless, no significant 
differences were found for the proportions of those who reached the SBP target 
during the three consecutive years from 2008 to 2010. Similarly to SBP, in 2009 as 
outlined in table 36 and Appendices 21 and 22, women had a higher proportion of 
reaching the DBP target than men (62% vs. 52%, P=0.05), but in 2010 the proportions 
between sexes were quite similar (74% female vs. 72% male, p=0.7). 
For women, the proportions of those reaching the SBP target increased gradually 
from 2008 to 2010; however among those aged 40-59 years a drop in this proportion 
was detected between 2008 and 2009 (49% vs. 46%; respectively) as seen in table 37. 
At 2010, more than half of the women had met the SBP target (52%). In particular, 
older men (60+) had the lowest SBP target-met at 2010 (29%) followed by (42%) of 
men aged 40-59 years. Similar results were found for DBP; however reductions of 
target-met subjects in men aged 40-59 and (60+) were seen from 2008 to 2009 
(reduced by 17% and 24% respectively).  
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Table 36:  Proportions of men and women achieving the standard blood pressure targets: 2008 - 2010. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Outcome 
indicators 
2008  2009  2010  
Targets 
achieved for 
SBP: 
 
Women 
 
Men 
 
Total 
 
P-value 
 
Women 
 
Men 
 
Total 
 
P-value 
 
Women 
 
Men 
 
Total 
 
P-value 
Yes 94 
(45%) 
68 
(39%) 
162 
(42%) 
P=0.3 99 
(47%) 
58 
(34%) 
157 
(41%) 
P=0.006 108 
(52%) 
71 
(41%) 
179 
(47%) 
 
P=0.04 
No 115 
(55%) 
105 
(61%) 
220 
(58%) 
110 
(53%) 
115 
(66%) 
225 
(59%) 
101 
(48%) 
102 
(59%) 
203 
(53%) 
Targets 
achieved for 
DBP 
  
Yes 135 
(65%) 
117 
(68%) 
252 
(66%) 
P=0.5 130 
(62%) 
90 
(52%) 
220 
(58%) 
P=0.05 155 
(74%) 
125 
(72%) 
280 
(73%) 
 
P=0.7 
No 74 
(35%) 
56 
(32%) 
130 
(34%) 
79 
(38%) 
83 
(48%) 
162 
(42%) 
54 
(26%) 
48 
(28%) 
102 
(27%) 
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Table 37: Proportion of subjects archiving standard targets for blood pressure by age groups and sex: 2008 -2010. 
Clinical indicator 
(ADA target) 
Male    
 (n=173) 
 
Female  
(n=209) 
18-39 
(n=44) 
40-59 
(n=78) 
60+ 
(n=51) 
Total 18-39 
(n=53) 
40-59 
(n=96) 
60+ 
(n=60) 
Total 
SBP(<130mmhg)        
2008 50% 37% 33% 39% 43% 49% 40% 45% 
2009 36% 37% 25% 34% 51% 46% 47% 47% 
2010 52% 42% 29% 41% 53% 51% 52% 52% 
P value 0.27 0.75 0.69 0.32 0.59 0.77 0.44 0.39 
DBP(<80mmhg)        
2008 77% 62% 69% 68% 70% 65% 60% 65% 
2009 73% 45% 45% 52% 68% 60% 60% 62% 
2010 77% 72% 69% 72% 79% 72% 73% 74% 
P value 0.85 <0.01 0.02 <0.001 0.39 0.24 0.21 0.02 
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Results from the multilevel modelling are shown in table 38. Results indicated the 
rate of SBP and DBP changes among women and men adjusted for potential 
confounding factors including age group, anti-hypertension drugs, physical activity, 
and co-morbidities including: coronary heart disease and hyperlipidaemia and 
duration of diabetes.  
Among men, the average annual reduction of SBP was 1.02 mm Hg (95% CI: -1.80~-
0.24, P=0.01) as seen in table 38. However, this yearly rate reduction was not 
significant for DBP. Women had a lower average reduction of SBP level at a yearly 
rate 0.80 mm Hg (95% CI: -1.47 ~ -0.13, P=0.02) compared to men, whereas an 
average reduction of DBP level at a yearly rate was 0.71mm Hg (95% CI: -1.20~-0.22, 
P<0.01). 
Unexpectedly, patients from both genders women and men respectively who were 
prescribed anti-blood pressure drugs had higher points in their S/DBP [7.6 mm Hg 
(P<0.001) and 3.9 mm Hg (P< 0.001) vs. 6.7 mm Hg (p<0.01), and 3.7 mmHg 
(p<0.001)]. 
 Having regular physical activity was associated with lower S/DBP level in women 
although P-values were borderline significant (P=0.05 and 0.057 respectively). Also, 
for every 1-year increase of the duration of T2DM, the SBP level for women 
increased by 0.68 mm Hg (P<0.01, 95%CI: 0.29~1.06).  
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Table 38: Results from multilevel modelling on blood pressure for men and women: 2008-2010. 
 
→for multilevel analysis using SBP as a dependent variable, one observation was treated as an outlier (id=315) and excluded from the model. 
→for multilevel analysis using DBP as a dependent variable, two observations were treated as outliers (id=313 & id=31) and excluded from the 
model. 
 
  
Men 
 
Women 
  
Β 
 
P value 
 
95%CI 
 
Β 
 
P value 
 
95%CI 
SBP         
Year -1.02 0.01 -1.80 -0.24 -0.80 0.02 -1.47 -0.13 
Anti-BP drugs 6.70 <0.01 2.55 10.85 7.62 <0.001 4.25 11.0 
Physical activity     -2.78 0.05 -5.53 -0.03 
Duration of T2DM 
(yrs) 
    0.68 <0.01 0.29 1.06 
DBP         
Year 0.03 0.91 -0.55 0.62 -0.71 <0.001 -1.20 -0.22 
Anti-BP drugs 3.65 <0.01 1.26 6.04 3.92 <0.01 1.69 6.14 
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Section four: Discussion 
 
This final section of chapter five discusses the results addressed in section three and 
compares them with findings from studies carried out elsewhere. Discussion is 
classified into three main divisions including the process, intermediate outcomes of 
diabetes care, and differences in the control of these indicators among different age 
groups and genders. The main metabolic indicators for process and intermediate 
outcomes of care include glucose, blood pressure and lipid measurements. 
5.12 Process of diabetes care 
This study found that with regard to process measures, these were generally well 
met in the study period from 2008 to 2010, and the adherence rate to the guidelines 
was exceptional as reflected by the NWPOC score. 
The findings from this study on the proportion of people with T2DM having their 
measurements performed at least once annually within 1-year of follow-up for the 
study period are comparable if not higher with  studies carried out in the Gulf region 
(e.g., 180, ), Middle East (e.g., 199, 200), and Western countries (e.g., 203, 204, 205).  
Many reasons might enhance the adherence to the guidelines regarding process of 
diabetes care. The management agreement signed in 2006 with Johns Hopkins 
Medicine International and HAAD and the increase in the number of departmental 
audits might be some of the reasons helped in improving the process of diabetes care 
in the centre. The increase in the number of educational sessions provided to the 
people with T2DM in the centre helped increasing their awareness on the 
importance of attending appointments regularly; therefore the adherence rates to the 
appointments increased. Also, the establishment of new diabetes centres in Abu 
Dhabi motivated each centre to provide high quality of care. Changes in the 
healthcare professionals or employing new subjects might participate as well in 
improving the quality of T2DM care.  
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 Based on the mission of Tawam hospital to provide high quality of healthcare, it 
uses performance innovation program which is designed to monitor, evaluate and 
continually improve the care and services delivered (230).  The department of 
performance innovation has many responsibilities to improve the quality of 
healthcare such as supporting quality management activities, standardizing 
processes to meet hospital goals, supporting data aggregation, summarizing and 
analysing processes and providing training and ongoing facilitation for organization 
wide quality improvement teams.  The performance innovation council was 
established at Tawam hospital to assume oversight role of quality innovations at the 
hospital (230). This council includes senior hospital management, key stakeholders 
from medical divisions, staff members of department of performance innovation, 
and invited guests (230).  
As a consequence of following the performance innovation strategies at the hospital, 
compliance to the process of care increased; therefore the quality of care.  
5.13 Intermediate outcomes of diabetes care 
5.13.1 Glycaemic, blood pressure and lipid control 
Despite the high rate of testing in this study, sub-optimal management of glucose 
and SBP was investigated; more than 50% of the study population did not achieve 
the desirable targets for the HbA1c and SBP in the following years 2008, 2009 and 
2010.  For instance, in 2010 only 41% achieved the target of HbA1c, and 47% meet the 
target of SBP. This finding reveals that excellent performance on process of diabetes 
care does not essentially translate into good metabolic control (200). There are other 
factors affect the metabolic control related the patients, disease itself and system. For 
example, compliance to the medications use and lifestyle of the people with T2DM 
have a great impact on the control of diabetes.  However, in 2010 high rates of 
achievements of the DBP and LDL goals were found (73% vs. 72% respectively). 
I noted that for outcomes of glycaemic and SBP control, similar results are reported 
for other countries in the region such as the GCC (180), Lebanon (198), and Egypt 
(200). For instance, the results of the systematic review I carried out on the quality of 
diabetes care in the GCC addressed in chapter four, section three revealed that 
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management of T2DM in the GCC region – based on glycaemic-, blood pressure- 
and lipid- control indicators – to be suboptimal. Almost universally, fewer than 50% 
of patients reach targets for these clinical outcomes. 
Nevertheless, comparing the findings from this study with some studies carried out 
in other GCC countries (e.g., for glycaemic control: 123,, and e.g., for BP control: 185, 
186) the control of glucose and BP in this setting tends to be better. Still, high rate of 
blood pressure target achievement was attained in 83% of the sample of Afandi et al; 
the small sample (30 subjects) could be one of the reasons for this high achievement 
rate (180). 
Comparing the findings with studies carried out in developed countries at various 
levels of healthcare, the results were consistent with a number of their findings. In 
the UK, the target of HbA1c ≤ 7.5% was achieved only in 43%-48%, and the target of 
blood pressure <140/85mmHg was achieved in 36%-59% (203). Additionally, in 
Netherlands, the goal of blood pressure 135/85 mmHg was achieved only among 
20% of participants (231). Notably, lipid control findings were equivalent with 
studies carried out elsewhere (199-201). Yet noteworthy, participants at this study 
attained the target of LDL more successfully compared with people with diabetes in 
other Arab countries (e.g., 193, 199, 199-203).  
5.14 Differences in care associated with gender and age 
Findings from this study revealed variation in diabetes outcomes of care between 
younger and older patients as shown in the multilevel model. Compared to older 
individuals, younger individuals (<40 years old) have poorer HbA1c profiles. 
Although there were no significant differences of blood pressure level across age 
groups, it can be seen that during the three years proportion of those reached the 
target was consistently higher in younger age group than that of older age group. 
These findings concur with previous research that addressed the association 
between ageing and improved glycaemic control (175, 110), but an increment in the 
hypertension rate (175). 
In summary, I found that glycaemic and lipid control tend to be similar between 
sexes, similar to the findings of studies carried out elsewhere (207), still in this study 
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men had a slightly higher proportion of reaching the ADA targets. Unlikely to 
studies (175) that found women less successful in achieving the target goal for blood 
pressure, women performed better than men in this study on reaching the target of 
blood pressure, especially for the SBP in 2009 and 2010. 
I noted an encouraging progress with regard to intermediate outcomes of diabetes 
control including glycaemic and lipid between 2008 and 2010. This finding is in line 
with the evident progress in the intermediate outcomes of DM care in the developed 
countries such as UK and USA (e.g., 127). The UAE is following several objectives of 
the national strategy for the control of diabetes, actions proceeding to implement 
two of these objectives which are: (1) support continuous monitoring and evaluation 
of diabetes care; and (2) improve and promote the quality of diabetes care at three 
levels of healthcare system might help in improving both the process and 
intermediate outcomes of diabetes care in healthcare providing centres in the UAE 
(88). Also, following the performance innovation strategies at the hospital helped 
improving the quality of diabetes care. 
 
Furthermore, unpredictably the multi-level model showed that there is an increment 
in the levels of SBP / DBP in women and men who had been prescribed 
pharmacological medications to control high blood pressure. Similar results were 
found by Youssef et al in Egypt as patients who were prescribed anti-hypertensive 
drugs had about 11mmHg and 3 mmHg higher points in their S/DBP than those 
non-prescribed (199). 
Several reasons can contribute to the poor S/DBP control among this group, and 
might be related to the disease process itself (232). There is also evidence which 
support the important role of patients related factors such as understanding of 
hypertension and its complications and the importance of adherence to treatment 
including medications use (233). Researchers have identified several factors affecting 
non-adherence and they categorized them into: patient related factors, treatment 
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related factors, system related factors and healthcare professionals related factors 
(232). 
People with T2DM play a key role in managing their disorder. Daily they perform 
roughly 95% or more of the management of diabetes without consulting healthcare 
professionals (232,233). They have to cope with several challenges they face in their 
daily lives such as glucose monitoring and medication regimen within the context of 
other goals, physical activity, decision about the diet, other health issues, family 
demand and other personal concerns (232, 233).  Hence, adhering to the complex 
regimen including medication use and following healthy lifestyle may interfere with 
their coping with the disease.  
Diet is considered as an important part of the treatment plan; therefore people with 
T2DM should know about their food and calories in each meal. Also, being aware 
about reading food labels can help people with T2DM to make a better decision 
about their food choices.  
In T2DM, there is evidence that patient‟s adherence to medication is sub-optimal 
globally. For instance, a recent systematic review showed high rate of non-adherence 
to oral hypoglycaemic drugs and insulin (7-64% vs. 19-46%) (234).  
Better glycaemic control was associated with adherence to the treatment of diabetes 
medications in many studies. For instance, a drop in the HbA1c levels by 0.16% 
(p<0.001) as a result of 10% increment in the adherence rate to oral hypoglycaemic 
drugs (calculated based on prescription refill data) was documented by Schectman et 
al 2002 (232). Equally, Ho et al found 0.05% reduction in HbA1c levels (95% CI 
0.08%-0.01) due to improvement in the adherence to oral anti-diabetic medications 
(235). A further two studies also found similar results (236, 237). 
 Evidence showed that non-adherence to medications in chronic diseases such as 
T2DM and hypertension is common, and improving adherence to treatment 
including medication use could improve the treatment outcomes such as glycaemic 
and blood pressure control; therefore identifying variables that influence people 
with T2DM adherence to medications is essential. 
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In the west, several studies (e.g., 236-237) were carried out to explore predictors of 
non-adherence to pharmacological drugs in T2DM including medications used to 
regulate blood pressure as mentioned before. Nevertheless, no studies were found 
addressing the issue of adherence to diabetes treatment including medications in 
UAE. Some studies in the Arab countries reported the rate of non-adherence 
between 1.4%-27.1% (238, 239); however drawing a conclusion from this figure is 
limited by several flaws such as study design, sampling methods and sample size 
and methods of assessing and defining adherence used. 
Complete investigation of the reasons for the increase in the blood pressure among 
subjects being prescribed anti-hypertensive drugs was not performed in this study; 
however non-adherence to the treatment is proposed to be one of the causes. Non- 
adherence is a common problem in all chronic conditions as mentioned before; 
principally it is problematic in T2DM and blood pressure due to the complexity of 
treatment regimen including the use of combined drugs and life long duration of the 
disease (236, 237). 
“Clinical inertia” an issue associated with the healthcare professionals was 
suggested to be another reason not only for this paradox, but also for the sub-
optimal control of HbA1c and blood pressure in this study. Phillips et al have 
defined clinical inertia in the comprehensive review they carried out as a failure of 
the healthcare professionals to initiate or optimize therapy when indicated (240). 
Therefore, for people with un-controlled blood pressure and glucose who are 
already on pharmacological treatment, regular review for the drugs prescribed is 
essential. More research should focus on clinical inertia and pattern of drug usage 
and their correlation with metabolic control in the UAE. 
5.15  Strengths and limitations of the study 
 
This is the first study in Al-Ain and UAE to examine the quality of T2DM care using 
longitudinal data from 2008 to 2010, and the first to investigate and assess any 
differences in T2DM care provided to different age groups and genders. The 
followed methodology allowed random selections of participants thus reducing the 
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confounding effects of other contextual factors that could influence the quality of 
T2DM care. Also, the use of multi-level modelling allows for confounding variables 
and selects independents relationship with the quality indicators used in this study 
to assess the quality of T2DM care. 
 
There are limitations to this study, the analysis was performed at a single centre in 
the Al-Ain, and choosing a sample from a hospital would be another limitation, as 
many people with T2DM are managed in the primary care settings. However the 
results of this study will most likely to be representative of care provided in other 
diabetes centres in Al-Ain, given the similarity in organizational, structure, followed 
guidelines, physician‟s training and possibly small difference in patient 
characteristics. Another caveat is the use of medical records to assess the care 
provided to people with T2DM that depend on the quality of documentation and 
might not necessarily reflect the actual care delivered or outcomes. 
Data on BMI, patient‟s experience and quality of life was not possible to be collected 
in this study; therefore they were not included in the statistical analysis. Studying 
the association between these variables such as BMI and outcome of T2DM care is 
essential; hence we recommend future studies to consider studying these 
associations. 
Also, the results that stated worse glycaemic and blood pressure control among 
people with T2DM been prescribed anti-blood pressure drugs were limited by lack 
of detailed information on:  individual drugs, the cumulative doses and duration of 
treatment of each drug as they can interact with other factors influencing glycaemic 
and blood pressure control. Meanwhile, for people with T2DM with poor metabolic 
control, there is a call for reviewing the drugs profile and emphasising on improving 
the patient‟s adherence on drug use in the centre. 
5.16 Implication of the study 
This study provides useful baseline data about the quality of T2DM care in a 
diabetes centre, at a tertiary health care setting in Al-Ain. Results from this study are 
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comparable with other studies elsewhere; however there are still rooms for further 
enrichment. 
Identifying differences in diabetes care provided to different age groups and gender 
demonstrated in the study would assist healthcare professionals and policy planners 
and makers in addressing the problem and planning for quality improvement 
enterprises. 
It is particularly worrying that younger Emirates with T2DM had worse glycaemic 
control than older patients; given that the risk for both micro and macrovascular 
complications over a long period of time would increase. Hence, further 
investigations for the sub-optimal outcomes of care among this group are needed to 
optimize the care provided. 
As diabetes management relies on a great extent on the patient‟s life style, the use of 
interventions that are multi-faceted and holistic in approach would help in 
addressing the underlying causes of unhealthy lifestyle among people with diabetes 
(241). For instance, educational interventions targeting young population should be 
realistic, non-judgemental and focus on coping strategies (241). 
At the diabetes centre level, supporting continued monitoring and evaluation of the 
diabetes care are highly recommended to tackle any difference in care, and to 
improve and promote the quality of diabetes.  
However, as more than 70% of the UAE population is composed of expatriates that 
come from all over the world, more future research should target this group as well 
to investigate the quality of diabetes care and optimize its management. 
5.17 Conclusion 
This study demonstrates that there is an encouraging progress in the diabetes care 
reflected by the overall improvement in the mean of HbA1c, LDL and SBP, and the 
increment in the number of people reaching the target for the same indicators listed 
above for the consecutive years from 2008 to 2010. However, the results have shown 
that there is scope for additional enhancement, especially for a better glycaemic 
control among young patients and a better SBP control among males. Findings from 
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this study can help healthcare professionals and policy makers and planners in 
comparing performance and planning for quality improvement initiatives. 
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Chapter 6: Qualitative approach 
 
This chapter presents the qualitative approach used in this thesis. The chapter is 
classified into four main sections respectively including: literature review, methods, 
results, and discussion and conclusion.  
6.1 Introduction 
Measuring and improving quality of diabetes care remain important issues of 
concern worldwide (60-63). There is increasing evidence that diabetes care is 
suboptimal on the international level in terms of standards attained, degrees of 
variability and levels of accountability of health professionals (212, 204). Previous 
studies that have been local, observational or exploratory in nature have identified 
several factors influencing the quality of T2DM care. These studies often employed a 
theoretical framework that classified factors affecting the quality of diabetes care into 
three main categories: patient, healthcare professionals and organisational (242, 243). 
Factors related to patients (i.e., financial constraints, compliance with medications, 
life style recommendations and diet, gender issues, use of alternative medications, 
knowledge of diabetes and attendance to clinics) have been shown to affect the 
quality of T2DM care in previous studies (242). Other factors related to organisation 
and health professionals which include, availability of medications, heavy workload, 
waiting time at health centres (242-244), as well as motivation of the healthcare 
professionals, time with patients, role of nurses, shortage of staff, healthcare 
professionals‟ work time, team work, lack of feedback from specialists and lack of 
health professionals' training (242-244) have been shown to contribute to the 
explanation of variables that influence the care provided to people with T2DM. 
While a number of these studies identified factors related to the quality of T2DM 
care from the patient perspectives, there has been less focus on the healthcare 
professional‟s experience in providing this type of care, and even less known of the 
experience of healthcare professionals working in the UAE‟s healthcare settings. 
Healthcare professionals‟ knowledge and attitudes towards diabetes care are 
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essential in understanding the variables that might influence the care they provide to 
people with T2DM and ultimately the improvement of the quality of T2DM care. 
Moreover, factors influencing this type of care remain poorly defined and less 
investigated in the Middle East in general and the Gulf region specifically, despite 
the alarming prevalence known in this region. 
The UAE has the second highest prevalence rate of diabetes worldwide (90% of cases 
of diabetes are of type 2) (1) as addressed in chapter one, two and four. With one of 
highest rates globally, diabetes is a major public health concern and financial burden 
in this country. Moreover, this disease represents a real challenge to the health 
planners, policy makers, people with diabetes and their families and healthcare 
professionals (84). Findings from the cohort study carried out and presented in 
chapter five revealed that the control of diabetes in the diabetes centre is suboptimal 
as reflected by the glycaemic and blood pressure intermediate outcomes. Another 
important finding is that younger subjects with T2DM tend to have poorer outcomes 
compared to the older subjects however; an encouraging improvement was 
witnessed from 2008 to 2010. As a consequence of the findings from the cohort 
study, I used the qualitative approach to identify factors both facilitators and barrier 
affecting T2DM care. To optimize the management of people with T2DM and 
increase the quality of diabetes care in the UAE, it is essential to understand all the 
general and country-specific factors that influence the care provided to individuals 
with T2DM. 
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Section one: Literature review 
 
This section presents the literature review undertaken on the factors affecting the 
quality of diabetes care particularly type 2, along with the search method and 
outcomes of search. Findings from studies carried out in the developed and 
developing countries, particularly Arabic countries are addressed in sections 6.5.1 
and 6.5.2 respectively. Summaries are provided at the end of each section. After that, 
factors affecting the quality of T2DM care are classified into: patient, healthcare 
professionals and organization and discussed comprehensively in section 6.5.3. 
6.2 Aims of reviewing the literature 
The literature review was undertaken to identify and discuss potential factors had 
been suggested to affect the quality of care provided to people with diabetes from 
the literature. The main aims of the literature review are: (1) to comprehensively 
appreciate the available factors documented in the literature affecting the quality of 
T2DM that could be investigated in this study, and (2) to setup the interview guide 
including the questions that will be used to collect the needed information from the 
healthcare professionals. 
6.3 Search method 
A review was carried out in Feb-2009/March-2010. Potential studies were identified 
by: (1) searching the electronic databases mainly EMBASE, MEDLINE, CINAHL and 
the Cochrane Library using various key words such as (quality of care, barriers to 
diabetes care, facilitators to diabetes care, healthcare professionals, diabetes mellitus, 
type 2 diabetes); (2) searching reference lists in the retrieved studies and other 
relevant articles; (3) contacting investigators and experts in the fields for 
information; and (4) hand searching two journals established in the Saudi Arabia 
and UAE respectively including Saudi Medical Journal, and International Journal of 
Diabetes and Metabolism to find studies carried out in the Arabic and Gulf 
countries. 
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The search was not limited to any language to enable the capture of any study 
published in other language than English including the Arabic. All papers from 
developing countries have been referred to along with significant either positive or 
negative findings from other publications. 
6.4 Outcomes of the search 
I found many studies carried out in the western countries; however there was 
shortage in studies focusing on the factors affecting the quality of diabetes care in the 
Arabic and gulf countries. 
Factors affecting the quality of diabetes care either facilitators or barriers have been 
classified as mentioned in the introduction into three main categories including: 
patient, healthcare professionals and organization. The literature focuses on 
identifying these factors and investigating their relation to diabetes care. Diabetes 
care was assessed based on the outcomes of care including intermediate outcomes 
mainly glucose control and process of care outcomes. 
6.5 Findings from the literature review 
6.5.1 Studies from developed world 
This subdivision is divided into two main parts which presents findings from the 
literature on the factors both facilitators and barriers affecting diabetes care in the 
developed world from a number of systematic reviews and studies. The first part 
talks about the findings from the systematic reviews, while the second part explains 
the findings from other studies carried out in the developed countries and were not 
included in the systematic reviews. A summary of the key findings from studies 
carried out in the developed world is provided after section 6.5.1.2. 
6.5.1.1 Findings from the systematic reviews 
The main factors associated with diabetes care included in the systematic reviews 
were: structured care, diabetes management programs, information technology, 
adherence to medication, patient-healthcare provider interaction, and the use of 
community health workers. 
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 Structured care 
Griffin et al performed a systematic review of Randomised Controlled Trials  (RCT)  
of diabetes care in primary care settings, and they concluded that the un-structured 
care provided to people with diabetes in the primary care settings compared to 
hospitals was associated with greater mortality rates, poorer follow up and worse 
glycaemic control (244).  For example, the rate of loss to follow-up was higher among 
subjects randomised to primary care centres (Peto odds ratio 3.05, 95% CI: 2.15 to 
4.33) (244). Regarding metabolic control, specifically glycaemic control, the mean 
HbA1c was same or less in those been managed in the general practices as 
documented by the recent studies [the weighted difference in mean HbA1c % values 
was -0.005% (95%CI:  -0.26 to 0.25)] (244). Further, the mortality rate in the general 
practice was significantly higher than in hospitals (Peto odds ratio 1.61, 95% CI:  1.03 
to 2.51) (244). 
 
 Diabetes management programs 
Analysis of the results of a systematic review to evaluate the effectiveness of diabetes 
management programs on treatment outcomes suggested that they have overall a 
modest impact on glycaemic control, but this impact was statistically significant  
(pooled estimate, 0.5-percentage point reduction; 95% CI, 0.3 to 0.6 percentage 
points) (245). Added to the improvement in the glycaemic control, these 
management programs improved other outcomes including screening for 
retinopathy and foot complications, SBP, and serum lipids (245). Nevertheless, 
diabetes disease management programs tend to not have a significant effect on other 
outcomes such as screening for nephropathy, hospital admissions and patient 
knowledge. This result might be affected by the small number of studies evaluating 
these related outcomes of treatment (245). 
 
Information technology 
There is a growing body of evidence that emerging information technology can 
assist improving diabetes care. Based on the results of a systematic review carried 
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out by Jackson et al, several trials indicated significant improvement in glycaemic 
control reflected by reduction in HbA1c levels, as a consequence of using interactive 
computer-assisted technology in diabetes care (246). Also, significant enhancement 
in healthcare utilization, behaviours, skills and attitudes were indicated (246). 
 
Adherence to medications 
As discussed in chapter five, non-adherence to medications in T2DM is a common 
problem. 
A review by Haynes showed that adherence to medication by people with chronic 
diseases tends to be only 50% (247). Therefore, Haynes concluded that “increasing 
the effectiveness of adherence interventions may have far greater impact on the 
health of the population than any improvements in specific medical treatments" 
(247). 
 
In diabetes, a systematic review carried out to assess the adherence of people with 
diabetes to oral hypoglycaemic medications demonstrated a range of 36% to 93% 
(248).  Furthermore, in people with T2DM who are on oral hypoglycaemic drugs, a 
review of six RCTs comparing self-monitoring of blood glucose or/ and urine 
glucose with standard care found an association between improving glycaemic 
control and self-monitoring blood glucose (248). Unlike the results from this meta-
analysis, another meta-analysis of self-monitoring including eight RCTs showed no 
difference between the two methods including self-monitoring of blood glucose or/ 
and urine glucose with standard care (249). Hence, WeIschen et al concluded that 
more research should be carried out to evaluate the positive association of self-
monitoring with glycaemic control (249). 
 Healthcare professionals-patients interaction 
A systematic review was carried out to test the influence of modifying provider-
patients interaction and healthcare provider consulting style on people with diabetes 
outcomes and self-care included eight publications, mainly RCTs (250). This 
systematic review concluded that focusing on patient‟s self-care behaviours and 
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participation in diabetes care may be more effective than focusing on changing 
healthcare provider‟s consultation behaviours (250). Nevertheless, this systematic 
review was limited by the small number of studies analysed. 
 
The use of community health workers 
Community health workers have recently become involved in many community 
diabetes programs. Their effectiveness in improving the participant‟s knowledge 
and satisfactions had been supported by some studies (e.g., 251); however no data is 
available on their influence on health, quality of life and economic outcomes (251). 
6.5.1.2 Findings from other studies 
There are several studies (e.g., 252, 253) carried out in developed countries, and were 
not included in the systematic reviews. These have classified the factors both 
motivators and barriers to providing high quality of diabetes care into three main 
sorts namely: patient, healthcare professionals, and organization as mentioned 
earlier. These studies illustrated the dynamic interplay of patients, healthcare 
professionals and organisation factors in the management of diabetes. This 
classification is used in this chapter to discuss the findings from the literature on the 
potential factors influencing the care provided to people with diabetes in section 6.4. 
 
Summary 
In brief, systematic reviews conducted in the developed world showed a positive 
association between patient adherence to medications and structured recall system 
with improving the care provided to people with diabetes. However, ambiguous 
results found from reviewing other factors such as the use of information technology 
and the involvement of community health workers in diabetes care. Systematic 
reviews similarly to all research studies have their limitations, and most of the 
reviews included small number of studies; therefore their conclusions are uncertain. 
More studies both quantitative and qualitative are essential to identify factors 
affecting care provided to people with diabetes. 
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Notably, there are many factors related to patient, healthcare professional and 
organization influencing the diabetes care. A dynamic interplay between these 
factors has been demonstrated by a number of studies listed above. 
6.5.2 Studies from Arab countries 
Little work has been found regarding the factors associated with diabetes care in the 
Arab World.  
In the Gulf region, few studies investigated the quality of diabetes care and factors 
related to it. In Saudi Arabia, a comprehensive review on the factors influencing the 
care provided to people in the primary care, not specific to diabetes investigated six 
key factors (254). These factors included: management factors, organizational factors, 
implementation of evidence-based medicine (EBM), professional development, 
problems at the interface with secondary care, and organizational culture (254). For 
instance, several organizations related obstacles have been identified to providing 
high quality of care such as poor information system, stressful work conduction and 
shortage of resources (254). 
Another study was carried out in Saudi Arabia carried out by Khattab et al to assess 
the: (1)  role of the characteristics of diabetes care, (2) people with diabetes and, (3)  
diabetes in the prediction of compliance with diet, medications and appointments in 
primary care settings (255). Diabetes care was measured using the score system 
developed by Chesover et al (253). They found higher compliance with diet among 
male (p=0.01), and people with good diabetes control (p=0.01). Adherence to 
appointments was associated positively with T2DM (p<0.01) and good diabetes care 
(p<0.01) (264).  Overall, degree of diabetes control and duration of disease were 
closely associated with adherence to diet and appointments (p<0.05) (253). 
In the UAE, particularly Abu Dhabi an analysis of predictors of poor diabetic control 
among people with diabetes attending both primary and secondary care identified 
possible confounding factors related to the location of care and degree of disease 
control (41). Attending primary care centre was associated with poor glycaemic 
control than attending hospitals (p=0.03) (41). Also, people with diabetes who have 
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family history were better controlled than those without family history (p=0.015) 
(41). This finding may suggest the importance of „peer pressure‟ among people with 
diabetes in the UAE.  
In Oman, two qualitative studies were carried out to investigate factors influencing 
diabetes care from the perspectives of individuals with diabetes (229, 256). The first 
qualitative study was carried out at Muscat; using four focus groups discussion to 
explore the experience and views of subjects with T2DM regarding the medical 
encounters with their healthcare professionals in the primary care settings (229). The 
study explored some weakness regarding patient-healthcare professional‟s 
interactions and health care services in the primary settings (229). For instance, some 
patients experienced poor communication from the healthcare professionals 
reflected by for examples, un-friendly welcoming and poor attention to the patient 
due to the use of computers during the consultation time (229). Regarding patient 
centered care, patients stated that lack of encouragement to ask questions regarding 
the disease and it is management was common among healthcare professionals 
(229). Also, information about self-management such as self-monitoring of blood 
glucose and hypoglycaemia was lacking (229). Patients noted that they did not 
receive education about their diets and life style behaviors which play an important 
role in managing diabetes (229). Adding to this study, Al-Azri et al found several 
barriers to providing high quality of care to people with T2DM in primary care 
settings in Oman such as  delays in getting appointments, language barriers with 
nurses, long waits for ophthalmology appointments, lack of referral to dieticians and 
lack of proper utilization of waiting areas (256). 
 
Summary  
Findings from studies carried out in Tunisia and other Gulf countries investigated 
different factors influencing the care provided to people with diabetes and they are 
related to patient, healthcare professional and organization. The main organizational 
factors identified are shortage of resources such as equipments and healthcare 
professionals, stressful workload, variation in care provided by primary/secondary 
settings, and lack of referral to dietician and ophthalmology. Other factors related to 
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patients and healthcare professionals were reported such as patient-healthcare 
professionals interaction, language barriers between healthcare professional and 
patients, poor team-work, patient‟s characteristics such as sex and adherence to 
appointments and treatment. 
6.5.3 Factors affecting quality of diabetes care 
Facilitators and barriers to providing high quality of diabetes care related to the 
three chief players including patient, healthcare professional and organization 
separately are discussed in sections 6.5.3.1, 6.5.3.2, and 6.5.3.3 respectively.  
6.5.3.1 Health care professionals related factors 
In this part, I will list and explain the main findings on the factors related to the 
healthcare professionals affecting diabetes care based on the literature. These factors 
were: (1) physician characteristics, (2) physician‟s inertia, (3) healthcare 
professional‟s attitudes and beliefs, (4) patient/ healthcare professional‟s interactions 
(5) continuity of care, (6) clinical team, and (7) healthcare professional‟s motivation. 
Physician’s characteristics 
I found one prospective, and a number of cross-sectional studies carried out mostly 
in the primary care settings to investigate the influence of physician‟s characteristics 
on the quality of care provided to people with diabetes using various outcome 
measures. They investigated characteristics included age, gender, interest and 
continual medical education attendance of the physicians. 
Studies from the literature pointed out that the gender and age of the physicians 
influence the quality of the management of people with T2DM; however results of 
these studies are conflicting. Some studies (e.g., 257-259) indicated that higher 
quality of diabetes care was associated with younger and females physicians, but 
this is not always the case (e.g., 257, 258). For instance, in Netherland results from 
895 randomly selected people with T2DM showed that females physicians used to 
document the blood pressure more frequently than males physicians (0.30, 95% CI: 
0.12-0.71) (257). In the contrary, no alliance between glycaemic control and the sex of 
the general physicians was demonstrated among 610 individuals with T2DM in a 
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study performed in Danish general practices as indicated by the multivariate linear 
random effects model (p=0.76) (258). 
Other studies (e.g., 260) found differences in the Physician Decision Making (PDM) 
style between males and females physicians; nevertheless its impact on the quality of 
diabetes care is doubtful. For example, the adjusted analysis showed that female 
physicians had more participatory visits with their patients compared to male 
physicians (1.3 vs. 3.1, p=0.03; respectively) (260). Also Kenealy et al found that 
female physicians were much more likely than male physicians to refer all newly 
diagnosed people with diabetes to secondary services (Female: 68% and Male: 42.8%, 
p< 0.01) and routine shared care (Female: 74.7% and Male:  58.7%, p = 0.007) (261). 
Many studies in the literature examined the association between the physician‟s 
characteristics including the interest of physicians on diabetes and improved 
glycaemic control. A positive association between the two listed variables has been 
proved by the following studies (262-264), except study (265) as no significant 
difference in improving glycaemic control was found among physicians with more 
or less interest in diabetes compared to other diseases (p=0.44 vs. P=0.50; 
respectively). In this study, several reasons were attributed to the negative 
association between physician‟s characteristics including interest in diabetes 
compared to other disease and the improvement in the average trend in HbA1c over 
time (265). One of the reasons was that other factors rather than those related to the 
physicians such as patients and organization related factors can better explain the 
overall enhancement in the glycaemic control (265). 
Continual medical education is considered to be one of the important tools to update 
health professionals‟ knowledge; however studies found that even with appropriate 
knowledge, health professionals do not always adhere to the guidelines or the 
suggested advice (266, 267).  Lawler et al demonstrated in their study that physicians 
confirmed their requisition for the annual eye test nearly for all their patients; yet 
only 43% of the patients said that they were refereed by their physicians (268).  
Added to the low rate of the eye test referral, only 58% of the patients had HbA1c 
test documented in their billing‟s system, while more than 75% of the physicians 
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stated recommending HbA1c almost for all their patients (268). There are many 
causes for the lack of compliance to the guidelines by physicians as highlighted by 
Lawler et al including: deficiencies in the physician‟s knowledge, lack of physician‟s 
beliefs in the guidelines, patient‟s non-adherence, and implementation problems 
(268).  
 Health care professionals inertia 
Phillips et al have defined clinical inertia in the comprehensive review they carried 
out as a failure of the physicians to initiate or optimize therapy when indicated (240). 
This has been identified by many studies (269-272) of diabetes care as a major 
obstacle to achieving the targets of blood glucose and pressure. 
There are three major causes suggested for clinical inertia: (1) an overestimation of 
care provided; (2) the use of „soft‟ reasons to avoid optimization of therapy; and (3) 
lack of training, education and practice organisation focused on achieving 
therapeutic targets (269-272). 
Clinical inertia is multifaceted; further research is needed to investigate the 
association between clinical inertia and diabetes care. 
Healthcare professionals attitudes and beliefs 
Many studies have stated that doctors describe diabetes as a difficult disease to treat 
compared with other chronic conditions due to the complexity of treatment, 
unavoidability of future diabetes related complications, lack of effective drugs and 
behavioural changes required from the patients to achieve the treatment outcomes 
(273-275).   
Based on the findings from interview studies and surveys (273-275), doctors believe 
that factors related to the organisation such as lack of: support staff or team to work 
with, time, peer encouragement, incentives are more important barriers to good 
quality of diabetes care than their knowledge or attitude. 
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Patient-healthcare professional interaction  
Research has been carried out around the area of patient-healthcare professional 
interaction. Clinicians tend to view their own management based on the treatment 
plan and achieved outcomes while understanding the patient‟s concept about the 
disease and treatment is less considered or ignored in many cases (276). This could 
affect the treatment outcomes negatively as patients might not concur with the 
clinician‟s advice leading to clinician‟s frustration. 
Patient‟s view of the healthcare professionals was identified by one study as a reason 
for not responding to the clinician‟s advice (277). 
 Continuity of care 
Many studies focused on the continuity of care with a primary care provider and its 
association with the improving the quality of diabetes care. Some reported an 
association between continuation of care and improved patient satisfaction (273), 
while it was not always the case with outcomes of treatment (264). For instance in 
Muscat, capital of Sultanate of Oman a qualitative study was carried out to explore 
the perceptions of people with T2DM regarding the medical encounters and quality 
of interactions with the primary healthcare providers, found the lack of continuity of 
care with the same physician a barrier for good diabetes care (229). Added to this 
study Hanninen et al found continuity of care in people with T2DM tends to be a 
crucial factor of good Health-Related Quality of Life (HRQOL) as reflected by the 
HRQOL dimensions including: physical, role and social functioning, mental health, 
health perception and painlessness (264). Better mental health (2.48, 95% CI: 1.16-
5.32), less pain (6.02, 95% CI: 1.82-19.92) and feeling healthier (3.45, 95% CI: 1.52-7.87) 
were found in patients who had a permanent physician- patient relationship for 2- 
years (264). Nevertheless, less satisfactory blood glucose control was reported 
among this group (p=0.41) (264). 
Clinical team 
Positive perceptions of teamwork and team climate are often cited in qualitative 
research as facilitators of good diabetes care ( 252).  
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Emphasizing on the importance of team work in treating diabetes is crucial. In 
Australia, a large population-based study linked the quality of diabetes care based 
upon process of care with the involvement of a diabetes educator in the management 
of people with diabetes (252). Similarly, two other studies (230, 262) proposed a 
relation between the quality of diabetes care with access to a dietician. For example, 
access to hospital dietician reduced the random HbA1c level by a mean of 1.06% 
(p=0.01) in a group of 310 diabetic subjects (262). 
Healthcare professional motivation 
Motivation of healthcare professionals‟ in the management of T2DM is a complex 
issue, and is seen as a collective term covering multiple matters such as the 
healthcare professional‟s interests and intentions when providing quality of diabetes 
care (271). Although “motivation” is an un-specified term (271), its influence on the 
quality of diabetes care has been indicated by previous research (e.g., 242, 243). 
Several authors linked health professional‟s motivation to better therapeutic 
outcomes for patients with diabetes (270, 272). Motivation was one of the common 
health professional factors alluded to by the healthcare professionals themselves in 
many studies (e.g., 242, 243). For instance, healthcare professional‟s motivation was 
identified as one of the top five factors associated with improving either the process 
or outcome of diabetes care in primary care centres in Tunisia (242). However, 
factors affecting the motivation of healthcare professionals in the Middle East in 
general and the Gulf region specifically remain poorly defined and less investigated 
despite the alarming prevalence rate in the region. 
6.5.3.2 Patient factors 
The main factors related to the patients influencing the diabetes care investigated by 
other studies were demographic variables and adherence to treatment. Other related 
factors were studied as well but less frequently such as health beliefs of the patients 
and knowledge of diabetes and psychological factors. 
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Demographic variables 
The main patient‟s demographics have been tested in the literature as either 
potential barriers or motivators of care are: age, sex, duration of diabetes, BMI, 
treatment with insulin, existence of co-morbid diseases, smoking, educational level, 
and ethnicity. 
Evidently as indicated by many studies (e.g., 265, 278, 279) longer duration of 
diabetes was associated with poor glycaemic control. For example, Pringle et al 
found patients who were diagnosed within the previous seven years (n= 153) had 
better control compared to those diagnosed eight or more years (n=153) previously 
(p=0.005) (265). 
However, many studies have linked younger age to poor glycaemic control (e.g., 
280). For instance, Glycaemic control as an example was better in older individuals 
diagnosed with T2DM in HANES 1999-2000 and HANES (III) (1988-1994) as 
reflected by the Odds Ratio (OR)  for people aged between 20-44 and people aged ≥ 
65 years (OR: 1 vs. 1.58; respectively) (281). 
The association between gender of people with diabetes and the glycaemic control 
has been studied, but results are uncertain; however more evidence pointed out that 
females have poorer access to care than males (e.g.,262, 282) as addressed in chapter 
five, section one.  For example, in the UK, one of the studies demonstrated that 
patient‟s sex –females vs. males- affects significantly the value of random HbA1c 
(p=0.01) (265). Also, some studies (e.g., 206) found that female with diabetes were 
less successful achieving blood pressure targets than males (206). 
Furthermore, an association between BMI and poor glycaemic control was found in 
some studies (e.g., 226, 282), but this was not always the case in other studies (e.g., 
280). 
Further factors related to the patients associated with poorer diabetes care based on 
different outcome measures were investigated by other studies included smoking 
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(282), treatment with insulin (283-285), and existence of co-morbidities such as 
hypertension (283-285). 
Added to these patient‟s related factors, some studies found significant influence of 
the socio-economic factors such as deprivation and social status of patient‟s and 
diabetes care as discussed earlier in chapters five, section one. For instance, in the 
UK many studies addressed the differences in the care provided to people with 
diabetes in deprived areas compared to those living in less deprived or privileged 
areas (e.g., 285). In the US for example, un-insured patients tend to receive lower 
quality of diabetes care compared to those insured as indicated by many studies 
(e.g., 285, 286). 
Adherence  
In the care of people with diabetes, several studies have confirmed the importance 
role of adherence, especially to medications as outlined by subdivision 6.5.1.1 and 
section four of chapter five. 
There is great variation in the conceptual or operational definitions of treatment 
adherence. Closely related terms which have been used to refer to the concept are 
compliance, concordance, cooperation, mutuality and therapeutic alliance. The term 
"compliance" was defined by Sackett and Haynes  as  “the extent to which a person‟s 
behaviour (in terms of medication taking, following a diet, modifying habits, or 
attending clinics) coincides with medical or health advice” (287, 288). Failing to 
"comply" is usually associated with blame, whether this blame is placed on the 
doctors or patients (289, 290). Hence, terms like “adherence” or “concordance” are 
now more preferred.  The term "adherence" emphasises the need for agreement on 
part of the patient to the prescriber‟s recommendations, and that there is no reason 
to blame patients should they wish not to follow the treatment (289). While 
concordance focuses on the consultation process in which the doctor and patient 
agree therapeutic decisions incorporating their respective views, and extends to 
involve supporting patients in medicine taking (292). 
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Though non- adherence is a common problem in all chronic conditions; principally 
it‟s problematic in T2DM due to the complexity of treatment regimen including 
drugs and life long duration of the disease  as discussed in chapter five (292). Non- 
adherence has been the focus of many worldwide initiatives such as WHO, which 
addressed in its report 2003 that poor adherence to treatment of chronic conditions is 
a major public health problem (293). This problem imposes a recognizable financial 
burden upon modern health care systems (293, 288). In developed countries for 
instance, non-adherence was found to have a striking magnitude averaging about 
50% (293). 
Added to the financial burden on national economies, many consequences are 
associated with failure to take medications as intended such as therapeutic failure, 
disease progression, loss of productivity and the need for more aggressive treatment 
that can further increase the risk of drug-induced problem (294). 
Research has identified several factors affecting non-adherence and they categorized 
them into: patient related factors, treatment related factors, system related factors 
and healthcare professionals related factors (295-297) 
Type of drugs, degree of behavioural change required, complexity , duration, dosage 
all are examples of treatment related factors that might be associated with non-
adherence to medications (297). However, communication is the most widely 
healthcare professional studied factor in relation to patient adherence to medications 
(272). Improving adherence to treatment could be achieved by adopting a patient-
centred communication style (298). This style of communication involves a shift 
from focusing on the disease itself and it pathology toward thinking about the 
patient as an individual with problems (298). Several organizations related factors 
such as continuity of care and clinic waiting time are believed to influence patient 
adherence to medication (299). 
Despite the decades of research on adherence, there is no “gold standard” to 
measure it. Measuring health outcomes is one of the used methods that have some 
limitations. This method is limited as there is no straightforward relation between 
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adherence and health outcomes (300). Improvement in health could be due to other 
factors such as weight loss or adoption of healthier life style rather than following 
the prescribed regimen (296). 
In T2DM, there is evidence that patients adherence to medication is sub-optimal 
globally as addressed in subdivision 6.2.1.4, and section four of chapter five. For 
instance, a recent systematic review showed high rate of non-adherence to oral 
hypoglycemic drugs and insulin (7-64% vs. 19-46%) (296, 297).  
As explained in chapter five, better glycemic control was associated with adherence 
to the treatment of diabetes medications in many studies. For instance, drop in the 
HbA1c levels by 0.16%  (p<0.001) as a result of 10% increment in the adherence rate 
to oral hypoglycaemic drugs (calculated based on prescription refill data) was 
documented by Schectman et al 2002 (301). Equally, Ho et al found 0.05% reduction 
in HbA1c levels (95% CI 0.08%-0.01) due to improvement in the adherence to oral 
anti-diabetic medications (302).  
 
Other factors 
There are other important patient‟s related factors, but are difficult to measure and 
complex such as health beliefs and physiological factors. Also, there are other 
important factors including stress, family role and late morning hyperglycaemia. 
Nevertheless, in 1990s Simmons et al aimed to identify and then quantify barriers to 
diabetes care using an exploratory qualitative study approach among people with 
diabetes in New Zealand (303). More recently, to achieve the same aim, a cross-
sectional survey of roughly 4000 subjects with diabetes and healthcare professionals 
was undertaken by the same group (304). Several barriers to optimal diabetes care 
were identifies as displayed in table 39. These factors related to the patients are 
evolved around five main themes namely: educational, internal physical, external 
physical (system), psychosocial and psychological. 
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Table 39: Barriers to optimal diabetes care  
 
 
Educational 
 
        Psychosocial           Psychological 
 Low diabetes knowledge 
 
 Lack of public 
awareness 
 
 Health beliefs 
 Low knowledge of 
services 
 Lack of family 
support 
 
 Public health beliefs 
   Poor motivation 
  Communication 
difficulties 
 Low self- efficacy 
Internal physical 
 
  No symptom cues 
 Physical effects of 
treatment 
 
  Difficulty setting priorities 
 Family demands 
External physical   Negative perception of time 
 
 Personal finance issues   Emotional issues 
 
 Poor physical access to 
service 
  Precontemplative stage of change 
(Modified from Ref No: 303, 304) 
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6.5.3.3 Organisational factors 
Many cross-sectional observational studies have investigated the association 
between various organisational factors and the quality of diabetes care. Some 
identified factors tend to be specific to the study setting, and may not be transferred 
to other settings. However, among those transferable factors many have shown 
effects on diabetes care including: practice size and number of staff (227, 242, 243), 
co-operation between primary/secondary care (279, 243), consultation time (242), 
availability of the equipments in the health care setting (242, 243), structured records 
(227), availability of resources and treatment, particularly pharmacological treatment 
(220, 224), practice guidelines (220) and educational programs for people with 
diabetes (227). 
Practice size and number of healthcare professionals 
Many studies (e.g., 242, 243) found an association between the size of the healthcare 
setting and the number of healthcare professionals available with the quality of 
diabetes care. For instance, Campbell et al found from their analysis that large 
practices had higher scores for diabetes care than smaller practices; nevertheless 
higher score for access to care, and patient‟s satisfaction were assigned to smaller 
practices. This important finding in diabetes care emphasises that different types of 
practice may have different strong points (299). 
Co-operation between primary-secondary settings 
Diabetes is a chronic, multi-dimensional disease and even with high quality of care, 
particularly secondary prevention provided to people with diabetes in the primary 
care, expert help from the secondary practices is needed (49). Lack of co-operation 
between the primary-secondary care have been suggested as a barrier for providing 
high quality of diabetes care in some health systems (279). For example, in the UK 
results from 1320 questionnaires were reassuring and showed that roughly 80% of 
the practices receive adequate support from other healthcare professionals from 
secondary care settings, while already 60% have regular contact with them (267). In 
contrast, there was no communication between some primary practices with 
secondary care settings, yet still healthcare professionals feel adequately supported 
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without contact with their colleague working at the secondary healthcare settings 
(267). If supposing integrated diabetes care is provided to the patients, then a 
management protocol for people with diabetes should be shared between primary-
secondary settings; however  only half of the participated practices shared patient 
management protocol with colleagues working at secondary hospitals (273). 
Consultation time 
Many studies (e.g., 273, 268) supported that the length of consultation is associated 
with improving the quality of diabetes care. For instance, among 60 general practices 
in England, the length of consultation was found to be a predictor of quality of care 
(273). They demonstrated that practices with 10 minutes consultation booking 
intervals had higher scores for quality of clinical care compared to those with five 
minutes consultation booking intervals for all the three chronic conditions including 
asthma, angina and diabetes (273). For diabetes, the mean adjusted clinical scores 
(maximum=100) for 5 and 10 minutes consultation booking intervals were (55.1 vs. 
64.6; respectively) (273). 
Other factors 
Other organizational factors studied in the literature influencing diabetes care 
include presence of structured diabetes clinic (178), closeness of ophthalmologist 
(177), and access to health care services (286). Also, there is a growing body of 
evidence that link the improvement in the people with T2DM outcomes with the 
availability of structured recalled care (255). 
Distance between the healthcare providing location  from the patient‟s residence was 
studied as a factor affecting the healthcare. For instance, results from some studies 
(e.g., 242, 243) showed that longer distance between the home and the site of 
primary care is associated with poor chronic care in rural (242) compared to urban 
areas (243). 
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Section two: Methodology 
 
Section two of chapter six presents the methodology employed in this research 
commencing with the qualitative work. The aim of the qualitative methodology is to 
explore and identify factors, both barriers and facilitators that influence the care 
provided to people with T2DM at the diabetes centre of Tawam hospital. This 
section explains the rationale and use of qualitative method and data analysis along 
with common concerns in qualitative methodologies including sampling, access, 
ethical and validity issues. 
6.6 Aim, objectives and research questions 
The main aim, objectives and research questions of this qualitative work are listed 
below. 
Aim  
 To identify factors both facilitators and barriers that affect the quality of 
T2DM care at the diabetes centre based on the perceptions and attitudes of 
healthcare professionals at Tawam Hospital, Al-Ain, UAE 
 Objectives 
 to identify facilitators/ barriers to improving the quality of T2DM care related 
to the healthcare professionals work practices 
 to develop a frame of knowledge from the opinions, understanding and 
experiences of the healthcare professionals regarding the care of people with 
T2DM to improve quality of diabetes care 
Research questions 
 What are the main factors affecting the quality of T2DM care from the 
perceptions, experience and attitudes of healthcare professionals working at 
the diabetes centre at Tawam hospital? 
 What are the specific facilitators/ barriers to improving quality of T2DM care 
based on the experience, perceptions and attitudes of healthcare professionals 
at the diabetes centre at Tawam hospital? 
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6.7 Materials and design 
6.7.1 Rationale for using qualitative approach  
As described by Denzin and Lincoln in their book Handbook of Qualitative 
Research, qualitative research “is a multi-method in focus, involving an interpretive, 
naturalistic approach to its subject matter. This means the qualitative researchers 
study things in their natural settings, attempting to make sense of, or interpret, 
phenomena in terms of the meaning people bring to them” (305). The main goal of 
the qualitative research is the development of concepts that help us to understand 
social phenomena in natural settings, giving special consideration to the meanings, 
experiences and views of all the participants. 
There are several potential strengths of the qualitative research that are applicable to 
the health care setting.  In my case strengths that are related to this initial research 
are: (306-309) 
 understanding the barriers to quality of T2DM care and identifying obstacles 
to change  
 identifying facilitators to quality of T2DM care 
 enabling access to areas not amenable to quantitative research like attitudes, 
perceptions and beliefs of healthcare professionals 
The key focus of the research design is the consideration of best answer to the 
research questions. Based on the strengths listed above and the aim of this study to 
identify factors influencing T2DM care from the perceptions and attitudes of 
healthcare professionals; qualitative research was identified as an appropriate 
method to reach the goal of this research. 
6.7.2 Why semi-structured interview? 
After identifying the qualitative methodology for this study, the issue of developing 
and choosing appropriate research tools arise. This research aims to investigate and 
identify factors influencing the care provided to people with T2DM based on the 
beliefs, experience, attitudes and perceptions of healthcare professionals. In 
conformity with the aim of this study which depends on the healthcare 
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professional‟s perceptions, beliefs and experiences; semi-structured interviews were 
chosen as a mode of data collection.  
6.7.2.1 Definition and rationale 
There are three types of qualitative research interviews including: unstructured, 
semi-structured, and in-depth interviews. The unstructured interviews are the least 
structured interview followed by depth and then semi-structured (310). The first 
type is characterised as a participant-guided approach, and is useful when the 
researcher knows little about what is inquired (311). Secondly, in-depth interviews 
are designed to answer one or two issues but with much more details. Besides these 
two modes of qualitative interviews, the semi-structured interviews are conducted 
on the basis of a loose structure consisting of open-ended questions that define the 
area needed to be explored (311). 
“Semi-structured interviews are conducted on the basis of a loose structure 
consisting of open-ended questions that define the area to be explored, at least 
initially, and from which the interviewer or interviewee may diverge in order to 
pursue an idea or response in more detail” (310). This type of interviews, allows 
detailed exploration of participants‟ ideas about the topic being discussed (310). 
Within semi-structured interviews, a basic structure that defines the main topic is 
used; however discussing ideas and understandings that may not be expected by the 
researcher is flexible (312). This type of interviews gives the participants the freedom 
of response and description to illustrate the concepts (313). 
Based on the purpose of this study which needs gathering data regarding the 
interviewees‟ experience, perceptions, attitudes, beliefs and recommendations; semi-
structured interviews were used. A fixed set of topics were discussed with 
participants using a set of open-ended questions (312). 
6.7.3 Sampling 
6.7.3.1 Purposive sampling 
In contrast to quantitative research, qualitative research aims to reflect the diversity 
within a given population, rather than aspiring to be statistically generalisable or 
198 
 
representative (313). The qualitative method however, desires the perception gained 
from the study would show useful in other context that had likeness (313). 
Given the similarity in the health system and structure; we believe that findings 
from this study could be generalized and beneficial to other diabetes centres that 
provide secondary/ tertiary care to people with diabetes in Al-Ain and Abu Dhabi. 
Purposive or theoretical sampling is a specific type of non-probability sampling. In 
this sampling method, the process of sampling and data collection are guided by the 
objective of developing theory or explanation (314). Purposive sampling allows the 
researcher to select the most productive sample called „information rich‟ to be 
included in the study and answer the research question (314). Based on the 
qualitative aspect and objective of this initial study, purposive sampling is the ideal 
method for selecting participants. 
Homogenous purposive sampling was used to recruit participants as they were 
chosen to be „information rich‟. Nine semi-structured interviews were conducted 
with three diabetes specialists, two educators, two nurses, one dietician and one 
podiatrist. Table 40 provides a brief outline of some of the characteristics of the 
healthcare professionals who participated in this study. 
6.7.4 Target population 
Diabetes healthcare professionals working in the diabetes team including dieticians, 
specialist physicians, educators, nurses, podiatrists at the diabetes centre at Tawam 
Hospital. 
6.7.5 Selection criteria 
- Experience of the healthcare professionals at the diabetes centre at Tawam 
hospital (> one year) 
- Job position of the health care providers (dietician, specialist physician , 
educators, nurse, podiatrist) 
- Number of available healthcare professionals 
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6.7.6 Setting and participants 
The study was carried out in a diabetes centre located at a tertiary hospital in Al-Ain, 
Abu Dhabi. This centre provides resourceful inpatient and outpatient service for all 
people with diabetes including obstetric patients (230). It focuses largely on 
educating the people with diabetes and their families regarding diabetes and its 
management and educating them on the insulin pump use (230). Additionally, the 
centre has several clinics such as diabetic foot and paediatrics diabetic. 
 
This particular centre was chosen because of several reasons. Firstly, the study aims 
to identify factors affecting diabetes care both barriers and facilitators based on the 
perceptions, beliefs, experience and attitudes of the healthcare professionals. In this 
centre the diabetes care is provided through a team composed of different healthcare 
professionals such as physicians, nurses, diabetes educators and podiatrists. This 
would allow targeting the information rich subjects needed to achieve the study aim. 
Also, many of the healthcare professionals working in this centre are assigned to 
different primary care settings on regular basis; hence their experience and 
perceptions about the barriers and facilitators to healthcare professional‟s motivation 
in both settings would be utilised. 
 
Interviews were conducted with diabetes healthcare professionals at the diabetes 
centre at Tawam Hospital, Al-Ain. They were usually undertaken at the offices of the 
healthcare professionals at Tawam hospital. 
6.7.7 Sample recruitment 
A list of the healthcare professionals who work in the diabetes centre was obtained 
from the head of the centre along with their hospital‟s email addresses and the date 
of joining the centre. Healthcare professionals who had worked in the centre for one 
year or more, managing people with T2DM and were available during the interview 
period were contacted by email (see appendix 23). From the ten healthcare 
professionals who were contacted, nine agreed to be interviewed; therefore the 
response rate was 90%. 
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The interviewer (LA) conducted all the interviews in English, audiotape them and 
later simultaneously transcribed them. 
Table 40: participant‟s characteristics 
Interviewee Years worked in the profession 
Diabetes Specialist 1  >3 years 
Diabetes Specialist 2  >3 years 
Diabetes Specialist 3  >3 years 
Diabetes Educator 1  1-3 years 
Diabetes Educator 1  1-3 years 
Nurse 1  >3 years 
Nurse 2  1-3 years 
Dietician 1  1-3 years 
Podiatrist 1  1-3 years 
 Range for total sample: 5-15 split between different specializations or duplicate. 
6.7.8 Access issues 
6.7.8.1 Ethical approval 
In my case, ethical approval was granted for the study by Al-Ain medical district 
(refer to appendix 17). I therefore had official permission to visit the diabetes centre 
and interview the healthcare professionals, although further permission was 
required and obtained from the head of the centre. 
6.7.9 Interviews  
6.7.9.1 Data collection method 
Prior constructing the interviews, two procedures were undertaken namely planning 
and designing the interview questions and piloting. 
Planning and designing interview questions 
Firstly, in the planning process the following steps were followed: (1) listing all 
important topics of interest to the aim of the study; (2) assembling appropriate 
questions; (3) listing additional items and response formats that need to be 
developed; and finally (4) relating the questions to the aim of the interview. 
This was guided by literature review carried out on the factors that influence the 
care provided to people with T2DM addressed in section one. Also, I utilised from 
the semi-structured interview questions that were carried out by Hugh Alberti with 
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key informants in Tunisia to explore factors influencing the management of diabetes 
(242). 
Based on the findings from the literature on the factors that influence the T2DM care, 
which are chiefly classified and related to the patient, healthcare professional and 
organization as addressed in section one,  and the planning process, the interview 
questions were written. Structurally, the interview was divided into nine key 
sections as detailed in section 6.5.3.  
Questions 
As the format of the questions can influence the answer and comprehensives of the 
response, it was very important to spend sufficient time planning and formatting 
accurate and well-designed questions that meet the aim of the research. Therefore, 
some steps were undertaken to support the process of questions formatting and they 
were: (315) 
(1) Order and wording 
Orders:  the interview questions were divided into different sections, each section 
focuses on a specific theme. Under each section, questions were designed to explore 
and investigate more about the factors both motivators and barriers to diabetes care 
at the centre. 
Wording: to avoid ambiguity and retain rapport, questions were formatted in a 
simple, short, familiar words and phrases. Questions were designed to be short 
because people usually do not remember long ones and tend to answer the last part 
of the question only. For instance, to ask participants about their perception of the 
working in the team, I asked the following question “How do you perceive working 
with others?” To avoid confusion double negatives or tagging “or not”, and double 
barrelled questions where two questions are included in one question were never 
used. Tagging was avoided for the reason that the inadequate statement of the 
alternative opinion can be confusing. 
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(2) Questions form 
The interview included a combination of open and closed questions for examples 
refer to the interview guide (refer to appendix 24). For the clarification of reasons 
and explanation, I started by asking close question, then I followed it with open 
ones. For instance, I wanted to identify barriers for the involvement of other 
healthcare professionals in the diabetes team; therefore I asked a closed question to 
list the suggested professions for involvement in the diabetes team. Then an open 
question was asked to identify barriers from involving them as addressed below. 
 Which other health professions do you think could be involved in the team? 
 If any, what are the barriers from involving them? 
PROMPT IF NOT MENTIONED 
What about lack of diabetes training? 
What about lack of resources? 
What about cost? 
A combination of open and close ended questions was used because using open-
ended questions can help in collecting rich information in some cases, but they are 
demanding for the respondent; therefore the gathered data could ranged from rich 
to poor. 
(3) Type of questions 
Questions were designed to be clear, specific, and in a case of complex questions 
they were split down into a series of simpler and shorter questions to be easier for 
understanding. For instance, I was looking to identify factors affecting the 
motivation of healthcare professionals in the diabetes centre, but as the term 
„motivation‟ is not clear enough, I asked a series of questions as listed below. 
 How would you describe care providers‟ motivation in managing people with 
diabetes? 
 What things do you think increase your motivation in managing people with diabetes 
in this centre? 
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 What things do you think decrease your motivation in managing people with diabetes 
in this centre? 
Some type of questions were avoided for specific reasons including: (1) leading 
questions as they bias respondent‟s replies; (2) loaded questions as they bias the 
respondent in a particular direction leading to biased answer (314, 315); (3) balance 
questions which are a form of leading questions as they lead to the failure in 
specifying alternatives clearly in the questions; and (4) attitude questions that are all 
worded positively as some people are automatic “yes” sayers instead for instance 
questions were asked in the format of “ Do you think”. For example, what do you 
think are the barriers from spending adequate time with each patient? 
Piloting the interview questions 
Secondly, after the planning process, piloting was carried out. Before piloting the 
interview questions with the population of interest, the interview questions were 
sent to two experts in the qualitative research (Y. P. and D. D) to acquire advice and 
feedback on the questions design. After receiving the feedback, some modifications 
were made on the questions, and they were tested on two colleagues to ensure 
validity and coverage; afterward questions were more formally developed and 
piloted. I used the “Think aloud” testing to ask some colleagues about what they 
think when they listen or read the interview questions and how they interpret with 
them to ensure the validity of the interview questions (315).  Based on the comments 
from the experts and those abstracted from the pilot interviews, modifications on the 
interview questions were done. Then a debriefing session with the supervisor took 
place to help in changing any questions that were difficult to respondent or 
misunderstood to finalize the interview questions. 
Finally, a second pilot was carried out with some participants before carrying out the 
initial interviews to modify any questions that were vague or difficult to understand. 
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6.7.9.2 Interview processes 
Figure 11: Interview processes 
 
 
 
As addressed in figure twelve, the interview underwent several steps starting with 
selection of information rich individuals; followed by the recruitment process where 
potential participants were contacted via emails and sent a cover letter explaining 
the purpose of the study and assuring the confidentiality (see appendix 23). This was 
finalized by piloting and conducting the interviews. 
The interviewer plays an important role in the interview process, and many 
evidence pointed out that interviewer with good persuasion skills and who are 
motivated would probably achieve higher response rates (314-316). Hence, in this 
case I carried out several steps to minimize the interviewer bias including: 
(1) I attended some training sessions and was trained by experts in social 
research to grasp the needed skills for carrying out semi-structured interviews 
and communicating effectively with the participants. In brief, I was trained on 
many essential skills including:  appearing and speaking neutral and not 
being surprised or disapproving in relation to response, avoiding the 
judgmental manner, expressing polite interest, asking a question in a non-
biasing and non-leading ways, and motivating interviewee to respond by 
making them feel valued. 
(2) I reviewed the interview questions one by one with the research team 
composed of the supervisor and two researchers to ensure that I understand 
why each question is being asked, what does each question mean, and to 
clarify any final ambiguities. 
(3) I followed the Patton strategies to keep or maintain control of the interview 
including: knowing the purpose of the interview; asking the right question to 
get the needed information; and giving appropriate both verbal and non-
verbal feedback (332). 
Selection of 
interviewees 
Recruitment of 
interviewees 
Piloting the 
interview 
Conducting the 
interview 
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6.7.9.3 Recording the interview 
There are different ways to record qualitative interviews including notes written at 
the time and afterwards and audio taping. In my case, I used audio tapes to record 
the interviews; permission of the participants was sought explaining the importance 
of audio tapes in helping the interviewers checking the accuracy of the reported 
interviewee views. In brief, this method was used rather than other methods to 
record the interviews because of several reasons including: writing notes at the time 
can interfere with the process of interviewing; and writing after wards can lead to 
missing out some details. 
6.7.9.4 Interview guide 
The concept of the interview guide was structured to cover all the factors both 
facilitators and barriers affecting diabetes care in the diabetes centre of Tawam 
hospital. From the literature review as addressed in section one, evidence reveals 
that factors influencing the care of diabetes are classified under three key groups 
namely patient, organization and healthcare professionals. Under each group as 
found from the literature review, several facilitators and barriers to providing high 
quality of diabetes care are listed. 
Taking this in mind, the interview guide was designed to collect the needed data on 
the factors affecting diabetes care at the diabetes centre related to these three main 
active players in diabetes care (refer to appendix 24). 
The interview guide is divided into nine main sections including: introduction; 
warm-up; overall factors affecting diabetes care; motivation of healthcare 
professionals; training healthcare professionals; team work; and healthcare 
professionals attitudes and beliefs. The final section included discussing other 
factors that were not mentioned or covered in the interviews, and recommendations 
to improve the care provided to people with diabetes in the centre. A brief summary 
of each section is documented below. 
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Introduction 
The interview was started with giving an introduction about the interviewer, the 
study and its aim. Also, a brief explanation of the ethical issues such as 
confidentiality and anonymity was given.  
Warm-up 
After the introduction, some questions were asked to know more about the 
participants e.g., role in the management of diabetes, nationality and experience in 
the diabetes centre. Also, the participant‟s overall perception about the management 
of diabetes in the centre was viewed. 
Factors affecting diabetes care 
In this section, questions were asked to identify in general factors both facilitators 
and barriers to providing high quality of diabetes care in the centre. 
Motivation of healthcare professionals 
As motivation of healthcare professionals in the management of diabetes is a 
complex area, a question was asked firstly to describe motivation. After that, 
questions asked were focusing on the factors including both motivators and barriers 
to healthcare professional‟s motivation in the management of diabetes in the centre.  
Training healthcare professionals 
Training healthcare professionals is a wide topic; therefore to narrow it down, I 
started by asking a question regarding the meaning of training to each participant. 
Then this was followed by questions aimed to specify the sorts of training needed in 
the diabetes centre, and identify both barriers and motivators to training. 
Team-work 
I started this section by asking about the composition of the team that provide 
diabetes care in the diabetes centre. Then, I asked participants about their 
perceptions of the team they work with. Questions about the rewarding and 
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problematic aspects of working with the diabetes team in the diabetes centre were 
asked. 
After that, questions on the other health professions needed to be involved, and 
barriers for their involvement in the team were inquired. 
Patient-healthcare professionals interactions 
In this section, questions were asked to identify factors both barriers and facilitators 
for providing effective patient- healthcare professional interactions. Questions on the 
consultation time, and barriers for spending adequate time with patients were 
requested. 
Healthcare professionals attitudes and beliefs about T2DM 
I aimed in this section to understand and find the perceptions of healthcare 
professional in the diabetes centre on T2DM, and reasons for these perceptions. After 
that, I was looking to know if these perceptions about T2DM influence the 
management of diabetes in the centre. 
Other factors/ recommendation 
Participants were encouraged to list any other factor that I didn‟t mention or discuss 
in the interview. Also, I asked the participants if they have any recommendation to 
improve the care provided to people with diabetes in the centre. 
6.8 Logistics 
Materials needed for each interview included: interview guide, tape recorders, tapes 
and extra batteries. 
6.9 Data analysis 
Based on the nature of the qualitative research, the analysis of its data is a continual 
process commencing during data collection, and counting throughout the time of the 
study (316, 317). I used thematic analysis to analyse the data from the interviews. 
Further explanation on thematic analysis is provided below. 
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6.10 Thematic analysis  
Definition and rationale 
There are different approaches for the analysis of qualitative data including thematic 
content, grounded theory and frame work analysis. Based on the aim of the study to 
explore and identify factors both barriers and facilitators that influence quality of 
T2DM at Tawam hospital from the perceptions of healthcare professionals; thematic 
analysis was followed. 
“It is the analysis of the data to categorize the recurrent or common themes” (317). 
This method was developed to meet the needs of investigating the experiences, 
meanings, and the reality of the participants which help achieving the study target 
(317). 
Furthermore, I followed several processes in order to analyse the collected data 
thematically. These processes included the following: (315-317) 
(1) Categorizing  respondent‟s accounts in ways that could be summarized 
(2) Comparing the accounts with each others to classify themes that are common 
and re-occur. In this step, I used the “scissors and paste” technique to ease the 
comparing process. 
(3) Coding the identified themes, elements of coding may be predetermined by 
the research questions. The supervisor was asked during the data analysis 
stage to agree on the evidence for themes and codes. The simple, early system 
of classification evolved into more sophisticated coding. 
Data included  
Transcripts of semi-structured interviews with healthcare professionals at the 
diabetes centre of Tawam hospital. 
Stages of analysis 
All documents were systematically searched and coded into nodes based on the 
identified potential barriers or facilitators to T2DM care at the diabetes centre of 
Tawam hospital. During the analysis process and based on the new data collected, 
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nodes were regularly reviewed and re-grouped or re-classified. However, both 
barriers and facilitators were coded into the same nodes during the coding process. 
Later, while investigating the most commonly coded nodes, the factors were 
identified as to whether it was a potential barrier or facilitator to good care or both. 
As seen in figure thirteen, I followed five principal stages in the analysis of the data 
including: (1) familiarization, (2) generating initial codes, (3) searching for themes, 
(4) reviewing themes, defining and naming themes, and (5) producing the report. 
Each stage is described below. 
(1) Familiarization 
Familiarization started with the collection of data from the healthcare professionals 
at the diabetes centre, and then rechecking the transcripts to ensure accuracy. Before 
starting the coding process, I listened to the audio tapes repeatedly and read the 
transcripts to be familiar with the data. 
(2) Generating initial codes 
At this stage, the transcripts were read and re-read before giving initial codes. The 
initial codes were constructed manually using highlights and underlines, and then 
saved as Word documents. In my case, manual coding had many advantages: (1) it 
allowed me to code and abstract the themes in a much more casual position, as the 
coding could be done without switching on the computer; (2) I benefited from being 
close to the data in the constantly applied comparison technique. 
To allow easier access to the data, I established five folders depending on the source 
of data including: diabetes nurse, educators, dietician, podiatrist and specialist 
physician. Each transcript was saved in the form of a Word document, and for 
coding process the right half of the page was kept blank, after printing each 
transcript individually the coded sentences were underlined for easy search. After 
accomplishing the coding for each transcript, all the codes were written on a 
separate page and put on the front page of the transcript with the notes indicating 
the location of the codes such as „ shortage of staff‟ p.11, line 13.  
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To make the comparisons between different participants or within the same 
participant easier, I pulled all sub-categories in one document. By using constant 
comparison to identify the relationship between codes, themes and different levels of 
themes, these sub-categories were sorted into piles of themes. Following this process, 
the categories were formed, and any data that failed to enter the sub-categories were 
put in a temporary Word file. 
(3) Reviewing themes 
Sub-themes including mainly motivators and facilitators influencing the care 
provided to people with diabetes, and codes were refined by reading and reviewing 
extracts. Also, I used the input from the supervisor to refine and made these sub-
themes and codes sound coherent. The unfitted codes were re-examined to be 
further refined.  
(4) Defining and naming themes 
In this stage, I tried to draw the themes together to examine the meaning behind 
them and elaborated them to define and refine all of the themes. Four chief themes 
were generated namely: (1) motivation of healthcare professionals in the 
management of diabetes; (2) training healthcare professionals; (3) Emirate‟s cultural 
impact on the diabetes management; and (4) team-work. Under each main theme, 
sub-themes including facilitators and barriers for providing high quality of diabetes 
care were generated. 
(5) Producing the report 
I wrote the results that I found from the data analysis, and compared my findings 
with studies carried out elsewhere. After that, the report was submitted to the 
diabetes centre. To make the findings available for other healthcare professionals, 
policy makers, managers and researchers, results were submitted and accepted for 
publication in a scientific journal (see annex 1). Data from this report can be used as 
a baseline for other researchers in the UAE and Gulf countries as well to further 
identify the factors affecting diabetes care and optimize this care. 
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Figure 12:  Flow chart for thematic analysis 
 
                                                   Familiarization with the data 
 
                                                        Generating early codes &  
                                                           Searching for themes 
                                                        
Reviewing themes 
 
                                                  Defining and naming  
                                                          themes 
 
Reporting the findings 
 
6.11 Confidentiality and anonymity 
Issues of confidentiality and anonymity are significant in the field of qualitative 
research, as particularly during the informal discussion times, participants may 
reveal more information than they intended. In my report, publication and thesis, all 
sources of quotes are given as a role of the source (nurse, diabetes educator, 
dietician, etc.) to protect confidentiality and anonymity of the participants. 
6.12 Personal bias 
In my case, there were two factors that could potentially affect the integrity of my 
research and its presentation. Firstly, I was requested to write a report of my 
findings to the Al-Ain medical district aiming to improve the care provided to 
people with diabetes at Tawam hospital. Potentially, I may have sought to present 
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the findings in a favourable light. Secondly, my own positive experience of Tawam 
hospital and some of the healthcare professionals could influence my writing of the 
article, report and indeed this study. However, being aware of these potential biases 
I have sought in all results from the interviews to present both the potential positive 
and negative findings based on the barriers and facilitators to care identified. Using 
my reflexive approach, made these potential biases explicit and reflect on their 
potential impact. 
6.13 Language issues 
UAE is an Arabic country where Arabic is the first spoken language. However, 
based on the different cultural backgrounds of the healthcare professionals at the 
diabetes centre of Tawam hospital, English is used as a language of communication 
between them. Hence, all the interviews were carried out and transcribed in English. 
6.14 Validity issues 
The rigours or validity of qualitative research is an essential issue. I followed several 
steps to ensure the quality of the qualitative research and the obtained analysis was 
rigours: (313-317) 
(1) I provided clear exposition of the actual followed data collection and analysis 
method including a short description on the method of coding development 
as presented in section 6.7.6.1 to ensure transparency and maximize 
reliability. 
(2)  I included sufficient data in the written account to allow the reader to judge 
whether the interpretation offered is adequately supported by the data, 
examples are available in section three. 
(3) I discussed elements in the data that contradict or appear to contradict to 
maximize the validity. They are called disconfirming evidence “deviant 
cases”. Examples are available in section three. 
(4) I compared findings from this work with the findings from others in the same 
field to ensure that the work is comparative. Section four includes comparison 
of my findings with other studies in the same field. 
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(5) I followed the following steps to maximize reflexivity including: theoretical 
openness; awareness of the social setting of the research itself, awareness of 
the wider social context; getting rid of  personal and intellectual biases at the 
outset of any research report to enhance the credibility of the findings; and 
methodological openness.  Therefore, prior to the study, I wrote an initial 
declaration of all my beliefs and reflected on it during the analytical process. 
(6) I used respondent validation by presenting back a summary of the findings 
orally to the participants; to compare my account with the participants, and to 
establish the level of correspondence between the two sets. The reactions and 
comments of the participants were noted  
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Section three: Results of the thematic analysis 
 
This section presents the findings of the thematic analysis, describing the most 
frequently cited factors affecting the care provided to people with diabetes by 
healthcare professionals working at the diabetes centre, Al-Ain. The results fulfil the 
following objective: To identify factors both barriers and facilitators affecting the 
quality of T2DM care in the diabetes centre, Tawam hospital. 
 
Four principal themes namely: (1) motivation of the healthcare professionals, (2) 
training healthcare professionals, (3) Emirate‟s cultural impact on diabetes care, and 
(4) team work were identified from the thematic analysis and discussed in this 
section respectively. 
6.15 Coding  
117 codes were identified from the semi-structured interviews.  
6.16 Prioritising the factors 
The frequency of each factor was coded, counted and classified based to its sources 
including diabetes specialist, nurse, educators, dietician and podiatrist. The aim was 
to give a general idea of the most frequently cited factors by the sources.  
Quotations from interviews have been selected to represent the themes most 
commonly cited. 
6.17 Results  
As listed in table 41, healthcare professionals mentioned various factors influencing 
the care they provide to people with T2DM. Some of these mentioned factors were 
believed to be facilitators for providing or improving the quality of diabetes care, 
while others were believed to be barriers. 
Under each chief theme, when applicable sub-themes including either facilitators 
and/ or barriers were documented. These motivators and/ or barriers were related 
to the three main active players in the care of T2DM as addressed in sections one and 
two including: patient, healthcare professional and organization. Added to those 
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main players, other factors related to the culture such as language differences were 
identified and addressed in this section. 
Noticeably, there was an obvious overlap between factors related to the patients, 
healthcare professionals and organisation affecting the T2DM care in the diabetes 
centre. 
„I believe that the care we provide to diabetic patients is affected by many things 
related to patients, organization and healthcare professionals. Identifying these factors 
could play a role in improving the quality of diabetes care. The roles of care providers 
and patients are very important, and their co-operation can lead to successful 
management of the disease‟. (Specialist Physician) 
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Table 41: The top twenty factors influencing the quality of diabetes care at the diabetes centre 
 
Factors Total Diabetes 
specialists 
Nurses Educators Dieticians Podiatrists 
1. Motivation of care providers 
 
8 3 2 2 0 1 
2. Heavy workload 
 
8 3 2 2 1 0 
3. Patient‟s characteristics 
 
      
3.1 Patient‟s age 
 
7 2 1 2 1 1 
3.2 Cultural background of the patients 
 
7 3 1 1 1 1 
3.3 Patient‟s adherence to the management plan 
 
7 3 1 2 1 0 
3.4 Patient‟s co-ordination regarding behavioural changes 
 
6 3 0 2 1 0 
3.5 Patient‟s gender 
 
5 1 1 1 1 1 
4. Care provider- patients relationship 
 
6 1 1 2 1 1 
5. Poor role of the PHC sector 6 3 1 1 0 1 
6. Language differences between care providers and 
patients 
6 2 2 1 0 1 
7. Effective team work 6 2 1 1 1 1 
217 
 
8. Lack of clinical pharmacist 5 2 1 1 1 0 
 
9. Training healthcare professionals 
 
      
9.1 Training care providers on the skills needed for 
behavioural changes 
 
5 1 1 2 1 0 
9.2 Training care providers on communication skills 4 1 1 1 1 0 
9.3 Training nurses on diabetes management  4 2 1 1 0 0 
10. lack of general physician within the centre 
 
4 3 0 1 0 0 
11. lack of the involvement of the social workers with the 
centre 
 
4 2 1 1 0 0 
12. Shortage of diabetes educators 
 
4 1 1 2 0 0 
13. lack of patient‟s awareness regarding diabetes and its 
complications 
 
4 1 1 1 0 1 
14. Lack of resources 
 
3 2 0 0 1 0 
15. Lack of staff regular meeting 
 
3 2 0 0 0 1 
16. Lack of co-ordination with the lab department 
 
3 3 0 0 0 0 
17. Lack of organization 3 2 1 0 0 0 
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18. Time management skills of care providers 
 
3 1 1 1 0 0 
19. Non-adherence to the appointments by patients  
 
3 2 1 0 0 0 
20. Lack of ophthalmologist 
 
3 2 0 1 0 0 
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6.17.1 Motivation of healthcare professionals (Theme one) 
Motivation of healthcare professionals was seen as a collective term covering 
multiple issues such as the healthcare professional‟s interest and patient‟s role and 
response. 
The healthcare professionals working at the diabetes centre described the term 
„motivation‟ in different ways; however it was chiefly expressed as the interest to 
manage people with diabetes, desire to achieve treatment targets and prevent 
diabetes related complications. 
„For effective management of diabetes all care providers should be motivated and 
interested about the disease and its management. They must know and update their 
knowledge regarding diabetes and its treatment‟. (Specialist Physician) 
In this study, the identified potential factors were classified as either facilitators or 
barriers to the healthcare professional‟s motivation in the diabetes care as seen in 
tables 42 and 43 respectively.  Several facilitators and barriers to the healthcare 
professional‟s motivation in the management of diabetes were identified and were 
sub-classified and related to the patient, healthcare professionals and organization as 
documented below.  
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Facilitators 
 
 
Total Diabetes 
specialists 
Podiatrist dieticians educators nurses 
 
Patients related 
 
 
 
 
 
 
 
 
 
 
 
 
 
Compliance to the treatment regimes 
 
8 3 1 1 2 1 
Awareness on diabetes and its complications 
 
8 3 1 1 2 1 
Appreciation of healthcare professional‟s efforts in the 
management of diabetes 
 
7 3 1 1 2 0 
Providing feedback to the healthcare professionals 
 
7 2 1 1 2 1 
Patient‟s characteristics 
 
6 1 1 1 2 1 
 Age 
 
5 1 0 1 2 1 
 Gender 
 
4 1 1 1 1 0 
 Educational level 
 
 
8 3 1 1 2 1 
Healthcare professionals relates 
 
      
Good communication skills 
 
8 2 1 1 2 2 
Good time management skills 
 
6 1 1 1 2 1 
       
       
Table 42: Facilitators to the motivation‟s of healthcare professionals 
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Organization related 
 
      
Satisfaction of payment 9 3 1 1 2 2 
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Barriers 
 
 
Total Diabetes 
specialists 
Podiatrist dieticians educators nurses 
 
Patients related 
 
 
 
 
 
 
 
 
 
 
 
 
 
Non-compliance to the treatment regimens 
 
8 3 1 1 2 1 
Lack of awareness on diabetes and its complications 
 
8 3 1 1 2 1 
Patient‟s characteristics 
 
 Literacy 
 Elderly 
 
 
 
8 
7 
 
 
3 
2 
 
 
1 
1 
 
 
1 
1 
 
 
1 
2 
 
 
1 
1 
Misunderstanding the role of diabetes educators 
 
7 2 1 1 2 1 
Preference to receive the entire management from the 
physicians 
 
7 3 0 1 2 1 
Fear from attending appointments with the podiatrist 6 2 1 0 2 1 
 4 1 1 1 1 0 
Un-willingness to spend sufficient time with healthcare 
professionals 
 
8 3 1 1 2 1 
Healthcare professionals related 
 
      
Perceptions and attitudes about diabetes 
 
5 1 0 1 2 1 
       
       
       
Table 43: Barriers to the motivation of the healthcare professionals 
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Organization related       
 
Heavy workload 
 
8 
 
 
3 
 
0 
 
1 
 
2 
 
2 
       
Preference to receive care from the secondary/ tertiary care 
 
Interruptions during consultations 
 
Lack of incentives 
6 
 
6 
1    
3 
 
1 
 
0 
0 
 
           1 
 
 1 
1 
 
1 
 
0 
1 
 
2 
 
0 
1  
 
1 
 
0 
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Perceived facilitators to the motivation of healthcare professionals 
Patient related factors 
Participants attached importance to the role of patients in increasing their 
motivation. It was felt if patients co-operated with them, complied with treatment 
regimens or plans, followed their recommendations and instructions, and were 
aware of the nature of their disease then therapeutic targets can be achieved and 
diabetes related complications can be either prevented or delayed. Healthcare 
professionals expressed satisfaction when their efforts to manage each case were 
appreciated by their patients. Other interviewees felt satisfied when they received 
positive feedback from their patients regarding the care they provided. 
 
„Enrolling patients in the treatment strategy is an important tool to achieve the 
desired targets. If the patient understands clearly what is needed from him/her then 
achieving the treatment targets would be easy. When the targets are achieved I feel 
satisfied and motivated to manage the case‟. (Specialist Physician) 
 
„Active role of the patients in the management of their disease and their co-operation 
with the care providers are important. Patient is the main key and their active 
participation in the management plan is associated with providing high quality of 
diabetes care‟. (Specialist Physician) 
„When patient‟s respond to my treatment instructions and recommendations and the 
targets are achieved I feel rewarded and motivated‟. (Specialist Physician) 
When healthcare professionals were asked about patient characteristics that 
impacted their level of motivation, they identified characteristics including age, 
gender and educational level. For instance, participants noted that in most cases 
patient who are highly educated comply with treatment plans and achieve target 
outcomes more successfully. 
 
„I feel motivated when I deal with patients who are educated, they can respond to my 
recommendations and instructions more easily and effectively compared to non-
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educated patients. I explain for them the diet plan they have to follow and discuss the 
reasons for that, they agree and adhere to the plan which assist achieving the 
treatment targets successfully‟. (Dietician) 
 
„Planning the treatment strategy with the educated patients is much easier than with 
illiterate. From my experience at the diabetes centre, I believe that educated patients 
reach the treatment much easier and quicker than illiterate patients‟. (Specialist 
physician) 
 
Healthcare professionals related factors 
Good communication and time management skills were common themes among 
healthcare professionals who openly expressed that the nature of their effective 
interactions result in increased level of motivation regarding the management of 
their patients. Healthcare professionals at the diabetes centre also revealed that 
communication skills such as encouraging patients to take part in consultation, 
keeping good eye contact and attentive listening help to facilitate better interaction 
between healthcare professionals and the patients. In most of the cases, participants 
shared feeling pleased, highly motivated and satisfied when they were able to 
communicate effectively with their patients. 
 
„Being friendly with the patients is important to build a good relationship. I try to 
listen to them and encourage them to ask any question so that we can communicate 
effectively‟. (Diabetes Educator) 
 
Organization related factors 
Healthcare professionals at the diabetes centre showed satisfaction with regard to 
the amount of payment they receive and thought that they are well paid for the 
rigorous work they completed daily, and which, in turn increased their enthusiasm 
and motivation regarding the management of their patients. 
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Perceived Barriers for the motivation of healthcare professionals 
Patient related factors 
Healthcare professionals identified some patient-related factors as key barriers to 
motivation. Misunderstanding the role of diabetes educators, non-compliance with 
treatment plans including medication use and lack of awareness of diabetes and its 
complications were common themes that emerged among participants who openly 
expressed frustration over expected therapeutic outcomes. 
 
„Patients at the diabetes centre are still not aware of the role of the health educators in 
diabetes management which do not only affect the treatment plan with some cases, but 
also the relationship between the healthcare provider and patients is affected 
negatively. The diabetes educators feel that some patients do not appreciate their 
efforts in diabetes management; therefore they become less motivated to be enrolled in 
the treatment strategy‟. (Diabetes Educator) 
 
„Many patients are not aware of the complications related to diabetes, and the 
importance of effective management of the disease which make achieving the treatment 
goals challenging‟. (Podiatrist) 
Patient‟s characteristics other than educational level, including patient‟s age was 
revealed by the healthcare professionals to be one of the barriers to deliver high 
quality of T2DM care. In specific, healthcare professionals commented that they felt 
communicating with people with T2DM at successive age challenging because of 
several reasons. One of the reasons is the need for providing intensive care for older 
patients as the prevalence of diabetes related complications is higher among this age 
group. Therefore, it‟s important to communicate effectively with those patients in 
order to reach the treatment goals and normalize their metabolic indicators such as 
HbA1c and blood pressure measurements.  Effective communication with old 
people with T2DM obliges special skills as they might be exposed to hearing or 
vision deficits related to the age. 
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„It‟s very difficult to transfer information regarding the life style including exercises 
and changing food habits to illiterate and elderly patients. In many cases, they refuse 
to listen to us and refuse to follow the needed instructions‟. (Dieticians) 
„In the diabetes centre we deal with different age groups. I find treating elderly a 
challenging task due to the complexity of the disease accompanied by complications 
related to the age and diabetes. Also, communicating with this age group needs special 
skills‟. (Specialist physician) 
Some healthcare professionals acknowledged that some patients prefer to receive the 
entire management of their diabetes care from the diabetes specialists only, which 
reduce the motivation and involvement of other healthcare professionals in the 
management of those patients. When asked about the expected reasons for the 
preference to receive care from the specialist physicians, participants equated this to: 
(1) the lack of confidence on other healthcare professionals „non-doctor staff‟ , and 
(2) lack of awareness of the role of other healthcare professionals rather than 
diabetes specialists in the management of diabetes which may contribute to 
disjointed care. 
 
Participants also addressed the wide variation in patients‟ willingness to spend time 
with healthcare professionals in the centre. They believe that allocating sufficient 
time is important to deliver the needed information. Time allocated for each case is 
different depending on the complexity and the management plan. Healthcare 
professionals were upset with the number of people with T2DM who do not 
appreciate spending sufficient time with them, as they want only to collect their 
prescriptions rather than listings and discussing the treatment strategy with their 
healthcare professionals. 
 
„There are some patients‟ related barriers to effective patient-professionals interaction. 
For example, some patients do not like spending time with healthcare professionals, 
they just want to take the prescription and run away. They do not want to listen to 
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the healthcare professionals‟ instruction or education, while others will stay, listen 
and take part in the management plan‟. (Specialist Physician)  
 
Participants mentioned that the issues of fear from attending appointments with a 
podiatrist among Emirates with T2DM results in not attending appointments with 
the podiatrist, poor interaction between the podiatrist and patients and reduction in 
the podiatrist‟s motivation to get involved in further management of patient care. 
This fear from attending the appointments with a podiatrist was linked to the stories 
patients hear from either their families or friends regarding the role of podiatrist in 
toe and feet amputation in diabetic patients.  
 
„From my experience at the diabetes centre, I believe that some patients feel frightened 
from attending appointment with podiatrists and in many cases refuse to attend these 
appointments. A lot of these patients might hear some stories of toe amputations in 
one of their family members or friend and relate them to podiatrists‟. (Podiatrist) 
Healthcare professionals related factors 
Healthcare professionals at the diabetes centre had various perceptions about 
diabetes including complex, difficult to manage, hard, needs intensive care and a 
multi-dimensional disorder. Interviewees declared that healthcare professionals‟ 
attitudes and beliefs about T2DM can act as a barrier to increased motivation. In 
most of the cases, healthcare professionals voiced concern about diabetes being a 
„complex‟ disease that needs intensive care. 
In this study, participants listed several reasons for their perception about this 
disorder as presented in table 44. The reasons included the following: complexity of 
treatment, behavioural changes required by patients, inevitability of future 
complications, lack of effective drugs, complications related to diabetes, the use of 
multi-drugs to manage the disease and the role of patients in the patients in 
managing diabetes. 
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However, diabetes related complications was the most common cited reason for the 
healthcare professionals‟ perception about T2DM followed by the complexity of 
treatment and the role of the patients to manage the disease. 
„Diabetes is a complex disorder. It needs intensive care to be managed properly and to 
prevent the diabetes related complications from occurring. If occur, the management 
of the disease becomes harder‟. (Podiatrist) 
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Table 44: Reasons for the healthcare professionals‟ perception about T2DM 
Reasons for care providers perceptions Total Diabetes 
specialists 
Podiatrist dietician educator nurse 
Diabetes related complications 8 
 
3 1 1 2 1 
Complexity of treatment  7 
 
3 0 1 2 1 
Behavioural changes required by patients 6 
 
3 0 1 2 0 
Inevitability of future complications 5 
 
3 1 0 1 0 
Lack of effective drugs 3 
 
2 0 0 1 0 
The use of multi-drugs 4 
 
3 0 1 1 0 
The role of patients to manage the disease 7 
 
3 0 1 2 1 
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Organizational related factors 
Healthcare professionals commented on the undesirable effects of the burden of a 
heavy workload in their daily routine. In this study, participants expressed their 
discomfort regarding the heavy workload as recognized from the frequent reported 
words „busy‟, „stressful‟, „tired‟. Some healthcare professionals mentioned that many 
people with diabetes prefer to complete their management in the diabetes centre 
after their referral from the primary care settings even if their disorders become 
under-control, which increases the load on the centre. They expressed frustration 
that the workload increases their stress and reduces the quality of care they provide 
to their patients in some situations. Participants pointed out that they have a busy 
clinic; therefore the time they spent with each patient roughly 10-15 minutes, in 
some situations, is limited. Training and involving other healthcare professionals in 
the diabetes team was highly recommended by the participants. They suggested the 
involvement of more of the two healthcare professions that are already available in 
the centre including dieticians and educators. Other healthcare professionals that are 
not available in the centre and highly indorsed were: general physicians (GPs), 
clinical pharmacists, physiotherapists and ophthalmologists. 
„Patients need to know more about their drugs and side effects, they should be 
educated enough about the importance of pharmacological treatment in managing 
diabetes. The availability of a clinical pharmacist would be helpful. He/ she can 
educate patients regarding the medication use. Patients will feel more comfortable to 
have this service available in the centres instead of waiting for long time roughly one 
hour in-front of the pharmacy to receive their medications‟. (Nurse) 
„Care provided to diabetic patients at the primary care centres is not optimal; therefore 
once a patient is referred to the diabetes centre and the disease is under control she/he 
refuses going back to the primary care centres. Involving GPs in the centre would 
reduce the workload on the diabetes specialist and build patient‟s confidence in the 
ability of GPs to manage diabetes‟. (Specialist physician) 
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„I think our job at the diabetes centre keeps us busy all the time, we have too many 
patients which is really stressful; and we try to provide the same quality of care to all 
patients‟. (Specialist Physician) 
 
„We need GPs in the centre. They can help us to deal with simple cases that need only 
follow up, and can deal with the refill prescription. By doing so, our workload can be 
reduced and quality of the care provided to diabetic patients would be better‟. 
(Specialist physician) 
Some participants were not pleased with the number of interruptions during their 
consultations with patients by other healthcare professionals or patients. For 
instance, it was reported that some healthcare professionals seek advice from their 
colleagues on the management of some cases, while their colleagues are counselling 
other patients. Also, interviewees mentioned that some patients interrupt the 
consultation time to confirm the date or time of their following appointments or to 
ask for a refill prescription. Some healthcare professionals viewed interruptions as a 
hindrance in communication between the patient and healthcare professionals and 
limited the consultation time; and as a consequence motivation of delivering high 
quality of care would be reduced. 
 
„In some occasions some of the healthcare providers interrupt me more than one time 
during patient counselling for advice on other cases which limits my time with the 
patient that I already communicating with‟. (Specialist physician) 
„Some patients interrupt me while I have other patients in the office either by coming 
to the office directly or by calling me to ask about the following appointment or 
medicines that they use. I feel by doing this, the time that I allocate to each patient is 
highly reduced‟. (Specialist physician) 
One of the participants stated that Lack of incentives could reduce their motivation 
regarding the care they provide. This healthcare professional, explained that 
applying an incentive system in the centre can increase the motivation of the 
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healthcare professionals in the management of T2DM as they will feel rewarded for 
their hard and extra work they perform in some occasions. 
„Many healthcare professionals are working very hard in the centre such as diabetes 
educators and nurses and in some situations they do extra duties, but they do not 
receive any incentives for that which decreases their motivation. While many 
countries in Europe, for instance UK and New-Zealand use the incentive system 
which is really rewarding‟. (Podiatrists) 
6.17.2 Training (Theme two) 
Participants described training as attending conferences, departmental meetings 
academic courses and workshops related to diabetes and its management. Others 
added being trained by other experts in the field of diabetes treatment, and being 
certified in specific areas related to diabetes management. For instance, some of the 
diabetes nurses at the diabetes centre attended specific training courses and became 
certified for example in the use of insulin pumps. 
Training healthcare professionals on the patient‟s education, promoting behavioural 
changes (e.g. life style changes) and communication skills were highly advocated by 
the healthcare professionals at the diabetes centre. They supposed that being trained 
on skills needed for effective communication, patient education and promoting 
behavioural changes to Emirates with T2DM in the diabetes centre are essential to 
improve the patient-healthcare provider interactions and communications, and 
enhance achieving the treatment goals; therefore improve the quality of T2DM care. 
Many factors both facilitators and barriers to training healthcare professionals at the 
diabetes centre have been listed and discussed by the participants. Factors tend to 
facilitate training healthcare professionals in the diabetes centre found to be solely 
related to the organization. Beside, perceived barriers to training were related to 
healthcare professionals and organizational factors. 
 „I think providing healthcare professionals with special training on the 
communication skills is required to improve the interactions between patients and 
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healthcare providers and therefore enhance management of the disease as we didn‟t 
receive sufficient training during our academic study‟. (Specialist physician)  
 „Good communication skills with the patients are very important, we should show 
that we care about them so that they feel comfortable and trust us. To achieve better 
outcomes we should improve the way we communicate through with people with 
diabetes. There is a room for improvement at the diabetes centre‟. (Specialist 
physician) 
„Big part of the management plan relies on the behavioural changes required by the 
patients; especially nutritional changes. In my opinion, providing us as diabetes care 
providers with courses on behavioural changes and related skills would be very 
useful‟. (Podiatrist) 
Perceived facilitators to training  
Organizational related factors 
Several facilitators to training have been cited by the nurses working at the diabetes 
centre including training nurses on diabetes and its management by holding regular 
nursing departmental presentations and meetings, and providing nurses regularly 
with useful resources such as educational materials. 
„For us as nurses, we don‟t have any barriers for training and updating our 
knowledge regarding diabetes and its management. We have a lot of useful training 
sessions. I feel that I‟m back to school days as I have a lot of materials to read when 
I‟m back home‟. (Nurse) 
„We have regular weekly training sessions, which keep us updated and increase our 
knowledge on diabetes and its treatment‟. (Nurse) 
Perceived barriers to training 
Organization related  
Many barriers to training were associated with the organization. For instance, 
participants pointed out that due to the lack of accreditation from the hospital to 
some educational programs, healthcare professionals do not get involved in some 
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useful courses. Also, they mentioned that they do not get involved in some useful 
training sessions due to the lack of co-ordination and co-operation with the 
hospital‟s continuous education department. Other obstacles for training related to 
the organization were heavy workload, shortage of staff in some occasions and lack 
of time. 
„Some training programs are not accredited by the hospital‟s management 
department; therefore trainers would not benefit from attending these programs or 
apply what they learned. For example, we have some nurses who attended some 
educational courses and are certified as diabetes educators, but not accredited by the 
hospital. Therefore instead of educating patients they are doing other things‟. 
(Specialist physician) 
„Sometimes, shortage in the number of staff can stop us from attending training 
activities related to diabetes and its management. For example, if my partner is on 
leave, I would be the only one in the centre and no one can take my place if I‟m 
interested to attend a course or any training activity. Shortage of support staff is a 
problem‟. (Dietician) 
„I‟m a certified insulin pump educator, I can hold training sessions for other nurses 
and educators on the use of insulin pumps, but we have limited time. We have the 
option of meeting on the weekend but this option will not suit everybody. The second 
option would be either coming earlier about 30 to 60 minutes before the working time 
or spending the same amount after working hours which is again not the ideal option 
for everyone‟. (Diabetes educator) 
„We do not find it easy to apply for a training course or attend some related sessions. 
The process is long, and we have to complete a lot of paper work. Also, the continuous 
education department at the hospital do not co-ordinate with us properly or ease the 
application process‟. (Dietician) 
Further organizational impediments to training healthcare professionals in the 
diabetes centre that were less cited included financial barriers, lack of organization 
and lack of resources  
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„For me as healthcare professional, I think  the high cost of some training activities 
can halt me from getting involved in such activities‟. (Educator) 
„Some people name it lack of staff and it could be, but I believe that in any department, 
organization is important. I think it is all about organization not shortage of staff. If 
well planned and organized then shortage of staff would not present as a barrier to 
training‟. (Specialist physician) 
Healthcare professionals related  
Participants mentioned that lack of healthcare professional‟s interest in attending the 
specific training sessions is worrisome. Many of the healthcare professionals such as 
nurses are not interested in diabetes; therefore their lack of interest regarding this 
chronic disorder and its management would reduce their enthusiasm to attend 
related training activates such as seminars and workshops. As a consequence, 
participants commented that healthcare professionals should be interested about 
diabetes and aware about the nature of its management before getting involved in 
the management of people with diabetes. 
 „A lot of care providers such as dietician and nurses are not interested in diabetes and 
do not find it an attractive field; therefore they do not like to attend any activities 
related to the disorder or not keen to update their knowledge regarding diabetes‟. 
(Specialist physician) 
6.17.3 Cultural impact (Theme three) 
Healthcare professionals at the diabetes centre talked about the significant influence 
of the Emirate‟s culture on the behaviours and beliefs of Emirates with T2DM. In this 
study, they cited different barriers “country-specific” to providing or improving 
high quality of T2DM care related to the Emirate culture as listed in this section. 
„I believe that the Emirate culture affects the behaviours of all Emirates. For those 
with T2DM, changing some of the behaviours which are risky or nu-healthy is a 
difficult task‟. (Dietician) 
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Perceived barriers related to the Emirate culture 
Healthcare professionals at the diabetes centre addressed and attached high 
importance to the impact of the Emirate‟s culture on life style behaviours and health 
beliefs. Participants believed that changing health risk behaviours that are related to 
the Emirate‟s culture is a difficult task, and needs special skills and competencies 
that are not taught, to convince the patients to adapt to new, and at times 
untraditional, desired behaviours.  Also, interviewees expressed their worries about 
the common health beliefs among Emirate people with T2DM, and identified 
patient‟s cultural beliefs as a key barrier to achieve the treatment goals; therefore 
reduce the healthcare professionals‟ motivation. This worry was equated to the use 
of traditional-herbal medicines in the management of their patient‟s glucose level 
without the use of pharmacological medicines.  
 
„It‟s very difficult to communicate with the Emirate patients regarding lifestyle 
changes; especially nutritional changes. For example, eating too many dates is 
believed not to raise the sugar levels. Special training for health professionals working 
in the diabetes field on the behavioural changes would be very useful‟. (Dietician) 
 
Given the fact that healthcare professional workings at the diabetes centre are 
multinational, one of the participants expressed his concerns about language 
difference between the healthcare professional and patient. This healthcare 
professional felt that the presence of a translator cannot solve this issue completely 
as language difference could act as an obstacle for delivering the needed information 
to the patient; therefore the communication between them would be affected. 
 
„I‟m a healthcare provider coming from Europe and I find it difficult to communicate 
with the Emirate people with diabetes even with the presence of a translator‟. 
(Podiatrist) 
6.17.4 Team work (Theme four) 
The diabetes team members at Tawam hospital are composed of diabetes specialist, 
nurse, educator, podiatrist and dietician. Facilitators and barriers to effective team 
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work were identified and listed in this part. Factors tend to facilitate team-work in 
this study setting was related to the healthcare professionals and organization 
factors as addressed in subdivision 6.11.4.1.  In the contrary, identified barriers to the 
effective team-work in the diabetes centre were related to the organizational and 
cultural factors as outlined in subdivision 6.11.4.2. 
Perceived facilitators to effective team work 
Healthcare professionals related  
Participants perceived co-operation between the team members at the diabetes 
centre as the principal facilitator to the effective team work. They feel satisfied with 
the level of co-ordination and co-operation between the team members in the centre 
and they believe that all of them work hard to deliver high quality of care to people 
with T2DM.  
 „From my experience at the diabetes centre, I feel satisfied working such co-operative 
team members‟. (Nurse) 
Organization related 
Interviews at the diabetes centre expressed their satisfaction about the work 
environment, and they described it as an encouraging, respectful and pleasant place 
to work in. They feel that the work environment encourages them to co-operate with 
other team members and to deliver high quality of diabetes care. 
„I‟m very happy to work in this centre. It‟s an excellent place where you feel respected 
and encouraged to co-operate with your colleagues to deliver outstanding care to 
people with diabetes in Al-Ain‟. (Specialist physician) 
Perceived barriers to effective team work 
Cultural related factors 
Healthcare professionals working at the diabetes centre are multinational; therefore 
they have different cultural backgrounds and different first spoken languages. 
Interviewees stated that differences in the language and culture between the 
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healthcare professionals in the diabetes centre could be one of the barriers to the 
effective team work as these differences limit the communication between the team 
members. 
„I believe that we do not communicate effectively as team members due to the different 
cultures we belong to. We come from different countries and have different 
behaviours. These differences work as barriers between us as care providers‟. 
(Specialists physician) 
Organizational related factors 
Some participants mentioned that lack of feedback is one of the barriers between the 
team members in the diabetes centre. Therefore, they suggested holding regular 
meetings in the department to enhance the communication, promote feedback and 
get rid of the cultural barriers between the team members. 
 „We work with complicated cases; therefore the communication and providing 
feedback between all the team members is essential to come up with an action plan 
that help in achieving the treatment goals, but due to lack of feedback and 
communication between the healthcare providers the quality of care provided could be 
affected negatively. For example, some patients would not be referred to the 
neurologist as a result of lack of communication‟. (Podiatrist) 
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Section four: Discussion 
 
This final section of chapter six discusses the results addressed in section three and 
compares them with the findings from studies carried out elsewhere. Discussion was 
classified based on the main themes outlined in section three including motivation of 
healthcare professionals, training healthcare professionals, team work and Emirate‟s 
cultural impact on diabetes care. Under each theme, I discussed the findings on the 
factors both facilitators and barriers affecting diabetes care in the diabetes centre and 
compared them with other studies. Then, the limitations and strengths of this 
qualitative work were addressed along with its implication. 
6.18 Motivation of healthcare professionals  
I identified several facilitators and barriers to the motivation of healthcare 
professionals regarding the management of T2DM in the diabetes centre that were 
associated with healthcare professionals, patients and organization. Facilitators and 
barriers were divided under these three main classifications as explained below. 
 
Healthcare professional related factors 
In this study, I found that healthcare professional‟s interest in diabetes can increase 
their motivation to provide optimal care to subjects with T2DM. Similarly to findings 
from the other studies (262, 263). In the contrary, Hansen et al did not find a 
significant difference in glycaemic control among physicians with more or less 
interest in diabetes compared to other diseases (279). Several reasons might attribute 
to this finding as addressed in section one of this chapter. 
In terms of healthcare professional‟s perceptions and attitudes about T2DM, I found 
that in this setting, healthcare professional‟s perceptions about T2DM can de-
motivate them regarding the management of the disease. Healthcare professionals at 
the diabetes centre described T2DM as a difficult disease to treat compared with 
other chronic conditions due to the complexity of treatment, unavoidability of future 
diabetes related complications, lack of effective drugs and behavioural changes 
required by the patients to achieve the treatment outcomes similar to findings from 
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other studies (264).  Besides, some physicians in this study consider T2DM as a 
„mild‟ disorder compared with other health problems similar to findings by Walker 
et al (318). 
Added to these findings, many healthcare professionals in this study believed that 
factors related to the organisation such as lack of support staff or team to work with, 
lack of time and peer encouragement are considered more important barriers to their 
motivation and good quality of diabetes care than their beliefs or attitudes about 
diabetes.  Many studies in the literature demonstrated comparable findings (e.g., 
274, 275, 245) as addressed in section one of this chapter.  
Relationship between the healthcare professionals and individuals with diabetes was 
seen as an important factor affecting the motivation of healthcare professionals in the 
diabetes centre. This relationship is affected strongly by the communication between 
these two panels. Despite the widespread acknowledgment of the importance of 
communication between healthcare professionals and people with diabetes, this 
subject is not always emphasized during academic study or medical training (319). 
Dr. Aus Alzaid raised the issue of the importance of effective communication 
between people with diabetes and healthcare professionals, and stated that this 
important skill was not accentuated enough by training healthcare professionals 
practicing in Saudi Arabia (320). Research from developed world indicated that 
communication between healthcare professionals and patients are consistently weak 
(319). However, there is strong evidence demonstrating that effective 
communication between healthcare professionals and people with diabetes can 
increase treatment outcomes, patient‟s satisfaction, compliance with therapeutic 
regiments and appointments (319). As seen in figure 14, improving communication 
between healthcare professionals and patients is linked with short, medium and 
long term outcomes. For instance, in medium term, better utilization of the health 
services and enhanced compliance to the therapeutic regimes could be attained. 
Reduction in the mortality, morbidity and enhancing education can be achieved as a 
long term outcome (319). 
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“Unfortunately, effective communication does not always occur naturally, nor it is 
easily acquired. Even when client and provider come from the same geographic area 
and speak the same language, they often have different educational, socio-economic 
and cultural backgrounds.  Moreover, their expectations about the health encounter 
may be different, or they may be faced with other problems, such as lack of privacy 
during the encounter, or time constraints due to heavy patient loads” (319). As a 
consequence, empowering healthcare professionals with essential skills to 
communicate effectively with people with diabetes is important.  
 
Figure 13: Factors affecting healthcare professionals- patient communication 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Modified from reference No: 319) 
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Patient related factors  
Findings from this study confirm that successful involvement of Emirates with 
T2DM in the management of diabetes is essential and can increase clinical outcomes, 
healthcare professionals‟ motivation, and therefore the quality of diabetes care. 
Emirates with T2DM should be empowered with knowledge and education about 
the disease and how to carry self-management on daily life. Application of 
knowledge and techniques should be guided by a relevant, coherent educational 
philosophy to empower patients (317). People with T2DM play a chief role in 
managing their disorder, daily they perfume roughly 95% or more of the 
management of diabetes without consulting healthcare professionals (242, 243).  
They have to cope with several challenges they face in their daily lives such as 
glucose monitoring and medication regimen within the context of other goals, 
physical activity, decision about diet, other health issues, family demand and other 
personal concerns (240, 242). Low knowledge about diabetes found to be one of the 
educational patients‟ related barriers to optimal diabetes care (320). Therefore, more 
emphasis should be placed on educating Emirates with T2DM; and their families on 
the disorder, methods to carryout self-care tasks and to cope with the complex 
health systems. 
In Oman for instance, people with diabetes noted that they did not receive sufficient 
education about their diets and life style behaviors which play an important role in 
managing diabetes (321). Also, in another study carried out in Oman, lack of 
knowledge among people with diabetes was common; particularly information 
about self-management such as self-monitoring of blood glucose and hypoglycaemia 
was lacking (195). Moreover, in the UAE Al Kaabi et al concluded that dietary 
practice among 409 people with diabetes in Al-Ain was inadequate (141). These 
results might be affected by the fact that 50% of the sample was illiterate.  
Besides that, Habiba et al identified factors both facilitators and barriers affecting 
weight management among people living in the Gulf (321). They found that despite 
the awareness of the risks and complications related to overweight/ obesity; people 
did not follow any strategy to control their weight such as getting involved in 
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physical activities or following healthy diet (321). As a consequence, different 
strategies should be used focusing on educating people with diabetes, and 
emphasizing on promoting health to both chronically ill people and healthy 
individuals to improve and control people‟s health.   
In terms of T2DM, using medical approach as a primary source for patient education 
or health promotion would not be sufficient as T2DM is caused by multi-factors that 
were mentioned earlier in chapter one. Involving other effective sources than 
healthcare professionals in promoting health and education people with diabetes, 
including community, schools and urban planners can help reaching and promoting 
health to a wider population, and delivering better health services (322). More 
research studies focusing on the perspectives of Emirates with T2DM on the care 
they receive should be carried out in the UAE in order to optimize diabetes care.  To 
provide optimal diabetes care; it‟s essential to see through the eyes of Emirates with 
T2DM, in sequence to increase their satisfaction on the level of knowledge and 
education they receive from the healthcare professionals. Also, the level of 
knowledge and education should be measured to identify the related educational 
barriers to providing optimal diabetes care; therefore effectively implement patient-
centred model. 
Furthermore, I found in this setting some Emirates with T2DM miss-understand the 
role of some healthcare professionals such as educators. Therefore, these healthcare 
professionals‟ motivation to manage those patients is reduced. A recent editorial 
made by Dr. Aus Alzaid at the British Journal of Diabetes and Vascular Disease 
stated that Saudis with diabetes expect the physicians to be the primary source for 
treatment and knowledge; therefore they dismiss the role of other healthcare 
professionals (320). For that reason, more awareness on the role of the healthcare 
professionals rather than the physician in T2DM management as optimizing the 
metabolic control, delaying or preventing the disease related complications and 
improving the quality of life should be disseminated not only to people with T2DM, 
but other members of society also. Lack of knowledge on the service was identified 
elsewhere as a personal educational barrier to providing high quality of diabetes 
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care (320). Therefore, Emirates with T2DM being treated in the centre should be 
introduced and informed about the services offered by the centre, and the 
multidisciplinary management they receive from the diabetes team members.  
 
Also, due to the worries they have regarding toes/ foot amputations, those 
individuals with T2DM do not attend appointments with podiatrists.  Physical effect 
of the treatment is one of the patient‟s related barriers „internal physical‟ identified 
by Simmons et al (304).  Also, emotional issues, lack of public awareness and lack of 
family support could be other barriers for those Emirates with T2DM to utilize from 
the podiatry services provided in the centre (304). 
 
Furthermore, participants addressed the problem of patient non-compliance to 
medications in this setting, which can delay the achievement of treatment goals or 
lead to the development of diabetes related complications. In T2DM, there is 
evidence that patients adherence to medication is sub-optimal globally as addressed 
in section one of this chapter. For instance, a recent systematic review showed high 
rate of non-adherence to oral hypoglycaemic drugs and insulin (7-64% vs. 19-46%; 
respectively) (302). The involvement of a clinical pharmacist in the diabetes team, 
which is highly suggested by the healthcare professionals in the diabetes centre 
would help not only enhancing the adherence of people with diabetes to their 
medications through education, but the load on other healthcare professionals 
regarding education about the pharmacological treatment would be reduced also. 
 
Organization related factors 
In this study, participants were satisfied with the amount of payment they receive; 
however one of them pointed out on the need to implement an incentive system 
similarly to other western countries such as UK in order to increase healthcare 
professionals motivation; therefore quality of diabetes care. As in the study carried 
out in Tunisia, lack of incentives was seen as a barrier for healthcare professionals to 
provide optimal care (242, 243). In the UK since the establishment of QOF in 2004, 
substantial improvements in the quality of diabetes care have been reported as 
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reflected by the QOF indicators (174). Nevertheless, in the UAE healthcare 
professionals are well paid, therefore introducing the incentive system alone would 
not be the effective solution to motivating healthcare professionals; and therefore 
improving quality of diabetes care. Using and combining different strategies to 
motivate healthcare professionals and increase the quality of T2DM care would be 
useful. 
 
Our finding regarding workload and how it can increase healthcare professionals 
stress and reduces their motivation, and the quality of care they provide to people 
with T2DM in the diabetes centre, concur with findings from other studies (e.g., 242, 
243). In Saudi Arabia for instance, stressful work conditions was seen as an obstacle 
for providing optimal care to people with chronic diseases (255). 
Diabetes is a chronic, multi-dimensional disease and even with high quality of care, 
particularly secondary prevention provided to people with diabetes in the primary 
care, experts help from the secondary practices is needed (43). In this study, I found 
people with diabetes prefer to complete receiving their care from the diabetes centre 
after referral from the primary care setting, which add more work load on the centre. 
Preference to complete the management in the secondary rather than primary care 
might be due to several reasons mentioned by the participants such as poor care 
provided in the primary setting and beliefs among Emirates that care provided in 
the secondary/ tertiary settings is superior. Results from a study carried out in a 
primary care centre in Abu Dhabi in the late 1990‟s among Emirates with diabetes 
was associated with poor glycaemic control for those attending primary care settings 
than attending hospitals (p=0.03) (41). However, recently this might not be the case, 
as many indicators reported by the health bodies in the UAE such as MOH showed 
improvement in the primary care performance. Despite this, more studies should be 
carried out to evaluate and improve the quality of diabetes care in the primary care 
settings in the UAE. 
 
The principal role of the primary care setting in the management of diabetes 
particularly type 2, should be reinforced through communication and co-operation 
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across the primary and secondary/ tertiary care settings in the UAE. Attachment of 
diabetes physicians to the primary care settings on regular bases is suggested to 
increase the confidence of Emirate people with diabetes on primary care.  Lack of co-
operation between the primary-secondary care has been suggested as a barrier for 
providing high quality of diabetes care in some health systems (e.g., 242). In Saudi 
Arabia, Al-Khattab et al identified several barriers in their comprehensive review for 
providing optimal care to chronic diseases in primary care settings. One of these 
barriers was problem at the interface with secondary care (255). Therefore, if people 
with diabetes are to be managed in both settings a management protocol should be 
shared between the primary- secondary settings (255). 
 
Furthermore, I found in the diabetes centre some Emirates with T2DM are not 
willing to spend sufficient time with their healthcare professionals to discuss the 
management of their conditions, which is an important area that needs more 
attention. Many studies (e.g., 242, 243) supported that the length of consultation is 
associated with improving the quality of diabetes care as addressed in section one of 
this chapter. 
Interruption from other healthcare professionals and patients during consultation 
time was another important issue mentioned by healthcare professionals at the 
diabetes centre as a barrier for healthcare professional‟s motivation, providing good 
patient communication and high quality diabetes care. Also, these interruptions 
were believed to disturb the privacy of consultations. Similarly, findings from 
another study demonstrated that interruptions during consultation time by other 
colleagues or patients disrupt the privacy of consultation between patients and 
healthcare professionals (229). Lack of a regulations regarding the consultation time 
could be one of the causes for these interruptions; therefore establishing specific 
guidelines that protect the privacy of consultation time in the centre is highly 
suggested. 
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6.19 Training healthcare professionals 
Training healthcare professionals on the patient‟s education, promoting behavioural 
changes (e.g. life style changes) and communication skills were highly advocated by 
the healthcare professionals at the diabetes centre, and believed to improve diabetes 
care. In the same line, Al-Mandhari et al stated that to increase the quality of 
diabetes care in Oman several interventions should be initiated, one of these 
interventions is training healthcare professionals on the skills needed for 
behavioural changes (323).  
One facilitator to the training was highlighted by the nurses and was related to the 
organizational factors. Besides that, a number of barriers have been listed and 
discussed by the participants affecting training healthcare professionals, and these 
barriers were related to healthcare professionals and organization as addressed 
below. 
Healthcare professionals related factors 
Lack of interest in diabetes was one of the barriers to get involved in the training 
related activities. Studies found in the literature focused on the association between 
healthcare professionals‟ interest in diabetes and intermediate outcomes, specifically 
improvement in glycaemic control (e.g., 265) as addressed in section one, however 
no studies yet investigated the association between healthcare professionals‟ interest 
in diabetes and involvement in diabetes related training. 
On the other hand, as documented in section one many studies in the literature 
focused on the continual medical education, which is considered to be one of the 
important tools to update health professionals‟ knowledge; however studies found 
that even with appropriate knowledge, health professionals do not always adhere to 
the guidelines or the suggested advice (266, 274). 
Organization related factors 
The departmental training that nurses receive on regular bases was seen as a 
facilitator for training; therefore using the available departmental resources would 
play an important role in training healthcare professionals on the needed skills. 
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A number of barriers to the involvement of the healthcare professionals in the 
training activities in the diabetes centre related to the organization were listed. These 
barriers include lack of resources, lack of time and shortage of staff, equally to 
findings from studies carried out elsewhere (242, 243). Also, lack of co-operation and 
co-ordination between the hospital‟s continuous education department and diabetes 
centre was identified as a barrier for the involvement of healthcare professionals in 
the diabetes related activities. 
6.20 Team work 
There is a growing body of evidence (e.g., 264, 242) as pointed out in the literature 
review section one of this chapter on the importance of effective team work in 
improving the care provided to people with diabetes. In this setting, I found 
facilitators to effective team work are related to the healthcare professionals and 
organization. However, barriers to effective team work found in this study are 
linked to the organizational and cultural factors. 
Organization related factors 
The environs of work described as „pleasant‟ , „excellent‟ and „respectful‟ was seen as 
a motivator to effective team work in the diabetes centre, similar to studies carried 
out elsewhere (263, 291). 
Healthcare professional related 
Positive perceptions of teamwork and team climate are often cited in qualitative 
research as facilitators of good diabetes care, similar to the finding from this study 
(264, 242). 
Cultural related factors 
In this study, as the healthcare professionals belong to different ethnicities, I found 
cultural and language difference between the team members act as barriers for 
effective team-work. These differences tend to limit the communication and 
feedback between the team members; therefore holding regular meeting was highly 
250 
 
suggested by the participants to overcome this barrier. Others suggested the 
implementation of a feedback system. 
6.21 Emirate‟s cultural impact on diabetes care 
The Emirate culture had a significant impact on behaviours and health beliefs of the 
patients attending the diabetes centre. In the Arab world, local traditions and 
religious conditions and attitudes influence the control of diabetes and other 
diseases significantly (324). The residents of the Emirates, like other people living in 
the surrounding Gulf countries, have special behaviours and beliefs with regard to 
health issues and nutrition. For example, consuming large amount of dates is 
believed to cure many diseases as this fruit is mentioned in the Holy Quran. Dates 
are rich in nutrition and have several health benefits; however for people with T2DM 
controlling the amount of dates consumed is important (324). Health beliefs and 
physiological factors are not only difficult, but complex to be measured; nevertheless 
Simmons et al identified psychosocial and psychological barriers to improving 
diabetes care related to the patients such as patient‟s health beliefs and public health 
beliefs (304). Understanding health beliefs in the UAE, specifically those related to 
T2DM is essential; they define the unique perspectives of individuals within a 
culture (324). According to Jackson health beliefs affect healthcare professional‟s 
behaviour, perception of health and decision to access and follow through with 
health care treatment by patients (325). The assumptions of healthcare professionals 
regarding the cultural needs of Emirates with T2DM and lack of cultural 
understanding of health beliefs could be obstacles for providing competent care 
(325). Hence, general understanding of the Emirate culture, which is an Arabic 
Muslim culture, and related health beliefs regarding T2DM in the UAE could 
improve the diabetes care. This can be achieved through discussion with people with 
diabetes and their families, better dialogue with religious authorities and 
improvement of communication between healthcare professionals and people with 
diabetes (325).  
6.22 Strengths and limitations of the study 
To my knowledge this is the first study carried out in the UAE to identify factors 
affecting the quality of T2DM care from the perceptions, attitudes and experience of 
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healthcare professionals. The followed approach in this study using the qualitative 
method helped identifying the facilitators/motivators and barriers to improve the 
quality of T2DM care based on the perceptions, attitudes and experience of 
healthcare professionals. Another strength of this study is the diversity of healthcare 
professionals providing such care and the ability to compare and contrast their 
experiences and perceptions. 
A major limitation of this study is the small sample size; however, this did not seem 
to affect the findings as participants were selected to contribute „rich‟ information. 
Another limitation is that the study was conducted in one specialist diabetes centre, 
and the findings may not be generalisable to other diabetes centres in the UAE. 
However, I believe that findings from this study could be especially informative and 
beneficial to other diabetes centres that provide secondary and tertiary care to 
people with diabetes living in Al-Ain given the similarity in the health system and 
structure to that of the larger Abu Dhabi area. 
6.23 Implications of the study 
Findings from the interviews revealed a number of factors that contributed to 
healthcare professionals‟ level of motivation in the management of diabetes care that 
are not currently fully addressed in the UAE. Specifically, from a cultural 
perspective, findings suggest providing diabetes healthcare professionals with 
knowledge about the Emirate culture may be an important step in developing 
culturally-sensitive and culturally-appropriate training programs. Increased 
knowledge about culture-specific health beliefs related to T2DM and “risky 
behaviours” such as sedentary lifestyle and food intake may provide an opportunity 
to improve clinical decision-making and thus improve quality of T2DM care. Also, 
findings from this study suggest involving the patient in the management plan and 
enabling them to be a full partner and an expert in managing diabetes. This could be 
achieved by effective education and support not only from healthcare professionals 
but also families and the society. 
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Furthermore, in the diabetes centre level, our findings have implication for involving 
other healthcare professionals such as GPs and clinical pharmacists in the diabetes 
team to improve metabolic control, adherence to medications and reduce workload; 
therefore enhance the quality of T2DM care. 
As more than 70% of the UAE‟s population is composed of expatriates that come 
from all over the world, future research should focus on the motivation of the 
healthcare professionals  providing diabetes care not only to Emirates, but to 
expatriates living in the UAE also to optimize the care provided to `all people with 
diabetes. 
 
In this study, I focused on the health care professionals‟ perceptions, experiences and 
attitudes to identify the factors affecting the quality of care provided to people with 
T2DM. However, I believe that identifying the factors affecting diabetes care need 
the involvement of both healthcare professionals and patients. Consequently, more 
studies should be carried out focusing on the patient‟s and healthcare professional‟s 
perceptions, experiences and attitude as both have a crucial impact on the quality of 
diabetes care. 
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Chapter  7: Discussion and conclusion 
 
This final chapter is classified into two main sections. The first section combines and 
presents the key findings from previous chapters. The previous chapters four, five, 
and six have presented independently the key results from the systematic reviews, 
quantitative and qualitative components of this thesis. 
The second section of this chapter presents a discussion of the main findings within 
the context of previous relevant work. Also, the strengths and limitations along with 
the implications of this study for clinical practice and policy level are addressed. 
Finally, a conclusion of this thesis is provided. 
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Section one: Summary of key findings 
 
This section presents a summary of the main results obtained from this thesis, firstly 
results from the systematic reviews. Secondly, a description and examination of 
quality of diabetes care in Al-Ain, particularly from Tawam hospital‟s diabetes 
centre for the consecutive years from 2008 till 2010 are provided. Finally, the factors 
influencing the care provided to people with T2DM from the perceptions, attitudes 
and experiences of healthcare professionals practicing at Tawam hospital‟s diabetes 
centre are identified and outlined. 
7.1 Summary of the systematic reviews main findings 
Chapter four presents the comprehensive results of the systematic reviews carried 
out as part of this thesis. However, in this subdivision I will highlight the key 
findings. 
7.1.1 Prevalence of T2DM in the GCC 
 The descriptive results from the review indicated that prevalence of T2DM in 
the GCC countries ranged between 4.3%-34.9% for studies published between 
1980 and 2009. 
 The study was also suggestive that the prevalence of T2DM increases with 
age (at least to 50-60 years), and that urban residence is associated with higher 
prevalence rates. 
 The sub-analysis suggested that the estimated prevalence had increased 
across the three time periods including: (1) 1980-1989; (2) 1990-1999; and (3) 
2000-2009 respectively (3.58% [95% CIs, 1.94-5.23; 2 studies]; vs. 4.01% [95% 
CIs, 3.58-4.43; 10 studies]; vs. 5.06% [95% CIs, 4.02-6.09%; 10 studies ]). The 
differences in the estimated prevalence rate of T2DM in the GCC countries 
between the three periods was not statistically significant p=0.9. 
 The subgroup analysis by country indicated that the estimated prevalence 
rates of T2DM between GCC countries are comparable. 
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7.1.2 Prevalences of overweight, obesity, hyperglycaemia, hypertension and 
dyslipidaemia in the GCC 
 The reported prevalence rates of overweight (BMI 25 to < 30) in adults ranged 
from 26.3 % to 48 % in males, and 25.2 % to 35 % in females. 
 The reported general prevalence rates of obesity (defined as BMI > 30) in 
adults ranged from 13.05 % to 37 % in males, and 16 % to 49.15 % in females. 
 The relatively comprehensive study of IGT is suggestive of a recent and on-
going increase in prevalence, with the latest published figures suggesting 
rates of perhaps 10 – 20 % in the adult population. 
 There has been relatively little research of the prevalences of hypertension 
and dyslipidaemia in the GCC region and a lack of consistency in definitions 
used for study.  Accordingly, estimates of prevalence vary: between 6.6 and 
33.6 % for hypertension, between 2.7 and 51.9 % for dyslipidaemia, and it is 
unclear what additional factors may have impacted on these ranges. 
7.1.3 Quality of T2DM management in the GCC 
I found management of T2DM in the GCC region – based on glycaemic-, blood 
pressure- and lipid- control indicators – to be suboptimal. 
Glycaemic control 
 Consistently, < 50 % of patients achieved target glycaemic control. 
 Plotting the values across time, there was no obvious indication of recently 
improving/declining control. Process measures were less commonly 
investigated, and of variable outcome (0.4 – 98 % achieved). 
Blood pressure control 
 The < 130/< 80 mmHg or < 130/< 85 mmHg targets respectively were met in 
between 6.8 % and 32 % of patients with a history of hypertension, and 
between 14.2 and 42.1 % of the remaining samples, with one exception. 
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Dyslipidaemia control 
 The definitions of dyslipidaemia used were variable and utilised various 
aspects of the lipid profile.  LDL was the most commonly used clinical 
outcome, with a consistently applied target of < 2.6 mmol/L.  This was met in 
approximately 30 - 50 % of patients, including in the cases of populations 
being entirely with or entirely without a history of dyslipidaemia. 
7.2 Summary of the quantitative study main findings 
Chapter five presents the comprehensive results of the cohort study carried out as 
part of this thesis. However, in this subdivision I will highlight the key findings. 
7.2.1 Process of T2DM care measures 
 Outstanding achievement rates of recording of HbA1c, LDL, SBP and DBP 
during 1-year of care for the following years: 2008, 2009 and 2010 were found. 
 The frequency of measurements of the listed indicators was three times or 
more in some cases annually for the consecutive years from 2008 to 2010. 
7.2.2 Intermediate outcomes of T2DM care measures 
Glycaemic control 
 The proportions of patients who reached the HbA1c target were not 
significantly different between women and men respectively at each year 
[(22% vs. 18%, p=0.3 at 2008), (28% vs. 25%, p= 0.5 at 2009), and (41% vs. 42%, 
p= 0.9 at 2010)]. 
 The proportions of people with T2DM who reached the target increased 
across years at each age group for both genders; however significant 
differences of these proportions across the three years were only found at 
older age group (> 40 years old) for both sexes. 
 Results from the multilevel modelling indicated in men an annual average 
reduction of HbA1c level was 0.5% (95% CI:-0.56 ~ -0.43, P<0.001).  Generally, 
HbA1c level of people who aged 60+ was significantly lower than for those 
aged 18-39 years  by roughly 0.7% (95% CI:-1.19 ~ -0.14, P=0.01) during this 
period, but not  for those aged 40-59. Prescribing oral anti-hypoglycaemic 
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drugs was associated with roughly 4.2% (95% CI: -0.85 ~ -0.01, P=0.05) 
reduction in the HbA1c levels. 
 Results from the multilevel modelling indicated in women an annual average 
reduction of HbA1c level was 0.5% (95% CI:-0.57~-0.44, P < 0.001). Women 
who were in successive age including those between 40-59 and above 60 years 
respectively had significantly lower HbA1c level on average 0.49% (95% CI: -
0.98 ~  -0.004, P=0.05), and 0.77% (95% CI: -1.31~ -0.23,  p< 0.01). 
Blood pressure control 
 Overall women were more successful in achieving the ADA targets for 
S/DBP respectively compared to men [(47% vs. 52%, P <0.01), and (34% vs. 
41%, p=0.04)] vs. [(62% vs. 52%, P=0.05), and (74% vs. 72%, P=0.7)]. 
 The proportions of those meting the SBP target increased gradually from 2008 
to 2010; however among those aged 40-59 years a drop in this proportion was 
detected between 2008 and 2009 (49% vs. 46%; respectively). 
 Results from the multilevel modelling indicated in men an average annual 
reduction of SBP was 1.02 mm Hg (95% CI: -1.80~-0.24, P=0.01); however this 
yearly rate reduction was not significant for DBP. 
 Results from the multilevel modelling indicated in men an average annual 
reduction of DBP was 0.71mm Hg (95% CI: -1.20~-0.22, P<0.01); however in 
women the average reduction of DBP level at a yearly rate was 0.80 mm Hg 
(95% CI: -1.47 ~ -0.13, P=0.02). 
 Results from the multilevel modelling indicated that in women and men 
respectively who were prescribed anti-blood pressure drugs, had higher 
points in their S/DBP [(7.6 mm Hg, P<0.001 and 3.9 mm Hg, P< 0.001) vs. (6.7 
mm Hg, p<0.01 and 3.7 mmHg, p<0.001)]. 
Lipid control 
 The proportions of patients who reached the LDL target were not 
significantly different between women and men respectively at each year 
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[(56% vs. 55%, p=0.8 at 2008), (57% vs. 60%, p= 0.7 at 2009), and (70% vs. 74%, 
p= 0.4 at 2010)]. 
 Both genders had significant improvement of reaching the target across the 
years; however only significant differences were detected at age group 40-59, 
of which patients who reached the target increased from 53% at 2008 to 76% 
at 2010 (p <0.01). 
 Results from the multilevel modelling indicated in both sexes an average 
reduction of LDL level at a yearly rate was 0.15 mmol/l (95% CI: -0.2~-0.1, 
P<0.001). 
Improvement from 2008 to 2010 
 The quality of T2DM care improved gradually from the year 2008 till 2010 as 
reflected by the 4vOOc score. The mean of the score increased gradually from 
2008 to 2010 respectively [2.27 (95% CI: 2.18-2.37) vs. 2.62 (95% CI: 2.52-2.71)]. 
 The glycaemic control improved significantly in the consecutive years from 
2008 to 2010. Comparing the reduction in the HbA1c level with the baseline 
data from 2008 with 2010 respectively, a substantial improvement was found: 
[8.5% (95% CI 8.33-8.67) vs.  7.5% (95% CI 7.36-7.63); P <0.001]. 
 The DBP control did not show any significant differences as reflected by the 
mean DBP level during the three years. However, range of 95% CI for mean 
DBP level at year 2009 and 2010 was not overlapped, hence it can be 
concluded that a significant reduction was found for these two years. A minor 
reduction in the SBP was found from 2008 to 2010. 
 The lipid control improved significantly from 2008 to 2010. The average level 
of LDL was 2.60 mmol/L (95% CI: 2.51-2.70) at 2008, which was then reduced 
by 0.17 mmol/L to 2.27 mmol/L (95% CI: 2.21-2.33) at 2010. 
7.3 Summary of the qualitative study main findings 
Chapter six presents the comprehensive results of the qualitative study carried out 
as part of this thesis. However, in this subdivision I will highlight the key findings. 
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 Factors both facilitators and barriers to providing high quality of diabetes care 
in the diabetes centre, found to be related to the patient, healthcare 
professionals, organization and Emirate‟s culture. A dynamic interplay 
between these factors has been demonstrated. 
 Four chief themes emerged from the thematic analysis including motivation 
of healthcare professionals, training healthcare professionals, team work and 
Emirate‟s cultural impact on diabetes care. Factors both facilitators and 
barriers to providing high quality of diabetes care related to these chief 
themes are addressed under each theme when relevant. 
7.3.1 Motivation of healthcare professionals 
Factors related to the healthcare professionals 
Facilitators/ motivators 
 Healthcare professional‟s interest in diabetes is suggested to increase their 
motivation to provide optimal care to subjects with diabetes in the diabetes 
centre. 
Barriers 
 Healthcare professionals at the diabetes centre described diabetes as a 
difficult disease to treat compared to other chronic conditions due to the 
complexity of treatment, unavoidability of future diabetes related 
complications, lack of effective drugs and behavioural changes required by 
the patients to achieve the treatment outcomes. These perceptions and 
attitudes about diabetes were suggested to de-motivate the healthcare 
professionals themselves regarding the management of the disease. 
Factors related to the patients 
Facilitators/ motivators  
 Successful involvement of Emirates with T2DM in the management of 
diabetes. 
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 Awareness about the disease, its complications and the importance of its 
management. 
 Patient‟s characteristics such as education. 
Barriers  
 Patient non-compliance to medications, which can delay the achievement of 
treatment goals or lead to the development of diabetes related complications. 
 Patient‟s characteristics such as old age and low educational level. 
 Miss-understanding the role of some healthcare professionals such as 
educators. 
 Preference to receive the entire management by the diabetes physician only. 
 Un-willingness to spend sufficient time with healthcare professionals for 
consultation. 
 Low attendance rates to the appointments with podiatrists due to the worries 
people with T2DM have regarding toes/ foot amputations. 
Factors related to the organization 
Facilitators/ motivators  
 Satisfaction with the amount of payment. 
Barriers  
 Lack of an incentive system. 
 Heavy workload. 
 Shortage of staff in some occasions. 
 Lack of communication and co-operation between the primary and 
secondary/ tertiary care settings. 
 Interruption from other healthcare professionals and patients during 
consultation time. 
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7.3.2 Training healthcare professionals 
Factors related to the healthcare professionals 
Facilitators/ motivators  
 Arranging regular departmental training sessions. 
Barriers  
 Lack of interest in diabetes. 
Factors related to the organization 
Barriers  
 Lack of resources. 
 Lack of time.  
 Shortage of staff. 
 Lack of co-ordination between the continuous education department at the 
hospital and the diabetes centre. 
7.3.3 Team work 
Factors related to the organization 
Facilitators/ motivators  
 The environs of work described as „pleasant‟, „excellent‟ and „respectful‟. 
Factors related to the healthcare professionals 
Facilitators / motivators  
 The positive perceptions of teamwork and team climate. 
Barriers  
 Cultural and language differences. 
 Lack of feedback. 
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7.3.4 Emirate‟s culture impact on diabetes care 
Barriers  
 Special behaviours and beliefs with regard to behaviours, health issues and 
nutrition. 
 The use of herbal medicines. 
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Section two: Overall discussion 
 
The second section of this chapter presents a discussion of the main findings from 
the systematic reviews, quantitative and qualitative components of this thesis within 
the context of previous relevant work. Further, the previous section summarized the 
key findings from the systematic reviews, quantitative and qualitative components 
of this thesis; however in this section I will compare the results of this study with 
results from the previous literature reported in chapters four, five, and six. 
 
Also, the strengths and limitations along with the implications of this study for 
clinical practice and policy level are addressed. 
7.4 Systematic reviews: What do these reviews add to the literature? 
It‟s important to acknowledge that these systematic reviews are the first have been 
undertaken in the countries of the GCC. There were several methodological 
challenges; in particular, the different populations studied and methods used to 
assess glycaemic status, define diabetes and its adverse outcomes such as 
hypertension and hyperlipidaemia. 
7.4.1 Prevalence of T2DM in the GCC 
Comparing the findings from this systematic review with other literatures, this 
systematic review: 
 Provides additional evidence on the prevalence of diabetes chiefly type 2, 
which is increasing at an alarming rate in the GCC. 
 Supports the evidence linking age with increased prevalence of T2DM. The 
study was suggestive that prevalence increases with age (at least to 50-60 
years). The importance of age as a risk factor is consistent with previous data 
discussed in chapter four (section one), from many contexts. 
 Supports the evidence linking geographical location with increased 
prevalence of T2DM. The study was suggestive that urban residence is 
associated with higher prevalence. 
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 Adds to the body of evidence that the risk of T2DM is related to the risk 
factors such as obesity/ overweight and physical inactivity. I found that the 
observed high prevalence of diabetes in the GCC states is likely to be 
associated with the high prevalences of risk factors for T2DM in this region. 
7.4.2 Prevalences of overweight, obesity, hyperglycaemia, hypertension and 
dyslipidaemia in the GCC 
Comparing the findings from this systematic review with other literatures, this 
systematic review:  
 Provides additional evidence that the prevalence of overweight and obesity 
are high in the GCC. The prevalence of overweight to be 25 – 50 %, obesity 10 
– 50 %, relatively found to be high in females and higher with advancing age 
to threshold levels between 30 – 40 and 50 – 60 years. 
 Support evidence that demonstrated an increment in the prevalence of 
hyperglycaemia in the recent years. 
 Supports evidence linking advancing age to increased hyperglycaemia. 
 Suggests association between female sex in increased prevalence of 
hyperglycaemia in the GCC.  
 Indicates that the prevalences of hypertension and dyslipidaemia are 
increasing in the GCC, which would be in keeping with a more widespread 
trend as addressed in chapter four (section two). 
7.4.3 Quality of T2DM management in the GCC 
Comparing the findings from this systematic review with other literatures, this 
systematic review: 
 Adds new evidence to the growing body of evidence that the quality of T2DM 
care is suboptimal globally. The management of T2DM, as indicated by the 
three major intermediate outcome measures (glycaemic control, blood 
pressure and lipid profile), to be sub-optimal in the GCC countries. However, 
for both clinical- and process- outcomes, similar results are reported for other 
countries in the region such Lebanon (203) and Egypt (204-206). In 
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comparison with a selection of reports from various levels of healthcare in the 
UK (204, 205), USA (206, 207) and Australia (211), clinical outcomes in the 
GCC countries were generally lower, but this was not always so.   
 Shows that with regard to intermediate outcomes of diabetes control, there 
has been evident progress in at least the UK and USA (207, 208), which I have 
not observed here to be the case in the GCC region. 
 Indicates that a number of secondary prevention strategies have been 
established and believed to help in raising the quality of management in this 
region. 
7.5 Quality of T2DM care in Al-Ain 
It‟s important to acknowledge that this is the first study in Al-Ain, and UAE to 
examine the quality of T2DM care, and assess any improvement in this care using 
longitudinal data from 2008 to 2010. Also, it‟s the first study to investigate any 
differences in the care provided to different age groups and genders in Al-Ain and 
UAE. 
Comparing the findings from this quantitative study with other studies carried out 
in the developed countries and other Arab countries, this study: 
 In terms of process of diabetes care, shows that the proportion of people with 
T2DM having their measurements performed at least once annually within 1-
year of follow-up for the study period are comparable if not higher with 
studies carried out in the Gulf region (e.g., 87,89,90), Middle East (e.g., 204-
206), and Western countries (e.g.,207). 
 Adds to the available body of evidence that the management of T2DM 
particularly focusing on glucose and SBP is sub-optimal. More than 50% of 
the study population did not achieve the desirable targets for the HbA1c and 
SBP in the following years 2008, 2009 and 2010. 
 Supports the evidence revealing that excellent performance on process of 
diabetes care does not essentially translate into good metabolic control. 
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 Shows better glycaemic and blood pressure control in this setting compared 
to other GCC countries (e.g., for glycaemic control: 84, 87, and e.g., for BP 
control: 89, 90). 
 Indicates that the quality of T2DM control, particularly glycaemic, blood 
pressure and lipid are consistent with studies carried out in developed 
countries at various levels of healthcare (e.g., 202). 
 Supports the evidence that found association between ageing and improved 
glycaemic control (222, 210), but an increment in the hypertension rate (305). 
As in this study, compared to older individuals, younger individuals (<40 
years old) have not as good HbA1c profiles. Although there were no 
significant differences of blood pressure level across age groups, it can be seen 
that during the three years proportion of those reached the target was 
consistently higher in younger age group than that of older age group. 
 Indicates no differences in T2DM care between women and men similarly to 
many studies discussed in chapter five. 
 Does not support findings from other studies (e.g., 176, 216) discussed in 
chapter five that relate gender –women- to poorer achievement of standards 
of care. In this study, women performed better than men on reaching the 
target of blood pressure, especially for the SBP in 2009 and 2010. 
 Indicates an encouraging progress with regard to intermediate outcomes of 
diabetes control including glycaemic and lipid between 2008 and 2010. This 
finding is similar to the evident progress in diabetes care in the developed 
countries such as UK and USA (e.g., 208, 210). 
 Shows that subjects with T2DM being prescribed drugs to regulate their blood 
pressure had poorer outcomes compared to those were not prescribed drugs. 
Similar results were found in Egypt, patients who were prescribed anti-
hypertensive drugs had about 11mmHg and 3 mmHg higher points in their 
S/DBP than those non-prescribed (205).  Several reasons have been suggested 
such as adherence to medications and clinical inertia. 
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7.6 Factors affecting the quality of T2DM care in Al-Ain 
It‟s important to acknowledge that this is the first study in Al-Ain and UAE to 
identify factors both facilitators and barriers that affect the quality of T2DM care at 
the diabetes centre based on the perceptions and attitudes of healthcare 
professionals. Also, this is first study to develop a frame of knowledge from the 
perceptions, understanding and experiences of the healthcare professionals 
regarding the care of people with diabetes. 
It‟s essential to recognize the dynamic interplay in the interactions between the 
factors affecting the quality of diabetes care in this study including: patients, 
healthcare professionals, organization, and cultural factors. 
Factors related to the patients 
Comparing the findings from this qualitative study with other studies carried out in 
the developed and other Arab countries, this study: 
 Supports the evidence on the important rule of adherence in achieving the 
treatment outcomes. Non-adherence to treatment was identified as one of the 
patient‟s related barriers to achieving the standard therapeutic targets in 
Emirates with T2DM being treated in the diabetes centre.  
 Adds more evidence to other qualitative studies that stressed on the 
importance of patient‟s health beliefs and education in improving diabetes 
care.  
 Supports the evidence from other qualitative studies which demonstrated that 
empowering people with T2DM in the management plan could improve the 
outcomes of care. 
 Suggests that Emirates with T2DM should be educated and aware about the 
services they receive from the diabetes centre, and the multidisciplinary 
management they receive from the diabetes team members. 
 Suggests that more attention and awareness on the importance of spending 
sufficient time with the healthcare professionals is required and should be 
spread to people with T2DM. 
268 
 
 Proposes several barriers to improving quality of diabetes care related to the 
patient‟s demographics such as old age and literacy in the diabetes centre 
similarly to findings of many studies addressed in the chapter six.  
Factors related to the healthcare professionals 
Comparing the findings from this qualitative study with other studies carried out in 
the developed and other Arab countries, this study:  
 Reveals that healthcare professionals motivation is the most important factor 
in this setting similar to findings elsewhere (254, 255). 
 Supports the evidence from the literature that links healthcare professional‟s 
interest in diabetes to increasing the motivation of healthcare professionals. 
 Adds to the evidence from the literature on the influence of the healthcare 
professional‟s perceptions and attitudes about diabetes on the care they 
provide to people with T2DM in the diabetes centre. Healthcare professionals 
at the diabetes centre described diabetes as a difficult disease to treat 
compared with other chronic conditions due to the complexity of treatment, 
unavoidability of future diabetes related complications, lack of effective drugs 
and behavioural changes required by the patients to achieve the treatment 
outcomes similar to findings from other studies (254, 255).   
 Supports the idea that shortages of staff, heavy workload, teamwork and 
communication between primary/secondary care all are potentially 
important areas as demonstrated by many studies in the literature. 
 Adds more evidence to the growing body of evidence on the importance of 
communication between healthcare professionals and people with T2DM and 
its rule in increasing the quality of T2DM care. Therefore, training healthcare 
professionals on the skills needed for educating patients, promoting 
behavioural changes (e.g. life style changes) and communicating with people 
with T2DM effectively were highly advocated by the healthcare professionals 
at the diabetes centre, and believed to improve diabetes care. 
 Supports the evidence from the literature on the positive perceptions of the 
teamwork and team climate as facilitators of good diabetes care. 
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 Provides insight on the importance of cultural and language difference 
between the team members as they act as barriers for effective team-work. 
Factors related to the organization 
Comparing the findings from this qualitative study with other studies carried out in 
the developed and other Arab countries, this study: 
 Shows that participants are satisfied with the amount of payment they 
receive. 
 Supports findings from other studies that providing incentives can improve 
the quality of diabetes care. The need to implement an incentive system 
similarly to other western countries such as UK in order to increase healthcare 
professional‟s motivation was pointed out by one of the participants in this 
study. Similarly to the study carried out in Tunisia, lack of incentives was 
seen as a barrier for healthcare professionals to provide optimal care (254). In 
the UK since the establishment of QOF in 2004, substantial improvements in 
the quality of diabetes care have been reported as reflected by the QOF 
indicators (344). Nevertheless, in the UAE healthcare professionals are well 
paid, therefore introducing the incentive system alone would not be the 
effective solution to motivating healthcare professionals; and therefore 
improving quality of diabetes care. Using different strategies to motivate 
healthcare professionals and increase the quality of T2DM care would be 
useful. 
 Supports the evidence that associates the workload with increasing healthcare 
professionals stress and reduces their motivation and the quality of care they 
provide to people with T2DM. Findings from the diabetes centre concur with 
findings from other studies (e.g., 254, 255). In Saudi Arabia for instance, 
stressful work conditions was seen as an obstacle for providing optimal care 
to people with chronic diseases (269). 
 Supports the idea of the need to strengthen the communication and co-
ordination between the primary/ secondary care in the UAE. Attachment of 
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diabetes physicians to the primary care setting on regular bases is suggested 
to increase the confidence of Emirate people with diabetes on primary care.  
 Supports evidence that Interruption from other healthcare professionals and 
patients during consultation time is a barrier for healthcare professional‟s 
motivation, providing good patient communication and high quality diabetes 
care.  Also, these interruptions in the diabetes centre were believed to disturb 
the privacy of consultations. Similarly, findings from another study carried 
out in Oman, demonstrated that interruptions during consultation time by 
other colleagues or patients disrupt the privacy of consultation between 
patients and healthcare professionals (239). 
 Proposes that good time management and organization skills could improve 
the care provided to people with T2DM in the diabetes centre in Al-Ain. 
Factors related to the Emirate‟s Culture 
In terms of the influence of Emirate‟s culture on the quality of T2DM care in Al-Ain, 
this study: 
 Indicates that the Emirate‟s culture has a significant impact on behaviours 
and health beliefs of the Emirates with T2DM. 
 Emphasises on the importance for the healthcare professionals to understand 
health beliefs in the UAE, specifically those related to T2DM as they define 
the unique perspectives of individuals within a culture (338). 
Quality measurement 
As discussed in chapter one, Maxwell identified six dimensions to measure the 
quality of healthcare believing that quality of care can‟t be measured using a sigle 
dimension (64, 65). Based on the findings from this thesis, I used these six 
dimensions to measure the quality of T2DM care in the diabetes centre. 
1- Acceptability: more research should be carried out to measure the satisfaction 
of people with T2DM on the care they receive, and identify any obstacle based 
on the beliefs of the people with T2DM; therefore improve the quality of 
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T2DM care. Also, standards of communication between healthcare 
professionals and people with T2DM should be assessed aiming to enhance 
the communication between the two panels. Privacy of consultation should be 
ensured in the centre as many healthcare professionals raised the issue of 
interruptions during the consultation by other patients and healthcare 
professionals; thus more regulations should be initiated to protect the privacy 
and confidentiality of consultation time.  
2- Effectiveness: the overall results from the cohort study showed that the care 
provided to people with T2DM is suboptimal based on the glycaemic and 
blood pressure measurements. Despite the suboptimal control, the 
improvement in the results between 2008 and 2010 was positive and 
emphasized the possibility of improving the quality of T2DM care in the 
centre.  More research should be carried out to assess the technical 
effectiveness measuring the adequacy of equipments and staffing in the 
department. However, results from the qualitative study indicated the need 
for increasing the number of dieticians in the centre to reduce to the workload 
because only one dietician is available. Also, involving a clinical pharmacist 
would improve treatment outcomes; so the quality of T2DM care. 
3- Efficiency and economy: more research should focus on the unit-cost and 
compare it with the unit-cost with other diabetes centres in Abu Dhabi.  
4- Access: Emirates with T2DM from all the UAE cities can be transferred to this 
centre from their primary care settings. Also, they can book appointments 
directly from the centre.  However, long distance for people travelling from 
other emirates to Abu Dhabi would be one of the barriers to the services 
provided by the centre. More research should assess the referral waiting 
times. 
5- Equity: based on the results from the cohort study equal services were 
provided to people from different age groups and genders. However, 
compared to older individuals, younger individuals (<40 years old) have 
poorer HbA1c profiles; therefore this specific age group should be targeted by 
special educational programs. Also, the use of intensified and supervised life-
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style modifications could improve the treatment outcomes among this 
groups.  
6- Relevance to need for the whole community: based on the population needs 
this centre was established.  
 
7.7 Strengths and limitations of the study 
Principal strength 
The main strength of this study is using respectively both quantitative and 
qualitative approaches to examine the quality of T2DM care in Al-Ain, and identify 
factors affecting it. Additionally, as this study is one of the first to be carried in Al-
Ain, findings are more likely to be transferable to Abu Dhabi and other cities in the 
UAE. 
Strengths of the systematic reviews, quantitative and qualitative studies are 
addressed below. However, the limitations of them are explained in chapters four, 
five and six respectively. 
 
Strengths of the systematic reviews 
 The first systematic reviews have been undertaken in the countries of the 
GCC to estimate the prevalence rates of T2DM and its adverse outcomes, and 
to examine the quality of T2DM management.  
 The use of focused research questions. 
 The use of rigorous search strategies. 
 
Strengths of the quantitative study 
 The first study in Al-Ain and UAE to examine the quality of T2DM care using 
longitudinal data from 2008 to 2010. 
 The first study in Al-Ain and UAE to investigate and assess any differences in 
T2DM care provided to different age groups and genders. 
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 The followed methodology allowed random selections of participants thus 
reducing the confounding effects of other contextual factors that could 
influence the quality of T2DM care. 
 The use of multi-level modelling allows for confounding variables, and selects 
independents relationship with the quality indicators used in this study to 
assess the quality of T2DM care. 
 The longitudinal analysis of data used appropriate statistical analysis for 
comparison such as repeated measures data for process, and intermediate 
outcomes for each patient at each year from 2008 till 2010. Hence, any 
potential bias caused by patient‟s difference is excluded. 
 The use of different quality indicators including process and intermediate 
outcomes of care to assess the quality of T2DM care. 
 
Strengths of qualitative work 
 The first study in Al-Ain and UAE to identify factors influencing the care 
provided to people with T2DM. 
 The use of reflective approach in this study improved the validity of the 
results. 
 The use of „rich informative‟ subjects in the sample including members of the 
diabetes team to collect the needed data. 
 The interview guide and thematic analysis both were revised by two experts 
in the qualitative field. 
7.8 Implications of the research 
This research has important implications for clinical practice in Al-Ain and UAE as 
well other GCC countries, as many of findings are likely to be transferable to these 
countries. 
The implications of the systematic reviews, quantitative and qualitative works are 
discussed in details in chapters four, five and six respectively. Further, it‟s 
recommended that healthcare professionals, managers, and policy makers in the 
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UAE take these results into consideration in order to develop and implement 
culturally appropriate innervations to improve the quality of T2DM care. 
Several strategies have been followed to disseminate the results from this research 
nationally and internationally.  On the level of the UAE, a full report of the study 
was submitted to the HAAD for consideration. In addition to my aim to improving 
the quality of T2DM care in Al-Ain and UAE, it is hoped that results from this study 
will be helpful to other GCC countries. With this in mind, the results from this study 
have been presented at several international conferences (IDF congress in Dubai 
2011, International Diabetes Epidemiology Group in UAE 2011 and Society for 
Academic Primary Care meeting 2010 in UK). In addition, to publicise the findings 
from this study, the three systematic reviews have been published, and the 
quantitative and qualitative components of this research have been accepted for 
publication in scientific journals. Copies of all published paper have been included 
in annex one. 
7.9 Future research needs 
Following findings from this study, future research needs are classified into two 
main areas including: worldwide, and within Al-Ain and UAE. 
Worldwide 
 As many studies in the literature and results from this study supports the 
influence of healthcare professionals motivation on diabetes care, more 
research studies are needed worldwide focusing on assessing the relation 
between healthcare professionals motivation and diabetes care, and 
identifying factors affecting the motivation of healthcare professionals to 
optimize diabetes care. 
 In multicultural societies, the role of cultural health beliefs play a crucial 
role in diabetes management; therefore more research studies should focus 
on cultural health beliefs of people with diabetes. 
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Within Al-Ain and UAE 
 In the diabetes centre level, results from this study showed that there is 
improvement in the care provide to people with T2DM in the diabetes centre 
in Al-Ain; however in light of glycaemic and SBP measurements, the control 
of this two variables were suboptimal. Therefore, more studies should be 
carried out to investigate the reasons for the suboptimal control of these 
indicators. 
 More research studies should be carried out to assess the medication use and 
adherence among T2DM subjects to improve the clinical outcomes of care. 
 Results showed that T2DM is influenced by many factors including patients, 
healthcare professionals, organization and Emirate‟s culture from the 
perceptions and attitudes of healthcare professionals. However, the 
perceptions and attitudes of patients who play an active rule in the 
management of diabetes was not sought; therefore more research studies 
focusing on patient‟s side are needed. 
 As primary care in the UAE is providing care to people with T2DM, assessing 
and evaluating this care and identifying the motivators and barrier to 
improve the quality of T2DM care in this setting are required. 
 More studies and RCTs should be performed in the UAE to help initiating 
culturally appropriate quality improvement interventions. 
7. 10 Conclusion 
The crisis of diabetes, chiefly type 2 is challenging healthcare professionals, people 
with diabetes, policy makers and healthcare planners globally. Overall findings from 
this thesis indicated the need for emphasizing on the three chief components of the 
global strategy including surveillance, prevention and management to prevent 
NCDs including T2DM in the UAE.  
An important finding from the systematic reviews carried out as part of this thesis  
indicated the dramatic raise overtime in the prevalences of T2DM, obesity, 
overweight, hypertension and hyperlipidaemia in the UAE and other GCC 
countries.  
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The „obesogenic‟ and „diabetogenic‟ environments, which are becoming the norm in 
the UAE and other GCC countries; especially among people at younger age are the 
main causes for these epidemics. The abundance of “energy-dense- food”, frequent 
snaking, low fruits and vegetables intake, and high rate of soft drinks consumption 
in the regions were associated with the rapid growth in the prevalence of 
overweight/ obesity (326). The Emirate‟s culture impact on the health beliefs and 
behaviours play an important role in increasing the prevalence rates of diabetes and 
its adverse outcomes in the UAE, and negatively affect the treatment outcomes in 
people with T2DM as found from the qualitative study. Acting on the modifiable 
risk factor that increase the risks of T2DM such as overweight and obesity is 
important and can help prevent or manage diabetes and its related complications 
effectively.  
 
To act on these risk factors and reduce the burden of T2DM and its adverse 
outcomes, concerted efforts are required at all local levels in the UAE including the 
government, public, media and medical community (323). Policy makers in the UAE 
made several decisions that have a good impact on T2DM and its adverse outcomes. 
For instance, since 2009 the UAE started using the policy tools to ban high fat snacks 
and fast food in all public and private schools to act on the high prevalence rates of 
overweight/ obesity among school population. Additionally, many achievements 
from the national diabetes strategy in the UAE were outlined in 2009 in terms of 
spreading awareness to the people with diabetes and the society, and promoting 
health. In terms of spreading awareness to the society, some actions are already 
undertaken in the UAE such as promoting awareness on healthy diet and physical 
activity. Despite all these efforts, the prevalence rates of T2DM and its adverse 
outcomes are growing progressively.  There is a need in the UAE to conduct more 
research studies on the life-style interventions to prevent T2DM epidemic and its 
adverse outcomes from escalating, and improve the treatment outcomes in people 
with T2DM. These research studies would help decision planners and makers, 
managers and healthcare professionals to plan and execute better quality culturally-
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sensitive interventions. Collaboration and joint planning between different health in 
the UAE should be strengthened through the development of national planning 
framework.  
 
The WHO most effective interventions implemented to reduce the risk factors for the 
NCDs including T2DM, especially un-healthy diet included several actions such as 
initiating regulations to reduce salt, sugar and fat intake in food, and promoting 
public awareness about diet and physical activity. In the UAE, adopting such 
interventions would be useful, also to increase the outcomes of preventive programs, 
policies on taxation and trade food urban planning would be effective if set with the 
consideration of public health. Behaviours changes programs encouraging physical 
activity and healthy diet should be initiated and should target people at different age 
groups including those at schools, universities and workplaces. By targeting people 
from different ages, more awareness on the key modifiable risk factors in the UAE 
such as physical inactivity, obesity and un-healthy nutrition would be emphasised. 
The comprehensive and integrated actions led by the UAE‟s government are 
important to support these interventions.  
 
Another significant finding from this study reflected by the quantitative constituent 
and systematic review on the quality of T2DM in the GCC is that a large proportion 
of Emirates with T2DM (roughly > 50%) received sub-optimal care as reflected by 
glycaemic and blood pressure control, particularly systolic blood pressure. This 
finding is a clear indicator for the need to improve the care provided to those people. 
Despite the fact that DM care tends to be sup-optimal worldwide, improving this 
care in a country with an alarming prevalence of DM is essential to help delaying or 
preventing the expensive DM related complications and improve the quality of life 
to the patients. One of the objectives of the national diabetes strategy in the UAE for 
2009-2018 is to improve and promote the quality of diabetes care at the three levels 
of healthcare system. To achieve these objective several actions should be 
implemented as outlined in the national strategy such as supporting monitoring and 
evaluating of DM care, and promoting and supporting research in diabetes. The 
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recent establishment of the diabetes registry to monitor the onset and prognosis of 
diabetes in the UAE is considered as an important action. Continuous audits and 
more research studies are needed to investigate the reasons for the poor outcomes 
for the control of diabetes, and barriers from improving care provided to people 
with diabetes.  
 
T2DM care is influenced by many factors including patient, healthcare professional 
and organization. Findings from the qualitative study I carried out emphasised on 
the need of empowering Emirates with T2DM with the needed knowledge and 
education to increase healthcare professional‟s motivation and treatment outcomes. 
Emirates with T2DM should be involved successfully in the management plan. They 
should be the centre of focus; and should be provided with regular updates on their 
process and intermediate outcomes of care measurements by their healthcare 
professionals to enable them evaluate and monitor their clinical improvement.  
Involvement of people with diabetes in the management of their disorders requires 
good healthcare professionals-patients relationship that could attained through 
effective communication as was outlined by the qualitative study. Communication 
between healthcare professionals and subjects with diabetes is like art, therefore 
healthcare professionals should be trained on the skills needed for effective 
communication. Findings from the qualitative study carried out in the diabetes 
centre emphasized on the need to train healthcare professionals on the needed skills 
for effective interpersonal communication as it was believed to improve treatment 
outcomes, healthcare professional‟s motivation and the quality of diabetes care.  
Specific programs were used in developing countries including Egypt, Trinidad and 
Honduras to assess the efficacy of specific techniques in enhancing interpersonal 
communication between patients and healthcare professionals not specified to 
diabetes. Overall improvement in the treatment outcomes was demonstrated as a 
result of effective communication between healthcare professionals and their 
patients. Policy planners and makers and healthcare professionals could utilize from 
the programs and strategies used in developing countries to enhance communication 
between healthcare professionals and people with diabetes in the UAE. This can be 
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achieved by developing local appropriate initiatives. Enhancing communication 
between healthcare professionals and people with diabetes in the UAE has the 
potential of making the health system more efficient and cost effective in the long 
term (319). 
 
Additionally, as findings from the quantitative study showed that subjects with 
T2DM being prescribed anti-hypertensive drugs had poorer control compared to 
those were not on pharmacological medications; more attention should be given to 
the proposed causes for this finding including adherence to medications, clinical 
inertia and side effects from the medications. Healthcare professionals at the 
diabetes centre commonly cited that non-adherence to treatment is an obstacle for 
achieving the treatment outcomes; as a result the educational programs should 
highlight the significant of compliance to therapeutic regimes. Having clinical 
pharmacists within the diabetes centre would help increasing the adherence of 
people with T2DM to their medications. The qualitative and quantitative 
components of this thesis emphasized on the importance of identifying factors 
affecting adherence to medications among people with T2DM in the UAE. As the 
national diabetes strategy in the UAE aims to promote research focusing on diabetes; 
more studies should focus on identifying factors that influence adherence to 
medications and clinical inertia in T2DM as these important areas didn‟t receive any 
attention yet.  
 
Another worrying finding demonstrated from the quantitative study and was 
supported by the findings from the literature review on the quality of T2DM care 
worldwide is that, younger Emirates with T2DM were having worse glycaemic 
control compared to older patients; given that the risk for both micro and 
macrovascular complications over a long period of time would increase. This sub-
optimal T2DM care could be influenced by many factors related to the patients, 
healthcare professionals or organization. People with diabetes at younger age should 
be targeted by specific educational programs, and interventions aiming to improve 
the management of diabetes among them. Findings from the qualitative study 
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indicated that many Emirates with diabetes, particularly those at young age are not 
willing to spend sufficient time with the healthcare professionals to discuss the 
management plan instead they prefer collecting their prescriptions and run away. As 
there is strong evidence linking sufficient consultation time to better health 
outcomes as highlighted in chapter six; this could be one of the reasons participating 
in the poorer achievement of treatment outcomes among young subjects with T2DM 
compared to older subjects.  
To manage T2DM effectively, people with diabetes should adhere to the therapeutic 
regime including medication use, self-management and behavioural changes needed 
to achieve the required therapeutic goals. In the UAE, people with diabetes should 
have a better understanding and awareness that medical approaches used to manage 
diabetes do not depend solely on the use of pharmacological drugs; therefore they 
should pay attention to the consultation with healthcare professionals. Educational 
programs with emphasis on the importance of consultation time are needed to 
change this attitude among Emirate with diabetes. 
Another key finding from the qualitative study is the importance affect of healthcare 
professional‟s motivation on diabetes care. In order to increase their motivation, 
many actions should be implemented as discussed before in chapter six. The 
workload was one of the main factors that de-motivate healthcare professionals in 
the diabetes centre; therefore it should be reduced by reinforcing the role of primary 
care in the management of diabetes. Despite the large efforts of the health bodies in 
the UAE to strengthen the role of primary care in the management of NCDs 
including T2DM, still Emirates with T2DM prefer to receive their care from 
secondary/ tertiary settings. The cause of the preference to receive care from 
secondary/ tertiary care in the UAE is that Emirates with T2DM consider the care in 
the primary care settings to be poor compared with secondary/ tertiary settings. 
Lack of confidence on the role of GPs in the management of diabetes is another 
concern among Emirates with diabetes. To enhance the perceptions of Emirates with 
T2DM on the effective role of primary care in the management of diabetes several 
actions have been suggested by the healthcare professionals as discussed in chapter 
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six. In brief, attaching GPs in the secondary/ tertiary care settings, and involving the 
diabetes specialists in providing care at least once weakly in the primary care 
settings would increase the confidence of people with T2DM on the GPs, and 
primary care settings.  Another important factor that found from the qualitative 
study reducing the motivation of healthcare professionals is dismissing the role of 
non-physicians such as educators, dieticians and pharmacists in the management of 
diabetes. This issue needs attention from healthcare professionals and policy 
planners and makers as it can affect the treatment outcomes negatively. Emirates 
with T2DM should have a better understanding on the role of other non-doctor staff 
in the management of diabetes in order to enhance the relationship with those 
healthcare professionals, increase their motivation and therefore increase the quality 
of care.  
The overall improvement in the quality of diabetes care in the diabetes centre 
demonstrated by the quantitative study, and reflected by the improvement in the 
intermediate outcomes indicators for the consecutive years from 2008 to 2010 is 
encouraging. Another encouraging finding was the outstanding achievement in the 
process of diabetes care as reflected by the proportion of participants had the 
measurements for the metabolic indicators documented yearly from 2008 to 2010, 
and the high frequency (≥ 3 times) for each measurement performed annually. This 
is a clear indication that HAAD is working hard to improve the quality of services to 
the population of Abu Dhabi. HAAD is looking to develop a strong, sustainable 
health care system in the capital of the UAE.  Since 2009, HAAD focuses on 
improving the medical outcomes and public health for people living in Abu Dhabi. 
In conclusion, giving the alarming raise in the prevalence of diabetes chiefly T2DM 
in the UAE continues dialogue between advocates of diabetes control and policy 
planners and makers is essential to improve the quality of care, and reduce its 
burden. More research should be performed in the country level to meet the local 
needs, and help policy planners and makers developing local appropriate strategies 
and interventions to tackle the epidemic of T2DM and improve care to people with 
diabetes.  
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Appendix 1: PRISMA checklist --„Prevalence of T2DM management in the states of the GCC: a systematic review‟ 
Section/topic  # Checklist item  
Reported 
on page 
#  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  50 
INTRODUCTION   
Rationale  2 Describe the rationale for the review in the context of what is already known.  50-51 
Objectives  3 Provide an explicit statement of questions being addressed with reference to participants, interventions, 
comparisons, outcomes, and study design (PICOS).  
51 
METHODS   
Protocol and registration  4 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, 
provide registration information including registration number.  
52 
Eligibility criteria  4 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years 
considered, language, publication status) used as criteria for eligibility, giving rationale.  
52 
Information sources  6 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to 
identify additional studies) in the search and date last searched.  
52 
Search  7 Present full electronic search strategy for at least one database, including any limits used, such that it could 
be repeated.  
52-53 
Study selection  8 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if 
applicable, included in the meta-analysis).  
53-54 
Data collection process  9 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any 
processes for obtaining and confirming data from investigators.  
54 
Data items  10 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions 
and simplifications made.  
55 
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Risk of bias in individual 
studies  
11 Describe methods used for assessing risk of bias of individual studies (including specification of whether this 
was done at the study or outcome level), and how this information is to be used in any data synthesis.  
54-55 
Summary measures  12 State the principal summary measures (e.g., risk ratio, difference in means).  55 
Synthesis of results  13 Describe the methods of handling data and combining results of studies, if done, including measures of 
consistency (e.g., I
2
) for each meta-analysis.  
55 
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Appendix 2: PRISMA checklist –„the prevalences of overweight, obesity, hyperglycaemia, hypertension and dyslipidaemia in 
the states of the GCC: a systematic review‟ 
 
Section/topic  # Checklist item  
Reported 
on page 
#  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  68 
INTRODUCTION   
Rationale  2 Describe the rationale for the review in the context of what is already known.  68-69 
Objectives  3 Provide an explicit statement of questions being addressed with reference to participants, interventions, 
comparisons, outcomes, and study design (PICOS).  
69 
METHODS   
Protocol and registration  4 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, 
provide registration information including registration number.  
69 
Eligibility criteria  4 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years 
considered, language, publication status) used as criteria for eligibility, giving rationale.  
69 
Information sources  6 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to 
identify additional studies) in the search and date last searched.  
69 
Search  7 Present full electronic search strategy for at least one database, including any limits used, such that it could 
be repeated.  
69 
Study selection  8 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if 
applicable, included in the meta-analysis).  
70 
Data collection process  9 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any 
processes for obtaining and confirming data from investigators.  
70 
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Data items  10 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions 
and simplifications made.  
69-70 
Risk of bias in individual 
studies  
11 Describe methods used for assessing risk of bias of individual studies (including specification of whether this 
was done at the study or outcome level), and how this information is to be used in any data synthesis.  
69-70 
Summary measures  12 State the principal summary measures (e.g., risk ratio, difference in means).  71 
Synthesis of results  13 Describe the methods of handling data and combining results of studies, if done, including measures of 
consistency (e.g., I
2
) for each meta-analysis.  
71 
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Appendix 3: PRISMA checklist –„the quality of T2DM management in the states of the GCC:  a systematic review‟ 
 
Section/topic  # Checklist item  
Reported 
on page 
#  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  89 
INTRODUCTION   
Rationale  2 Describe the rationale for the review in the context of what is already known.  89-90 
Objectives  3 Provide an explicit statement of questions being addressed with reference to participants, interventions, 
comparisons, outcomes, and study design (PICOS).  
90 
METHODS   
Protocol and registration  4 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, 
provide registration information including registration number.  
90-91 
Eligibility criteria  4 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years 
considered, language, publication status) used as criteria for eligibility, giving rationale.  
91 
Information sources  6 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to 
identify additional studies) in the search and date last searched.  
91 
Search  7 Present full electronic search strategy for at least one database, including any limits used, such that it could 
be repeated.  
90 
Study selection  8 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if 
applicable, included in the meta-analysis).  
91 
Data collection process  9 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any 
processes for obtaining and confirming data from investigators.  
90-91 
Data items  10 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions 
and simplifications made.  
90-91 
Risk of bias in individual 
studies  
11 Describe methods used for assessing risk of bias of individual studies (including specification of whether this 
was done at the study or outcome level), and how this information is to be used in any data synthesis.  
91 
317 
 
Summary measures  12 State the principal summary measures (e.g., risk ratio, difference in means).  92 
Synthesis of results  13 Describe the methods of handling data and combining results of studies, if done, including measures of 
consistency (e.g., I
2
) for each meta-analysis.  
92 
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Appendix 4:  Review protocol -„Prevalence of T2DM management in the states of 
the GCC: a systematic review‟ 
 
Background 
The World Economic Forum rates chronic diseases one of the „top 6‟ Global Risks (1).  
They carry enormous levels of morbidity and have become major bearers of 
mortality.  Diabetes mellitus is a chronic metabolic disorder caused by defects in 
insulin secretion, insulin action, or both.  If ineffectively controlled, the resulting 
chronic hyperglycaemia is associated with numerous disabling complications, and 
the International Diabetes Federation (IDF) 2010 estimate suggests that diabetes 
mellitus accounts for 6.8 % of all-cause mortality in the 20 – 79 age group (2).  90 % of 
cases of diabetes mellitus are of type 2 diabetes mellitus (3), a form of diabetes 
characterised by insulin resistance with a relative or real insulin deficiency.  Over the 
past 3 – 4 decades there has been a global expansion in the prevalence of type 2 
diabetes, associated with population growth, ageing, urbanisation and lifestyle 
changes (4, 5). These trends pose a particular risk to low- and middle- income 
countries, where most diabetes and most deaths from diabetes occur (5), where a 
greater proportion of individuals affected by type 2 diabetes are of working age (< 
70 years; 6), where changing demographics predict the greatest increases in 
prevalence, lifestyle changes anticipate relatively high increases in prevalence, 
interventions are likely to be fewer, and individuals generally pay a larger share of 
health costs. 
The states of The Co-operation Council for the Arab States of the Gulf (GCC) exhibit 
some of the highest rates of type 2 diabetes in the world.  Five of the International 
Diabetes Federation‟s IDF „top 10‟ countries for diabetes prevalence in 2010 and in 
2030 are projected to be in this region (1).  Currently, the IDF estimates suggest that 
in 2010 the ranking of countries by highest prevalence of diabetes starts as follows 
(2):1. Nauru, 2. United Arab Emirates (UAE), 3. Kingdom of Saudi Arabia (KSA), 4. 
Mauritius, 5. Bahrain, 6. Reunion, 7. Kuwait, 8. Oman, 9. Tongo, 10. Malaysia. 
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The anticipated prevalences for diabetes 2010-2030 in the Gulf countries are: United 
Arab Emirates (UAE) 18.7-21.4%, Kingdom of Saudi Arabia (KSA) 16.8-18.9%, 
Bahrain 15.4-17.3%, Kuwait 14.6-16.9% and Oman 13.4-14.9% (1).  Rates in Qatar are 
also relatively high (15.4 % comparative prevalence).  Prevalence estimates for 2030 
(based only on anticipated changes in population size and demographic; 7) suggest 
the same will be true then.  These likely underestimates (7) nevertheless anticipate 
prevalence in the IDF‟s „Middle East-North Africa‟ region will be 93.9 % higher in 
2030 (2). 
The recent and rapid socio-economic development of the GCC countries has been 
associated with this rising prevalence.  The IDF suggests that even in the absence of 
further economic development (that is, based on changes in population demography 
alone), the number of people with diabetes in its Middle East-North Africa region 
will increase 94% from 2010 to 2030.  Only the Sub-Saharan African region is 
expected to see a greater increase in the number of cases of diabetes (98%) during 
this period (1).  
Review question 
A literature search was used to identify material relevant to the following review 
question: 
- What is the prevalence of type 2 diabetes in populations of the GCC 
region?   
Inclusion criteria 
Types of studies 
Studies that used designs from the used list of acceptable methods including: 
observational study (cross sectional, descriptive, ecological, cohort, case-control).  
Types of participants 
Subjects residing in the GCC countries at all ages, sexes and ethnicities were 
included, resident and expatriate populations, urban and rural, of all socioeconomic 
and educational backgrounds in the GCC.  
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Exclusion criteria 
 Studies that used qualitative methods such as focus group and based on 
opinions 
 Studies where population is mainly pregnant women with type 2 diabetes, or 
people with other types of diabetes   
Study selection 
Study collection will be conducted in two stages: (1) an initial screening of the 
title/abstract against inclusion criteria to identify any relevant paper will be carried 
out by one reviewer (L.A) ; (2) screening of the full paper  that identified to be 
relevant from the first stage, and it will be carried out by 2 reviewers (L.A and A.M). 
If disagreement regarding any study eligibility appears, it would be resolved 
through discussion and asking for the opinion of the third reviewer (A. M). 
No limitations on publication type, publication status, study design or language of 
publication will be imposed. 
Data extraction/quality assessment 
The data captured for each study will include data relating to, (1) methods (study 
design, recruitment, measurement tools, analysis); (2) participant characteristics (3) 
setting, and (4) outcomes (those observed, their definitions, results of analysis, 
length of follow-up).  Study quality was assessed using a checklist adapted from the 
Centre for Reviews and Dissemination guidelines (8).  Data extraction will be 
performed, in duplication, by two reviewers (L.A, A.M). 
Data synthesis 
Synthesis will include summarising the results of the data extraction process, 
considering the strength of evidence relating to each of our questions, and 
examination of results inconsistent with our formed proposals.   
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Appendix 5: Research questions using PICO-„Prevalence of T2DM management in the states of the GCC: a systematic review‟ 
 
 
- Research question: What is the prevalence of type 2 diabetes in the populations of the GCC region? 
 
Patient/Population 
 
Outcomes 
 
People living   in the GCC Prevalence of: type 2 diabetes  
 
GCC: Qatar, United Arab Emirates UAE, Kingdom of Saudi 
Arabia KSA, Kingdom of Bahrain, Sultanate of Oman, Kuwait 
Prevalence: statistics, epidemiology  
 
Type 2 diabetes mellitus: Diabetes mellitus, Non-insulin 
dependent diabetes mellitus,  T 2 DM,  impaired glucose 
tolerance,  MODY or NIDDM, diabetes insipidus 
 
 
 
 
 
AND 
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Appendix 6: search strategy- „Prevalence of T2DM management in the states of the 
GCC: a systematic review‟ 
Search strategy to identify studies from electronic databases 
The followed steps for the search strategy included: (1) formatting a well defined 
review question to maintain the transparency for the review process; (2) revising the 
review question using PICOS elements (Population, Intervention, Comparators, 
Outcomes, Study design) (appendix 2); (3) defining the inc/exclusion criteria for the 
study; (4) producing a list of synonyms abbreviations and spelling variants; (5) 
combining the PICOS elements using Boolean logic (AND, OR); (6) devising a search 
strategy using both indexing terms and free text; (6) reviewing the search strategy; 
(7) pilot the search strategy on one database EMBASE; (8) review the search strategy 
with another colleague (w. I); (9) repeat the search strategy and finalize it. 
Describing electronic database searches 
The Medline and Embase were searched separately on 15/07/2009 and the search 
was repeated on 03/07/2010 (via Dialog and Ovid, respectively; 1950 to July week 1, 
and 1947 to 2010 July) using the following search strategy: 
Type 2 diabetes 
(1) exp diabetes mellitus, non-insulin-dependent/ 
(2) exp insulin resistance/ 
(3) impaired glucose toleranc$.tw. 
(4) glucose intoleranc$.tw. 
(5) insulin$ resistanc$.tw. 
(6) (MODY or NIDDM).tw. 
(7) ((typ$ 2 or typ$ II) adj diabet$).tw. 
(8) ((keto?resist$ or non?keto$) adj diabet$).tw. 
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(9) ((adult$ or matur$ or late or slow or stabl$) adj diabet$).tw. 
(10) (insulin$ defic$ adj relativ$).tw. 
(11) pluri?metabolic$ syndrom$.tw. 
(12) 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 
(13) exp diabetes insipidus/ 
(14) diabet$ insipidus.tw. 
(15) 13 or 14 
(16) 12 or 15 
(17) Exp prevalence/ 
(18) Exp epidemiology/ 
(19) Stat$.tw. 
(20) 17 or 18 or 19 
The states of The Co-operation Council for the Arab States of the Gulf  (GCC) 
(21) ((Saudi or emirates or Kuwait or Oman or Bahrain or Qatar) adj5 
(middle east* or Arab*)).mp. [mp=title, original title, abstract, name of 
substance word, subject heading word, unique identifier] 
Prevalence of type 2 diabetes in the GCC 
(1) 21 and 20 
(2) 16 and 20 
Describing journal hand searches 
1 International Journal of Diabetes and Metabolism searched  for the period 
1993 to 2009 
2 Saudi Medical Journal for the period 2000 to 2010 
Describing the methods used to search relevant internet sources   
1 The International Diabetes Federation (2009) IDF 
(http://www.diabetesatlas.org/) was searched using the on-site search 
engine. The section of the website labelled Diabetes Atlas 4th ed. was searched 
in detail. 
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2 The World Health Organisation (2009) WHO 
(http://www.WHO.int/mediacentre/factsheets/fs312/en/) was searched 
using on-site search engine. The section of the website labelled Fact sheet N 
312 Diabetes was searched in detail. 
 
Describing other searches included 
1 The reference lists of included studies in the review were scanned for relevant 
studies. 
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Ref/dates of study Quality assessment checklist (1) 
Al-Lawati &Jouilahti/ 1991 1-Y, 2-Y, 3-Y, 4-Y, 65-N, 6-N, 7-NA 
Asfour et al/ 2000 1-Y, 2-Y, 3-Y, 4-Y, 5-N, 6-N, 7-NA 
Al-Lawati et al/ NR 1-Y, 2-Y, 3-Y, 4-Y, 5-N, 6-N, 7-NA 
Balasy & Radwan/ 19892; 9 Full article not available for assessment 
Townsend/ NR 1-Y, 2-Y, 3-Y, 4-N, 5-Unclear, 6-N, 7-NA 
Glasgow et al/ 1995 1-N, 2-partially, 3-N, 4-N, 5-N, 6-Y, 7-NA 
El-Hazmi et al/ NR 1-Y, 2- Incomplete, 3-Y, 4-Y, 5-Y, 6-N, 7-NA 
Bacchus et al/ NR 1-Y, 2-Incomplete, 3- Y, 4- Y, 5-N, 6- Some, 7-NA 
Fatani et al/ NR  1-Y, 2-Y, 3-Y, 4-Y, 5-N, 6-N, 7-NA 
Anokute et al/ 1985-1987 1-Y, 2-Y, 3-Y, 4-Y, 5-Y, 6-N, 7-NA 
Abu-Zeid and Al-Kassab/ 1989 1-Y, 2-Incomplete, 3-Y, 4-Y, 5-N, 6-N, 7-NA 
Abdella et al/1989-1990 1-Y, 2-Y, 3-Y, 4-N, 5-Y, 6-N, 7-NA 
 Al-Lawati & Mohammed / 1991 1-Y, 2-Y, 3-Y, 4-Y, 5-N, 6-N, 7-NA 
Mahfouz et al/1993 1-Y, 2-Y, 3-Y, 4-Incomplete, 5-N, 6-N, 7-NA 
El-Hazmi et al/ 1991 1-Y, 2-Y, 3-Y, 4-Y, 5-N, 6-N, 7-NA 
 El-Hazmi et al/1991 1-Y, 2-Y, 3-Y, 4-Y, 5-N, 6-Some, 7-NA 
Al-Nuaim/ 1991-1993 1-Y, 2-Incomplete, 3-Y, 4-Y, 5-Y, 6-Some, 7-NA 
Al-Shammari et al/ 1993-1994 1-Y, 2-Y, 3-Y, 4-Y, 5-Y, 6-N, 7-NA 
Al-Mahroos & McKelcue/ 1995-1996 1-Y, 2-Y, 3-Y, 4-Y, 5-N, 6-N, 7-NA 
Al-Mahroos and Al-Roomi/ NR 1-Y, 2-Y, 3-Y, 4-Y, 5-Y, 6-N, 7-NA 
Al-Nozha et al/ 1995-2000 1-Y, 2-Incomplete, 3-Y, 4-N, 5-Y, 6-N, 7-NA 
Malik et al/ 1999-2000 1-Y, 2-Y, 3-Y, 4-Y, 5-Y, 6-N, 7-NA 
Al-Asi/ 2000 1-Y, 2-Y, 3-Y, 4-Y, 5-N, 6-N, 7-NA 
 Al-Moosa et al/ NR 1-Y, 2-Incomplete, 3-Y, 4-Y, 5-N, 6-Y, 7-NA 
Moussa et al/ 2000-2002 1-Y, 2-Incomplete, 3-Y, 4-Y, 5-N, 6-Y, 7-NA 
Baynouna et al/ 2004-2005 1-Y, 2-Y, 3-Y, 4-N, 5-Y, 6- N, 7-NA 
 Saadi et al/ 2005-2006 1-Y, 2-Y, 3-Y, 4-Y, 5-N, 6-Y, 7-NA 
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R: rural residents; U: urban residents; SR: self-reported diagnosis; PD: previous diagnosis; CBG: capillary blood glucose; RBG: random blood glucose 
 
Quality assessment checklist (1) 
 
Was the aim of the study stated clearly? 
Was the methodology stated? And was it appropriate? 
Were appropriate methods used for data collection and analysis? 
Was the data analysis sufficiently rigours? 
Were preventive steps taken to minimize bias? 
Were limitations of the study discussed? 
In systematic review, was search strategy adequate and appropriate? 
 
Bener et al/ 2009 1-Y, 2-Y, 3-Y, 4-Y, 5-Y, 6-Some, 7-NA 
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Ref/dates of 
study 
Country  Sampling Population characteristics 
% male Age Range (years) 
  
Nationality; U/R  
Population sampled Response rate Sample size 
Al-Lawati 
&Jouilahti/ 
1991 
Oman Households  91% 5096 
 
41.9  
 
20 to > 80 U/R mix 
Asfour et al/ 
2000 
Oman Households 93% (males 92%, 
females 94%) 
5838 49.8 20 to > 80 Omani; U/R mix 
Al-Lawati et 
al/ NR  
Oman 
 
 
 
Households 
 
83% 5847 Urban: 
48.8; Rural: 50.3 
20 to > 60  
Balasy & 
Radwan/ 
19892; 9 
UAE Health centre4  15175 NR8   
 
Townsend2; 9/ 
/ NR  
UAE PC  336 NR 8 >20 U/R mix 
Glasgow et 
al2 / 1995  
UAE PC  < 33 % of > 29809 NR8 >30 U/R mix 
(El-Hazmi et 
al2 / NR 
KSA Households 95% 25337 46.2 < 14 to > 60 Saudi 
Bacchus et al/ 
NR 
KSA Working 3  1385 100  < 15 to > 65 Saudi, R 
Fatani et al/ 
NR 
KSA Households - 5222 53.1 15 to >55  
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Anokute et 
al/ 1985-
1987 
KSA University  - 3158 100  Mean ages by subgroup: 
31, 23 and 41 years 
86.3 % Saudi; U 
Abu-Zeid 
and Al-
Kassab/ 
1989 
KSA Households 87% 1419 49.4  10 to > 60 98 % Saudi; 
„semiurban‟/R 
Abdella et 
al/1989-
1990 
Kuwait Households - 7831627 
 
Approximately: 50 < 20 to > 60 Kuwaiti; U/R mix 
Al-Lawati 
& 
Mohammed 
/ 1991 
Oman Households - 4682 42.8 
 
>20 U/R mix 
Mahfouz et 
al/1993 
KSA PC - 600132 NR8 > 5  
El-Hazmi 
et al/ 1991 
KSA Household - 23493 46 2-70 Saudi 
El-Hazmi 
et al/1991 
KSA Household Roughly 95% 2060 48.5 14 to >50 Saudi 
Al-Nuaim/ 
1991-1993 
KSA Households 69% 13177 52 15 to >60 Saudi 
Al-
Shammari 
et al/ 1993-
1994 
KSA Working5 - 2990 NR8 Unclear 94.7% Saudi 
Al-
Mahroos & 
McKelcue/ 
Bahrain Households 59-70% 2002 58.6 Males: 40 – 59 
Females: 50 – 69 
Bahraini 
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Summary of cross-sectional studies investigating prevalence of type 2 diabetes within populations of the GCC region 
R: rural residents; U: urban residents; SR: self-reported diagnosis; PD: previous diagnosis; CBG: capillary blood glucose; RBG: random blood 
glucose 
1995-1996 
Al-
Mahroos 
and Al-
Roomi/ NR 
Bahrain Households 59-70% 2013 58 Males: 40 – 59  
Females: 50 – 69 
Bahraini 
Al-Nozha 
et al/ 1995-
2000 
KSA Households 98.2% 16197 47.6 30-70 Saudi 
Malik et al/ 
1999-2000 
UAE Households 89% 5844 42.7 < 14 to > 60 UAE residents; '80 % 
U' 
Al-Asi/ 
2000 
Kuwait Working6 89.4% 3282 85 54 % < 40  62 % Kuwaiti 
Al-Moosa 
et al/ NR 
Oman Working 96% 5847 Urban: 
48.8; Rural: 50.3 
20 to > 60  
Moussa et 
al/ 2000-
2002 
Kuwait School-children  128918 41 6 – 18 Kuwaiti 
Baynouna 
et al/ 2004-
2005 
UAE Households 40.8% 817 49.3 20 to > 60 Emirati 
Saadi et al/ 
2005-2006 
UAE Households  2396 49.1 18 to > 70 Emirati; U 
Bener et al/ 
2009 
Qatar PC 77.9% 1117 51.1 20 – 59 U/ 
„semiurban‟ 
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1. Abstract only reviewed (full paper not available); 2.Full data unavailable; 3. Government/ municipal salaried workers; 4. Nature of clinic unclear; 
5. Employees of Saudi National Guard and dependents; 6. Employees of Kuwait Oil Company; 7. N = 130364 (urban group), 131023 (rural group); 8. 
Males and females included; 9. Pilot study; 10. Rates of diabetes as subject of consultation (not rates of diagnosis) investigated; 11. Until 59 years, no 
trend thereafter; 12. Falling after 60 years in one clinic; 13. Age significantly associated with DM (multiple logistic regression analysis): peak age 
DM 40 - 49 years  
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Ref/dates of 
study 
Diagnostic criteria Results Study limitations 
Criteria followed Method of 
screening 
Prevalence of DM Others 
Al-Lawati &Jouilahti/ 
1991 
WHO 1985  Overall prevalence of DM ( Males: 9.7  
Females: 9.8) 
Mean BMI increased from 
24.3kg/m2 in 1991 to 25.2/kg/m2 
in 2000 among males (P<0.001). 
Among females, it decreased 
from 26.3 kg/m2 to 25.8 kg/m2 
(P<0.001) 
In both gender, mean BMI 
increased with age and peaked in 
the age group (40-49) 
No statistical analysis; 
Characteristics of population 
studied unclear 
Asfour et al/ 2000 WHO 1999/ SR OGTT Crude prevalence of DM: 10% in both 
gender. 
Prevalence of DM rose through life in 
both gender to a maximum of > 30%  
 
IGT was more common in 
female than male: 13% vs. 8% 
respectively. 
In both gender, the prevalence of 
IGT increased with age, it peaked 
in the age group (60-69)  
Limitation of the study not 
discussed  
Steps taken to minimize bias not 
discussed 
Al-Lawati et al/ NR WHO 1999 FPG Prevalence of DM among male and 
female: 11.8% vs. 11.3% respectively 
(P=0.275)  
Prevalence of DM rose with age 
and exceeded 20% in both 
genders at the age of 50 years 
IGT was more prevalence among 
males than females 7.1% vs. 
5.1% (P<0.001) 
Dates of investigation unclear  
 Balasy & Radwan/ 
1989 
NR  Age adjusted prevalence rate for DM: 
5.69% 
Prevalence of DM among males vs. 
females: 1.81% vs. 2.58% respectively  
The age specific prevalence of 
DM was steadily increasing until 
age 59 in both genders.  
 
Townsend/ NR WHO 1980 Random 
capillary blood 
sampling in 
non-diabetic 
subjects was 
compared with 
OGTT in 
Overall prevalence unclear 
6.2% , > 30 years found to be diabetic 
19% of subjects >20 years had IGT 
- in previously undiagnosed: 4.8 
There was no apparent 
correlation of undiagnosed DM 
with BMI 
Dates of investigation unclear; 
Characteristics of study 
population not well documented 
(e.g. sex) 
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known diabetic 
samples 
Glasgow et al/ 1995 Previously diagnosed NR The rate of DM from the two 
databases for UAE citizens >30 years: 
5.7% and 11.2%  
In one of the databases the rate of 
DM increased from 1.4% in the 
age group 30-34 years to 
between 8.9% and 11% in the 
age group > 40-44 years.  
At the other database, the DM 
rates increased from 21% in the 
age group 30-34% to 21.6% in 
the age group 60-64, and 
decreased to 4.2% in people ≥ 65 
years. 
Rates of diabetes as subject of 
consultation (rather than rates of 
diagnosis) investigated. 
Diagnosis of DM not confirmed 
El-Hazmi et al/ NR WHO 1980/1985 FPG The prevalence of T2DM and IGT: 
5.63% and 0.5% respectively in males, 
in females: 4.53% and 0.72% 
respectively  
 
The prevalence of T2DM was 
0.12% and 0.79% in people< 14 
and people aged 14-29 years 
respectively. In the age ≥ 60, the 
rate increased to 28.8% and 
24.9% in males and females 
respectively. 
Dates of investigation unclear; 
Results by sex (*table 3) not 
available 
Bacchus et al/ NR WHO 1980 FPG and 
OGGT 
No diabetic cases in people <24 years 
0.3%: age group 25-34 years 
2.6%: age group 35-44 years 
9.6%: age group 45-54 years 
11%: age group 55-64 
65% of people with DM were 
overweight vs. 26% of people 
without DM 
Sample not representative for 
the whole population 
Recruitment process not 
specified 
Fatani et al/ NR Random CBG > 11 
mM/ WHO 1980 
(OGTT) 
ICT, OGGT overall prevalence DM 4.3 %; 
prevalence DM lower in men (2.9 %) 
vs. women (5.9 %; p< 0.001) 
Overall prevalence IGT 1.1 %; 
In subjects > 15 years, 
prevalence 4.0 % in men, 9.5 % 
in women (p < 0.001) 
 prevalence of DM higher in 
higher income groups (p < 0.001)  
Age, income and BMI were 
associated with blood glucose by 
multiple logistic regression 
analysis (p < 0.004, p < 0.0001 
and p < 0.045 respectively) 
Dates of study unclear 
Selection method of houses for 
sampling not reported 
Anokute et al/ 
1985-1987 
2x fasting CBG > 7.8 
mM 
FPG  overall prevalence 'positive' FBG 
(unconfirmed DM): 6.0 % 
The age specific prevalence 
increased with age to a maximum 
of 33.8% for the age group ≥ 50 
Recruitment procedure not 
reported 
No statistical analysis 
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years. Sample not representative for 
the whole population 
(male university community) 
Abu-Zeid and Al-
Kassab/ 1989 
PD/ 2-hour fasting 
post-meal CBG > 
11.1 mM 
FPG and IGT Overall prevalence DM 4.6 %, higher 
in men (5.5 %) than women (3.6 %; p 
< 0.05);; overall prevalence IGT: 3.7 
%; higher in women (4.9 %) vs. men 
(2.5 %; p < 0.01) 
Prevalence by sex was 
statistically significant (P<0.05) 
Prevalence rose with age 
steadily, it peaked among age 
people aged ≥ 45 years (P<0.001) 
Statistical tests not well 
described 
Abdella et al/1989-
1990 
WHO 1985 (2)  Overall prevalence DM: 7.6 % prevalence in urban area: 5.6 %; 
prevalence in rural area: 10.0 %; 
prevalence generally increased 
with age in both sexes in both 
areas; prevalence was generally 
greater in females (neither tested 
for significance) 
Mean BMI was 31.8±6.3 and 
28.5±5.1 in females and males 
respectively 
Only cases sufficiently severe to 
merit hospital clinic attendance 
were identified 
Al-Lawati & 
Mohammed / 1991 
WHO (1985)/ADA 
(1997) criteria for 
DM 
OGGT Prevalence of DM: 10.5 % by WHO 
criteria, 8.2 % by ADA criteria 
Prevalence of IGT 10.5 % by WHO 
criteria, 5.7 % by ADA criteria 
The difference in the prevalence 
of DM was less profound (10.5% 
by the WHO criteria vs. by ADA, 
P<0.0001) 
Characteristics of population 
studied unclear 
Mahfouz et al/1993 „Hospital-confirmed‟ 
(following repeat 
RBG > 7.8 mM) 
Random blood 
glucose 
Prevalence DM 9.7 % in males, 9.8 % 
in females Prevalence IGT 8.1 % in 
males, 12.9 % in females 
 Sampling method not clear 
Nature of population registered 
with health centres not specified 
El-Hazmi et al/ 
1991 
WHO 1980/1985 OGGT and IGT The prevalence of T2DM: 4.9% 
The prevalence of IGT: 0.7% 
The prevalence of DM peaked in 
the age group≥ 30 years 
(P<0.001) 
Limitation of the study not 
discussed  
Steps taken to minimize bias not 
discussed 
El-Hazmi et 
al/1991 
 
WHO 1980/1985 
OGGT and IGT The overall prevalence of T2DM: 
6.89%; IGT: 0.77% 
73% of female both diabetic or 
non-diabetic were estimated to be 
either obese or overweight 
compared to 50% of their male 
counterparts 
Limitation of the study not 
discussed  
Steps taken to minimize bias not 
discussed 
Al-Nuaim/ 1991-
1993 
WHO 1985 OGGT and IGT Overall prevalence DM: 12 % in urban 
males, 7 % rural males, 14 % urban 
females, 8 % rural females 
Overall prevalence IGT: 10 % in urban 
Age adjusted prevalence DM 
significantly higher in urban vs. 
rural population (p = 0.0001 for 
both male and female groups) 
Limitation of the study not 
discussed  
Steps taken to minimize bias not 
discussed 
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males, 8 % in rural males, 11 % in 
urban females, 8 % in rural females 
 
Prevalence of obesity (BMI > 30 
kg/m2) among males and females 
respectively was 15% and 24% 
(P=0.001) 
Al-Shammari et al/ 
1993-1994 
Previously diagnosed - Overall prevalence DM 12.2 %  Methods not well described 
Demographics of total 
population not available 
Diagnosis not confirmed; 
sample misses more problematic 
cases ('referred to hospital 
clinic') 
Sample not representative for 
the whole population (National 
Guard employees and 
dependants) 
Al-Mahroos & 
McKelcue/ 1995-
1996 
WHO 1985 OGGT and IGT Overall prevalence DM: 29.8 %; 
prevalence DM in males 40 - 49: 22.9 
%; in males 50 - 59: 29.6 %; in 
females 50 - 59: 35.4 %; in females 60 
- 69: 37.6 % 
Overall prevalence IGT: 17.9 %; 
prevalence IGT in males 40 - 49: 16.6 
%; in males 50 - 59: 15.8 %; in 
females 50 - 59: 19.4 %; in females 60 
- 69: 22.4 %; OR for DM in women 
1.27 (95 % CI 0.96 - 1.66) 
28% of subjects had BMI≥ 30 
kg/m2, only 42% rated 
themselves as overweight. 
Limitation of the study not 
discussed  
Steps taken to minimize bias not 
discussed 
Al-Mahroos and 
Al-Roomi/ NR 
 
Treatment/ WHO 
1985 
OGGT and IGT overall prevalence DM 30 %  Method of blood sampling not 
reported 
Al-Nozha et al/ 
1995-2000 
ADA 1997 OGGT and IGT Overall prevalence DM 23.7 %; 
prevalence higher in males: 26.2 % (95 
% CI 25.2 - 27.2) vs. females 21.5 % 
(95 % CI 20.6 - 22.4; p < 0.0001) 
(significance unclear); overall 
prevalence IFG 14.1 % (no gender 
difference) 
DM more prevalent in urban 
(25.5 %) vs. rural (19.5 %) areas 
(p < 0.0001); rates of DM 
increased with advancing age 
sample selection method not 
clear 
Limitation of the study not 
discussed  
Steps taken to minimize bias not 
discussed 
Malik et al/ 1999-
2000 
WHO 1999 OGGT, IFG 
and IGT 
overall prevalence DM: 21.4 % (95 % 
CI 20.4 - 22.4 %); prevalence in men 
Roughly 22% of the sample had 
BMI (35-39.9) 
Selection of subjects 
intentionally biased towards 
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20.4 % (18.8 - 22.0 %); prevalence in 
women 22.3 % (20.9 - 23.7 % 
Prevalence in UAE citizens 25 %, 
expats 13 - 19 %  
Prevalence IFG: 4.5 % (3.7 - 5.3 %) in 
men, 7.2 % (6.3 - 8.1 %) in women 
(significantly higher in women, p < 
0.01) 
40% had (BMI 25-29) UAE citizens 
Al-Asi/ 2000 Medication/ FBG > 7 
mM 
 Overall prevalence of DM: 17% Overall prevalence of overweight 
(BMI 25-29.9) was 48% , obesity 
(BMI >30) : 27% 
Sample not representative for 
the whole population 
 
Al-Moosa et al/ 
NR 
SR/ WHO 2000 FPG overall prevalence DM: 11.6 % (11.8 
% in males, 11.3 % in females; 17.7 % 
in urban population, 10.5 % in rural 
population); urban residence 
significantly associated with DM 
(adjusted OR) = 1.7 (95% CI 1.4–2.1), 
for every 5 year increase in age, 1.2 
greater odds of DM (95 % CI 1.4 - 2.1) 
The prevalence of obesity 
(BMI≥30) among sample : 
21.5% 
Dates of investigation unclear 
Secondary data collection 
Moussa et al/ 
2000-2002 
Previous diagnosis of 
T2DM (made by 
WHO 1985 (2) and 
ADA 1998, 2000 
criteria 
FPG Overall prevalence DM: 34.9 per 
100000 (95 % CI 24.7 - 45.1); males 
47.3 per 100000 (CI 28.7-65.8); 
females 26.3 per 100000 (CI 14.8-
37.8); significantly higher prevalence 
T2DM in males (p = 0.05) (p = 0.013 
on age-adjusted data)) and with 
advancing age (p = 0.026). 
 Secondary data collection 
Baynouna et al/ 
2004-2005 
ADA 2005/ 
medication/ SR 
OGGT and IFG Overall prevalence DM 23.3%; 
prevalence by age and gender: males: 
5.1 % 20 - 29 years, 11.1 % 30 - 39 
years, 29.5 % 40 - 49 years, 35.5 % 50 
- 59 years, 55.9 % > 60 years; females: 
1.7 % 20 - 29 years, 5.3 % 30 - 39 
years, 26.2 % 40 - 49 years, 27.1 % 50 
- 59 years, 43.3 % > 60 years; overall 
prevalence IFG not reported, but 
prevalence reached 20 % 'as early as' 
20 - 24 years in males, 35 - 39 years in 
Prevalence of obesity (BMI ≥30) 
was greater in females than 
males (46.5% vs. 28.3%, P<0.01 
respectively) 
Statistical analysis was not 
described clearly 
Study limitations not discussed 
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Summary of cross-sectional studies investigating prevalence of type 2 diabetes within populations of the GCC region 
females 
Saadi et al/ 2005-
2006 
Self-reported + 
current oral 
medication/insulin, 
or WHO 1999 
OGGT and IGT Overall prevalence DM: 10.2 % (9.4 
% in males, 11.1 % in females); 
prevalence in 30 - 64 years population: 
20.6 % (17.7 % in males, 22.1 % in 
women); prevalence IGT: 22.8 % 
(19.7 % in males, 24.3 % in females) 
 Potential of under- or 
overestimation of the reported 
rate of diabetes diagnosis 
(10.2%) based on disease 
reporting rate 
% of subjects out of those 
sampled households (2455) was 
underwent testing was small 
Bener et al/ 2009 Self reported and 
currently taking oral 
medication or WHO 
2006 criteria 
OGGT and IGT Overall prevalence DM: 16.7 % (15.2 
% males, 18.1 % females); overall 
prevalence IGT: 12.5 % (12.3 % 
males, 12.8 % females); age 
significantly associated with DM (p = 
0.0001, multiple logistic regression 
analysis); peak age DM 40 - 49 years 
(58 %) 
Central obesity was common in 
76.3%, p<0.001 
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Appendix 10: Review protocol- „Prevalences of overweight, obesity, 
hyperglycaemia, hypertension and dyslipidaemia in the GCC: a systematic 
review‟ 
Background  
The increasing prevalence of diabetes mellitus, particularly type 2 diabetes mellitus, 
is well documented (1).  Type 2 diabetes is currently estimated to account for 
approximately 90 % of the global diabetes burden (2).  Together with similar trends 
in other non-communicable diseases, it leads to risks not only for individuals, but for 
health systems, social systems, and state economies – those less established being at 
particular risk.  This risk is in part to do with an anticipated relatively dramatic rise 
in countries with relatively young populations, and economic infrastructure, as they 
undergo the apparent and predicted increases in prevalence of diabetes associated 
with changes in lifestyle/economic development, and population growth.  Even 
when based on changes in population size and demographic alone (3), the highest 
predicted future increases are expected in the International Diabetes Federation‟s 
„African‟ region (estimated: 98.1 % increase 2010 – 2030), followed by the „Middle 
East-North Africa‟ region (estimated: 93.9 % increase 2010 – 2030; 4). The Middle 
East-North Africa region already carries some of the highest rates of diabetes in the 
world.  Indeed, the countries of the Co-operation Council for the Arab States of the 
Gulf (GCC) include those currently ranked 2, 3, 5, 7 and 8 for diabetes prevalence 
among the 216 countries for which data are available (4).  
I anticipated that this high prevalence in the GCC states is associated with higher 
prevalences of risk factors for type 2 diabetes in this region.  The International 
Diabetes Federation suggests the following as risk factors for type 2 diabetes: age, 
obesity, family history, physical inactivity, race/ethnicity and gestational diabetes.  
Of the modifiable risk factors, physical inactivity appears (on scoping searches) to 
have been surprisingly little studied in this region, although it is likely to be 
correlated with overweight/obesity, which has been relatively well considered. 
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Review question 
A literature search was used to identify material relevant to the following review 
question: 
- What are the prevalences of overweight/obesity, hyperglycaemia, 
hypertension and dyslipidaemia in the GCC region? 
Inclusion criteria 
Types of studies 
Studies that used designs from the used list of acceptable methods including:  
randomized controlled trial, observational study (cross sectional, quasi-experimental 
and interventional).  
Types of participants 
Type 2 diabetic patients at all ages, sexes and ethnicities were included, resident and 
expatriate populations, urban and rural, of all socioeconomic and educational 
backgrounds in the GCC.  
Types of outcome measures 
Prevalence rates of: hyperglycaemia, hypertension, obesity/overweight and 
dyslipidaemia. 
Exclusion criteria 
 Studies that used qualitative methods such as focus group and based on 
opinions 
 Studies where population is mainly pregnant women with type 2 diabetes, or 
people with other types of diabetes   
Study selection 
Study collection will be conducted in two stages: (1) an initial screening of the 
title/abstract against inclusion criteria to identify any relevant paper will be carried 
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out by one reviewer (L.A) ; (2) screening of the full paper  that identified to be 
relevant from the first stage, and it will be carried out by 2 reviewers (L.A and A.M). 
If disagreement regarding any study eligibility appears, it would be resolved 
through discussion and asking for the opinion of the third reviewer (A. M). 
No limitations on publication type, publication status, study design or language of 
publication will be imposed. 
Data extraction/quality assessment 
The data captured for each study would include data relating to, (1) methods (study 
design, recruitment, measurement tools, analysis); (2) participant characteristics (3) 
setting, and (4) outcomes (those observed, their definitions, results of analysis, 
length of follow-up).  Study quality will be assessed using a checklist adapted from 
the Centre for Reviews and Dissemination guidelines (6).  Data extraction will be 
performed, in duplication, by two reviewers (L.A, A. M) 
Data synthesis 
Data synthesis will include summarising the results of the data extraction process, 
considering the strength of evidence relating to various questions formulated a priori 
, and examination of results inconsistent with our formed proposals.  
In addition to examining the prevalence of the particular risk factors in the GCC 
states, we were interested in the following: 
7. any trends in prevalence across time 
8. any differences by country 
9. any trends in prevalence associated with age 
10. sex differences 
11. location (urban/rural) differences 
12. prevalence in children 
 In the cases of hypertension and dyslipidaemia, synthesis will be limited by the 
number of studies indentified, and in these cases description and discussion suffices. 
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Appendix 11:  Research question using PICOS- „ Prevalences of overweight, obesity, hyperglycaemia, hypertension and 
dyslipidaemia in the GCC: a systematic review‟ 
 
- Research question: What are the prevalences of overweight/obesity, hyperglycaemia, hypertension and dyslipidaemia in the GCC region? 
 
Patient/Population 
 
Outcomes 
 
People living   in the GCC Prevalence of: overweight/obesity, hyperglycaemia, hypertension and 
dyslipidaemia  
 
GCC: Qatar, United Arab Emirates UAE, Kingdom of Saudi Arabia KSA, 
Kingdom of Bahrain, Sultanate of Oman, Kuwait 
Prevalence: statistics, epidemiological data 
Overweight/ obesity 
Hyperglycaemia: hyperglycemia, impaired glucose tolerance 
Hypertension: high blood pressure, hypertensan, systolic/diastolic 
blood pressure 
Dyslipidaemia:  hyperlipidaemia,  hypercholesterolemia, 
hypercholesterolaemia,  hypertriglycerdaemia,  hypertriglycerdemia 
 
 
AND 
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Appendix 12: Search strategy- „Prevalences of overweight, obesity, 
hyperglycaemia, hypertension and dyslipidaemia in the GCC: a systematic 
review‟ 
 
Search strategy to identify studies from electronic databases 
The followed steps for the search strategy included: (1) formatting a well defined review 
question to maintain the transparency for the review process; (2) revising the review 
question using PICOS elements (Population, Intervention, Comparators, Outcomes, Study 
design) (appendix 1); (3) defining the inc/exclusion criteria for the study; (4) producing a list 
of synonyms abbreviations and spelling variants; (5) combining the PICOS elements using 
Boolean logic (AND, OR); (6) devising a search strategy using both indexing terms and free 
text (MeSH search term used were the name of the GCC countries with each of the included 
risk factors, as well as the following terms: „prevalence‟, „epidemiological data‟, „statistics‟; 
(6) reviewing the search strategy; (7) pilot the search strategy on one database EMBASE; (8) 
review the search strategy with another colleague (w. I); (9) repeat the search strategy and 
finalize it. 
Describing electronic database searches 
The Medline and Embase were searched separately on 15/07/2009 (via Dialog and 
Ovid, respectively; 1950 to March week 4, and 1947 to 2010 March 21 to July 2010 ) 
using the following search strategy: 
Hyperglycaemia 
(1) Exp hyperglycemia/ 
(2) Exp blood glucose/ 
(3) Blood glucose$.tw. 
(4) High blood glucose$.tw. 
(5) 1 or 2 or 3 or 4 or 5 
Blood pressure 
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      (6) exp hypertension/ 
      (7) hyperten$.ti. 
      (8) blood pressure$.tw. 
      (9) (blood adj pressure).ti. 
      (10) 6 or 7 or 8 or 9 
Blood lipid 
      (11) exp cholesterol/ 
      (12) exp hyperlipidemia/ 
     (13) cholesterol$.tw. 
     (14) lipid$.tw. 
     (15) hyperlipid$.tw. 
     (16) 11 or 12 or 13 or 14 or 15 
Obesity/overweight 
(17) obesity/ 
(18) exp weight gain 
(19) body mass index/ 
(20) body mass index.tw. 
(21) (overweight or over weight).tw. 
(22) (adipos $).tw. 
(23) fat overload syndrome$.tw. 
(24) (overeat or over eat).tw. 
(25) (overfeed or over feed).tw. 
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(26) obes$.tw. 
(27) weight gain.tw. 
(28) 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 
GCC 
(29) ((Saudi or emirates or Kuwait or Oman or Bahrain or Qatar) adj5 (middle east* 
or Arab*)).mp. [mp=title, original title, abstract, name of substance word, subject 
heading word, unique identifier] 
Hyperglycaemia and GCC 
(30) 5 and 29 
Hypertension and GCC 
(31) 10 and 29 
Hyperlipidaemia and GCC 
(32) 16 and 29 
Obesity/overweight and GCC 
(33) 28 and 29 
Describing journal hand searches 
 International Journal of Diabetes and Metabolism searched  for the period 1993 to 
2009 
 Saudi Medical Journal for the period 2000 to 2010 
Describing the methods used to search relevant internet sources   
 The International Diabetes Federation (2009) IDF (http://www.diabetesatlas.org/) 
was searched using the on-site search engine. The section of the website labelled 
Diabetes Atlas 4th ed. was searched in detail. 
 The World Health Organisation (2009) WHO 
(http://www.WHO.int/mediacentre/factsheets/fs312/en/) was searched using on-
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site search engine. The section of the website labelled Fact sheet N 312 Diabetes was 
searched in detail. 
 American Heart Association (2010) 
(http://www.americanheart.org/presenter.jhtml?identifier=4756) was searched 
using on site search engine. The section Metabolic Syndrome was searched in detail   
Describing other searches included 
 The reference lists of included studies in the review were scanned for relevant 
studies. 
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Appendix 13: Review protocol- „Quality of T2DM management in the GCC: a 
systematic review‟ 
Background 
The Co-operation Council for the Arab states of the Gulf (GCC) exhibit some of the 
highest rates of T2DM in the world with rates reaching 35% in some population (1).  
Five of the IDF‟s „top 10‟ countries for DM prevalence in 2010 and in 2030 are in this 
region (UAE, KSA, Bahrain, Kuwait and Oman) (1). The recent and rapid socio-
economic development of the GCC countries, correlated with a shift in prevalence in 
various (types of) diseases, including T2DM, has characterised the changes in 
disease burden anticipated and appearing in current low- and middle-income 
countries.  However prevalence in the GCC region is still increasing and the IDF 
anticipates based only on changes in population, age and urban/rural distribution of 
population (i.e. assuming no change in prevalence rates and thus probably an 
underestimation) that it will undergo a 93.9 % increase by 2030 (1).  Only the Sub-
Saharan African region is expected to see a greater increase in prevalence (98.1 %; 
IDF, 2009) (1). Due to the high prevalence of DM in the GCC and increased economic 
cost to society, this disease represents a real challenge to the health care planners. 
The increased cost includes its effects on morbidity, employment, productivity, 
premature mortality and the increased use of health services (2). Although the 
expansion in the GCC region has occurred at a relatively rapid rate, we may still 
expect that the disease course, and therefore the size of the (potential) epidemic, can 
be prevented, reversed, halted, slowed, as it has been in other contexts (e.g. the 
Diabetes Control and Complications Trial (DCCT) and The UK Prospective Diabetes 
Study (UKPDS) (3).  
However, due to the increasing evidence that diabetes care is sub-optimal on 
international level in terms of the standards attained, the degree of variability and 
the level of accountability of health professionals; improving and measuring quality 
of health care are becoming important issues world-wide. These are now in national 
agendas of health systems in several countries such as USA and UK (4-5). Little is 
known about the quality of diabetes control in the GCC; therefore a structured and 
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systematic approach is needed to assess the quality of clinical care among those 
subjects. 
Review question 
A systematic literature search was carried out to identify information relevant to the 
following review questions: 
3. How good is current control of type 2 diabetes in the GCC region, based 
on glycaemic-, blood pressure- and lipid- control indicators? 
Inclusion criteria 
Types of studies 
Studies that used designs from the used list of acceptable methods including:  
randomized controlled trial, observational study (cross sectional, quasi-experimental 
and interventional).  
Types of participants 
Type 2 diabetic patients at all ages, sexes and ethnicities were included, resident and 
expatriate populations, urban and rural, of all socioeconomic and educational 
backgrounds in the GCC.  
Types of outcome measures 
Primary outcomes 
(1) Blood glucose control:  
Clinical Outcome measure 
 Glucose level measurement (HbA1c , FBG, postprandial  glucose level and 
random glucose measurements) 
Process measure 
 Frequency of glucose level documentation annually 
(2) Blood pressure control:  
Clinical Outcome measure 
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 Systolic and diastolic blood pressure levels measurements 
Process measure 
 Frequency of blood pressure level documentation annually  
 
(3) Blood lipid control : 
Clinical Outcome measure 
 Lipid levels measurement (HDL, LDL, triglycerides  and cholesterol)  
Process measure 
 Frequency of blood lipid level documentation annually 
Exclusion criteria 
 Studies that used qualitative methods such as focus group and based on 
opinions 
 Studies where population is mainly pregnant women with type 2 diabetes, or 
people with other types of diabetes   
Study selection 
Study collection will be conducted in two stages: (1) an initial screening of the 
title/abstract against inclusion criteria to identify any relevant paper will be carried 
out by one reviewer (L.A) ; (2) screening of the full paper  that identified to be 
relevant from the first stage, and it will be carried out by 2 reviewers (L.A and A.M). 
If disagreement regarding any study eligibility appears, it would be resolved 
through discussion and asking for the opinion of the third reviewer (A. M). 
No limitations on publication type, publication status, study design or language of 
publication were imposed. 
Data extraction/quality assessment 
The data captured for each study included data relating to, (1) methods (study 
design, recruitment, measurement tools, analysis); (2) participant characteristics (3) 
setting, and (4) outcomes (those observed, their definitions, results of analysis, 
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length of follow-up).  Study quality was assessed using a checklist adapted from the 
Centre for Reviews and Dissemination guidelines (6).  Data extraction was 
performed, in duplication, by two reviewers. 
Data synthesis 
Data synthesis included summarising the results of the data extraction process, 
considering the strength of evidence relating to each of our questions, and 
examination of results inconsistent with our formed proposals.  Synthesis was 
limited by the numbers of studies, particularly in consideration of the identified 
quasi-experimental studies (see „Results‟), and thus for this set of data, description 
and discussion suffices. 
References 
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from: http://www.diabetesatlas.org/ 
9. Profile of diabetes mellitus in Dubai. Dubai Health Authority statistical news 
2005. Available from: URL:  
10. http://www.who.int/countryfocus/cooperation_strategy/ccs_are_en.pdf 
11. UK Prospective Diabetes Study Group. Tight blood pressure control and risk 
of macrovascular and microvascular complications in type 2ádiabetes: 
UKPDS 38. BMJ 1998 Sep 12; 317(7160):703-13. 
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13. A First Class Service: Quality in the new NHS.  Department of Health; 1998. 
14. Centre for Reviews and Dissemination (2009) Systematic reviews: CRD's 
guidance for undertaking reviews in health care [Internet]. York: University 
of York; 2009 [accessed July 2010]. Available from: 
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Appendix 14: Research questions using PICOS-„ Quality of T2DM management in the GCC: a systematic review‟. 
 
(1) Research question: How good is current control of people with type 2 diabetes in the GCC regions, based on glycaemic, blood pressure- 
and lipid- control indicators? 
i) The question as a testable hypothesis: in people with type 2 diabetes in the GCC (P), do the indicated levels of blood glucose, 
pressure and lipids control (I) results in good diabetes management (O)? 
 
Patient/Population 
 
Intervention Outcomes 
 
People with type 2 diabetes mellitus  in the GCC  Level of blood glucose, pressure and lipids 
Control  
Diabetes management  
Alternative Words 
 
Type 2 diabetes mellitus: Diabetes mellitus, 
Non-insulin dependent diabetes mellitus,  T 2 
DM,  Diabetes type 2,  Type 2 diabetes, 
diabetics  
GCC: Qatar, United Arab Emirates UAE, 
Kingdom of Saudi Arabia KSA, Kingdom of 
Bahrain, Sultanate of Oman, Kuwait 
Blood glucose: high blood glucose,  
hyperglycaemia, hyperglycemia, HbA1c, 
glyclated haemoglobin  levels , Fasting blood 
glucose levels, FBG, Postprandial  blood 
glucose level  
Blood pressure: High blood pressure, 
diastolic/ Systolic blood pressure,   
hypertension, BP, HTN ,hypertensan 
Blood lipid: High blood lipid, 
hyprcholesterolaemia, hypercholesterol,  
hyperlipidemia, hyperlipidemaemia, 
hyperlipidemic, hypertriglycerdemia  
Management: control, reduction,  improvement, 
enhancement 
 
(2) Research question: Have implemented strategies (including public health/ preventive strategies) improved management of type 2 diabetes in the 
GCC countries?  
ii) The question as a testable hypothesis: in people with type 2 diabetes in the GCC (P), do the implemented strategies (public health/ 
preventive) (I), Improve management of type 2 diabetes (O)? 
AND AND 
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Patient/Population 
 
Intervention Outcomes 
 
People with type 2 diabetes mellitus  in the GCC  Implemented strategies (public health/ 
preventive)  
Management of type 2 diabetes  
Alternative Words 
 
Type 2 diabetes mellitus: Diabetes mellitus, 
Non-insulin dependent diabetes mellitus, T 2 
DM,  DM/,Diabetes type 2, Type 2 diabetes, 
diabetics  
GCC: Qatar, United Arab Emirates UAE, 
Kingdom of Saudi Arabia KSA, Kingdom of 
Bahrain, Sultanate of Oman, Kuwait 
 National diabetes programmes, national 
guidelines,  prevention programmes, public 
health programmes, diabetes management 
programmes 
Management: control, reduction, enhancement, 
improvement 
 
 
AND AND 
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Appendix 15: Search strategy- „Quality of T2DM management in the GCC: a 
systematic review‟ 
Search strategy to identify studies from electronic databases 
The followed steps for the search strategy included: (1) formatting a well defined 
review question to maintain the transparency for the review process; (2) revising the 
review question using PICOS elements (Population, Intervention, Comparators, 
Outcomes, Study design) (appendix 1); (3) defining the inc/exclusion criteria for the 
study; (4) producing a list of synonyms abbreviations and spelling variants; (5) 
combining the PICOS elements using Boolean logic (AND, OR); (6) devising a search 
strategy using both indexing terms and free text; (6) reviewing the search strategy; 
(7) pilot the search strategy on one database EMBASE; (8) review the search strategy 
with another colleague (w. I); (9) repeat the search strategy and finalize it. 
Describing electronic database searches 
The Medline and Embase were searched separately on 15/07/2009 and the search 
was repeated on 03/07/2010 (via Dialog and Ovid, respectively; 1950 to July week 1, 
and 1947 to 2010 July) using the following search strategy: 
Type 2 diabetes 
(22) exp diabetes mellitus, non-insulin-dependent/ 
(23) exp insulin resistance/ 
(24) impaired glucose toleranc$.tw. 
(25) glucose intoleranc$.tw. 
(26) insulin$ resistanc$.tw. 
(27) (MODY or NIDDM).tw. 
(28) ((typ$ 2 or typ$ II) adj diabet$).tw. 
 
(29) ((keto?resist$ or non?keto$) adj diabet$).tw. 
(30) ((adult$ or matur$ or late or slow or stabl$) adj diabet$).tw. 
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(31) (insulin$ defic$ adj relativ$).tw. 
(32) pluri?metabolic$ syndrom$.tw. 
(33) 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 
(34) exp diabetes insipidus/ 
(35) diabet$ insipidus.tw. 
(36) 13 or 14 
(37)  15 OR 12 
Blood glucose 
(38) Exp blood glucose/ 
(39)  Blood glucose$.tw. 
(40) Exp hyperglycemia/ 
(41) 17 or 18 or 19 
Blood pressure 
      (21) exp hypertension/ 
      (22) hyperten$.ti. 
      (23) blood pressure$.tw. 
      (24) (blood adj pressure).ti. 
      (25) 21 or 22 or 23 or 24 
Blood lipid 
      (26) exp cholesterol/ 
      (27) exp hyperlipidemia/ 
     (28) cholesterol$.tw. 
     (29) lipid$.tw. 
     (30) hyperlipid$.tw. 
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     (31) 26 or 27 or 28 or 29 or 30 
The states of The Co-operation Council for the Arab States of the Gulf  (GCC) 
    (32) United Arab Emirate.tw. 
    (33) Qatar 
    (34) Kuwait 
    (35) Sultanate of Omn.mp. or Oman.tw. [mp=title, original title, abstract, name of 
substance word, subject heading word, unique identifier] 
    (36) Kingdom of Bahrain.mp. or Bahrain.tw. [mp=title, original title, abstract, 
name of substance word, subject heading word, unique identifier] 
    (37) Kingdom of Saudi Arabia.mp. or Saudi.tw. [mp=title, original title, abstract, 
name of substance word, subject heading word, unique identifier] 
   (38) ((Saudi or emirates or Kuwait or Oman or Bahrain or Qatar) adj5 (middle east* 
or Arab*)).mp. [mp=title, original title, abstract, name of substance word, subject 
heading word, unique identifier] 
Type 2 diabetes and blood glucose and the GCC 
(39) 16 and 20 and 32 
(40) 16 and 20 and 33 
(41) 16 and 20 and 34 
(42) 16 and 20 and 35 
(43) 16 and 20 and 35 
(44) 16 and 20 and 36 
(45) 16 and 20 and 37 
(46) 16 and 20 and 38 
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Type 2 diabetes and blood pressure and the GCC 
(47) 16 and 25 and 32 
(48) 16 and 25 and 33 
(49) 16 and 25 and 34 
(50) 16 and 25 and 35 
(51) 16 and 25 and 36  
(52) 16 and 25 and 37 
(53) 16 and 25 and 38 
Type 2 diabetes and blood lipid and the GCC 
(54) 16 and 31 and 32 
(55) 16 and 31 and 33 
(56) 16 and 31 and 34 
(57) 16 and 31 and 35 
(58) 16 and 31 and 36 
(59) 16 and 31 and 37 
(60) 16 and 31 and 38 
Describing journal hand searches 
3 International Journal of Diabetes and Metabolism searched  for the period 
1993 to 2009 
4 Saudi Medical Journal for the period 2000 to 2010 
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Describing the methods used to search relevant internet sources 
3 The Qatar Diabetes Association website 
(http://www.qda.org.qa/output/page4.asp) was searched using the on-site 
search engine. The section of the website labelled guidelines and instructions 
was scanned in detail. 
4 The Oman Diabetes Association website 
(http://omandiabetes.org/static/index.html) was searched using the on-site 
search engine. The section of the website labelled publications was scanned in 
detail.   
5 The Kuwait Diabetes Society website (http://www.kds-kw.net/) was 
searched using the on-site search engine. The section of the website labelled 
news was searched in detail.  
6 The International Diabetes Federation (2009) IDF 
(http://www.diabetesatlas.org/) was searched using the on-site search 
engine. The section of the website labelled Diabetes Atlas 4th ed. was searched 
in detail. 
7 The World Health Organisation (2009) WHO 
(http://www.WHO.int/mediacentre/factsheets/fs312/en/) was searched 
using on-site search engine. The section of the website labelled Fact sheet N 
312 Diabetes was searched in detail. 
8 The UAE National Diabetes Committee (2009) (http:// api.ning.com) was 
searched using on-site search engine. The section of the website labelled 
National Diabetes Guidelines: United Arab Emirates 2009 was searched in 
detail. 
Describing other searches included 
 The reference lists of included studies in the review were scanned for 
relevant studies. 
Dr. Mohsen S. Eledrisi from Saudi Arabia was contacted for further information. 
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Appendix 16:  Study quality assessment- „Quality of T2DM management in the GCC: a systematic review‟. 
 
 
Ref/dates of study Quality assessment  checklist (1) 
Famuyiwa et al / 1988 - 1-Y, 2-Y, 3-Y, 4-N, 5-Unclear, 6-N, 7-NA 
Al-Shammari et al / 1993 - 1994 1-N, 2-N, 3- Unclear, 4- N, 5-N, 6-Y, 7-NA 
Khorsheed et al / 1998 - 2000 1-N, 2-Incomplete, 3- Y, 4- Not well described, 5- Unclear, 6-N, 7-NA 
Akbar/ 1999 - 2001 1-Y, 2-Y, 3-Y, 4-Y, 5-N, 6-N, 7-NA 
Al-Turki / 2000 - 2001 1-Y, 2-Unclear, 3- Y, 4-N, 5-Unclear, 6-N, 7- NA 
Al-Ghamdi / 2002 - 2003 1-N, 2- Y, 3-Y, N, 4- Unclear, 5- N, 6- N, 7-NA 
Al-Hussein  / 2003-2004 1-Y, 2-incomplete, 3- Y, 4- Y, 5- Unclear, 6- N, 7-NA 
Afandi  et al / 2005 1-Y, 2-Y, 3-Y, 4- Unclear, 5- Unclear, 6- N, 7- NA 
Qari / 2005 1-Y, 2-Y, 3- Y, 4- Y, 5- Partially, 6-N, 7-NA 
Kharal et al / 2005- 2006 1-Y, 2-Y, 3-Y, 4-Y, 5-Y, 6-partially, 7-NA 
Saadi et al/2005 - 2006 1-Y, 2-Y, 3-Y, 4-Y, 5-N, 6- Y, 7-NA 
Al-Shaikh / Not reported 1-Y, 2-Partially , 3- Unclear, 4-Unclear, 5-N, 6- N, 7-NA 
Al-Kaabi  et al / 2006 1-Y, 2-Y, 3- Y, 4- Y, 5-Unclear, 6 –Partially, 7-NA 
Al-Elq / 2006 1-Y, 2-Y, 3-Y, 4-Y, 5- Unclear, 6-Y, 7-NA 
Eledrisi et al / Not reported 1-Y, 2-Y, 3-Y, 4- Y, 5-Unclear, 6-N, 7- NA 
Sequeira et al / 2001 1-N, 2-Y, 3-Y, 4-Y, 5-N, 6-Partially, 7- NA 
Al-Khaja et al/ 2001 1-Y, 2-Y, 3-Y, 4-Y, 5-N, 6-N, 7-NA 
Al-Khaja et al/ Not reported 1-Y, 2-Y, 3-Y, 4-Y, 5-N, 6-N, 7-NA 
Al-Shehri/ 2003 – 2004 1-Y, 2-Y, 3-Y, 4-Y, 5-N, 6-N, 7-NA 
El-shafie et al / 2006 - 2007 1-Y, 2- Y, 3-Y, 4-Y, 5- N, 6- N, 7-NA 
Akbar et al/ 2000 - 2001 1-Y, 2-Y, 3-Y, 4-Y, 5- N, 6-N, 7-NA 
Reed  et al 2001 1-Y, 2-Y, 3- Y, 4- Y, 5- Unclear, 6-Y, 7- NA 
Andrews/ 1998 - 2000 1-Y, 2-N, 3- Unclear, 4-Y, 5-Unclear, 6-N, 7-NA 
Udezue et al/ 1998-2002 1-Y, 2- Partially stated, not entirely appropriate , 3- not entirely appropriate, 4- 
Unclear, 5-N, 6- N, 7-NA 
Al-Adsani et al/ 2001-2003 1-Y, 2, Unclear, 3-Unclear, 4-Y, 5-Unclear, 6-Y, 7-NA 
Khattab et al/ 2002 - 2005 1-Y, 2-Y, 3-Y, 4-Y, 5-N, 6-N, 7-NA 
Moharram et al/ 2006-2007 1-Y, 2-Y, 3-Y, 4-Y, 5-Y, 6-Y, 7-NA 
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Quality assessment checklist (1) 
Was the aim of the study stated clearly? 
Was the methodology stated? And was it appropriate? 
Were appropriate methods used for data collection and analysis? 
Was the data analysis sufficiently rigours? 
Were preventive steps taken to minimize bias? 
Were limitations of the study discussed? 
In systematic review, was search strategy adequate and appropriate? 
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Appendix 17: Ethical approval for the quantitative and qualitative studies 
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Appendix 18: Data collection tool 
Age:                                                                                    Sex: F/M                                                                             
Duration of T2DM: 
Smoking: Y/N                                                                    Physical activity: Y/N 
Criterio
n 
number 
Criterion 2008 2009 2010 
1 Blood glucose management 
 1.1 Has blood glucose 
been measured 
within the last year? 
  
 
Y/ N 
 
Y/ N 
 
Y/ N 
 1.2 If yes, how often was 
HbA1c levels measured? 
 
 Once 
annually 
 Twice 
annually  
 More 
than 
twice 
annually 
 Once 
annually 
 Twice 
annually  
 More 
than 
twice 
annually 
 Once 
annually 
 Twice 
annually  
 More 
than 
twice 
annually 
 1.3 What were the 
measurements for the 
HbA1c? 
1- 
2- 
3- 
1- 
2- 
3- 
1- 
2- 
      3- 
 1.4 Has the person‟s 
blood glucose been 
controlled by lifestyle 
interventions? 
 
 
Y/ N 
 
Y/ N 
 
Y/ N 
 1.5 Is the patient 
receiving oral blood 
lowering therapy? 
 
Y/ N 
 
Y/ N 
 
Y/ N 
 1.6 Is the patient on 
insulin therapy? 
 
Y/ N 
 
Y/ N 
 
Y/ N 
2 Blood pressure management 
 2.1 Has the person‟s 
blood pressure been 
measured within the last 
year? 
 
 
Y/ N 
 
Y/ N 
 
Y/ N 
 2.2 If yes, how often was 
the blood pressure 
measured? 
 
 Once 
annually 
 Twice 
annually 
 More 
than 
twice 
annually 
 
 Once 
annually 
 Twice 
annually 
 More 
than 
twice 
annually 
 
 Once 
annually 
 Twice 
annually 
 More 
than 
twice 
annually 
 
362 
 
 2.3 What were the 
measurements for the 
blood pressure? 
1- 
2- 
       3- 
1- 
2- 
      3- 
1- 
2- 
       3- 
 2.4 Is the patient taking 
any medications to 
regulate the blood 
pressure? 
 
 
Y/N 
 
Y/N 
 
Y/N 
 2.5 If yes, was blood 
pressure control and 
medication use 
reviewed? 
 
Y/N 
 
Y/N 
 
Y/N 
3 Blood lipid management 
 3.1 Has the person‟s 
blood lipid been 
measured within the last 
year? 
 
Y/N 
 
Y/N 
 
Y/N 
 3.2 If yes, how often was 
the blood lipid 
measured? 
 
 Once 
annually 
 Twice 
annually 
 More 
than 
twice 
annually 
 
 Once 
annually 
 Twice 
annually 
 More 
than 
twice 
annually 
 
 Once 
annually 
 Twice 
annually 
 More 
than 
twice 
annually 
 
 3.3 What were the 
measurements for the 
blood lipids? 
1- 
                 2- 
3- 
1- 
2- 
      3- 
1- 
2- 
      3- 
 3.4 Is the patient taking 
any medications to 
regulate the blood lipids? 
 
 
 
Y/N 
 
Y/N 
 
Y/N 
4 Anti-thrombotic therapy 
 4.1 Is the patient taking 
any thrombotic drugs? 
 
 
 
Y/N 
 
Y/N 
 
Y/N 
 Which anti-thrombotic 
drug the patient is been 
prescribed? 
 Aspirin 
 
 Plavix 
 
 
 
Y/N 
 
Y/N 
 
 
 
Y/N 
 
Y/N 
 
 
 
Y/N 
 
Y/N 
5 Co-morbidities 
 5.1 Does the patient 
suffer from: 
 coronary heart 
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disease 
 hypertension 
 heart failure 
 atrial 
fibrillation 
 renal failure 
 peripheral 
vascular 
disease 
Y/N 
Y/N 
Y/N 
Y/N 
Y/N 
Y/N 
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Appendix 19: Proportions of women and men reaching the HbA1c targets: 2008-
2010 
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Appendix 20: Proportions of women and men reaching the LDL targets: 2008-2010 
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Appendix 21: Proportions of women and men reaching the SBP targets: 2008-2010 
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Appendix 22: Proportions of women and men reaching the DBP targets: 2008-2010 
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Appendix 23: Cover letter  
 
Dear, 
 
My name is Layla Alhyas. I am a PhD student in the department of and Public health 
at the Imperial College London and a clinical pharmacist from the UAE Ministry of 
Health. I am conducting a research study on the factors affecting the quality of type 
2 diabetes care at the diabetes centre as part of the requirements of my degree, and I 
would like to invite you to participate. This study is sponsored by the UAE Ministry 
of Higher Education and Research. 
 
I am aiming to provide key recommendations to improve the quality of type 2 
diabetes management at Tawam Hospital. If you decide to participate you will be 
asked to meet with me for an interview about type 2 diabetes management at 
Tawam Hospital. The interview should last about 10 minutes. 
 
Participation is confidential. Study information will be kept in a secure location at 
the university. Participation is anonymous. 
Taking part in the study is your decision. We will be happy to answer any question 
you have about the study. You may contact me (email: l.alhyas08@imperial.ac.uk) or 
my supervisor (email: a.majeed@imperial.ac.uk)  
 
 
Thank you for consideration. If you would like to participate please contact me on 
the provided email to discuss participating. 
 
With kind regards, 
 
Layla 
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Appendix 24: Interview guide 
 
Research Topic: factors affecting the quality of type 2 diabetes management at 
Tawam hospital 
Aim:   
To identify the factors both facilitators and barriers affecting quality of type 2 
diabetes management at the diabetes centre, Tawam hospital based on the 
perceptions and beliefs of health professionals with focus on factors related to health 
professionals. 
 Objectives: 
 to identify barriers to improving the quality of diabetes care related to the 
health care providers‟ work practices 
 to identify facilitators to improving the quality of diabetes care related to the 
health care providers‟ work practices 
 to develop a frame of knowledge from the perceptions, understanding and 
experiences of the health care providers regarding the management of people 
with diabetes to improve quality of diabetes care 
Research questions: 
 What are the main factors affecting the quality of type 2 diabetes management 
at the diabetes centre at Tawam hospital? 
 What are the main factors related to health care providers that affect the 
quality of type 2 diabetes management at the diabetes centre at Tawam 
hospital? 
 What are the specific barriers to improving quality of type 2 diabetes care 
based on the beliefs of health care providers at the diabetes centre at Tawam 
hospital? 
 What are the specific facilitators to improving quality of type 2 diabetes care 
based on the beliefs of health care providers at the diabetes centre at Tawam 
hospital? 
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 What are the suggestions of the health care professionals to improve the 
quality of care provided to people with diabetes at the diabetes centre at 
Tawam hospital? 
 
1. Introduction 
 Introduce the study, its aims and the researchers 
 Brief discussion of ethical issues i.e. confidentiality, anonymity and recording 
2. Warm up 
 Name 
 Job position 
 What is your role in managing people with diabetes?   
 How long have you been involved in your role? 
 What is your view of the management of diabetes in Tawam hospitals‟ 
diabetes centre? 
 
3. Factors affecting the quality of managing people with diabetes 
We know that all over the world, the care of people with diabetes is variable. Many 
variables can influence the care provided to people with diabetes. Things that have 
been looked at in other countries are to do with the patient, the health professionals 
and the organisation of care.  
For you as a care provider at the diabetes centre of Tawam hospital, can you name 
for me some of the things that you think affect the quality of care you provide to 
people with diabetes? 
What are the things do you think help producing high quality of care to people with 
type 2 diabetes in the centre? 
What are the things do you think prevent producing high quality of care to people 
with type 2 diabetes in the centre? 
4. Motivation of health care providers 
How would you describe care providers‟ motivation in managing people with 
diabetes? 
What things do you think increase your motivation in managing people with 
diabetes in this centre? 
What things do you think decrease your motivation in managing people with 
diabetes in this centre? 
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5. Training 
 Training diabetes care providers to improve the quality of care provided to people 
with diabetes is important.  
How would you describe training diabetes care provider in managing people with 
diabetes? 
PROMPT IF NOT MENTIONED 
What about attending conferences? 
What about attending academic courses? 
What about taking part in workshops? 
What about taking part in diabetes related activities? 
What sorts of training for health care providers at the diabetes centre do you think is 
needed and can improve the quality of diabetes management? 
PROMPT IF NOT MENTIONED 
What about training in communication skills? 
What about training in skills needed for behavioural changes? 
Why do you think that providing these sorts of training could improve the quality of 
care provided to people with diabetes at the diabetes centre? 
 What do you think are the barriers that present at the diabetes centre for training?  
What do you think are the facilitators that present at the diabetes centre for training?  
6. Team work 
The management of people with diabetes is complex and multi-dimensional; 
therefore working in a team to effectively manage people with diabetes is essential. 
In Tawam hospital diabetes centre, you wok in a team to manage people with 
diabetes. 
How do you perceive working with others? 
Who are involved in the diabetes team that you work in? 
What things you find working with this team are rewarding? 
What things you find working with this team are problematic?  
Who other care providers do you think could be involved in the team? 
If any, what are the barriers from involving them? 
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PROMPT IF NOT MENTIONED 
What about lack of diabetes training? 
What about lack of resources? 
What about cost? 
Why do you think their involvement will be useful? 
7. Patient- care provider interaction 
Effective interaction between care providers and patients is essential and can help 
achieving the treatment goals.  
As a diabetes care provider at the diabetes centre what things do you think affect 
your interactions with people with diabetes?  
What are the barrier you think from producing effective patient-provider 
interactions at the diabetes centre? 
PROMPT IF NOT MENTIONED 
What about: 
 Language  
 Cultural background 
 Time with each patient 
 Gender 
 Age 
8. Time with patients 
Spending adequate time with patient is important for effective patient-provider 
interaction 
Usually how long do you stay with each patient?  
Do you think this time you spend with each patient is adequate? 
From your experience at the diabetes centre, what are the things that affect the time 
you spend with patients? 
What are the barriers as you think from spending adequate time with each patient? 
9. Care providers preceptions and beliefs 
Many care providers rate diabetes as harder to treat than other chronic conditions. 
What is your perception about this disorder? 
What are the reasons behind that? 
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PROMPT IF NOT MENTIONED 
What about:  
 Lack of effective drugs 
 Complexity of treatment 
 Behavioural changes required by the patients 
 Inevitability of future complications 
Do you think this perception or beliefs affect the quality of care you provide to 
people with type 2 diabetes? 
If yes, how do you think this perceptions or beliefs can affect the quality of care you 
provide to people with diabetes?  
10. Other factors/ recommendations  
What are other health care providers‟ factors in general that were not mentioned and 
you think they affect the quality of diabetes care at the diabetes centre at Tawam 
hospital? Do you have any specific recommendations to improve the quality of 
diabetes care at Tawam hospital? 
 
11. Closing 
 Before we finish, I would like to know if there is anything else you would like 
to say about the topic we have discussed. 
 Thank you so much for participating. Your time is much appreciated 
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(6) Layla Alhyas, Jessica D. Jones, Dalia Dawoud and Azeem Majeed. Factors 
affecting the motivation of healthcare professionals providing care to 
Emirates with type 2 diabetes in diabetes centre at a tertiary care in Al-Ain, 
United Arab Emirates: A qualitative study. JRSM short reports. 2012. In press.  
Reviews of Papers: 
(1) “Increased length of inpatient stay and poor clinical coding in people with 
diabetes and with foot disease: a point prevalence study”. JRSM short reports, 
2011 
(2) “Hypertension and type 2 diabetes: a cross sectional study in Morocco”. Pan 
African Medical Journal, 2011. 
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(3) “Diabetes mellitus in genetically isolated population in Jordan: prevalence, 
awareness, glycemic control, and associated factors”. Journal of diabetes and 
its complications. 
(4) “Long-acting nifedipine for hypertensive patients in the Middle East and Morocco: 
Observations on efficacy and tolerability of monotherapy or combination therapy”. 
Journal of Integrated Blood Pressure Control.  
Professional training/ Workshops 
 December/ 2011: Diabetes Epidemiology Training Course-  International 
Diabetes Epidemiology Group, United Arab Emirates 
 September /2011: World Health Organization- Health System Development 
course  
 June-July /2010: University of London, London School of Hygiene and 
Tropical Medicine- Intensive Course in Epidemiology and Medical Statistics 
 September/ 2011:  University of London, London School of Hygiene and 
Tropical -Advanced Course in Epidemiological Analysis 
 November/2010:  Social Research Association-Designing a Qualitative Study 
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 2012: Non-communicable diseases in the low and middle income countries 
symposium. Imperial college London. Poster presentation “The quality of 
type 2 diabetes care provided to Emirates patients in a diabetes centre located 
at a tertiary care setting in Al-Ain, United Arab Emirates: a retrospective 
cohort study”. 
 2011:  12th symposium of International Diabetes Epidemiology Group. Oral 
presentation “Risk factors for type 2 diabetes in the Gulf: Systematic review2 
Sharjah, United Arab Emirates. 
 2011: International Diabetes Federation. Dubai Congress.  Poster presentation 
“Quality of type 2 diabetes management in the Gulf: systemic review”.  
Dubai, United Arab Emirates 
 2011: The society for Academic Primary Care, Annual Scientific Meeting  Oral 
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Presentation “Risk factors for type 2 diabetes in the Gulf: Systematic review”. 
Cambridge University, UK 
 2010: Imperial College London, department of Primary care and Social 
Medicine. Oral Presentation “Prevalence of type 2 diabetes in the Gulf: a 
systematic review”.  Imperial College London, UK 
 2010: The Society for Academic Primary Care, Annual Scientific Meeting. 
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